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SUMMARY of CHAPTER 2 - Literature Review 
OBJECTIVE 
To review the history, epidemiology, clinical and microbiological manifestations of 
tuberculosis (TB) with emphasis on drug-resistance. 
To review the pharmacotherapy of TB with particular emphasis on pharmacokinetic 
and pharmacodynamic considerations and the drugs: isoniazid and rifampicin. 
DATA SOURCES 
The current medical literature, including primary and secondary references. 
References were identified using electronic retrieval systems such as Medline and the 
Iowa Drug Information Systems as well as published abstracts from scientific 
meetings. 
STUDY SELECTION 
While data relating to the primary research questions were targeted , some 
background information was included so as to contextualise the study within the South 
African context. Data supporting and disputing the specific study objectives are 
presented. 
DATA SYNTHESIS 
There is a global increase in the incidence of TB despite the availability of a sound 
scientific strategy for its control. The WHO has declared the TB crisis in South Africa 
to b.e the worst in the world. The human immunodeficiency virus (HIV) epidemic is a 
major contributor to this "global emergency". An increase in drug-resistant TB has also 
been noted globally although the exact extent of the problem in South Africa is not 
known. 
Malabsorption of the anti-TB drugs in HIV+ and acquired immunodeficiency syndrome 
(AIDS) patients has been noted and has sound mechanistic explanations. However 
some studies have failed to confirm early case reports of malabsorption. If proved 
correct this has serious public health implications particularly in areas with a high 
prevalence of HIV infection. Apart from treatment failure in the individual patient, 
absorption of a single drug in a TB drug regimen equates to monotherapy and has 
been associated with the acquisition of drug resistance. 
The available drugs against TB are being depleted as a result of drug resistance and 
there appears to be very few, if any, promising agents on the horizon. The importance 
of studying available agents to better understand their use is therefore emphasised. 
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SUMMARY of CHAPTER 3 - Temporal Trends in 
Mycobacterium Tuberculosis Drug Resistance in 
Kwazulu-Natal, South Africa: 1983 To 1995 
OBJECTIVE 
To determine temporal trends in Mycobacterium tuberculosis drug resistance in 
KwaZulu-Natal , South Africa between 1983 and 1995. 
DESIGN 
Routine drug susceptibility data from the central provincial mycobacteriology 
laboratory in KwaZulu-Natal, South Africa for the 13 year period from 1983 to 1995 
were analysed. The laboratory used the 1 % proportional method in Lowenstein-
Jensen medium for susceptibil ity testing throughout the study period. 
RESULTS 
A total of 21 704 sputum samples from which M. tuberculosis was cultured, were 
subjected to susceptibility testing. Multi-drug resistance (MOR-TB) , defined as 
combined resistance to isoniazid (INH) and rifampicin (RFA) was 2.2% in 1983 and 
3.7% in 1995 (p = 0.01). Examination of the temporal trends in MOR-TB revealed a 
downward trend from 2.6% in 1984 to 0.9% in 1987 (chi square for linear trend 9.34 ; 
P = 0.002). The prevalence did not change much between 1987 and 1990 followed by 
an upward trend from 1.1 % in 1990 to 3.7% in 1995 (chi square for linear trend 30.56; 
p < 0.001) . Resistance to INH alone was 6.7% in 1983 and 7.0% in 1995 (p = not 
significant) and for RFA alone 8.1 % and 7.2% (p = not significant) , respectively .. All 
other drugs tested showed a statistically significant decrease in drug resistance 
between 1983 and 1995 viz. streptomycin (13.7% and 7.7%; P < 0.001), ethionamide 
(9.3% and 4.5%; p < 0.001), thiacetazone (7 .8% and 3.2%; p < 0.001) and ethambutol 
(3.4% and 2.1 %; P = 0.01). 
CONCLUSIONS 
Following an initial downward trend, a significant increase in the prevalence of MOR-
TB was noted. It is particularly disconcerting that there was a reversal in a previous 
downward trend in MOR-TB. While these data cannot simply be extrapolated to all 
patients with TB due to the selective basis on which susceptibility tests were 
requested, they nevertheless provide valid temporal trends. 
SUMMARY OF CHAPTERS 4 to 7 - Pharmacokinetic 
and Pharmacodynamic Characteristics of Isoniazid 
and Rifampicin in Patients with Multi-drug-Resistant 
Tuberculosis 
OBJECTIVE 
To investigate if there is an association between the pharmacokinetic parameters of 
isoniazid (INH) and rifampicin (RFA) and multi-drug resistant tuberculosis (MDR-TB) 
in HIV positive (HIV+) and HIV negative (HIV-) patients. 
To describe the pharmacokinetic and pharmacodynamic characteristics of INH and 
RFA in MDR-TB and drug-sensitive TB patients stratified according to HIV status. 
DESIGN 
Prospective case-control pharmacokinetic study. 
SETTING 
King George V Hospital, a large specialist referral TB in-patient treatment facility in 
Durban, KwaZulu-Natal, South Africa 
PATIENTS 
A total of 138 adult pulmonary tuberculosis patients: 62 MDR-TB (21 HIV+ and 41 
HIV-) and 74 drug-sensitive TB (37 HIV+ and 36 HIV-; 1 not classified). A further 2 
patients (1 HIV+ and 1 HIV-) could not be classified according to drug susceptibility 
status. 
METHODS 
Single daily doses of INH (300 or 400 mg) and RFA (450 or 600 mg) were 
administered under supervision for 2-5 days prior to the study. Any other drug 
treatment prescribed for TB or concomitant complaints was noted but not 
discontinued. Thereafter 6 blood samples were drawn over 2 dosing intervals at 0, 1, 
2,4,8 and 12 hours after dose administration. Clinical, socio-demographic, 
radiological (extent and severity of lung involvement), clinical chemistry (liver function 
tests) and microbiological (drug susceptibility and minimum inhibitory concentration 
(MIC)) data were collected. Serum drug concentrations were determined using a 
validated high performance liquid chromatography (HPLC) assay. 
Pharmacokinetic data analysis was conducted according to the population approach 
using the NONMEM program as well as with non-compartmental methods. 
RESULTS 
Results from the non-compartmental analysis were similar to those obtained from the 
population approach. Upon initiation of treatment, the average 54-kg patient had a 
CUF for RFA of 7.7 Uhr. After continuous daily treatment, maximal enzyme auto-
induction was reached at approximately 10 days at which time the CUF was 15.6 Uhr. 
The mean population V/F for RFA was 26.5 L at initiation of treatment and 42.1 L after 
10 days of therapy. The inter-individual variability (% coefficient of variation [CV] for 
RFA was 39% for CUF and 26% for V/F. Residual variability was described with a 
proportional component of 39% and an additive component of 0.05 Ilg/ml. 
The proportion of INH fast acetylators in the population was found to be in the majority 
(85%). The mean population CLIF was 13.0 Uhr for fast acetylators and 4.7 Uhr for 
slow acetylators. The V/F for INH was 50.0 L. The inter-individual variability in INH . 
CUF was 32% for slow acetylators and 41 % for fast acetylators. There was also a 41 
% variability in V/F. Residual variability was described with a proportional component 
of 28% and an additive component of 0.02 Ilg/ml. 
The pharmacokinetic parameters for both INH and RFA obtained in this study 
compare well with that reported in the literature. 
Population pharmacodynamic parameters (maximum serum concentration 
[Cmax] :MIC ratios , time above the MIC and area under the curve [AUC] above the 
MIC) for INH and RFA were described and represent potential benchmarks for future 
prospective clinical evaluation. 
CONCLUSIONS 
There was no association between the pharmacokinetic parameters of INH and RFA 
and MDR-TB. Neither was there any association between HIV status or degree of 
immune compromise as determined using HIV viral loads and the pharmacokinetic or 




The World Health Organisation has declared tuberculosis (TB) to be a global public 
health emergency with an estimated one-third of the world's population being infected 
with Mycobacterium tuberculosis. It is estimated that the number of active TB carriers is 
about 20 million with more than 3 million deaths annually (WHO, 1994). 
The incidence of TB has been increasing globally in recent years, partially due to the 
human immunodeficiency virus (HIV) epidemic. More ominous, however, has been 
the increasing occurrence of strains of Mycobacterium tuberculosis that are resistant 
to currently used chemotherapy (Edlin et a/. 1992; Iseman, 1993; Bloch et a/. 1994; 
Neville et a/. 1994). If this resistance includes resistance to isoniazid (INH) and 
rifampicin (RFA) in combination, then the deadly, almost incurable, "third epidemic" of 
multi-drug resistant tuberculosis (MDR-TB) emerges (Kochi et aJ. 1993; Neville et a/. 
1994). 
Several of the "hotspots" for MDR-TB identified by the WHO exist in sub-Saharan 
Africa (Cohn et a/. 1997; Macready, 1997). This is not surprising given the poor TB 
cure rates in many of these countries. However, it is particularly disconcerting that the 
TB situation in South Africa should have been labelled " .. . the most serious in the 
world" despite the relative affluence of this country. This invidious conclusion was the 
result of a 1996 review by the WHO and the South African Department of Health 
(WHO, 1996). They suggested that the formula for this "crisis" was the high TB case 
rates, the emergence of MDR-TB and the growing HIV epidemic. 
There is a paucity of information on the exact extent of the MDR-TB problem in South 
Africa. In a study of newly admitted Black TB patients in South African hospitals, 
researchers from the Medical Research Council demonstrated a marked decrease in 
primary and acquired drug resistance over the period 1965 to 1988 (Weyer and 
Kleeberg, 1992). There has been no investigation into the trends in drug resistance 
thereafter. 
KwaZulu-Natal, one of South Africa's 9 provinces, is reported as having the highest 
prevalence rate of HIV infection (27 %) compared to the other provinces which have 
prevalence rates that range from 6 % in the Western Cape to 23 % in Mpumalanga 
province (Department of Health, 1998). The province ranks fifth in terms of the estimated 
incidence of TB (WHO, 1996). There is currently no published data on the prevalence of 
MDR-TB in the province. 
The first aim of this study was to determine the temporal trends in M. tuberculosis 
drug resistance using routine drug susceptibility data from the central provincial 
Mycobacteriology Laboratory in KwaZulu-Natal, South Africa. This is addressed as a 
distinct study in Chapter 3, which provides the setting for the second major component 
of this thesis. 
Chapter 1 Introduction 
Several authors have shown that the greatest predictor for drug-resistant TB is a history 
of prior treatment for TB (Iseman, 1993; Frieden et al. 1993; Cole and Telenti, 1995). 
While re-infection with drug-resistant strains has been reported (Iseman, 1993), there is 
a strong suggestion of an inadequately treated initial infection usually due to poor 
treatment adherence. The observation, however, that tubercle bacilli can survive in cells 
and tissues of the patient despite the adequate and regular administration of drugs 
(Grange, 1990) leads one to query reasons other than poor compliance as an 
explanation for treatment relapses and drug resistance. Case reports of patients with 
acquired immunodeficiency syndrome (AIDS) have shown malabsorption of the anti-TB 
drugs (Berning et al. 1992; Peloquin et al. 1993; Patel et al. 1995). This is of grave 
concern and has serious implications for TB control programmes, particularly in areas 
with a high HIV seroprevalence. Abnormal pharmacokinetics in the individual patient 
receiving a multi-drug combination chemotherapy regimen may result in monotherapy if 
only one drug is absorbed - an untenable situation in TB treatment. 
Sahai et al (1997) prospectively evaluated the role of HIV infection on the absorption of 
anti-TB drugs in volunteer grou'ps of symptomatic and asymptomatic HIV positive 
patients (with no TB) and found reduced total drug exposure to RFA and pyrazinamide. 
In a similar prospective evaluation in AIDS patients with concurrent TB infection, 2 . 
studies (Choudhri et al. 1997; Taylor and Smith, 199B) were unable to reproduce these 
findings of reduced absorption. 
While several patients in the case reports (Peloquin et al. 1993; Patel et al. 1995) were 
infected with MDR-TB, no study has prospectively investigated the association between 
anti-TB drug pharmacokinetics and drug resistance. Such an association has been 
suggested by (Bradford et al. 1996) in their observation of the changing epidemiology 
of acquired drug resistance in San Francisco. 
Therefore the second major aim of this study was to investigate if there is an 
association between drug pharmacokinetic parameters and MDR-TB in HIV positive 
(HIV+) and HIV negative (HIV-) patients. Pharmacokinetics were investigated using 
non-compartmental analysis techniques as well as a compartmental model based 
population approach. The latter approach utilised Non-linear Mixed Effects Modelling as 
implemented in the NONMEM program (Boeckmann et al. 1994). The NONMEM 
approach provided the opportunity to investigate the influence of a wide variety of 
concurrent clinical scenarios such as drug and disease interactions on the 
pharmacokinetics of INH and RFA. This was facilitated by a quasi-experimental design 
in which attempts were made to minimise disruptions to the normal hospital ward 
programme and to study the drugs under conditions of routine use. 
Finally, the pharmacokinetic parameters in the individual patient were used to predict 
t~e time course of INH and RFA concentrations. This was used to predict the ratio of 
the maximum drug concentration (Cmax) to the minimum inhibitory concentration (MIC), 
the time serum concentrations remained above the MIC (t>MIC) and the area under the 
serum concentration versus time curve (AUC) above the MIC. In this way, the 
pharmacodynamic parameters for INH and RFA were described in MDR-TB and drug-
sensitive TB patients. 
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To review the history, epidemiology, clinical and microbiological manifestations of 
tuberculosis (TB) with emphasis on drug-resistance. 
To review the pharmacotherapy of TB with particular emphasis on pharmacokinetic 
and pharmacodynamic considerations and the drugs: isoniazid and rifampicin . 
DATA SOURCES 
The current medical literature, including primary and secondary references. 
References were identified using electronic retrieval systems such as Medline and the 
Iowa Drug Information Systems as well as published abstracts from scientific 
meetings and discussions with experts in the field. 
STUDY SELECTION 
While data relating to the primary research questions were targeted, some 
background information was included so as to contextualise the study within the 
global and the South African context. Data supporting and disputing the specific study 
objectives are presented. 
DATA SYNTHESIS 
There is a global increase in the incidence of TB despite the availability of a sound 
scientific strategy for its control. The WHO has declared the TB crisis in South Africa 
to be the worst in the world. The human immunodeficiency virus (HIV) epidemic is a 
major contributor to this "global emergency" . An increase in drug-resistant TB has also 
been noted globally although the exact extent of the problem in South Africa is not 
known. 
Malabsorption of the anti-TB drugs in HIV+ and acquired immunodeficiency syndrome 
(AIDS) patients has been noted and has sound mechanistic explanations. However 
some studies have failed to confirm early case reports of malabsorption. If proved 
correct this has serious public health implications particularly in areas with a high 
prevalence of HIV infection. Apart from treatment failure in the individual patient, 
absorption of a single drug in a TB drug regimen equates to monotherapy and has 
been associated with the acquisition of drug resistance. 
The available drugs against TB are being depleted as a result of drug resistance and 
there appears to be very few, if any, promising agents on the horizon. The importance 
of studying available agents to better understand their use is therefore emphasised. 
Chapter 2 Literature Review 
Drug Resistant Tuberculosis - An Epidemiological, Clinical and 
Microbiological Perspective 
INTRODUCTION 
The chemotherapy of TB uses a combination of anti-TB drugs which has activity 
against one or more of several identified bacterial sub-populations depending on 
metabolic activity and environmental physicochemical properties. Mutations to drug 
resistance among the anti-TB drugs occurs at a low but constant rate. Thus the 
combination chemotherapy of 3-4 drugs assumes"a low probability of simultaneous 
resistance to all drugs used in the regimen (Davidson, 1987). As a result of this sound 
scientific strategy, the incidence of TB decreased and was thought to be nearing 
elimination in many developing countries (Daniel, 1991) . 
However, recent years have seen a marked increase in the incidence of TB in general 
and MDR-TB in particular. This prompted the World Health Organisation (WHO) to 
make an unprecedented declaration of TB being a global emergency. The 
International Union Against Tuberculosis and Lung Disease (IUAT~D) and the WHO 
estimate that approximately 1.7 billion persons, or one-third of the world's population 
is infected with Mycobacterium tuberculosis. They estimated the number of active TB 
carriers globally to be 20 million with more than 3 million deaths annually (WHO, 
1994). 
In 1996 the WHO and the South African Department of Health conducted a combined 
review of the TB Control Programme in South Africa. They concluded that South 
Africa's high TB case rates, the emergence of MDR-TB and the growing HIV epidemic 
combine to make the country 's TB crisis the most serious in the world (WHO, 1996). 
Why is this curable disease resurfacing as a public health nightmare? 
This chapter reviews the history, epidemiology, clinical and microbiological 
manifestations of TB and of drug-resistant TB. A brief account of the 
pharmacotherapy of TB is also presented together with pharmacokinetic and 
pharmacodynamic considerations with particular emphasis on INH and RFA. 
HISTORY 
TB appears to have afflicted mankind from ancient times. The skeletal remains of a 
Neolithic man found near Heidelberg in Germany (5 000 BC) and that of several 
Egyptian mummies (3 700 to 1 000 BC) suggests the presence of TB of the spine. 
Early physicians like Aristotle and Hippocrates called TB a "phthisis", a Greek word 
meaning wasting away. This was later translated into English as "consumption". 
Sylvius first applied the term "tubercle" to the typical nodular lesions he found at post 
mortem examinations and from this arose the term tuberculosis (Metcalf, 1991). 
In 1882 Robert Koch isolated and cultured Mycobacterium tuberculosis from crushed 
tubercles thereby establishing the true aetiology and infectious nature of the disease. 
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Soon after Koch's discovery, Farlanina indicated that pneumothorax was the sole and 
non-elective treatment for TB (Grassi and Peona, 1995). In addition, TB treatment 
from the mid 1800's to the early 1900's consisted of placing patients in sanatoria . The 
prescription was one of fresh air and rest. 
The discovery of streptomycin in 1943 by Waskman marked what is commonly 
referred to as the era of TB chemotherapy. The introduction of INH in 1952 and RFA 
in 1966 were 2 further important milestones in the treatment of TB (Grassi and Peona, 
1995). However, since 1970, there have been no new classes of antimicrobial agents 
specifically included into the armamentarium against TB (Cole and Telenti, 1995). 
More recently, the macrolides and the quinolones hold some promise of becoming 
useful additions to the regimen (Mandell and Petri, 1996). 
INFECTION AND DISEASE 
TB is an infectious disease caused primarily by Mycobacterium tuberculosis. Other 
species implicated in causing infection in humans include M bovis and M africanum 
although infection with these species is rare. The disease most commonly affects the 
lungs although any body site can be involved (Daniel, 1991). 
TB is nearly always transmitted through infectious particles that are released into the 
air by a patient with active pulmonary disease. This occurs when the patient coughs, 
sneezes, speaks or sings. These droplets stay suspended in the air for several hours. 
If inhalation of these particles by another person occurs, then the tubercle bacillus 
enters the lymphatics and bloodstream and spreads throughout the body. 
Within 2-6 weeks, most immunocompetent individuals develop cell-mediated immunity 
to the infection. Lymphocytes and macrophages infiltrate the lesions containing the 
bacillus, killing most of the bacilli and walling off the infection. At this point, the 
infected person is usually asymptomatic and may remain so for life. Within 2 to 10 
weeks after infection, most infected individuals show a positive reaction to the 
purified-protein derivative (PPD) skin test, and may show a healed, calcified lesion on 
the chest radiograph - a condition known as latent infection (Daniel, 1991). 
Those infected have a 10% lifetime risk of developing active TB disease. The 
organism remains dormant in the remaining 90% of people who are not considered to 
be contagious (Zeind et a/. 1996). 
Physical or emotional stress can destroy the balance between the immune system 
and the infection, leading to clinically active disease. Conditions associated with 
progression to clinical disease include previously untreated infection, intravenous drug 
abuse, diabetes mellitus, prolonged corticosteroid use, immunosuppressive therapy, 
various carcinomas, gastrectomy, cachexia and HIV infection (Zeind et a/. 1996). 
The progressive loss of immune function as a result of HIV infection is a powerful risk 
factor for the activation of latent TB. In HIV+ patients the lifetime risk of developing 
active TB is increased to 8% per year. Recent molecular epidemiology reports 
suggest that in HIV+ and AIDS patients, TB occurs more often as recently acquired 
infection rather than as reactivation of a latent focus (Zeind et a/. 1996). 
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CLINICAL PRESENTATION 
The vast majority of TB patients have pulmonary TB. In the USA, extra-pulmonary TB 
accounts for 15% of cases and symptoms depend on the site of involvement (Zeind et 
al. 1996). In pulmonary TB, the typical generalized symptoms are weight loss, 
malaise, fever and night sweats. With progression of the disease, the patient may 
develop a persistent cough that often produces sputum . 
However, these "classical" symptoms are frequently absent, and the onset is 
insidious, with the diagnosis only being considered when a chest radiograph is 
performed. The typical radiological findings include patchy or nodular infiltrates in the 
apical areas of the upper lobes or the superior segment of the lower lobes. As the 
infection progresses, cavitation is often seen. Patients often only present for medical 
attention when dramatic symptoms such as haemoptysis occur. At this point, patients 
typically have large cavitary lesions with high mycobacterial loads (Daniel, 1991). 
In the early stages of TB in patients with HIV infection, chest radiographs are 
indistinguishable from patients who are seronegative. However, as the level of 
immune compromise progresses, there is less necrosis and cavitation, the chest 
radiographs show predominantly diffuse or miliary infiltrates while the 
immunocompetent patients show focal infiltrates and/or cavitation (Wilkinson and 
Moore, 1996b; Zeind et al. 1996). 
MYCOBACTERIOLOGY 
The tubercle bacillus is a slender, straight, or slightly curved aerobic bacillus, less 
than 0.5 f.lm in diameter and 1 to 4 f.lm in length. It differs from bacteria in 2 notable 
ways. First, the TB bacillus replicates at a much slower rate - generally every 24 
hours instead of every 20-40 minutes. Second, because of its waxy outer layer, the 
bacillus does not stain well with Gram's stain. Instead Ziehl-Neelsen or fluorochrome 
stains must be used to detect the organism in biological specimens - usually sputum. 
It is this property that gives rise to the term acid-fast bacillus (AFB) when referring to 
mycobacteria (Daniel, 1991). 
EPIDEMIOLOGY OF TUBERCULOSIS 
"The 2 essential factors for the rapid spread of TB are crowded living conditions 
favouring the spread of infection and a population with little native resistance" 
(Des Prez and Heim, 1990) 
The early European colonialists and travellers are credited with introducing TB into 
South Africa. This occurred during the course of their journeys to the East via the 
Cape of Good Hope and during the early days of colonisation. In 1867, the English 
epidemiologist William Budd wrote in The Lancet: 
"Everywhere along the African sea-board, where blacks have come into contact and 
intimate relations with the whites, phthisis causes a large mortality among them. In the 
interior, where intercourse with the whites has been limited to casual contact with a 
few great travellers or other adventurous visitors, there is reason to believe that 
phthisis does not exist. " 
Budd 1867 cited by (Metcalf, 1991) 
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During the early 1900s, the migrant labour system and the conditions in the gold and 
diamond mines of South Africa contributed to the increase in TB incidence in the 
Black population. Medical examinations were cursory and failed to identify those unfit 
for work on the mines. The mines were poorly ventilated and very humid. Mine 
workers worked for long hours in close proximity to each other. They were housed in 
overcrowded compounds without partitions and their diets were woefully inadequate. 
The practice of repatriating mine workers who developed TB played a key role in 
disseminating the disease to the rural areas (Metcalf, 1991). 
However, the exact size of the TB problem in this country has probably always been 
under-estimated. Notification systems in most countries are known to have the 
problem of under-reporting. In South Africa this was compounded by the fragmented 
health systems implemented by the apartheid policies of the previous regime. 
The introduction of chemotherapy saw a global decrease in TB morbidity and mortality 
(Daniel, 1991; Dooley et al. 1992). In the USA, in 1953, the first year of national 
reporting, there were 84 304 cases of TB. By 1985, only 22 201 cases were reported 
(Zeind et al. 1996), the lowest number recorded over the previous 3 decades. 
However around 1989, just when projections for the total elimination of TB were being 
calculated, a global increase in TB incidence was noted. In the USA, in 1993 there 
were 26 287 cases i.e. a 14% increase over the 1985 figures (Zeind et al. 1996) . 
A similar pattern to the global epidemiological picture of a decline and a subsequent 
increase in TB incidence has also been seen in South Africa (Department of Health, 
1992). 
This reversal in the downward trend and its underlying causes has been referred to as 
the "U-shaped curve of concern" (Reichman, 1991). The HIV epidemic is probably the 
heaviest contributor to the rise in TB cases worldwide. . 
The overall incidence of TB has been estimated to be around 311 per 100 000 in 
South Africa (WHO, 1996). However, the true incidence of T8 for 1996 was 362 per 
100 000 (Department of Health 1998). There is an uneven distribution of the case 
loads across the 9 provinces of the country. The highest rates are reported in the 
Western Cape (737 per 100 000) and the lowest rates in the Northern Province (44 
per 100 000). KwaZulu-Natal ranks fifth with an estimated annual incidence of 120 per 
100 000. The racial distribution shows that the highest risk is among the so-called 
"Coloured" people of the Western Cape. The Black population has a high and stable 
prevalence while the Indian and White populations have low and falling rates (WHO, 
1996). 
The HIV epidemic in South Africa is escalating at an alarming rate. Over a period of 7 
years the prevalence of HIV infection rose more than 14-fold from 0,76 % in 1990 to 
14.07 % in 1996 (Abdool Karim et al. 1997). This can be expected to increase the TB 
case notifications dramatically. 
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EPIDEMIOLOGY OF DRUG-RESISTANT TUBERCULOSIS 
In 1994 Neville et al warned of the "third epidemic" that threatens to add to the 
already aismal combination of TB and HIV i.e. MDR-TB. This concern was in 
response to numerous reports of MDR-TB occurring in the USA. 
Frieden et al (1993) reported the emergence of drug-resistant TB in New York City. 
These authors examined drug resistance in 466 isolates (90%) available from 518 
patients with positive cultures for M. tuberculosis during April 1991 . Overall , 33% had 
isolates that were resistant to at least one drug. Of these, 26% of isolates were 
resistant to INH, 22% to RFA, and 19% had MDR-TB as defined in this study. 
The Centers for Disease Control and Prevention (CDC), USA suggested a number of 
factors that could have contributed to the outbreaks of MDR-TB in hospitals and 
correctional facilities from 1990 through 1992 (Anonymous1991 ; Doole et al. 1992). 
There was a high mortality among these patients, ranging from 43% to 89%. In 
addition, the median interval from diagnosis to death was very short, only 4 to·16 
weeks. The factors identified bear general applicability outside the USA. They include 
patient non-adherence with therapy, sub-optimal treatment regimens, overall poor 
response to therapy in MDR-TB, prolonged infectiousness, severe 
immunosuppression, inadequate infection control measures, and susceptible contacts 
in close proximity to increased numbers of TB patients (Anonymous1991 ; Doole et al. 
1992). 
The first three of these factors were emphasised by Goble et al (1993) who 
retrospectively reviewed treatment of 171 patients with MDR-TB . This primarily 
immunocompetent group had the disease for a median of six years and received a 
median of six anti-TB drugs. All patients were noted to have an isolate that was 
resistant to a median of six drugs. Despite individually tailored regimens, an overall 
response rate of only 56% was seen. RFA resistance was associated with suboptimal 
or irregular dosing and/or the administration of RFA as the single effective agent. 
Edlin et al (1992) evaluated an outbreak of MDR-TB among hospitalised patients with 
AIDS in New York, and emphasised the last three factors i.e. severe 
immunosuppression, inadequate infection control measures, and susceptible contacts 
in close proximity to increased numbers of TB patients. The authors compared 
exposure among 18 AIDS patients who had developed MDR-TB with that among 30 
controls who had contracted a susceptible strain of TB. The patients with MDR-TB 
were more likely to have been hospitalised in the same wards and in rooms near 
patients with infectious drug-resistant TB. In addition, of 16 patient's rooms that were 
tested with airflow studies, only one had the recommended negative pressure 
ventilation required for efficient infection control in this setting (Edlin et al. 1992). 
There is a paucity of good quality prevalence data on resistance to the anti-TB drugs 
in South Africa. This is unfortunate, as surveillance of drug resistance is vitally 
important for purposes of TB programme evaluation. An increase in drug resistance is 
generally indicative of poor programme management - irrespective of whether the 
resistance noted is initial drug resistance or acquired drug resistance. 
The South African Medical Research Council (MRC) has been monitoring drug 
resistance trends as part of their National TB Research Programme. In a study of 
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newly admitted black TB patients in South African hospitals , Weyer and Kleeberg 
(1992) from the MRC demonstrated a marked decrease in primary and acquired ?rug 
resistance over the period 1965 to 1988. The drugs tested were INH, streptomycin, 
RFA, ethionamide and ethambutol. The authors noted that the prevalence of MDR-TB 
was below 2% in 1988. 
At a sentinel surveillance site at Hlabisa Health Ward, in rural KwaZulu-Natal, using a 
careful study design to eliminate bias , only 1 case (0.3%) of MDR-TB in 335 . 
consecutive incident cases of pulmonary TB was noted during 1994 (Wilkinson et al. 
1996c) . The results from this site are probably reflective of its good programme 
management that includes directly observed ther~py (DOT) (Wilkinson et al. 1996a) . 
A report by Weyer et al (1995) noted that MDR-TB was between 1.1 and 4% (primary 
and acquired drug resistance respectively) in the Western Cape during 1994. This is 
the province with the highest prevalence of TB in South Africa. 
MECHANISMS FOR DRUG-RESISTANT TB 
Drug resistance in Mycobacterium tuberculosis occurs by random, one step 
spontaneous mutations at the gene loci of the chromosomes, at a low but predictable 
frequency. Clinically, drug-resistant TB arises slowly, usually as a result of selection 
pressure exerted by inadequate therapy. Fortunately resistance to one drug is not 
associated or linked with another unrelated drug. However, cross-resistance among 
members of a similar class, such as rifamycins and fluoroquinolones does occur. 
The mutations may affect one or more genes responsible for drug action. This may 
manifest as increased synthesis of a target enzyme for drug action thus rendering the 
drug less effective to inhibit growth of the microorganism. Alternately, they may alter a 
primary drug target or the drug's transport system into the microorganism (Rastogi 
and David, 1993). 
The probability of drug-resistant mutants is depicted by the formula P=1-(1-r)n, where 
P is the probability of drug-resistant cases, r is the probability of drug-resistant 
mutants, and n is the number of bacilli in the lesion. The value of r for RFA is 10-8, that 
for INH, streptomycin , ethambutol, kanamycin and para-aminosalicylic acid is of the 
order of 10-6 , and that for ethionamide, capreomycin, cycloserine and thiacetazone is 
10-3. When 2 drugs are used in combination , the value of r becomes the product of the 
individual r's e.g. the probability of initial combined resistance to INH and RFA is 10-8 X 
10-6 = 10-14. When 3 drugs are used as the combination regimen, the value of r 
becomes very low indeed (10-18 to 10-2°) - emphasising the potential role of 
combination chemotherapy in reducing the probability of drug resistance in TB 
chemotherapy. 
The role of the number of bacilli (n) in the lesion also influences the probability of 
drug-resistance as shown in the formula . Cavitary lesions usually contain from 108 to 
10
9 
organisms. This is thus the potential location at which maximal drug resistance 
can occur. 





Initial resistance is defined as the presence of drug resistance to 1 or more drugs in a 
new patient with TB presenting for treatment. This category includes patients wit~ 
primary resistance, as well as those with undisclosed acquired resistance, who eIther 
cannot recall or who conceal prior therapy. 
Primary resistance is defined as resistance to anti-TB drugs in a patient who has 
never received chemotherapy. It can be caused by infection with drug-resistant 
organisms from another patient with acquired drug-resistance, or because of infection 
with naturally resistant wild strains. Due to the difficulty in differentiating between 
primary resistance from undisclosed acquired resistance, the term initial resistance is 
preferred. 
Acquired resistance is defined as resistance to anti-TB drugs that arises as a result of 
poor adherence to the recommended regimen or poor prescribing. 
FACTORS FAVOURING THE EMERGENCE OF DRUG-RESISTANT TB 
Poor patient adherence is widely reported to be a major cause of drug-resistant TB. 
Other causes include inadequate therapy, in particular monotherapy, addition of a 
single drug to a failing regimen , an insufficient number of active drugs in the regimen , 
erratic drug taking, sub-optimal drug dosages and poor absorption (Frieden et a/. 
1993; Iseman, 1993; Yew and Chau, 1995). 
In developing countries, socio-economic factors such as poor nutrition, poverty, 
unemployment, overcrowding , illiteracy, social stigmatization and minimal access to 
medical care are all contributory factors to failure of effective treatment (Sumartojo, 
1993). These will predispose to drug resistance. 
Further problems peculiar to many developing countries are issues related to drug 
acquisition, distribution and supply. Concerns have also been expressed about the 
production and marketing of sub-standard formulations with poor bioavailability of the 
component ingredients (Gangadharam, 1993; Yew and Chau, 1995). 
Epidemiological studies have identified several factors that favour the emergence of 
drug resistance in general. They include a history of previous anti-TB drug therapy, 
patient non-adherence with therapy, sub-optimal treatment regimens, overall poor 
response to therapy in MDR-TB, prolonged infectiousness, severe 
immunosuppression, inadequate infection control measures, and susceptible contacts 
in close proximity to increased numbers of TB patients (Iseman, 1993; Davidson, 
1987; Yew and Chau, 1995). 
The concurrent increase in both HIV infection and drug-resistant TB and the 
occurrence of MDR-TB in patients with HIV infection in the USA suggests that HIV 
may favour the emergence of drug resistance. There are several reasons for the 
association apart from HIV infection per se. Many of the outbreaks occurred- in 
settings where HIV+ patients received care. It is now well described that HIV+ patients 
who are exposed to TB (drug-sensitive or drug-resistant) are much more likely to 
develop active TB rapidly compared to those who are HIV- (Daley et a/. 1992; Zeind 
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et al. 1996). The HIV+ patients are likely to have higher mycobacterial loads and thus 
have a higher probability of harbouring more drug-resistant mutants. 
Pharmacotherapy of Tuberculosis with particular emphasis on the 
Pharmacology and Pharmacokinetics of INH and RFA 
RATIONALE FOR THE PHARMACOTHERAPY OF TUBERCULOSIS 
In considering the susceptibility of M tuberculosis to antimicrobial agents and the 
development of rational drug therapy, it is important to appreciate the physicochemical 
properties of the tissues in which the bacilli reside and their metabolic activity. These 
are embodied in Mitchison's separate populations hypothesis which proposes the 
following theoretical model for:rB infection (Mitch is on, 1992). 
M tuberculosis grows very rapidly and the bacilli load is high in the cavitary lesions, 
where growth conditions are favourable because of high oxygen content and a neutral 
pH. This subpopulation is particularly vulnerable to INH and to a lesser degree to 
RFA, streptomycin and ethambutol. 
A second slow-growing subpopulation exists in an acidic environment located mainly 
intracellularly. Pyrazinamide is particularly active in an acidic medium (pH 5.3 to 5.5) 
and thus is very effective in killing thissubpopulation. The other drugs in the regimen 
INH, RFA and ethambutol are less active against these organisms. The extended 
action of pyrazinamide is explained by theorising that the acidic environment 
favourable to its action. also exists extracellularly where there is an inflammatory 
response. 
The third subpopulation is located mainly in caseous material where the pH is neutral 
but the oxygenation is poor, and these organisms grow very slowly with occasional 
spurts of active growth. They are killed most efficiently by RFA due to the rapidity with 
which its bactericial action commences. 
The fourth subpopulation is completely dormant and anti-TB drugs have no activity 
against this subpopulation. 
On the basis of animal experiments and clinical trials, the anti-TB drugs may be 
classified into 3 categories (Mitch is on, 1985): 
Qrugs with Resistance Prevention Activity 
These agents, when combined with others, can prevent the emergence of resistant 
mutants to the companion drug. In this category, INH and RFA are the most effective, 
followed closely by ethambutol and streptomycin. Pyrazinamide and thiacetazone are 
less effective in preventing the emergence of resistance. 
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Drugs with Early Bactericidal Activity 
These agents induce a rapid decrease in the number of living bacilli in the sputum at 
the beginning of treatment. They rapidly reduce the bacillary load in the patient and 
quickly convert the sputum cultures to negative, thus reducing the risk of transmission . 
INH is the most effective drug in this category, followed by ethambutol and RFA. 
Drugs with Sterilising Activity 
These drugs have the ability to kill all the tubercle bacilli in the lesions of experimental 
TB in animals and probably also in human disease. They reduce the relapse rate to a 
minimum within a short period. RFA and pyrazinamide have the greatest sterilising 
activity; INH is weaker; streptomycin, ethambutol , and thiacetazone have little activity. 
Thus the best anti-TB drug regimen is one that combines drugs that are effective 
against all the identified subpopulations and have properties of early bactericidal 
activity, prevention of resistance and sterilising acitvity. 
The crucial role played by INH and RFA in anti-TB drug regimens is clearly evident. 
Most short course chemotherapy regimens included these 2 drugs with streptomycin 
or ethambutol and pyrazinamide included at least for the first 2 months (Davidson and 
Le, 1992). More recently, due to its side effects and the inconvenience of parenteral 
therapy, streptomycin has been largely removed from the regimen. Further, it has 
been recommended that ethambutol be used only in areas with a high prevalence of 
INH resistance. 
PHARMACOLOGY AND PHARMACOKINETICS OF RIFAMPICIN 
Rifampicin (rifampin) is a brick red crystalline powder that is a synthetic derivative of a 
natural antibiotic rifamycin B produced by Streptomyces mediterranei. Its activity 
against mycobacteria is characterised by a high sterilising activity and an ability to 
eliminate semi-dormant or persisting organisms (Reynolds, 1993). When included in 
multi-drug combination regimens, RFA has the ability to prevent the emergence of 
resistance to its companion drugs (Mitchison, 1985). 
Microbial Spectrum of Activity 
RFA owes its antimicrobial action to interference with the synthesis of nucleic acids by 
inhibiting DNA-dependent RNA polymerase. Its selective toxicity is due to its ability to 
inhibit the enzyme at relatively low concentrations in relation to the concentration 
required to inhibit mammalian RNA synthesis (Mandell and Petri, 1996). 
RFA inhibits the growth of a wide range of gram positive bacteria especially 
Staphylococci but is less active against gram negative organisms. The sensitive gram 
negative organisms include Neisseria meningitidis and N gonorrhoea and Legionella 
spp. It also has activity against Chlamydia trachomatis and some anaerobic bacteria 
(Reynolds, 1993). At high concentrations (500 to 1000 X that against bacteria), RFA 
has activity against viruses such as herpes, adenovirus and pox virus (Mandell and 
Petri, 1996). Although it has no activity against fungi, it does enhance the action of 




RFA also has activity against atypical mycobacteria such as M kansasii, M 
scrofulaceum and M intracel/ulare. The MIC for susceptibile mycobacteria ranges from 
0.1 to 2 J..Lg/ml while that for other organisms (Chlamydia and StaphylococcI) is lower 
at 0.01 to 0.02 /lg/ml (Dol/ery, 1991b; Reynolds, 1993) . 
Resistance to RFA occurs rapidly if the drug is used alone due to the occurrence of 




. Thus in 
TB and leprosy regimens, RFA is always used in combination with other drugs to 
delay or prevent the emergence of drug resistance (Reynolds, 1993). 
Pharmacokinetics 
Table 2.1 is a summary of the pharmacokinetic parameters for RFA reported in the 
literature. The data presented is illustrative rather than exhaustive e.g. data from the 
excellent review by Kenny and Strates (1981) is not included in the table. This was 
because the authors of that review recalculated many of the parameters. This. could 
have introduced a source of error as the present review also involved calculation of 
CL using data from the references cited. 
Absorption 
RFA is well absorbed from the GIT with peak plasma concentrations of 7 to 9 /lg/ml 
being achieved 1 to 4 hours after a dose of 600 mg. There is however, considerable 
interindividual variation in absorption characteristics (Reynolds, 1993; Kenny and 
Strates, 1981; Gelman and Rumack, 1998). 
Food may delay the rate of RFA absorption. Although some have suggested that the 
extent of absorption may also be affected, all researchers have not consistently 
observed this (Kenny and Strates, 1981). Gastric pH is also of importance and 
acidification of the gastric juice increases solubility and hence absorption and serum 
concentrations while alkalinity has the opposite effect (Kenny and Strates, 1981). 
The bioavailability of RFA has been reported to be 90 to 95% (Gelman and Rumack, 
1998). The serum concentrations of RFA are influenced not only by GIT absorption 
but also by the rate of biliary and renal excretion (Kenny and Strates, 1981). There is 
no appreciable first pass effect following a first dose but this might occur after 
repeated doses as a consequence of hepatic enzyme induction. 
Distribution 
RFA is highly lipid soluble and at physiological pH, only about 25% of the drug is 
ionised. It thus undergoes rapid tissue distribution into most organs, tissues, bone and 
body fluids including exudates into tuberculous lung cavities. High concentrations 
appear in the lachrymal glands and tears where a reddish colour is often noted. 
Cerebrospinal fluid concentrations are approximately 10 to 20% of serum 
concentrations but may be increased when the meninges are inflamed (Kenny and 
Strafes, 1981; Gelman and Rumack, 1998). There is evidence to suggest that RFA 
may cross the placenta. Foetal levels approximately 33% that of the mother have 
been noted (Kenny and Strafes, 1981) and RFA may also appear in the breast milk. 
Plasma protein binding has been estimated at 60-80% with approximately 30 to 41 % 
of that being bound to albumin (Kenny and Strates, 1981). The volume of distribution 
is approximately 0.9 Ukg (Gelman and Rumack, 1998) to 1 Ukg (Dol/ery, 1991b). 
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Table 2.1 - Pharmacokinetic parameters for rifampicin reported in the literature 
Description n Dose/Study tmax Cmax V AUC CL t% Reference 
Day (hours) (Jlg/ml) (Ukg) Jlg.hr/ml (Uhr) (hours) 
Crossover bioavailability study in 10 600mg 2.1 - 2.3 10.6 - 11.6 72.6 - 76.7 7.8-8.3 1.7 - 2.3 (Acocella et al. 1988a) 
healthy volunteers. Free versus fixed 
dose triple drug combination 
formulation. 1 week washout period. 
Other drugs studied were INH and 
PZA. Study was conducted on Day 1 of 
drug administration i.e. pre-enzyme 
auto-induction. 
Review of the literature 600mg 2-4 7 - 10 1 1 - 6 (Oollery, 1991b) 
Day 1 131.4 4.6 3.4 
Day 2 84.6 7.1 2.9 
Day 6 100.5 6.0 2.5 
Day 14 87.7 6.8 2.1 
Review of the literature 600mg 2-4 (Reynolds, 1993) I 7-9 . 
Day 1 2-5 
Post induction 2-3 
Review of the literature 600mg 1 - 4 8 - 9 0.9 (Gelman and Rumack, 1998) 
Day 1 1.5 - 5 
Post induction 2-3 
Prospective study in pulmonary TB 13 11 .5 mg/kg (Acocella et al. 1988b) 
patients (mean mass 58; range 45 - Day 1 2.6 9.9 71 .0 9.4 3.6 
87kg). Bioavailability of a fixed dose Day 15 2.8 10.2 49.7 13.4 1.4 
triple drug combination formulation Day 30 2.6 8.6 44.6 15.0 1.9 
determined periodically over a 60 day Day 60 2.2 9.5 47.9 13.9 2.0 
, period. Other drugs studied were INH 
i and PZA. 
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Table 2.1 - Pharmacokinetic parameters for rifampicin reported in the literature (continued) 
Description n Dose/Study tmax Cmax V AUC CL" t% Reference 
Day (hours) (Ilg/ml) (Ukg) Ilg.hr/ml (Uhr) (hours) 
Prospective study in pulmonary TB 8 600mg daily ~4 ±8 45.5 - 51.4 11 .7-13.2 ± 3 (Ellard et al. 1986) 
patients. 43 - 60kg. Crossover 8 600mg 56.7 -68.6 8.8 -10.6 
bioavailability study of free and fixed 3xweekly 
dose triple drug combination 
formulation. 2 study centres one using 
daily treatment and 1 using 3 x a week 
(intermittent) treatment. Other drugs 
studied were INH and pyrazinamide. 
Treated for ~14 days prior to the study. 
Healthy volunteers (mean mass 73 kg; 12 8.8 mg/kg 1.7 - 3.2 6.3 - 11 .8 36 - 70.2 9.2 -17.8 2.5 - 4.7 (Acocella et al. 1985) 
range 62 - 100 kg). Subgroups of 
subjects received RFA alone, and in 
free and fixed form with INH, PZA. 
Latter 2 preparations given in crossover 
design with a 1 week washout period. 
Various groups analysed separately. 
Other drugs studied were INH, 
pyrazinamide and streptomycin. RFA 
auto-induction not mentioned. 
Calculated from data in the cited literature using CL = Dose/AUC 
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Metabolism 
RFA is metabolised in the liver to desacetylrifampicin, a more polar compound that is 
more amenable to biliary secretion . The other important metabolite is 3-formyl 
rifampicin , which is formed by hydrolysis and is excreted in the urine. There are 
suggestions that the excretory capacity of the liver may be subject to saturation since 
increasing the dose above 450 mg does not increase the bile concentrations of the 
drug (Kenny and Strates, 1981; Dol/ery, 1991b). 
After RFA and its main metabolite desacetylrifampicin are excreted in the bile, RFA is 
reabsorbed into the blood while the metabolite is not i.e. RFA undergoes 
enterohepatic recycling (Kenny and Strates, 1981; Reynolds, 1993). The quantity of 
RFA secreted into the bile is significant with 44-54, 60 and 84 mg being obtained 12-
16 hours after oral administration of 150, 300 and 600 mg of RFA respectively (Kenny 
and Strates, 1981). 
After first administration of an 9ral dose, serum concentrations are similar to that after 
IV administration suggesting little first-pass metabolism. However, repeated 
administration induces the enzymes of the endoplasmic reticulum with resultant 
increase in the metabolism of both RFA (auto-induction) as well as other drugs 
undergoing hepatic biotransformation. In published reports of RFA auto-induction , this 
effect manifested as a decrease in serum concentrations, AUC and half-life with 
repeated administration (Kenny and Strates, 1981) . 
Self-induction of RFA metabolism during daily and intermittent chemotherapy was 
studied by monitoring the changes in the serum half-life of the drug over a 4-week 
period in patients with pulmonary TB. RFA 450 mg was administered to 8 patients 
who received treatment daily, 7 on thrice weekly and 7 others on twice-weekly 
treatment. Serum half-,I ife was computed from concentrations of the drug determined 
at 3, 4.5 and 6 hours after drug administration, on admission and at 1, 2 and 4 weeks 
after start of treatment. In the daily series, the mean serum half-life decreased from 
4.9 hours on admission to 3.6 hours at 1 week and treatment beyond this had no 
further effect. In the thrice-weekly series, maximal induction was observed at the 2nd 
week, the mean values on admission and at 2 weeks being 5.8 and 3.7 hours, 
respectively. In the twice-weekly series, maximal induction was observed only at the 
4th week, the mean values on admission and at 4 weeks being 4.9 and 3.7 hours, 
respectively (Immanuel et al. 1989). The results of other studies examining RFA auto-
induction are shown in Table 2.1. 
The increased clearance of RFA noted upon repeated administration returns to the 
un-induced values as early 1 week after termination of drug therapy (Kenny and 
Strates 1981; Zeind et a11996) 
Excretion 
The principal excretion pathway for RFA is via the bile where the drug undergoes 
enterohepatic recycling until eventual excretion into the faeces. The kidney is a 
secondary excretion pathway and the urine appears orange to brick red in colour in 
the presence of RFA. This provides a useful indicator of patient adherence to therapy. 
When the biliary excretion pathway is saturated (e.g. with doses in excess of 450mg), 
the urinary concentrations may increase. However, while dose modification may be 
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necessary in patients with impaired hepatic function or impaired biliary excretion , it is 
not usually necessary in patients with impaired renal function (Dol/ery, 1991 b). 
Clinical Uses 
RFA has good activity against a wide range of pathogens, and has demonstrated 
success in infections due to these organisms. However, in order to preserve a 
valuable drug for mycobacterial infections, and delay the emergence of drug 
resistance, RFA is largely reserved for use in a few specific indications viz. 
1. Mycobacterium tuberculosis infections at all sites. 
2. Prophylaxis against meningococcal meningitis. 
3. Opportunistic mycobacterial infections. 
4. Leprosy 
S. Prophylaxis in tuberculin positive children. 
Use in TB 
RFA forms part of the standard short course chemotherapy for the treatment of drug-
sensitive TB. It is used in a daily dose of 4S0mg (patients < SOkg) or 600mg (patients 
~ SOkg) for the first 2 months (intensive phase) in combination with INH, pyrazinamide 
and ethambutol followed by a further 4 months (continuation phase) in combination 
with INH. In the continuation phase, some countries use a regimen that involves larger 
doses of RFA administered on an intermittent schedule as opposed to daily 
administration. In children, a dose of 10 mg/kg is administered (Dol/ery, 1991b). 
Precautions and Contra-indications 
RFA should be used with caution in liver function impairment. While some authorities 
contraindicate its use in patients with jaundice, others advise cautious use with 
monitoring of liver function (Dol/ery, 1991 b) . 
RFA affects haem and bilirubin metabolism in man. Serum unconjugated bilirubin 
concentration may increase together with other liver enzymes such as a transient 
moderate elevation in alkaline phosphatase during the first 24 hours of treatment. 
Unless they continue to rise thereafter or there are other signs of liver function 
impairment, they are not an indication to discontinue treatment (Mandel/ and Petri, 
1996). 
Thrombocytopaenia, purpura, haemolytic anaemia and renal failure are indications for 
withdrawal of treatment. 
RFA may colour the faeces, saliva, sputum, sweat, tears, urine and other body fluids 
orange red. This coloration of body fluids may cause alarm if unexpected. Contact 
lens users may note permanent discoloration of their soft contact lenses (Mandel/ and 
Petri, 1996). 
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Adverse Reactions 
RFA is generally well tolerated . Side-effects are seen more often during intermittent 
therapy or when restarting interrupted therapy. They are usually due to sensitisation 
or enzyme inducer effects and consequent drug interactions. 
A cutaneous syndrome which presents 2-3 hours after daily treatment manifests as 
facial flushing, itching, rash or rarely eye irritation. A "flu-like syndrome" with fever, 
chills , headache and malaise is well described after intermittent RFA treatment. 
Hypersensitivity and sensitisation as well as a shock-like syndrome, and acute renal 
failure have been described. 
More serious side-effects necessitating drug withdrawal include effects on the blood 
such as thrombocytopaenia and purpura and are seen especially with intermittent 
regimens. There may also be leucopaenia and haemolytic anaemia. 
Hepatitis occurs rarely but may be aggravated by concomitant drugs or the presence 
of pre-exisiting liver disorders. An increased risk of venous thrombosis has been 
reported . 
Less severe but of irritation to the patient are the GIT adverse reactions which include 
anorexia, nausea, abdominal discomfort, diarrhoea and vomiting (Dol/ery, 1991b; 
Mandel/ and Petri, 1996). 
Drug Interactions 
RFA is well known for its ability to cause induction of the cytochrome P450 mixed 
function oxidase system - more specifically the cytochrome P4501llA system (Dol/ery, 
1991b). Consequently a wide range of drugs have been reported to interact with RFA. 
Table 2.2 is a selected summary of these interactions. When RFA treatment is 
removed, the enzyme induction effect slowly returns to normal after 1 to 2 weeks 
(Zeind et a/. 1996) or up to 30 days (Kenny and Strates, 1981). 
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Table 2.2 - Summary" of some selected clinically important drug interactions 
involving rifampicin and suggestions for their therapeutic management 
Agent Mechanism/Effect Management 
Antacids Increased pH reduces dissolution of Administer at least 2 hours apart. 
RFA and hence absorption . Also 
adsorption effect due to chelation with 
aluminium and magnesium ions. 
Anticoagulants Enzyme induction. Decreased Increase anticoagulant dose based on 
e.g. warfarin hypoprothrombinaemic effect. monitoring of prothrombin time. 
Beta-Blockers Enzyme induction . AUC of metoprolol Monitor therapeutic response and 
e.g. propranolol increased; CL of propranolol increase dose if necessary. 
. and metoprolol increased . . 
Contraceptives, Enzyme induction. Increased Use an alternate non hormonal form of 
oral metabolism of both the oestrogenic contraception. 
and the progesteronogenic 
components. Breakthrough bleeding 
and pregancies have been reported. 
Cyclosporine Enzyme induction. Low concentrations Monitor serum cyclosporine 
of cyclosporin with rejection of concentrations. Increased dose or 
allografts reported. frequency of dosing . Consider use of 
an alternative to RF A. 
Digoxin More likely to be significant in patients Monitor serum digoxin concentrations. 
with decreased renal function since Monitor for arrhytnmia control and 
digoxin is primarily eliminated by the signs and symptoms of heart failure . 
kidneys. 
Glucocorticoids Enzyme induction. Acute adrenal crisis Increase glucocorticoid dosage twofold 
e.g . prednisolone and adrenal insufficiency has been to threefold. 
reported in patients with Addison's 
disease given both drugs. 
Antifungals e.g. Enzyme induction and/or decreased Avoid this combination if possible. 
ketoconazole and ketoconazole absorption . Reduction in Some suggest that RFA and 
fluconazole RFA concentrations has also been ketoconazole doses be spaced 12 
reported . Some suggest that there hours apart. Monitor clinical response 
may be less of an effect on to ketoconazole , and increase dose if 
fluconazole. necessary 
Phenytoin Enzyme induction. Monitor phenytoin serum levels upon 
starting and stopping RFA treatment. 
Adjust dose if necessary. 
Hypoglycaemic Enzyme induction . Monitor blood glucose control on 
agents e.g. starting and stopping RFA . Adjust 
tolbutamide and dose of hypoglycaemic agent while 
other monitoring blood glucose 
sulphonylureas. concentrations. 
Theophylline Enzyme induction. Decreased efficacy Monitor serum theophylline levels on 
on starting RFA and toxic reactions on starting or stopping therapy. 
stopping RFA are possible. 
Verapamil Enzyme induction. Use of an alternative agent is 
recommended. If utilized, monitor 
patient for clinical response to 
Diltiazem Enzyme induction. 
verapamil. 
Alternative agent recommended 
because even a very large increase in 
oral diltiazem dose may not be 
sufficient (similar interaction with 
Diazepam 
verapamil). 
300% increase in diazepam oral Monitor clinical response. Increase 
clearance has been reported diazepam dose if necess~. 
Compiled from various reviews Including (Venkatesan, 1992; Zemd et al. 1996; Borcherding et al. 1992; Stockley, 
1996; Gelman and Rumack, 1998; Mandell and Petri, 1996). 
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PHARMACOLOGY AND PHARMACOKINETICS OF ISONIAZID 
INH is a white, odourless powder that is prepared by chemical synthesis. It is rapidly 
bactericidal to actively dividing Mycobacterium tuberculosis but only bacteriostatic to 
semi-dormant organisms (Reynolds, 1993). The drug has high activity in preventing 
the emergence of resistance against companion drugs in a regimen, as well as havin·g 
good early bactericidal activity. It is however less active than RFA and pyrazinamide 
as a sterilising agent (Mitchison, 1985). 
Microbial Spectrum of Activity 
Although the exact mechanism of action is unknown, INH appears to inhibit the 
biosynthesis of mycolic acids, which are important and unique constituents of the 
mycobacterial cell wall . INH may also have effects on nucleic acid biosynthesis and 
glycolysis. INH has specific activity against mycobacteria with minimal effects on other 
bacteria or any pharmacological effects in man. It may have some activity against 
other mycobacteria e.g. M kansasii. Its greatest bactericidal effect is on actively 
dividing bacilli, the effect on semi-dormant organisms being only bacteriostatic 
(Mandell and Petri, 1996). 
The MIC for M tuberculosis is 0.02 to 0.2 ~g/ml (Reynolds, 1993). 
Resistance to INH develops rapidly if used alone in active cl inical disease. This does 
not appear to be a problem when used in prophylaxis where the organism load is low. 
In any bacterial population in vivo, naturally occurring resistant mutants exist with a 
probability of 1 in 106 organisms (Dollery, 1991b; Mandell and Petri, 1996). 
Pharmacokinetics 
Table 2.3 records a summary of the pharmacokinetic parameters for INH reported in 
the literature. The list is illustrative rather than exhaustive - the intention is to provide 
an idea of the range in values reported. Several studies were excluded as the assay 
methodology used could have resulted in drug breakdown prior to assay. This is 
illustrated by the results of the study by Ellard et al1986 (Table 2.3) in which 
relatively low AUC values are reported . These authors stored their sample at -20°C 
for an undisclosed period of time prior to analysis. Our own experience (unpublished) 
and that of several other authors (Hutchings et al. 1983; Weber et al. 1983) is that 
storage at this temperature results in significant and rapid drug breakdown. 
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Table 2.3 - Pharmacokinetic parameters of isoniazid reported in the literature. 
Description n Dose/Study tmax Cmax V AUC CL t% Acetylator Reference 
Day (hours) (~g/ml) (Ukg) ~g.hr/ml (Uhr) (hours) Status 
Crossover bioavailability 10 250mg 1.1 -1.6 6.6-6.8 30.8 - 33.6 7.4 - 8.2 7.2 - 8.4 Not (Acocella et 
study in healthy volunteers. determined al. 1988a) 
Free versus fixed dose triple 
drug combination 
formulation. 1 week washout 
period. Other drugs studied 
were RFA and 
pyrazinamide. Study was 
conducted on Day 1 of drug 
administration. 
Review of the literature 300mg 1-2 3-7 0.6-0.8 0.5-2 Rapid (Oollery, 
2-6.5 Slow 1991a) 
Review of the literature 300mg 1-2 3-8 1 - 4 (Reynolds, 
1993) 
Review of the literature 5 mglkg 1-2 1-5 0.6 - 0.75 0.75 -1.8 Rapid (Gelman and 
2.3-3.5 Slow Rumack, 
1998) 
Prospective study in 13 4 .8 mg/kg Not (Acocella et 
pulmonary TB patients Day 1 1.5 8.0 34.7 8.0 2.5 determined al. 1988b) 
(mean mass 58; range 45 - Day 15 2.1 7.6 33.5 8.3 2.5 
87 kg). Bioavailability of a Day 30 1.9 7.1 30.6 9.1 2.3 
combination triple drug fixed Day 60 1.5 7.6 34.2 8.1 2.5 
dose formulation determined 
periodically over a 60 day 
period. Other drugs studied 
were RFA and 
pyrazinamide. 
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Table 2.3 - Pharmacokinetic parameters of isoniazid reported in the literature (continued). 
Description n Dose/Study tmax Cmax V AUC CL t% Acetylator Reference 
Day (hours) (J.!Q/ml) (Ukg) J.!Q.hr/ml (Uhr) (hours) Status 
Prospective study in 6 250 mg daily <2 2.5 9.1 - 9.2 27.2 - 27.5 2 Fast (Ellard et a/. 
pulmonary TB patients 2 250 mg daily 4.5 16.1-28.2 8.9 -15.5 3 Slow 1986) 
(mean mass 58 kg ; range 43 
- 60 kg). Crossover 7 750 mg 3 x weekly <2 10 33.8 - 34.8 7.2 -7.4 2 Fast 
bioavailability study of free 750 mg 3 x weekly 
and fixed dose triple drug 1 89.4 - 91.4 2."7 - 2.8 Slow 
combination formulation. 2 
study centres one using 
daily treatment and 1 using 3 
x a week (intermittent) , 
treatment. Other drugs i 
studies were RFA and 
pyrazinamide. 
Healthy volunteers (mean 12 5.3 mg/kg 1.5 -2.2 6.4 - 9.2 34.2 .. 49.7 7.8 - 11 .3 3.4 -4.2 2 Fast Acocella 
mass 73 kg; range 62 - 100 acetylators 1985 
kg). Subgroups of subjects but combined 
received INH alone, and in in the 
free and fixed form with RFA analysis 
and pyrazinamide. Latter 2 
preparations given in 
crossover design with a 1 
week washout period. 
Various groups analysed 
separately. Other drugs 
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Absorption 
After oral administration , INH is rapidly and completely absorbed from the 
gastrointestinal tract. Peak plasma levels of 3 - 8 IJ.g/ml occurs within 1-2 hours after 
oral administration of normal therapeutic doses to adults (Table 2.3). Food interferes 
with the rate of oral absorption (Dol/ery, 1991a; Zent and Smith, 1995). High 
carbohydate meals and various antacids reduce bioavailability. There is evidence of 
appreciable presystemic metabolism i.e. gut wall and liver (first-pass) metabolism. 
This may result in plasma concentrations in fast acetylators that are half those of slow 
acetylators after normal (300mg) doses (Dol/ery, 1991a). 
Distribution 
INH is distributed in total body water with an apparent volume of distribution of 61 % ± 
11 % of body weight. The volume of distribution is unrelated to acetylator status. 
INH has been detected in CSF, pleural effusions, faeces, saliva, placenta, breast milk, 
peripheral nerves and red blood cells in humans. High concentrations of the drug 
have been found in lung and skin which suggests that these organs may serve as 
storage sites. Binding of INH to plasma proteins is between 4 to 30% (Gelman and 
Rumack, 1998). 
Metabolism 
INH is extensively metabolised in the gut wall and the liver to metabolites devoid of 
anti-TB activity. Metabolism via the hepatic cytochrome P450 mixed function oxidase 
system accounts for 70 to 90% of the elimination of INH. Several metabolic pathways 
are involved. N-acetylation to acetyl isoniazid is the most important and the main 
determinant of the individual genetic differences in drug disposition. After ingestion, 
the urine contains INH, pyruvic acid hydrazone, a-ketoglutaric acid hydrazone, 
acetyl isoniazid, isonicotinic acid, isonicotinyl glycine, monoacetylhydrazine and 
diacetylhydrazine (Dol/ery, 1991 a) . 
Individuals are categorized as either fast or slow acetylators, depending on the rate of 
acetylation of INH in the liver. Approximately 50 to 60% of the South Indian, European 
or American negro populations are classified as slow acetylators. Inuit (Eskimos) and 
Orientals (Chinese and Japanese) are primarily fast acetylators (EI/ard, 1984). In 
South Africa, Bach et al (1976) found that 59% of Black South African patients were 
fast acetylators while Buchanan et al (1976) noted that 73% were fast acetylators. 
More recently, Parkin et al (1997) studied the phenotype and genotype of INH 
acetylation and noted that a larger proportion of South African patients were fast 
acetylators. 
The elimination of INH depends on acetylator phenotype with half-lives of 
approximately 0.5 to 2 hours being observed in the fast acetylators and 2 to 6.5 hours 
in slow acetylators (Table 2.3). Patients who are slow acetylators may be more 
susceptible to the side effects related to higher concentrations, such as peripheral 
neuropathy. On the other hand it has been postulated that hepatoxicity may be more 
common in fast acetylators, owing to the production of larger amounts of the 
metabolite acetylhydrazine which is thought to be involved in the development of this 
side-effect. However EI/ard (1984) evaluated the literature and concluded that 
clinically important hepatic toxicity is unrelated to acetylator status. 
The use of INH in daily and 2-3 times weekly regimens in fast acetylators are not 
associated with any negative effect on clinical efficacy (Reynolds, 1993). However, 
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once weekly regimens in fast acetylators have an unacceptable failure rate (Dol/ery, 
1991a). Thus it appears as though the rate of acetylation is of limited clinical 
signific9nce with the current mode of use of INH. 
While most authorities report INH metabolism as being either fast or slow, evidence 
from genotyping studies now indicate that there may be a trimodal distribution in INH 
metabolism (Parkin et al. 1997). 
Excretion 
Only a small amount of INH is eliminated unchanged by the kidneys. Therefore, 
dosage adjustments in patients with renal dysfunction are necessary only for 
individuals who are slow acetylators with a creatinine clearance less than 10 ml/min 
(Zeind et a/. 1996). Small quantities are also found in the faeces. The major portion of 
the drug appears in the urine as metabolites. INH is removed by dialysis (Reynolds, 
1993). 
Use in TB 
The almost sole indication for INH is in the prophylaxis and treatment of all forms of 
T8. As a prophylactic agent, doses of 4 - 8 mg/kg for 6 - 12 months have been used 
in high risk populations (Reynolds, 1993). 
In the treatment of T8, the vital role of INH in combination with RFA has been 
highlighted above. In the initial 2 month intensive phase of treatment, a dose of 5 
mg/kg is recommended (Reynolds, 1993), although in practice a standard dose of 300 
mg is used for patients less than 50 kg and 400 mg for those greater than 50 kg . In 
the continuation phase, the same dose is administered 2 - 3 times a week. 
Drug Interactions 
Several drug interactions have been reported with the use of INH in combination with 
other agents. INH is an inhibitor of cytochrome P-450-dependent microsomal 
pathways and may thus interact with other drugs that use this same metabolic 
pathway. These drug interactions usually result in increased concentrations of the 
drug whose metabolism is inhibited. The clinical effect of the interactions may be 
related to acetylator phenotype. A summary of some selected drug interactions is 
presented in Table 2.4. 
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Table 2.4 - Summary' of Some Selected Clinically Important Drug Interactions 
Involving Isoniazid 
Drug MechanismlEffect ManaQement 
Phenytoin Enzyme inhibition . Phenyytoin Monitor serum phenytoin levels. May 
concentrations t. Occurs mainly in need to decrease phenytoin dose. 
slow acetylators of INH. If RFA is 
given concurrently, phenytoin levels .!, 
i.e. induction effect outweighs INH's 
inhibitory effect. 
Carbamazepine Enzyme inhibition . Carbamazepine 
concentrations t. There may also be 
Monitor serum carbamazepine levels. 
May need to decrease dose 
an t in metabolism of INH to a . 
hepatotoxic metabolite. 
Ketoconazole Effect noted when INH was given with Monitor clinical response to the 
RFA. Reduced concentrations of ketoconazole. 
ketoconazole noted but INH 
concentrations may also be reduced. 
Antacids (aluminium Adsorption effect. May delay and Administer at least 2 hours apart. 
hydroxide) decrease absorption of INH. Monitor INH . 
Anticoagulants Reported only at a dose of 9 May need to decrease anticoagulant 
mg/kg/day. dose. 
Vitamin D Enzyme inhibition Monitor vitamin D levels as well as 
calcium phosphate levels in selected 
patients 
Benzodiazepines RFA's effect if given concomitantly May need to decrease dose of 
should also be considered. selected benzodiazepines. 
Ethionamide INH concentrations temporarily Monitor patients for signs of INH 
raised. Mechanism unknown. toxicity e.g. peripheral neuritis. 
Prednisolone INH metabolism is increased. INH Monitor patient for efficacy of INH and 
concentrations may be decreased by adjust INH dose as required . 
25% in slow acetylators and 40% in 
fast acetylators. 
Theophylline Potential decrease in theophylline Monitor serum theophylline 
clearance appears to occur at INH concentrations and adjust dose as 
doses greater than 300mg daily. If required. 
RFA is given concurrently, 
theophylline serum concentrations 
decrease (ie. induction effect 
outweighs INH's inhibitory effect) 
Compiled from various reviews mcludmg (Stockley, 1996; Zeind et a/. 1996; Gelman and Rumack, 1998; 
Reynolds, 1993) 
Adverse Reactions 
INH is generally well tolerated at the recommended doses. 
Peripheral neuropathy appears to be a dose-dependent adverse effect of INH that is 
reported by patients. It is uncommon at a dose of 5 mg/kg, occurring in 2% of patients 
receiving INH. At higher dosages, peripheral neuropathy may develop in 10 to 20% of 
the patients. INH-induced depletion of pyridoxine is the most likely cause of peripheral 
neuritis. Pyridoxine (15 to 50 mg/day) should be given with INH to people who have 
conditions in which neuropathy is common (diabetes, uraemia, alcoholism and 
malnutrition). For pregnant women and people who have a seizure disorder, it is also 
recommended that pyridoxine be given with INH. As indicated above, patients who 
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are slow acetylators may be more susceptible to the development of peripheral 
neuropathy. 
Hepatotoxicity associated with the use of INH occurs in approximately 1 to 2% of 
patients. Transient elevations in liver enzyme are often noted during INH treatment. 
However, in the majority of cases, these return to pretreatment values despite 
continuation of INH. In rare cases however, progressive liver dysfunction and severe 
and often fatal hepatitis have occurred. Although the mechanism of hepatitis is 
unknown, it is probably associated with hepatic metabolites. Other confounding 
factors such as age and alcohol use may also be implicated. 
It is recommended that baseline measurement of liver enzymes should be performed 
in patients receiving INH and should be followed up periodically. Patients should be 
questioned monthly for signs and symptoms of liver disease. They should be 
instructed to report to their physician any of the prodromal symptoms of hepatitis (e.g. 
malaise, fatigue, weakness, anorexia, or nausea). Should these symptoms appear or 
if the signs that are suggestive of hepatic damage occur (e.g. liver enlargement with 
tenderness, jaundice, or dark urine), prompt discontinuation of INH is warranted . 
Some clinicians recommend discontinuation of INH if transaminase values exceed five 
times normal when treating TB and three times normal when INH is used as a 
prophylactic agent (Zeind et al. 1996). 
Other rare adverse effects that are reported with INH administration include various 
central nervous system (GNS) toxicities (e.g. hallucinations, convulsions) , 
dermatologic (e.g . acne, allergic rashes) , haematologic (various anaemias including 
aplastic anemia, agranulocytosis, thrombocytopaenia and eosinophilia), and 
gastrointestinal effects. 
Pharmacokinetic and Pharmacodynamic Considerations in the 
Management of Tuberculosis 
The intrinsic in vitro susceptibility of a microorganism to an anti-microbial drug has 
been quantified using various methods that include MIG testing, minimum bactericidal 
concentrations and examinations of the kinetics of killing (time-kill curves) . The MIG 
has however been the most popular and widely used criterion since experience has 
shown a good correlation between susceptibility testing and clinical efficacy. 
In a clinical isolate, the true MIG can fluctuate due to a wide variety of methodological 
and other variables. These variables include changes in media, incubation time, 
temperature or method employed. These need to be standardised during MIG 
determination and considered when interpreting MIG values so as to reduce some of 
this variability. Further, the slow growth of mycobacteria in culture of 4-6 weeks using 
conventional solid media is a very real impediment to the effective use of MIG 
determinations in TB chemotherapy. However, the BAGTEGR radiometric system may 
be useful in providing results more rapidly - within 3 weeks (Yew and Ghau, 1995). 
Pharmacodynamics attempts to relate the drug concentrations achieved in the host to 
the concentrations required to inhibit or kill the microorganism. The most popular 
pharmacodynamic parameters include the Gmax:MIG ratio , the time above the MIG 
30 
Chapter 2 Literature Review 
and the AUC above the MIC. However historically, other parameters have been 
considered. Although theoretically feasible, most of these have the disadvantage of 
lack of prospective evaluation and correlation with clinical evidence of efficacy. 
The inhibitory quotient (Ellner and Neu, 1981) relates the achievable antimicrobial 
concentration at the infection site to the MIC of the infecting organism. This laboratory 
index assumes that a standard dose has been administered to a standard patient and 
makes no provision for altered pharmacokinetics. It derives all its antibiotic 
concentration data from the literature. The inhibitory quotient does not make provision 
for dosage calculations for a patient, since there is no dosage reference point. Further 
disadavantages include the absence of considerations relating to the height of the 
Cmax over the MIC or the duration that in vivo concentrations exceed the MIC. 
The intensity index is the ratio of the average steady-state concentration of the 
antimicrobial agent to the MIC, multiplied by the duration that concentrations exceed 
the MIC in a 72-hour period (Schumacher, 1982). Thus this parameter incorporates 
both the average concentrations above the MIC and the time that concentrations are 
maintained above the MIC. The data for this parameter are obtained from population 
studies describing the median MIC for bacterial species (MICgo values) and average 
steady state drug concentrations in volunteers. While this parameter seems to be 
logical, some unusual predictions were obtained during its application (Schentag et a/. 
1986). Based on intensity index data alone, it was concluded that ampicillin was more 
useful than dicloxacillin for Staphylococcus and gentamicin was more useful than 
tobramycin for general gram negative bacteria including Pseudomonas. Across class 
comparisons yielded even stranger results e.g . oral first-generation cephalosporins 
with long half-lives had greater intensity index values than the aminoglycosides while 
tetracycline was equal to the aminoglycosides and inferior to ampicillin. Thus this 
parameter should be limited to comparisons of organisms with known susceptibility 
exposed to reasonable' concentrations of drug. Like most of the other 
pharmacodynamic parameters, the absence of clinical correlation is a serious 
disadvantage. 
The ratio of the area under the serum concentration versus time curve (AUC) to the 
MIC has been applied to the evaluation of the third generation cephalosporins 
(Schentag et a/. 1986). Population values for bacterial MIC were used and serum 
concentrations from volunteer studies. The advantage of this pharmacodynamic 
parameter is that no peak concentration is required and the time above the MIC is 
included in the drug exposure parameter of AUC. The disadvantage is that the data 
are of clinical use only if the patient in question has an organism with similar 
susceptibility and has a pharmacokinetic profile identical to that of the volunteers used 
in the pharmacokinetic analysis. Some have modified the AUC:MIC parameter by 
c<?nsidering the concentrations of free drug only rather than both free and bound drug. 
This has implications for drugs that are highly protein bound. Although this parameter 
shows clinical promise, it has also not been tested prospectively. 
The serum bactericidal activity (Wolfson and Swartz, 1985) is the only 
pharmacodynamic parameter that has been clinically tested. This method integrates 
serum concentrations in the actual patient with the bacterial susceptibility of that 
patient's pathogen. It involves serum dilutions of the patient's serum against the 
bacterial pathogen. A serum bactericidal activity of 1:8 has been correlated with 
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efficacy in patients with neutropaenia given multiple antibiotic regimens and in those 
with endocarditis. 
The serum bactericidal activity obviates the need to measure the patient's antibiotic 
serum concentration or the bacterial MIC. Both factors are incorporated in the test 
method, even though neither is known exactly. Thus, bacteria of unusual susceptibility 
and patients with unusual pharmacokinetics can be evaluated by this technique. The 
technique can also evaluate the simultaneous effects of several concurrent antibiotics 
on one bacterium. 
A major limitation however, is that while the bactericidal activity identifies a patient 
who has been incorrectly treated, it provides no guidance on how to treat correctly. 
Secondly, the timing of bactericidal activity measurements is a matter of controversy. 
Some determine the bactericidal activity at peak, midpoint, trough, or even randomly. 
This problem is aggravated when several antibiotics whose pharmacokinetics may not 
be matched, are used concurrently, as it is never clear when to determine bactericidal 
activity or how to adjust doses. There are methodological problems with serum 
dilutions and the diluent to use. Some who have criticised the method as unreliable 
have recently introduced the serum bactericidal rate (Drake et a/. 1983). This is a 
time-related subculturing method performed on the bactericidal activity dilution of 1 :2. 
It appears to be a useful parameter of bactericidal activity, but no clinical trials have 
appeared to support its use as yet. Finally, with either method, it is always difficult to 
predict which bacterial culture a clinician will request bactericidal activity 
measurements - especially since such requests are likely to be made several weeks 
into treatment. Thus, the state of the art often remains ahead of the logistics of 
application with this technique. In spite of the problems, bactericidal activity methods 
are currently enjoying a renewed interest in both animal and patient studies. 
It is significant that none of these methods have been applied to the clinical evaluation 
of anti-TB drug therapy. One of the few reports that describe the pharmacodynamic 
parameters of the anti-TB drugs was that by Peloquin and {3erning (1994). These 
authors calculated the pharmacodynamic parameters of Cmax:MIC, time above MIC 
and AUC>MIC using population data and literature values of MIC (Table 2.5). The 
pharmacokinetic parameters were taken as the midpoint of the values reported in the 
literature. In this way the authors demonstrated the importance of INH and RFA when 
their pharmacodynamic parameters were compared to other anti-TB drugs. 
Studies conducted with bactericidal drugs against aerobic bacteria suggest that for the 
cell wall active drugs (e.g. beta-Iactam antimicrobials), maintaining the serum 
concentration above the MIC for the entire dosing interval (t>MIC) is the most 
important parameter for eradicating the organism (Peloquin, 1996). Among the anti-
TB drugs, INH, cycloserine, ethambutol , ethionamide and thiacetazone act primarily 
against the cell wall and thus t>MIC would be an important parameter to optimise 
when dosing with this drug. 
On the other hand, in the case of drugs that exert their effect on intra-cellular targets 
(e.g. aminoglycosides) the Cmax:MIC ratio is considered important as this ensures 
adequate penetration into the site of action. RFA, fluoroquinolones, capreomycin, 
pyrazinamide and clofazimine would fall into this category as they act on RNA 




Table 2.5 - Pharmacodynamic parameters for the anti-tuberculosis drugs 
(Peloquin and Berning, 1994) 
. 
DRUG Cmax:MIC t>MIC AUC>MIC 
Drugs acting primarily against the cell wall 
Cycloserine 3.8 22.5 195.5 
Ethambutol 25 mg/kg 10 13.0 23.4 
Ethionamide 1.6 1.5 1.0 
Isoniazid 
Fast acetylator 40 9.0 11 .6 
Slow Acetylator 40 18.0 19.2 
Thiacetazone 1.3 5.5 1.2 
Drugs acting primarily against intracellular targets 
Rifampicin 24.0 9.0 39.9 
Streptomycin 
22-25 mg/kg 3 times a week 18.8 11 .0 274.6 
12-15 mg/kg 5 times a week 10.0 8.0 124.5 
Ciprofloxacin 5.0 10.5 16.9 
Ofloxacin 5.0 15.5 47.4 
-AUC = area under the serum concentration versus time curve , Cmax - maximum serum concentration, MIC = 
minimum inhibitory concentration , t>MIC = t ime serum concentrations remain above the minimum inhibitory 
concentration . 
These authors suggest that research into establishing "normal" ranges for these 
pharmacodynamic parameters may facilitate the construction of novel dosing 
regimens that may take advantage of each drug's strengths. They allude to the 
possibility that these parameters may guide dosage in the treatment of MDR-TB. A 
disdavantage to the methodology used in their paper however is the use of literature 
values for the pharmacokinetic parameters and mean values for the MIC from 
possibly unrelated sources. 
A critical analysis of these attempts at pharmacokinetic-pharmacodynamic integration 
in the design of antimicrobial regimens reveals several promising approaches, but 
with the exception of serum bactericidal activity, none of the indices of susceptibility 
have yet been clinically evaluated. Rather, they have been used to compare the 
potential efficacy of different antibiotics of the same class or to suggest dosing 
guidelines. Most methods rely on population data alone, or attempt to integrate 
pharmacokinetic data from one study with pharmacodynamic data from an unrelated 
study. This provides minimal guidance on dosage adjustments for the individual 
patient. Clearly the ideal would be to derive the parameters using both 
pharmacokinetic and pharmacodynamic information from the same study. 
Altered Pharmacokinetics of the anti-TB drugs in the context of HIV 
infection and the acquisition of drug resistance 
Researchers from the National Jewish Center for Immunology and Respiratory 
Medicine were the first to observe possible malabsorption of the anti-TB drugs and to 
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suggest its link with HIV infection and AIDS (Berning et al. 1992). The physiological 
or pathological basis for alterations in pharmacokinetics as a consequence of HIV 
infection is presented hereunder followed by a review of the studies that examined the 
link between HIV and malabsorption. 
REASONS FOR ALTERED PHARMACOKINETICS IN HIV INFECTION 
In general , conditions likely to influence the pharmacokinetics of drugs are those 
which affect normal functioning of the gastrointestinal tract (GIT) , hepatic and renal 
systems. Patients with HIV infection and/or AIDS have been reported to have altered 
functioning of all 3 of these systems (Unadkat anti Agosti, 1990) . The severity of the 
alterations varies widely across individuals and often depends on the severity and 
stage of immune compromise. 
Gastrointestinal System 
Diarrhoea from any cause will result in a reduction in the extent of drug absorption. 
Diarrhoea is one of the most common GIT symptom reported in AIDS occurring in 50 
to 90% of individuals. It ranges in severity with fluid loss up to 17L per day reported. In 
addition to the more common diarrhoeal pathogens found in immunocompetent hosts, 
there is a wide variety of organisms implicated as aetiological agents in the HIV+ 
patient. These include Mycobacterium avium intracellulare, the protozoa 
Cryptosporidium and Isospora, cytomegalovirus and Salmonella. The human 
immunodeficiency virus itself has been found to infect the GIT mucosa and is 
associated with enteropathy (Unadkat and Agosti, 1990). 
Opportunistic infections that affect immunocompromised hosts such as oropharyngeal 
candidiasis , hairy leukoplakia, aphthous stomatitis, necrotising gingivitis, Karposi 's 
sarcoma and herpes simplex infection may also predispose to malabsorption 
(Unadkat and Agosti, 1990). This may be due to coating or destruction of the intestinal 
walls by these organisms (Peloquin, 1993). 
The pH of the stomach of patients with AIDS may be higher than that of normal 
patients (Unadkat and Agosti, 1990) and achlorhydria has also been reported. This 
has implications for the absorption of drugs that are weak acids or weak bases as pH 
affects the degree of ionisation according to the Henderson-Hasselbalch pH-partition 
hypothesis (Mandell and Petri, 1996). Weak acids will be ionised at alkaline pH and 
this will tend to retard absorption . In contrast drugs that are weak bases will be more 
unionised and their absorption will be promoted. 
In a review by Kenny and Strates (1981) an increased pH after administration of 
sodium bicarbonate was noted to reduce the extent of RFA absorption. In the same 
study, a decreased pH was associated with better drug absorption . The authors 
attributed this to a better solubility of RFA in acid pH. 
Hepatic System 
Some of the opportunistic infections in HIV+ patients may result in aberrations in liver 
function. This may alter the pharmacokinetics of the anti-TS drugs. These include the 
frequent occurrence of hepatitis due to hepatitis S, non-A, non-S hepatitis, 
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Mycobacterium avium intracellulare, cytomegalovirus, Epstein-Barr virus, 
Pneumocystis carinii pneumonia, fungi , lymphoma, Karposi 's sarcoma (Unadkat and 
Agosti, 1990). Drugs used to treat these infections may also affect liver function and 
hence drug metabolism e.g. sulphonamides, ketoconazole, amphotericin and 
zidovudine (Mandell and Petri, 1996). Biliary diseases seen in HIV infection include 
cholangitis secondary to cytomegalovirus or cryptosporidium, and obstruction 
secondary to lymphoma or Karposi's sarcoma (Unadkat and Agosti, 1990). 
The cytokines, interferon-a and tumour necrosis factor have been implicated in the 
inhibition of the metabolism of drugs via the cytochrome P450 oxidative pathways. 
Since patients with AIDS have been reported to have higher circulating concentrations 
of these 2 agents, it is reasonable to speculate that the oxidative metabolism of drugs 
in such patients is likely to be impaired. This has been suggested as the mechanism 
for the increased metabolism of antipyrine after zidovudine treatment. These authors 
suggest that circulating levels of interferon-a and tumour necrosis factor may 
decrease after zidovudine treatment resulting in an increase in the clearance of 
antipyrine (Unadkat and Agosti, 1990). Since the major metabolic pathway for INH is 
acetylation and for RFA is desacetylation, this is unlikely to be of clinical significance 
with these drugs. 
Patients with AIDS often suffer from a wasting syndrome that may result in 
hypoalbuminaemia. This latter effect may have implications for protein binding of 
drugs and hence affect the interpretation of the volume of distribution and clearance of 
drugs. 
Renal Function 
Renal diseases occur in 10 to 30% of AIDS patients. A distinct form of HIV-associated 
renal disease with a broad spectrum of severity and sometimes associated with 
proteinuria has been reported (Unadkat and Agosti, 1990). However, with the 
exception of severe renal disease, this is unlikely to cause alterations in the 
pharmacokinetics of INH and RFA, as the kidneys constitute a minor route of drug 
elimination for these drugs. 
REVIEW OF THE INVESTIGATIONS INTO THE PHARMACOKINETICS OF THE ANTI-TB 
DRUGS IN HIV INFECTION 
Berning et al (1992) were the authors of the first case report of malabsorption of the 
antimycobacterial drugs in an AIDS patient. A further review of serum concentrations 
of samples submitted to their laboratory at the National Jewish Centre for Immunology 
and Respiratory Medicine, Denver, USA for anti-TB drug assay, revealed an 
additional 32 instances of drug malabsorption. Rifampicin showed the worst 
absorption with 19 of 20 RFA measurements recorded as abnormal (Peloquin et al. 
1993). 
Following on these reports, Patel et al1995 reported on 2 patients with HIV infection 
b~in~. treated for TB who relapsed with drug-resistant isolates. In both patients, 
slgnrflcantly low serum concentrations of anti-TB drugs were confirmed at the 
laboratories of the Denver group. In demonstrating that malabsorption was associated 
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with the acquisition of drug resistance, these authors endorse the warning by Peloquin 
et al (1993), that fl •• • patients being treated for multidrug-resistant tuberculosis may 
be at particular risk for poor therapeutic responses if drug malabsorption occurs. " 
They emphasise that the absorption of only one drug in a multi-drug regimen may 
select for further drug resistance (Patel et al. 1995). 
Peloquin et al (1996) subsequently conducted a pilot study in which they compared 
the 2-hour post-dose concentration of anti-T8 drug with the expected normal ranges 
that they propose. They noted that 21 of 26 patients (81 %) had levels less than 90% 
of the predicted low end of the therapeutic range and 14 patients (54%) had levels 
less than 30% of the predicted minimum (Peloquin et al. 1996). They concluded that 
frequent and significant malabsorption occurred in HIV+, T8 patients with or without 
AIDS. 
These studies have limitations in that they report on retrospectively collected data or 
because they consisted largel.y of case reports. The 2-hours post-dose data point is at 
a highly variable part of the pharmacokinetic profile for drugs that display rapid 
absorption. It is subject to wide fluctuations and is difficult to interpret. This difficulty 
was acknowledged by Patel et al (1995) when they noted a peak RFA concentrati-on 
at 4 hours rather than 2 hours in one of the 2 patients in their report. 
In an attempt to resolve these difficulties, Sahai et al (1997) studied the 
malabsorption problem using a full prospective pharmacokinetic trial consisting of 13 
serum concentration pOints per patient. These authors examined the bioavailability of 
INH, RFA and pyrazinamide in 4 groups of 12 volunteers each. Group I consisted of 
healthy volunteers, while Groups 11 ,' 111 and IV were HIV+ patients without T8. The 
patients in these latter 3 groups had CD4+ counts of> 300/mm 3 (Group II -
asymptomatic HIV+), . < 200/mm 3 (Group 111- symptomatic HIV+) and < 200/mm 3 with 
~ 3 loose stools per day (Group IV - symptomatic HIV+ with diarrhoea). 
In the case of RFA, the study demonstrated that in all HIV+ patients, the AUC was 
68.4% lower (CI - 47.5 to 98.4%) and the Cmax was 58.8% lower (CI - 42.3 to 82%) 
than in healthy volunteers. A similar effect on AUC could not be demonstrated for INH 
although the HIV+ patients with diarrhoea (Group IV) displayed a lower Cmax for INH 
compared to the patients with symptomatic HIV but no diarrhoea (Group III) . 
The authors report a significant linear trend for decreasing Cmax values ()lg/ml) from 
Group I to Group IV for both RFA (9.29, 5.48, 5.27, 5.24 - p=0.006) and INH (5.97, 
5.12, 4.73, 3.69 - p=0.046) that apparently mirrors the stage of HIV disease. 
However, the results of this trend analysis are probably Clinically irrelevant since all 
patients had levels above the MIC for sensitive organisms. Further, the large 
'difference between Cmax for volunteers and HIV+ patients for RFA and that due to 
diarrhoea for patients on INH was responsible for the strong statistical Significance 
(low p value) of the trend analysis. 
These reports of reduced absorption in HIV+ patients were not confirmed by 2 recent 
pharmacokinetic studies in T8 patients conducted in Africa (Choudhri et al. 1997; 
Taylor and Smith, 1998). 
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The study by Choudhri et al (1997) conducted in Nairobi , Kenya found that neither 
HIV infection nor diarrhoea accounted for the interpatient variability in the AUC, Cmax 
or the terminal half-life (Biz) of INH or RFA. They studied the steady-state 
pharmacokinetics of INH, RFA and pyrazinamide in 29 adults (14 HIV+ and 15 HIV-) 
with TB. It was noted further that neither the AUC nor the t% of any of these drugs 
reflected interpatient differences in CD4 lymphocyte counts i.e. the severity of immune 
compromise did not influence the pharmacokinetics of the drugs. 
The study by Taylor and Smith (1998) was conducted in 13 HIV+ patients (with AIDS) 
and 14 HIV- patients hospitalised for TB in Cape Town, South Africa. These authors 
did not find the differences in AUC and Cmax that Sahai (1996) reported for RFA or 
any of the malabsorption problems previously reported. On the contrary, these 
authors noted better absorption of RFA in HIV+ patients as reflected in higher AUC 
values. They were unable to explain this discrepancy but speculated that it may have 
been due to altered serum protein binding or an underlying hepatic dysfunction. The 
study participants had received their medication under strict supervision for 3-5 days 
prior to the study. In addition they had received (unsupervised) daily doses of their 
anti-TB drugs for over 4 months prior to enrolment into the study. Although this 
information suggests that RFA enzyme auto-induction would have been maximal at 
the time of the study, the authors do not discuss or exclude this possible explanation 
for the higher AUCs in the AIDS group in their manuscript. It has been reported that 
RFA serum pharmacokinetic values return to the un-induced state within 30 days of 
termination of drug therapy (Kenny and Strates, 1981). Thus non-compliance and 
consequent absence of maximal enzyme auto-induction prior to recruitment into the 
study may offer a possible explanation for the higher AUCs of the patients in the AIDS 
group. 
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Chapter 3 
TEMPORAL TRENDS IN MYCOBACTERIUM 
TUBERCULOSIS DRUG RESISTANCE IN KWAZULU-
NATAL, SOUTH AFRICA: 1983 to 1995 
Summary 
OBJECTIVE 
To determine temporal trends in Mycobacterium tuberculosis drug resistance in 
KwaZulu-Natal, South Africa between 1983 and 1995. 
DESIGN 
Routine drug susceptibility data from the central provincial mycobacteriology . 
laboratory in KwaZulu-Natal, South Africa for the .13 year period from 1983 to 1995 
were analysed. The laboratory used the 1 % proportional method in Lowenstein-
Jensen medium for susceptibility testing throughout the study period. 
RESULTS 
A total of 21 704 sputum samples from which M. tuberculosis was cultured, were 
subjected to susceptibility testing . Multi-drug resistance (MDR-TB), defined as 
combined resistance to isoniazid (INH) and rifampicin (RFA) was 2.2% in 1983 and 
3.7% in 1995 (p = 0.01'). Examination of the temporal trends in MDR-TB revealed a 
downward trend from 2.6% in 1984 to 0.9% in 1987 (chi square for linear trend 9.34 ; 
P = 0.002) . The prevalence did not change much between 1987 and 1990 followed by 
an upward trend from 1.1 % in 1990 to 3.7% in 1995 (chi square for linear trend 30.56; 
p < 0.001). Resistance to INH alone was 6.7% in 1983 and 7.0% in 1995 (p = not 
significant) and for RFA alone 8.1 % and 7.2% (p = not significant), respectively. All 
other drugs tested showed a statistically significant decrease in drug resistance 
between 1983 and 1995 viz. streptomycin (13.7% and 7.7%; p < 0.001), ethionamide 
(9.3% and 4.5%; p < 0.001), thiacetazone (7.8% and 3.2%; p < 0.001) and ethambutol 
(3.4% and 2.1 %; p = 0.01). 
CONCLUSIONS 
Following an initial downward trend, a significant increase in the prevalence of MDR-
TB was noted. It is particularly disconcerting that there was a reversal in a previous 
downward trend in MDR-TB. While these data cannot simply be extrapolated to all 
patients with TB due to the selective basis on which susceptibility tests were 
requested, they nevertheless provide valid temporal trends. 
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Introduction 
The incidence of tuberculosis (TB) has been increasing globally in recent years , 
partially due to the human immunodeficiency virus (HIV) epidemic. More ominous, 
however, have been the reports of the rising prevalence of strains of Mycobacterium 
tuberculosis that are resistant to currently used chemotherapy (Edlin et al. 1992; 
Iseman, 1993; Bloch et al. 1994; Neville et al. 1994). 
In a study of newly admitted Black TB patients in South African hospitals, Weyer and 
Kleeberg (1992) demonstrated a marked decrease in primary and acquired drug 
resistance over the period 1965 to 1988. There has been no investigation into the 
trends in drug resistance thereafter. In 1996 the WHO and the South African 
Department of Health conducted a combined review of the TB Control Programme in 
South Africa . They concluded that South Africa's high TB case rates, the emergence 
of MDR-TB and the growing HIV epidemic combine to make the country's TB crisis 
the most serious in the world (WHO, 1996). 
KwaZulu-Natal, one of South Africa's 9 provinces, is reported as having the highest 
prevalence rate of HIV infection (27 %) compared to the other provinces which have 
prevalence rates that range from 6 % in the Western Cape to 23 % in Mpumalanga 
province (Department of Health, 1998). The province ranks fifth in terms of the estimated 
incidence of TB (WHO, 1996). There is currently no published data on the prevalence of 
MDR-TB in the province. 
The purpose of this study was to determine the temporal trends in M. tuberculosis 
drug resistance using routine drug susceptibility data from the Regional 
Mycobacteriology Laboratory in KwaZulu-Natal , Durban, South Africa. 
Methods 
The Mycobacteriology laboratory at King George V Hospital (KGV) in Durban is the 
central referral laboratory at which susceptibility testing for the anti-TB drugs is 
performed for hospitals and clinics in KwaZulu-Natal. Susceptibility tests are routinely 
requested by clinicians when patients with TB do not respond to standard TB 
treatment regimens, require re-treatment or when the clinician suspects drug-resistant 
TB. 
Tuberculosis drug susceptibility reports from KGV Mycobacteriology Laboratory that 
had been recorded in the laboratory register were computerised and analysed. 
Repeat or duplicate specimens with identical drug susceptibility patterns, presenting 
within a 3-month period of each other were identified using the first 4 characters of the 
patient's names and eliminated using a computer algorithm. 
During the period under study, drug susceptibility testing was conducted using the 
method advised by the Tuberculosis Research Institute of the Medical Research 
Council of South Africa (Nel et al. 1980). This is based on the 1% proportional 
method using Lowenstein-Jensen medium. A standardized inoculum was sub-cultured 
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onto Lowenstein-Jensen medium containing the following concentrations (Ilg /ml ) of 
drug: -
Isoniazid (INH) - 0.1 and 5.0 
Streptomycin - 5 
Ethionamide - 20 
Ethambutol - 2.8 
Rifampicin (RFA) - 28 
Thiacetazone - 1 
The laboratory reported results as resistant, sensitive or partially resistant based on 
growth of the organism in the drug-containing culture medium relative to growth on a 
drug-free control. In all analyses for this study, partial resistance was re-coded as 
sensitive for purposes of clinical interpretation. 
The statistical analyses were conducted using Epi-Info Version 6.04b (Center~ for 
Disease Control and Prevention (CDC), USA and WHO, Geneva). Comparisons and 
linear trends were evaluated using the extended Mantel Haenszel Chi-square test with 
the p<0.05 level regarded as statistically significant. This test reflects the departure of 
a linear trend from the horizontal i.e. from no trend (Armitage 1955). 
Results 
From 1983 to 1995, a total of 26 441 M. tuberculosis strains were isolated from 
sputum specimens and were subjected to susceptibility testing. There were 4737 
repeat specimens with identical drug susceptibility patterns presenting within a 3 
month period of each other that were identified and eliminated from further analyses. 
The study sample thus consisted of 21 704 isolates. Table 3.1 records the resistance 
rates to the 6 drugs tested and the rates for combined resistance to INH and RFA 
(MDR-T8) over the 13 year period. 
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Table 3.1 - Number (%) of resistant Mycobacterium tuberculosis isolates and notified cases of Tuberculosis during the period 1983 to 
1995 in KwaZulu-Natal, South Africa 
1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995' 
Isoniazid (INH) 
Number (%) 77 (6.7) 91 (8.1) 70 (7.3) 54 (5.9) 62 (6.0) 82 (6.8) 66 (5.5) 66 (5.4) 118 (7.8) 110 (8.0) 202 (8.4) 265 (7.9) 256 (7.0) 
Number of isolates tested 1150 1125 959 912 1026 1214 1192 1214 1510 1373 2392 3363 3653 
Rifampicin (RFA) 
Number (%) 93 (8.1) 98 (8.8) 84 (8.8) 54 (6.0) 26 (2.5) 51 (4.2) 40 (3.4) 44 (3.7) 104 (6.9) 104 (7.6) 171 (7.1) 220 (6.5) 264 (7.2) 
Number of isolates tested 1149 1116 956 906 1026 1213 1186 1204 1504 1372 2396 3376 3666 
Streptomycin 
Number (%) 158 (13.7) 150 (13.4) 110 (11 .5) 48 (5.3) 57 (5.6) 50 (4.2) 52 (4.4) 41 (3.4) 101 (6.7) 123 (9.0) 168 (7.1) 219 (6.5) 279 (7.7) 
Number of isolates tested 1152 1124 957 906 1026 1202 1188 1208 1503 1372 2379 3348 3644 
Ethionamide 
Number (%) 74 (9.3) 58 (5.2) 34 (3.6) 20 (2.2) 10 (1 .0) 18 (1 .5) 38 (3.2) 40 (3.3) 45 (3.2) 62 (4.5) 105 (4.4) 144 (4.3) 162 (4.5) 
Number of isolates tested 794 1119 956 906 1023 1204 1187 1202 1406 1368 2394 3352 3642 
Thiacetazone 
Number (%) 90 (7.8) 46(4.1) 12(1 .3) 11 (1 .2) 2 (0.2) 1 (0.1) 4 (0.3) 19(1.6) 19(1 .3) 36 (2.7) 61 (2 .6) 86 (2.7) 110 (3.2) 
Number of isolates tested 1148 1116 959 902 1024 1208 1186 1211 1492 . 1361 2374 3173 3448 
Ethambutol 
Number (%) 39 (3.4) 34 (3.0) 17 (1 .8) 4 (0.4) 1 (0.1) 5 (0.4) 6 (0.5) 4 (0.3) 10 (0.7) 30 (2.2) 25 (1 .1) 55 (1 .6) 77 (2.1) 
Number of isolates tested 1147 1123 956 909 1025 1211 1189 1210 1504 1361 2374 3357 3647) 
MDR-TB (INH + RFA) 
Number (%) 25 (2.2) 29 (2.6) 22(2.3) · 15(1 .7) 9(0.9) 13(1 .1) 9(0.8) 13(1 .1) 31(2.1) 37 (2.7) 63 (2 .6) 131 (3.9) 134 (3.7) 
Number of isolates tested 1135 1114 953 900 1011 1204 1180 1199 1497 1364 2382 3354 3648 
TB Case Rates at Hlabisa 301 336 312 624 703 827 839 
Health Ward2 
TB Notifications in KwaZulu- 9706 8815 8795 5573 8588 10889 9255 11003 11202 11563 9704 10354 10226 
Natal3 
Nearly all isolates were tested against the 6 drugs - minor differences in number of isolates tested per year were due to lack of growth of the organism in the control tube or to contaminated specimens. 
l Drug resistance data for 1995 consists of only 10 months of data . 
2(Wilkinson and De Cock, 1996a) 
3Source - Epidemiological Comments - Department of Health 
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Multi-drug resistance, defined as combined resistance to at lea.st I~H and RFA 
increased from 2.2% in 1983 to 3.7% in 1995 (p = 0.01). Examination of the temporal 
trends in MDR-TB (Figure 3.1) revealed a downward trend from 2.6% in 1984 to 0.9% 
in 1987 (chi square for linear trend 9.34; p = 0.002). MDR-TB was stable between 
1987 and 1990 and then an upward trend was noted from 1.1 % in 1990 to 3.7% in 
1995 (chi square for linear trend 30.56; p < 0.001) . 
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Figure 3.1 - Trends in Mycobacterium tuberculosis drug resistance to isoniazid (lNH) 
and rifampicin (RFA) alone and in combination (MDR-TB) in KwaZulu-Natal, South 
Africa 1983-1995 
Pulmonary TB notifications for whole of KwaZulu-Natal (Epidemiological Comments 
1983 to 1996) and for the sentinel surveillance site at Hlabisa Health Ward, KwaZulu-
Natal (Wilkinson and De Cock, 1996a), are recorded in Table 3.1 and plotted with the 
number of requests for drug susceptibility received by the laboratory for the period 
under study (Figure 3.2). 
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Figure 3.2 - Comparison of TB Case Loads for Hlabisa Health Ward and KwaZulu-
Natal in relation to the number of requests for drug susceptibility testing received by 
King George V Mycobacteriology Laboratory 1983 - 1995 
From 1983 to 1991, the number of requests for drug susceptibility runs approximately 
parallel with the number of cases of TB reported to the Department of Health. Since 
1991 however, the number of requests for drug susceptibility have continued to 
increase while there has been an apparent decline in TB notifications in the province. 
The data from Hlabisa Health Ward, however, shows a continued increase in TB case 
loads over this period. 
Discussion 
A significant increase in MDR-TB was noted over the 13 year period: 1983 - 1995. It 
is particularly disconcerting that the increase followed an initial downward trend that 
was reversed in 1989. This increase in MDR-TB occurred against a backdrop of a 
general decline in resistance to individual anti-TB drugs. 
While the proportion of MDR-TB is still relatively low, the absolute number of MDR-TB 
patients has been increasing. Thus while the percentage MDR-TB has increased from 
2.2% in 1983 to 3.7% in 1995, the actual number of MDR-TB cases being cared for by 
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the KwaZulu-Natal Health authorities has increased more than 5 times from 25 in 
1983 to 134 in 1995. This increased burden on State treatment facilities occurs in the 
context of a health care system that is stretched thin as it undergoes radical reform in 
post-apartheid South Africa. 
Approximately 18% of the specimens submitted for susceptibility testing were 
identified as being repeat requests and were counted once only for the purposes of 
this study. In most cases these were isolates from patients with MDR-TB who tended 
to visit several different clinics serviced by the laboratory before finally being admitted 
for in-patient management at KGV. 
Since the virulence of MDR-TB is similar to that of drug-sensitive TB (Iseman, 1993), 
this means that each case is a potential source of spread of infection unless adequate 
steps are taken to control the disease. When compared to drug-sensitive patients, 
these patients are likely to remain infectious for longer periods of time after 
commencement of drug therapy and thus would require longer periods of treatment 
that may include hospitalization. The slow growth of M tuberculosis in cultures and 
consequent delays before microbiological confirmation of drug resistance further 
compromises timeous institution of appropriate chemotherapy. Indeed some TB 
researchers (Veen, 1995) have speculated on whether current regimens for drug-
resistant TB have any impact at all on patient outcome when compared to the pre-
chemotherapy era. However if sputum positive MDR-TB patients are allowed to 
remain in the community, or if patients are allowed back into the community before 
completion of a full course of treatment, a very real danger exists of creating clusters 
of MDR-TB patients in communities burdened by years of socio-economic 
impoverishment. 
It is interesting to note that there has been a reversal in the downward trend in MDR-
TB during the latter 5 years of the study (Figure 3.1). It is tempting to speculate that 
the HIV epidemic may be a contributory factor. Several researchers in the Unite·d 
States have observed an association between drug-resistant TB and HIV infection 
(Anonymous 1991; Edlin et al. 1992; Doole et al. 1992). However, our own 
experience has not mirrored this. We examined the hospital records of 295 patients 
treated for tuberculosis at KGV between 1991 and 1994 and found no association 
between HIV status and drug resistance (Anastasis et al. 1997). Whether the reversal 
in MDR-TB drug resistance trends is an usual cyclical biological event or the "third 
epidemic" (Neville et al. 1994) will be determined by ongoing surveillance of these 
trends. 
This study has reported on temporal trends in drug-resistant TB in the most populous 
province of South Africa, but several limitations should be considered. Almost all of 
these are associated with the nature of retrospective analyses of routine laboratory 
data. The absence of demographic data or a differentiation between primary and 
secondary (acquired) infection in the laboratory records would have enabled the 
identification of potentially high-risk groups as has been recommended (Chaulet et al. 
1995). The proportions presented represents a mixture of primary and (mostly) 
acquired drug resistance. Due to the selective basis on which susceptibility testing 
was requested, the proportions calculated are not the true prevalence of drug-
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resistant TB. However, comparisons for trend purposes are valid since the indications 
for drug susceptibility testing changed little over the past few years . 
. 
An added advantage is that all susceptibility testing was conducted at the same 
laboratory in which the senior laboratory staff and microbiological methods remained 
constant during the study period. The laboratory at KGV serves a large catchment 
area of over a hundred clinics. It is unlikely that the policy for drug susceptibility 
testing changed during the first 8 years of the study as the number of requests for 
drug susceptibility ran approximately parallel to the number of TB notifications for the 
province (Figure 3.2). After 1991 , however, susceptibility requests continued to 
increase despite an apparent decrease in TB notifications. This corresponds to the 
time during which there was an increased level of awareness of the rising problem of 
MDR-TB and an increase in the number of patients co-infected with HIV and TB 
(Wilkinson and Moore, 1996b) . Thus clinicians may have been requesting drug 
susceptibility tests in an attempt to exclude MDR-TB in HIV+ patients who presented 
with poor clinical response to anti-TB treatment. It is reported that patients co~infected 
with HIV and TB have a similar response to treatment as patients without HIV 
infection, but have higher relapse rates (Narain et al. 1992). They are likely to be 
generally less well clinically because of other associated opportunistic infections. 
While this may explain the increase in the number of tests requested , the dramatic fall 
in the number of TB notifications after 1991 warrants careful assessment of the 
accuracy of this data. Experience from the Hlabisa Health Ward, a typical but well 
monitored rural community of approximately 180 000 inhabitants within KwaZulu-Natal 
(Wilkinson and Moore, 1996b) showed a contradictory increase in TB notifications for 
this same period . Perhaps the decline in the province's TB notifications reflects the 
logistical and administrative difficulties experienced during the amalgamation of the 
racially segregated health ministries at the time of South Africa's emerging 
democracy. 
Changes to National TB Control Programmes are often reflected epidemiologically on 
trends in drug resistance. In South Africa, the National Health Ministry determines TB 
treatment policies and there are usually only minor local differences in the adherence 
to these policies. There were no major changes in TB treatment policy such as the 
introduction of new drugs to the anti-TB drug regimen or the widespread 
implementation of directly observed therapy (DOT) throughout the province during the 
study period. 
Surveillance on trends in drug resistance impact on TB control programs and at a 
regional level will also inform the policies for local choices of initial therapy (Iseman, 
1993; Bloch et al. 1994). While most agree that non-adherence (compliance) with TB 
treatment regimens is a major risk factor for drug resistance, studies should include a 
search for the specific risk factors that are likely to cause a differential increase in 
MDR-TB as opposed to TB in general. 
Conclusions 
This survey of trends in drug resistance at a regional referral Mycobacteriology 
Laboratory over a 13 year period (1983 - 1995) has revealed a significant increase in 
MDR-TB in KwaZulu-Natal, South Africa. It is particularly disconcerting that the 
increase in MDR-TB followed an initial downward trend that was reversed in 1989. 
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Pharmacokinetic and Pharmacodynamic 
Characteristics of Isoniazid and Rifampicin in Patients 
with Multi-drug-Resistant Tuberculosis 
OBJECTIVE 
To investigate if there is an association between the pharmacokinetic parameters of 
isoniazid (INH) and rifampicin (RFA) and multi-drug resistant tuberculosis (MDR-TB) 
in HIV positive (HIV+) and HIV negative (HIV-) patients. 
To describe the pharmacokinetic and pharmacodynamic characteristics of INH and 
RFA in MDR-TB and drug-sensitive TB patients stratified according to HIV status. 
DESIGN 
Prospective case-control pharmacokinetic study. 
SETTING 
King George V Hospital, a large specialist referral TB in-patient treatment facility in 
Durban, KwaZulu-Natal, South Africa 
PATIENTS 
A total of 138 adult pulmonary tuberculosis patients: 62 MDR-TB (21 HIV+ and 41 
HIV-) and 74 drug-sensitive TB (37 HIV+ and 36 HIV-; 1 not classified). A further 2 
patients (1 HIV+ and fHIV-) could not be classified according to drug susceptibility 
status. 
METHODS 
Single daily doses of INH (300 or 400 mg) and RFA (450 or 600 mg) were 
administered under supervision for 2-5 days prior to the study. Any other drug 
treatment prescribed for T8 or concomitant complaints was noted but not 
discontinued. Thereafter 6 blood samples were drawn over 2 dosing intervals at 0, 1, 
2, 4, 8 and 12 hours after dose administration. Clinical, socio-demographic, 
radiological (extent and severity of lung involvement), clinical chemistry (liver function 
tests) and microbiological (drug susceptibility and minimum inhibitory concentration 
(MIC)) data were collected. Serum drug concentrations were determined using a 
validated high performance liquid chromatography (HPLC) assay. 
Pharmacokinetic data analysis was conducted according to the population approach 
using the NONMEM program as well as with non-compartmental methods. 
RESULTS 
Results from the non-compartmental analysis were similar to those obtained from the 
population approach. Upon initiation of treatment, the average 54-kg patient had a 
CUF for RFA of 7.7 Uhr. After continuous daily treatment, maximal enzyme auto-
induction was reached at approximately 10 days at which time the CUF was 15.6 Uhr. 
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The mean population V/F for RFA was 26.5 L at initiation of treatment and 42.1 L after 
10 days of therapy. The inter-individual variability (% coefficient of variation [CV] for 
RFA was 39% for CUF and 26% for V/F. Residual variability was described with a 
proportional component of 39% and an additive component of 0.05 Ilg/ml. 
The proportion of INH fast acetylators in the population was found to be in the majority 
(85%). The mean population CUF was 13.0 Uhr for fast acetylators and 4.7 Uhr for 
slow acetylators. The V/F for INH was 50.0 L. The inter-individual variability in INH 
CUF was 32% for slow acetylators and 41 % for fast acetylators. There was also a 41 
% variability in V/F. Residual variability was described with a proportional component 
of 28% and an additive component of 0.02 Ilg/ml. 
The pharmacokinetic parameters for both INH and RFA obtained in this study 
compare well with that reported in the literature. 
Population pharmacodynamic parameters (maximum serum concentration 
[Cmax]:MIC ratios , time above the MIC and area under the curve [AUC] above the 
MIC) for INH and RFA were described and represent potential benchmarks for future 
prospective clinical evaluation. 
CONCLUSIONS 
There was no association between the pharmacokinetic parameters of INH and RFA 
and MDR-TB. Neither was there any association between HIV status or degree of 
immune compromise as determined using HIV viral loads and the pharmacokinetic or 
pharmacodynamic parameters of INH and RFA. 
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PATIENTS AND METHODS 
Ethical Considerations 
The study protocol was approved by the University of Durban-Westville Ethics 
Committee (Approval Number 930188) . 
In accordance with WHO guidelines, patients were provided with pre- and on going post-
test counselling regarding the test for antibodies to HIV, by trained counsellors from 
KGV. 
All information obtained during the study was treated as confidential. Patients were 
identified by code number only - the key to which was known only to the principal 
investigator. 
Study Centre 
The study was conducted at King George V (KGV) Hospital, a 1311-bed state hospital 
with a psychiatric and T8 unit. The T8 section of the hospital is the larger, comprising 
901 beds. KGV is a referral hospital for patients primarily from the province of 
KwaZulu-Natal. Patients are referred from state or private hospitals, general 
practitioners and primary health care clinics. 
Patient/Subject Selection 
Using available microbiology reports in the patients' case notes, culture positive MDR-
T8 and drug sensitive adult T8 patients (18 - 65 years) were identified at the T8 
wards of KGV hospital over a 5 month period. These patients were counselled in their 
home language either individually or in groups and their informed consent to 
participate in the study was obtained (Appendix A) . Patients were excluded if there 
was a history of intolerance to INH or RFA, or if there were any contra-indications to 
multiple blood sampling such as mental confusion or poor venous access. 
During patient recruitment, attempts were made to ensure balanced selection into the 
4 study groups as shown in Figure 4.1. Once at least 25 patients had been recruited 
into a particular group, recruitment into that particular group stopped until 25 patients 
had been recruited into each of the other groups. Thereafter, the rest of the patients 
were recruited in a similar manner. 
Chapter 4 
Adult Pulmonary Tuberculosis Patients 
Multi-drug Resistant 
(resistant to at least INH and RFA) 
Drug-Sensitive 
(not resistant to INH or RFA) 
Patients and Methods 
HIV sera-positive HIV sero-negative HIV sero-positive HIV sero-negative 
Figure 4.1 - Description of the 4 study groups of adult pulmonary tuberculosis patients 
recruited into the study to determine the pharmacokinetic and pharmacodynamic 
characteristics of isoniazid and rifampicin . 
Sample Size 
A target sample size of 20 per group wa..s estimated to be required to detect a 50% 
difference between groups with 80% power and a 5% chance of incorrectly rejecting 
the null hypothesis (t-test). These calculations were based on a reported mean AUC ± 
standard deviation of 6.3 ± 3.5 /lg .hr/ml for INH in HIV- patients (Choudhri et a11997) . 
The work of Ette and Sun 1995 on sample sizes for population pharmacokinetic 
studies provided reassurance that this sample size would result in accurate and 
precise estimation of population pharmacokinetic parameters as well as the inter and 
intraindividual variability. 
Study Procedure 
After patient recruitment into the study based on the inclusion/exdusion criteria, their 
medical, family, social and drug history was recorded from their case records and from 
interviews with the patient. 
The once a day dosing regimen of INH and RFA was recommenced in those patients in 
whom these drugs had been discontinued i.e. primarily the MDR-T8 patients. This 
treatment was continued for a period of between 2-5 days prior to the pharmacokinetic 
study day. No other changes to the dosing regimens or normal ward routine were 
instituted. The dates and approximate times of administration of all medications were 
recorded during the 2-5 day period. 
Samples were taken over two consecutive dosing intervals to obtain samples 8 and 
12 hours after the dose on study day 1 and 24 hours (pre-dose), 1, 2 and 4 hours after 
the dose on study day 2 as follows: -
At 05hOO on the morning of study day 1, the nursing staff recorded the exact time of 
administration of INH and RFA. Later in the day, at approximately 13hOO, the patients 
were weighed, an in-dwelling venous cannula (VasofixR ) was inserted into a forearm 
vein and the 8-hour blood sample (8ml) was drawn into an additive-free blood collection 
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tube. A further blood sample (12-hour sample) was drawn at 17hOO. The in-dwelling 
venous cannula remained in-situ overnight. 
At 05hOO on the morning of study day 2, a blood sample was drawn prior to the 
administration of any medication. The INH and RFA dose were then administered 
under direct supervision and the exact time recorded . Thereafter, further blood 
samples (8ml each) were withdrawn at 1, 2 and 4 hours after administration of 
medication. The exact times of administration of all medications and meals were 
recorded by nursing staff for the duration of blood collection. A standardised hospital 
breakfast was served approximately 3 hours after drug administration . 
The motivation for drawing samples over 2 days was to minimise disruption of the 
ward at 05hOO, the usual time of drug administration, in order to insert in-dwelling 
venous cannulas. This strategy was also advantageous with respect to obtaining more 
information on intra-individual variability. 
After collection, samples were allowed to clot on crushed ice and then centrifuged for 15 
minutes at 3000 r.p.m. The serum was separated and aliquots transferred into three 
appropriately labelled polypropylene tubes. All tubes were stored on solid CO2 (dry ice) 
or in a -85°C freezer. The maximum time that samples remained on crushed ice was 5 
hours. Frozen serum was stored at -85°C for no longer than 30 days prior to drug 
concentration determination. 
An early morning sputum sample was collected before drug administration on either 
the first or the second study day and submitted for drug susceptibility confirmation and 
determination of the minimum inhibitory concentrations (MIC) to both INH and RFA. 
Radiology 
All patient's "on admission" radiographs (single postero-anterior) were examined by a 
specialist radiologist and graded according to the extent of disease and the presence 
and size of any cavities (Simon, 1966). 
In brief, the method involved dividing the radiograph of each lung field into 6 
segments. The extent of lung involvement was then graded on a 6 point scale. The 
lowest score of 1 was awarded to radiographs with less than 4 cm2 of lung 
involvement and the highest score of 6 to radiographs involving greater than 1 lung 
field . 
The lung cavitation was also graded according to a 6 point scale. A score of 0 was 
recorded if there were no cavities. Single cavities received scores of 1 to 3 while 
multiple cavities received scores of 4 to 6 depending on the diameter of the largest 
cavity. 
History of Tuberculosis Therapy 
All patients were questioned about previous anti-tuberculosis treatment and classified 
as either a new case or a re-treatment case. This classification was based on 
definitions outlined in the Standard Diagnostic and Treatment Protocol, Tuberculosis 
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Control Program, Department of Health, September 1996 (Department of Health, 
1996). 
1. New Case: a patient who had never received treatment for tuberculosis before -
excluding chemoprophylaxis. 
2. Re-treatment Case: A patient who was previously treated for tuberculosis and 
who presented with active tuberculosis again . These cases were further divided 
as follows: 
• Re-treatment after previous cure or treatment completion: A patient who was 
previously treated for tuberculosis and declared cured as demonstrated by 
negative bacteriology at six months or one who completed a course of treatment, 
but for whom no bacteriology results were available to demonstrate cure. 
• Re-treatment after previous treatment interruption or failure: A patient who 
was previously treated for fuberculosis and who interrupted treatment for a 
cumulative period of two months or longer over the total six month treatment 
period or one whose sputum was still bacteriologically positive at six months. 
Methodology for Investigations 
MYCOBACTERIOLOGICAL METHODS . 
All mycobacteriology procedures were conducted at the Department of Medical 
Microbiology, University of Natal. 
Sputum samples were decontaminated using a solution containing n-acetyl-I-cysteine, 
sodium hydroxide and sodium citrate according to established standard operating 
laboratory procedures. Auromine or Ziehl-Neelsen stained slides of the 
decontaminated sample were then examined microscopically. If mycobacteria were 
observed, then a direct susceptibility test was set up - otherwise the sample was 
inoculated onto Lowenstein Jensen agar, Middlebrook 7H11 agar or Middlebrook 
7H12 broth and incubated for approximately 6 weeks. Species identification was 
established using the niacin and nitrate methods (Nel et a/. 1980). 
Prior to susceptibility testing or minimum inhibitory concentration (MIC) 
determinations, the cultures were allowed to grow in Dubos broth for 3-S days at 37 
°C and the turbidity of the resulting broth culture was adjusted to a No. 1 McFarland 
standard. 
Susceptibility testing 
A standardized inoculum from Dubos broth was introduced onto Middlebrook 7H11 
agar plates containing the following concentrations of drugs: -
isoniazid 0.2 and 1.0J.lg/ml; rifampicin 1.0J.lg/ml; streptomycin 2.0 and 10.0 J.lg/ml; 
ethambutol7.S J.lg/ml; capreomycin 10.0 J.lg/ml; ethionamide S.O J.lg/ml; cycloserine 
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30.0 Ilg/ml; kanamycin 5.0 Ilg/ml ; ofloxacin 10.0 Ilg/ml ; ciprofloxacin 10.0 Ilg/ml and 
thiacetazone 1.0 Ilg/ml. 
A drug-free control plate was also prepared . The agar plates were incubated at 37°C 
in a CO2 incubator for 3 weeks at which time the mycobacterial growth on the drug 
containing plates were compared to those on drug-free control plates. Resistance was 
reported if there was ~ 1 % of growth on the drug-containing plate relative to the drug-
free control plate. 
Minimum inhibitory concentrations (MIC) 
MIC's for INH and RFA were determined radiometrically using the BACTEC
R 
320 TB 
(Bactlab Systems) instrument. This system uses Middlebrook 7H12B liquid medium that 
contains 14C labelled palmitic acid as the carbon source. Metabolically active 
mycobacteria release 14C02 into the gaseous layer at the top of the test vial , and the 
instrument quantitates a growth index on a scale of 0-999 units. 
Concentrated solutions of INH and RFA (Sigma Chemicals) were prepared and stored 
frozen at -70°C until required for addition into the BACTECR liquid media. A 
standardized inoculum of mycobacteria from Dubos broth was introduced into media 
containing the following drug concentrations (Ilg/ml): -
INH - 0.1; 1.0; 4.0; B.O and 16.0 
RFA - 0.5; 2.0; 4.0; B.O and 12.0 
The growth index in the drug-containing vials was compared to the growth index in a 
drug-free control vial. The instrument was operated according to the manufacturer's 
instructions and as per the standard operating procedures of the laboratory. 
Microbiological Definitions 
A multi-drug resistant patient was defined as a patient with resistance to at least both 
INH and RFA confirmed with drug susceptibility tests. 
A drug-sensitive patient was defined as a patient who was sensitive to both INH and 
RFA regardless of the presence of resistance to the other drugs tested. Where this could 
not be confirmed using susceptibility tests, the classification was based on the presence 
of at least 3 consecutive monthly sputum smears that were negative for acid fast bacilli. 
This latter clinical definition was also applied if resistance to any drug other than INH and 
RFA was noted. 
Patients who were resistant to either INH or RFA (but not both drugs concurrently) were 
not classified. 
HIV SEROLOGY AND VIRAL LOAD 
Patients' HIV status was determined using the AxSymR HIV-1/HIV-2 microparticle 
enzyme immunoassay (MEIA) System (Abbott Diagnostics). All positive results were 
checked using the VironostikaR HIV Uni-Form II plus 0 System (Organon Teknika) , an 
enzyme linked immunosorbent assay (ELISA) for the determination of antibodies to 
HIV-1 and HIV-2. 
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The viral load of patients who were found to be HIV+ was determined using the 
Amplicor HIV-1 Monitor RTest (Version 1.S). This is a Polymerase Chain Reaction 
(PCR) n'ucleic acid amplification test for the quantitation of HIV-1 RNA in clinical 
specimens. 
These tests were performed according to the manufacturer's instructions at the 
Department of Virology, University of Natal. 
LIVER FUNCTION TESTS 
Liver function tests (LFT) were conducted as part of the routine care of the patient and 
the results were obtained from the patients' case records. These tests were 
conducted at KGV laboratory on a Beckman CXSCE Autoanalyser (Beckman 
Instruments, United States) . 
TUBERCULOSIS DRUG ASSAYS 
The assay of INH and RFA in patient sera was conducted using a validated high 
performance liquid chromatographic (HPLC) assay technique at the Department of 
Pharmacology, University of Cape Town. The assay procedure was developed in-house 
(Zent and Smith, 1995) and is described briefly below. 
Both drugs were removed from serum by solid phase extraction on Bond ElutR C18 
columns (Analytichem International) . Unbound material was removed from the 
column with 2x2ml aliquots of methanol, followed by 2x2ml aliquots of water and 
finally 1 ml of O.OSM sodium phosphate buffer pH4.S (washing buffer) . Thereafter, 
O.Sml of patient serum was applied to the column, washed with 1 ml of washing buffer 
and eluted using O.Sml acetonitrile and O.Sml methanol to extract the INH and RFA 
respectively. 
RFA was assayed at room temperature by injection of the eluent onto a SpherisorbR 
SS C8 (1S cm x 0.46 cm) column fitted with a PelliguardR LC 8 (2.S cm x 0.46 cm) 
guard column. The mobile phase comprised 80% acetonitrile and 20 % of 0.1 % 
trifluoroacetic acid (TFA) in water. Ultraviolet detection occurred at a wavelength of 
270 nm. A maximum of 10 samples was extracted per batch of samples to ensure 
stability of the RFA during the assay. Under the chromatographic operating 
conditions, the retention time for RFA was approximately 4 minutes. 
For the assay of INH, 400 III of eluent was first evaporated to dryness on a centrifugal 
vacuum concentrator and then reconstituted with O.S ml of mobile phase. The 
resulting solution was injected at room temperature onto a SpherisorbR SS C8 
reversed phase column (2S cm x 0.46 cm) fitted with a PelliguardR LC 8 (2.S cm x 
0.46 cm) guard column. The INH was eluted isocratically using 4% acetonitrile and 
96% of 0.6% TFA in water and subjected to ultraviolet detection at a wavelength of 
270nm. The retention time for INH was approximately 3 minutes. 
The regression curves for both drugs were linear over the concentration range 0.02 -
20 Ilg/ml. Quantitation of the chromatograms was by the peak area method. The limit 
of quantitation (LQ) was O.OS Ilg/ml for both assays. The inter-day and intra-day 
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coefficient of variation for INH at 0.05 Ilg/ml ~as 4.3 % and for RFA at 0.05 Ilg /ml was 
5.81lg/ml. 
Pharmacokinetic and Statistical Analysis 
Data collected in the course of this study was organised and coded onto data collection 
forms before being captured into computer files. Computer management of the data 
utilised Microsoft Excel for Windows 95R Version 7. All data entries were cross-checked 
for accuracy of data capture. 
Demographic, clinical and radiological characteristics of the groups were compared by 
using the chi-square test for categorical variables. Analysis of variance (ANOVA), the t-
test or the Kruskal-Wallis test was used for continuous variables. Odds ratios were 
calculated as measures of association and 95% confidence intervals were used to 
indicate the precision of the point estimates. 
The software programme, Epi-Info Version 6.04b (Centers for Disease Control and 
Prevention (CDC), USA and WHO, Geneva), was used for statistical analysis. 
Unless otherwise indicated as more stringent, statistical significance,was assumed at the 
p < 0.05 level. 
NON COMPARTMENTAL PHARMACOKINETIC DATA ANALYSIS 
Data 
This analysis included only those patients in whom sufficient samples had been drawn to 
characterise the full concentration vs time profile (i.e. ~ 5 drug concentration data points) . 
In addition, any patient who had received additional unscheduled extra doses of INH or 
RFA were excluded from this data-set. Patients who had received INATR (containing INH 
in combination with thiacetazone) on a three times-a-day schedule were also excluded 
as blood samples were not drawn at "descriptive" times in these patients. 
Calculation of Parameters 
Pharmacokinetic parameters i.e. area under the serum concentration-time curve (AUC), 
the highest observed serum concentration (Cmax) and the time to the Cmax (tmax) were 
obtained using noncompartmental analysis (NCA) methods (WinNonlin Professional 
Edition Ver 1.5, Scientific Consulting Inc.). 
A 24-hour AUC was calculated as follows: steady state was assumed, the sample times 
for the 2 dosing intervals were combined and the concentration at the end of the dosing 
interval was assumed to be equal to that measured prior to drug administration. All 
serum drug concentrations reported as below the limits of quantitation (LQ) of the assay 
were recorded as 0.5xLQ i.e. 0.0251lg/ml. The terminal elimination half-life (tY2) was 
determined by curve stripping of the terminal elimination portion of the serum 
concentration versus time curve. Any concentration recorded as below LQ was 
excluded from the calculation of tY2. · Clearance (CUF) and apparent steady state volume 
of distribution (Vss/F) were calculated using non-compartmental methods and were 
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scaled to bioavailability (F) since there was no data from an intravenous reference 
product. 
The pharmacokinetic parameters were compared using ANOVA with Group status 
(Figure 4.1) as the treatment effect. If significant differences were found then pairwise 
comparisons were made using Duncan's multiple range test. 
POPULATION PHARMACOKINETIC ANALYSIS 
Data 
All patients receiving the drugs of interest were included in the NONMEM dataset. 
Covariates 
In addition to the primary research variables of drug susceptibility and HIV status, 
there were several other covariates that were tested for an influence on the 
pharmacokinetics of INH and RFA. The demographic characteristics investigated 
were age, weight and sex. The effect of severity of TB on the pharmacokinetics was 
evaluated using the radiographic severity score, associated disease states and the 
number of drugs to which an MDR-TB patient was resistant. All liver function results 
were also tested. Any concomitant medications administered within 48 hours of the 
pharmacokinetic study day were grouped together according to pharmacological 
class. These included enzyme inducers, enzyme inhibitors, antacids, drugs affecting 
gastric motility, non-steroidal anti-inflammatory drugs, iron preparations and 
antihistamines. The influence of other anti-TB drugs was tested individually. In the 
case of RFA, the number of days since starting treatment was used to determine the 
time of maximal enzyme auto-induction. Miscellaneous covariates tested for an 
influence on the pharmacokinetics of INH and RFA included the history of previous TB 
treatment. 
Missing Data 
During the NONMEM analysis, missing continuous data were re-coded to the median 
value. Those with missing indicator variables ('yes/no' data) were regarded as being 
negative for the covariate of interest. While this procedure is unlikely to influence the 
estimation of any parameter estimate, it may inflate the inter-individual variability. This 
should not have had any significant effect on the final results due to the low 
prevalence of missing data in this study. 
Description of Population Pharmacokinetic Models 
Compartment Model 
One- and two-compartment linear models were tested in order to determine the basic 
structural pharmacokinetic model for the INH and RFA population pharmacokinetic 
analysis. 
This was communicated to NONMEM by the choice of the appropriate ADVAN 
subroutines from the PREDPP library of subroutines. For the one-compartment 
model, ~DVAN 1 or 2 was selected for the zero order or first order absorption models, 
respectively. In the case of the two-compartment model, ADVAN 3 or 4 was chosen 
for the zero order or first order absorption, respectively. 
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In the case of the one-compartment model , the parameters of Cl and V were 
obtained by choosing the TRANS 2 program, which re-parameterises the elimination 
rate constant (KE) in terms of Cl and V. The two compartment model was re-
parameterized as Cl, central compartment volume (V2), inter-compartmental 
clearance (Q) and peripheral volume (V3) by means of the TRANS 4 subroutine. 
The first order absorption models parameterized the absorption process in KA while 
the zero order absorption models estimated the duration of the absorption process in 
the parameter 01. 
Assuming that the one- and two-compartment models are stated in more generic 
terms, viz. as X~ ~hi~~ is th~ /h observ~tion (i :e. ~ .drug c~ncentration at a specified 
time) from the I Indlvldualm a population of mdlvlduals (I =1,2, ... N) then the 
structural pharmacokinetics are described in a non-specific way by Equation 1. 
Equation 1 
The symbol f represents the structure of the compartment model, which is a function 
of the known quantities, x (Le. dose and time), and the parameters, ~ (e.g. KA, V and 
Cl). The quantities in x are measurable in the experiment and are therefore called 
fixed effects, in contrast to effects that are not known and are called random effects 
(see below). The parameters in the parameter vector ~ are called fixed effect 
parameters because they quantify the influence of the fixed effects on the dependent 
variable. 
Parameter model 
A general model for the fixed effects parameters ~j may be written as: 
~j = g(Zj, 8) 
Equation 2 
Here, g is a structural type model that is a function of the fixed effects Zj (e.g. 
continuous variables such as weight or categorical variables such as presence or 
absence of MOR-TS) and the fixed effects parameters 8. 
Pharmacostatistical Model 
The deviations of the parameters ~j for a particular individual from the true (but 
unknown) population mean values (inter-individual variability) were modelled using the 
exponential model. 
Equation 3 
H.er~ TJj are r~ndom variables which are assumed to be multivariate normally 
distributed, with zero means and whose squares represent the respective variances of 
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the parameter. These estimates were reported by NONMEM in its OMEGA matrix. 
The deviation of the observed concentration from that predicted by the model (intra-
individual or residual variability) was estimated using a combined additive and 
constant co-efficient of variation model. 
Equation 4. 
Here €(1 h represents the proportional component of the deviation while €(2) ij 
represents the additive part of the error. These error terms are also assumed to be 
random variables which are assumed to be multivariate normally distributed, with zero 
means and whose squares represent the respective variances of the concentration . 
These estimates were reported by NONMEM in its SIGMA matrix. 
Mixture Model 
The proportion of slow and fast acetylators of INH and the typical values of their 
pharmacokinetic parameters were determined using a mixture model (Appendix L) in 
the NONMEM program. 
A mixture model assumes that the population consists of 2 or more sub-populations, 
each approximating a normal distribution and each sub-population having its own 
model. It is not known a priori into which sub-population each individual in the 
population belongs, although it is assumed that 1 of the models describes the 
observations for that particular individual. NONMEM computes mixing probabilities 
corresponding to the sizes of the sub-populations. 
In this case of slow and fast acetylators, it was assumed that some fraction p of the 
population has one set of typical values for the pharmacokinetic parameters and the 
remaining fraction 1-p has another set of typical values. 
The parameter models were described as: 
Subpopulation 1: 
Subpopulation 2: 
CL = 81exp..,1 
V = 83exp..,2 
CL = 8281exp..,1 
V = 8483exp..,2 
The parameters 82 and 84 are the fractional differences in the typical values between 
the 2 sub-populations. 
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With a particular set of values for the population pharmacokinetic parameters and 
their estimates of variability , NONMEM classifies each individual into 1 of the 2 sub-
populations. For each possible model, the empirical Bayes posterior probability that 
the relevant model describes the observations is computed by the NONMEM 
likelihood function. The individual gets classified into the most probable of the 2 sub-
populations. 
Computer Software and Hardware 
Population pharmacokinetic data analysis was conducted using Nonlinear Mixed 
Effects Modelling with the first-order method as implemented in the computer 
program, NONMEMR Version IV Level 2.1. The companion programs
R 
to N~NMEMR 
were also used i.e. NMTRANR, the data pre-processor and PREDPP Version III 
Level 1.0 with its library of population pharmacokinetic models (Boeckmann et al. 
1994). All NONMEMR analyses were performed in DOSR windows on a Pentium 
200MMX IBMR-compatible personal computer operating under Windows 95R. All 
NONMEMR and related subroutines were compiled using the Lahey F77 -EM32 
Fortran 77 Language System (Lahey Computers Systems Inc 1992). 
Exploratory data analysis, model building and graphical presentations utilised XposeR 
Version 2.0 (Jonsson and Karlsson, 1997) within the S-Plus for WindowsR Version 3.3 
Release 1 environment (Mathsoft, Inc). 
Model building was conducted using a combination of the procedure described by 
Mandema et al (1992) and the NONMEMR Users Guides (Boeckmann et al. 1994) . 
The criteria for assessment of the different models are described in the Model 
Diagnostic Tools. 
Model Diagnostic Tools 
During model building, the effect of a change to the model was assessed by several 
goodness of fit characteristics. The primary criterion was the minimum value of the 
objective function (OBF). In addition , the effect on unexplained variability in the model 
and on graphical plots was also considered. 
Change in the Objective Function 
This global measure of goodness of fit is based on the final parameter estimates and 
is equal to minus twice the log likelihood of the data. A difference in the minimum 
value of the objective function (DOBF) between 2 models is asymtotically chi square 
distributed with degrees of freedom equal to the number of parameters added to the 
model. A decrease in OBF of ~ 3.84 is significant at p s; 0.05 when a single parameter 
has been added into the model. This was used as the acceptance criterion in the 
univariate analysis (Step 3) and in the model build-up (Step 4). An increase in OBF of 
~ 11 is significant at p s; 0.001 when a single parameter has been deleted from the 
model. This was used as the acceptance criterion during the model deletion stage 
(Step 5) as a "penalty" for the multiple comparisons. 
Decrease in Unexplained Variability 
This means that the addition of the parameter into the model "explains" some of the 
interindividual variability that was previously part of the random "noise". Sometimes 
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this could also have manifested as part of random intraindividual variability prior to 
elaboration of the model. 
Graphical Plots 
Model Prediction and Individual Predictions vs Dependent Variable 
The data should be distributed as close as possible to the line of identity i.e. the line 
corresponding to perfect correlation between predicted and observed concentrations: 
Model Predictions and Individual Predictions vs Independent Variable 
These graphs should mimic the graph of observed concentration vs time plot. 
Weighted Residuals vs Dependent and Independent Variable 
These plots should show no pattern . The unexplained part of the data should manifest 
as featureless random noise. Outlying values should remain within 3 weighted 
residual units. 
Stages in Population Pharmacokinetic Model Building 
Step 1 - Data Checkout 
A basic NONMEM run with no covariates was conducted to produce the tables 
necessary for data checkout in XposeR. 
Step 2 - Structural Pharmacokinetic Model Development 
The basic structural pharmacokinetic model was developed using the Model 
Diagnostic Tools described above. One and two compartment models were compared 
as well as various options to characterise the absorption profile i.e. first order, zero 
order or fixed absorption rate constant with estimated variability. If the estimate of any 
parameter (e.g. KA) required confirmation or needed to be fixed to a particular value 
(e.g. due to a absence of an adequate amount of data), then the sensitivity analysis 
procedure (Wade et al. 1993) was performed. In this procedure, the parameter was 
fixed to various values and the OBF and parameter estimates obtained were 
compared. This was with a view to determining a value of the parameter which 
resulted in stable parameter estimates and/or the lowest OBF. 
The exponential error model was used for inter-individual variability while the 
combined additive and exponential error model was used for the intra-individual 
variability. 
Step 3 - Exploratory Data Analysis and NONMEM Univariate Analysis 
At the end of Step 2, collections of the individual Bayesian estimates for each 
parameter in the model with no added covariates were obtained using the 
'POSTHOC' feature in NONMEM. 
Each collection was treated as data and its distribution and relationship with 
covariates were investigated using graphical displays and generalized additive models 
(GAM) in XposeR. The primary intention was to identify non-normal parameter 
distributions and to examine potential relationships between covariates and 
parameters. 
Simultaneously, each covariate was added into the parameter model (KA, CUF and 
V/F) one-at-a-time and its effect on the model was determined using the Model 
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Diagnostic Tools described above. The OBF value obtained from the final model in 
Step 2 was used as the reference in this univariate analysis procedure 
Step 4 - Step-wise Build-up to Full Model 
The covariates that caused a statistically significant improvement in the fit of the data 
in Step 3 were ranked according to the size of the DOBF. Covariates were then 
progressively added into the model starting with the covariate that caused the greatest 
DOBF and proceeding down the rank order established in the univariate analysis. The 
effect of each new addition was evaluated and it was retained only if the Model 
DiagnosticTools suggested an improvement in the fit of the data. Typically Step 4 
results in a fairly large full model. 
Step 5 - Step-wise Deletion to Final Model 
The complete model from Step 4 was likely to contain redundant, confounded or 
imprecisely estimated terms. The stepwise deletion of covariates was done in 2 
stages. 
Covariates in the full model were set to their NUll values (i.e. that value which 
effectively removes the parameter from the model) one-at-a-time (with replacement of 
the previously removed covariate) and the effect on the model fit was evaluated. The 
covariates were ranked according to the size of the increase in DOBF caused by their 
removal from the model. 
The covariates in the full model were subsequently removed in a step-wise manner 
according to the established rank order. At this stage of the model building, a 
covariate was only retained in the model if its removal caused an increase in DOBF of 
~ 11 as discussed above. 
Finally, the covariance step was implemented on the final NONMEM model to 
establish parameter preCision and correlations. The relative importance of the additive 
and constant coefficient of variation error estimates was evaluated with a view to 
determining whether a simpler error model would have been appropriate. 
Step 6 - Confirmation of Final Model 
The final NONMEM run was confirmed. The strategy employed was to delete those 
parameters with large relative standard errors (RSE) and whose confidence intervals 
included the NUll values. The validity of the deletion was confirmed if the magnitude 
of the standard errors and RSE's of the other parameters decreased. 
Interpretation of the NONMEM output 
The precision (RSE in percent) in estimating the parameters of the model was 
calculated by dividing the standard error of the estimate of each parameter by its 
value and expressing the result as a percentage (Boeckmann et al. 1994). 
The inter-individual variability in the primary pharmacokinetic parameters (KA, Cl, V, 
TLAG) was calculated by taking the square root of the individual elements of the 
OMEGA matrix and expressing the result as a percentage of the population mean 
values. 
The intra-individual variability was estimated by fixing the estimate of the SIGMA 
matrix to unity and redirecting the estimate into 2 e parameters, 1 for the CCV error 
component and the other for the additive error. These were coded in such a way as to 
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provide the estimates of the variability directly (Appendix Hand K) , i.e. without the 
need to obtain the square root of the parameter estimate. This code was also 
necessary in order to obtain some of the diagnostic plots in Xpose2R (Jonsson and 
Karlsson, 1997). 
The 95% confidence intervals (CI) for the parameters were calculated by adding the 
parameter estimate to ± 1.96 X the standard error of the estimate. 
CALCULATION OF THE DERIVED PHARMACODYNAMIC PARAMETERS 
The relationship between the pharmacokinetic parameters and the minimum inhibitory 
concentration is illustrated in Figure 4.2. 
Assumptions 
For purposes of these calculations, if the MIG was greater than the highest 
concentration tested, then the MIG was assumed to be equal to the highest 
concentration tested. If the MIG was lower than the lowest concentration tested, then 
the MIG was assumed to be equal to this lowest qmcentration tested. In the case 0"( 
INH, this was 16 and O. 1 Jig/ml respectively. For RFA, the corresponding assumed 
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Figure 4.2 - A hypothetical serum concentration versus time curve, displaying the maximum 
serum concentra~ion (<?max), the area under the curve (AUC), the time above the MIC (12 _ 
T1) , and t~e ~elatlonshlp between ~hese parameters and the minimum inhibitory concentration 
(MIC). Solid line = drug concentration; Dashed line = MIC (Peloquin, 1996) 
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Cmax:MIC 
The pharmacokinetic parameters used in these calculation.s ~ere the Bayesian . 
individual estimates obtained using the post-hoc feature within NONMEM. Cmax was 
calculated using Equations 5 and 6 (Gibaldi and Perrier, 1982) . 
t max 
= in (KA / KE ) + TLA G 
KA - KE 
Equation 5 
Where tmax is the time at which Cmax is achieved, KA is the absorption rate constant 
and KE=CLN. 
C 1 
__ D_o_s_e __ *_KA ___ * (( e -KE "I ) _ (e - KA "I » 
V * (KA - KE ) 
Equation 6 
Where t = tmax and Ct = Cmax i.e. the concentration at tmax• 
The Cmax was divided by the MIC to obtain the ratio of Cmax:MIC. 
T>MIC 
The time above the MIC (T>MIC) was determined using the Newton-Raphson iterative 
technique. 
In brief, the value of Ct in Equation 6 was replaced with the MIC value for the 
individual patient. Thereafter, the 2 time points (T1 and T2, . before and after 
attainment of the Cmax respectively) at which the patient's serum concentrations were 
equal to the MIC, were computed . 
AUC>MIC 
The AUC > MIC was calculated using Equation 7. In this equation, the total area 
between T1 and T2 is computed by integration of Equation 6. Thereafter the area 
below the MIC, given by the rectangle formed by the MIC and T2-T1 , is subtracted 
out. 
AUC >MIC =(( (2 Dose *KA *(e - KE " -e - KA") dt )- (MIC * (T 2 - Tl »)] 
JTI V * (KA - KE ) 
Equation 7 
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Demographics and Clinical Characteristics 
Results 
One hundred and forty six patients were invited to participate in this study. Eight 
patients declined and thus 138 patients were recruited into the study. Their 
demographic and clinical characteristics are sum~arised in Table 5.1 and listed in 
detail in Appendix B. 
The study population comprised of 135 African patients, the remaining 3 being 1 
White patient and 2 so-called "Coloured" patients. There were 62 MDR-TB patients 
and 74 drug-sensitive TB patients. The drug susceptibility status of 2 patients (1 HIV+ 
and 1 HIV-) was not classified as they were found to be resistant to INH alone. 
Therefore the sample for the comparative study of MDR-TB and drug-sensitive TB 
consisted of 136 patients. The remaining 2 patients were, however, included in the 
data set for the population pharmacokinetic analysis where covariC!tes other than 
MDR-TB were studied. In 10 of the patients, the organism failed to grow during drug 
susceptibility confirmation and their classification into the drug-sensitive TB group was 
based on the presence of at least 3 consecutive monthly sputum smears that were 
negative for acid fast bacilli. 
The mean age of the HIV+ patients was lower than that of the HIV- patients (31 .0 ± 
8.5 versus 39.4 ± 12.1 years; p<0.0001). There was no significant difference in the 
mean weight of the patients in the different groups. Although the HIV+ patients had a 
lower mean weight than the HIV- patients, this was not statistically significant (53.74 ± 
10.21 vs 56.45 ± 11.81 kg). 
There were more females than males recruited into the study, a larger proportion of 
whom were HIV+ (53% of females versus 31% of males; p=0.01) . There was no 
significant difference with regard to the sex distribution of subjects into the MDR-TB or 
drug-sensitive TB groups. 
There were significantly more MDR patients who had a history of previous treatment 
for TB (79%) compared to new cases (21%) (odds ratio 7.85, CI 3.34 to 18.77; 
p<0.0001). Among the re-treatment cases that developed MDR-TB, there was a larger 
proportion of patients whose previous treatment had been interrupted or failed . 
However this was not statistically significant (odds ratio 2.34, CI 0.74 to 7.48, p= 
0.08). 
The clinical condition most frequently encountered in association with TB was 
anaemia (35%). A large number of the HIV+ patients presented with oral candidiasis 
(24%). Two patients had genital herpes (viral load unmeasurable in 1 and 2.7x106 
copies per millilitre in the other) and 1 had Karposi's sarcoma (viral load 2. 7x1 05 
copies per millilitre). 
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Table 5.1 - Demographic and Clinical Characteristics of Multi-drug Resistant 
and Drug-Sensitive Pulmonary Tuberculosis Patients 
ALL MDR-TS DRUG-SENSITIVE TS 
PATIENTS HIV+ HIV- HIV+ HIV-
(n=138)1 (n = 21) (n = 41) (n = 37) (n = 36) 
Age (years) - mean ± sd 35.7± 11.5 33.2 ± 9.3 39.2 ± 10.5 29.2 ± 7.1 40.3 ± 13.5 
Weight (kg) - mean ± sd 55.2 ± 11 .2 53.2 ± 11 .3 56.1 ± 11.4 54.3 ± 9.7 57.2 ± 12.4 
Sex - number (%) of patients 
Males 61 (44) 8 (38) 24 (59) 10 (27) 18 (50) 
Females 77 (56) 13 (62) 17 (41) 27 (73) 18 (50) 
History of Prior TS - Number (%) of 
patients 
New Case 64 (46) 7 (33) 6 (15) 29 (78) 21 (58) 
Re-treatment -
After previous cure or treatment 24 (17) 4 (19) 9 (22) 2 (5) 9 (25) 
completion 
After previous treatment interruption or 50 (36) 10 (48) 26 (63) 6 (16) 6 (17) 
failure 
HIV Viral Load - copies of RNAlml 
Geometric mean 6.2 x 104 7.6x104 - 6.3 X 104 -
Median 6.9 x 104 9.3 X 104 - 7.2 X 104 -
Minimum 200 1.4 x 103 - 200 -
Maximum 2.7x106 2.4 x 106 - 2.7x106 -
Other Disease States - Number (%) 
of patients 
Anaemia 48 (35) 7 (33) 3 (7) 23 (62) 14 (39) 
Oral Candidiasis 18 (13) 3 (14) 2 (5) 11 (30) 2 (6) 
Diabetes mellitus 10 (7) - 6 (15) - 4 (11) 
Hypertension 7 (5) - 5 (12) - 2 (6) 
Epilepsy 6 (4) - - 5 (14) 1 (3) 
Congestive Cardiac Failure 3 (2) - 1 (2) - 2 (6) 
(3enital Herpes 2 (1) - - 2 (5) -
Karposi's Sarcoma 1 - - 1 (3) -
The total number of MDR-TB and Drug-sensitive TB patients does not add up to total number of patients Included In the study. This IS because 
the drug susceptibility status of 2 patients (1 HIV+ and 1 HIV-) could not be classified as they were found to be resistant to INH alone. The HIV 
status of 1 drug-sensitive patient could not be determined as the patient withdrew consent for HIV testing after recruitment into the study. 
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HIV Status and Viral Loads 
There were 59 HIV+ patients and 78 HIV- patients. The HIV status of 1 drug-sensitive 
TB patient could not be determined as the patient withdrew consent for HIV testing 
after recruitment into the study. A summary of the viral load data is presented in Table 
5.1 and reported in detail in Appendix C. 
A wide range in viral load was noted in the HIV+ patients. The majority of samples 
produced good viral RNA recovery. However, in samples from 2 patients, the assay 
repeatedly produced inadequate RNA internal controls while in a third patient, the 
system recorded a level of <200 copies of RNA per millilitre. One of these patients 
had concurrent genital herpes and severe oral candidiasis. In all of these 3 patients, 
their HIV status was confirmed using at least 2 immunoassay tests. These patients 
were retained as HIV+, a viral load of 0 copies per millilitre was recorded for the 2 
patients with inadequate RNA controls while the patient with a level of <200 was 
recorded as having a viral load of 200 copies per millilitre. 
There was no significant difference in the HIV viral load of the MDR-TB and the drug-
sensitive TB patients in the HIV+ sub-groups. 
Radiology 
Table 5.2 describes the severity of pulmonary involvement with TB after examination 
of a single posteroanterior (PA) chest radiograph. The radiographs for 3 patients could 
not be located at the time of this assessment and were therefore excluded. The 
majority of the patients included in the study had extensive lung field involvement with 
multiple cavitary lesions. There was no statistically significant difference between the 
4 groups or between MDR-TB and drug-sensitive TH patients with respect to the 
severity scores. However, the HIV+ patients (from both the MDR-TB and drug-
sensitive TB groups combined) had lower radiological severity scores than the HIV-
patients from these groups (extent 4.8 ± 1.1 vs 5.2 ± 1.0 p = 0.02; cavitation 3.8 ± 1.6 




Table 5.2 - Radiological Description of Disease Severity in Multi-drug Resistant 
and Drug-Sensitive Pulmonary Tuberculosis Patients 
SEVERITY DESCRIPTION ALL MDR-TB DRUG-SENSITIVE 
SCORE PATIENTS TB 
(n = 135)1 
HIV+ HIV- HIV+ HIV-
(n = 20) (n = 39) (n = 37) (n = 36) 
Extent of Lung Involvement (Number of 
1 
patients) 
$4cm2 2 - - 2 -
2 > 4cm
2 to < 1/6 of 1 lung field 1 - 1 - -
3 ~ 1/6 to <1/3 of 1 lung field 9 2 2 1 4 
4 ~ 113 to < 2/3 of 1 lung field 23 4 4 11 4 
5 ~ 2/3 to the whole of 1 lung field 44 10 13 12 8 
6 larger than 1 lung field 56 4 19 11 20 
Mean Severity Score ± sd for extent of 5.0 ± 1.1 4.8 ± 0.9 5.2 ± 1.0 4.7 ± 1.2 5.2 ± 1.1 
lung involvement 
Classification of Cavitation (Number of 
Patients) 
0 No cavities 7 1 - 5 1 
Single Cavity: 
1 $ 2cm in diameter 4 - 2 1 1 
2 >2cm to < 4cm in diameter 6 1 2 - 3 
3 ~ 4cm in diameter 7 2 2 2 1 
Multiple Cavities: 
4 largest cavity $ 2cm in diameter 62 9 15 21 16 
5 largest cavity> 2cm to < 4cm in diameter 22 2 10 5 5 
6 largest cavity ~ 4cm 27 5 8 3 9 
Mean Severity Score ± sd for lung 4.1 ± 1.5 4.2 ± 1.5 4.4 ± 1.3 3.6 ± 1.7 4.3 ± 1.5 
cavitation 
- - .. The radiographs for 3 patients could not be located at the lime of this assessment. The total number of MDR TB and Drug sensitive 
TB patients do not add up to total number of patients included in the study. This is because the drug susceptibility status of 2 patients (1 
HIV+ and 1 HIV-) could not be classified as they were found to be resistant to INH alone. The HIV status of 1 patient could not be 
determined as the patient withdrew consent for HIV testing after recruitment into the study. 
Liver Function Tests 
There were no significant differences among the 4 groups with regard to the serum 
liver enzyme measurements (Table 5.3). However, in the case of the gamma glutamyl 
transpeptidase (GGT), alanine transaminase (AL T) and the aspartate transaminase 
(AST) results, although the median values remained within the normal range, there 
were individual patients with results above the upper limit of the normal range. 
In the case of the measurements concerned with protein metabolism, the HIV-, MDR-
TB patients had significantly higher albumin levels than patients from the other groups 
(p < 0.001). This observation could not be extended into a statistically significant 
difference between either the MDR-TB and Drug-sensitive TB patients or the HIV+ 
and HIV- patients. 




Table 5.3 - Liver Function Test Results (median and range) in Multi-drug 
Resistant and Drug-Sensitive Pulmonary Tuberculosis Patients 
Results 
NORMAL ALL MDR-TB DRUG-SENSITIVE TB 
RANGE PATIENTS 
(n=123) 1 
HIV+ HIV- HIV+ HIV-
(n=19) (n=36) (n=32) (n=34) 
Alkaline phosphatase (ALKP) uti 83 79 79 89 81 
80-306 (43-261 ) (43-261 ) (47-131) (47-202) (45-232) 
Total bilirubin (Bill) Ilmolll 10 9 10 11 11 
3-17 (2-33) (3-21 ) (4-33) (2-23) (4-22) 
Albumin (ALB) gil 25 24 30 23 24 
38-48 (14-88) (14-36) (19-88) (15-36) (16-46) 
Globulin (GLOB) gil 52 65 48 56 47.5 
20-32 (24-107) (48-82) (24-87) (37-107) (24-80) 
Gamma glutamyl transpeptidase 37 47 32 .5 78.5 59 
(GGT) ull 11-49 (12-233) (21-150) (18-156) (12-134) (19-233) 
Alanine transaminase (AL T) ull 16 17 16 16.5 16 
0-41 (5-112) (7-37) (5-66) (9-112) (8-52) 
Aspartate transaminase (AST) ull 31 33 25 34 31 
0-37 (15-104) (16-66) (15-94) (17-87) (15-104) 
Liver function test results were not available for 15 of the 138 patients In the study. The total number of MDR-TB and Drug-sensitive 
TB patients does not add up to the total number of patients included in the study. This is because the drug susceptibility status of 2 
patients (1 HIV+ and 1 HIV-) could not be classified as they were found to be resistant to INH alone. The HIV status of 1 patient could 
not be determined as the patient withdrew consent for HIV testing after recruitment into the study. 
Appendix C is a detailed listing of the liver function test results for the individual 
patients. 
Mycobacteriology 
A summary of the mycobacteriology results is presented in Table 5.4 while individual 
patient's susceptibility results are recorded in Appendix D. 
In the MDR-TB patients, resistance to 2 drugs only, i.e. INH and RFA, was rare - the 
majority of patients, 52 of 62 (84%), patients displayed resistance to ~ 5 drugs. There 
was no significant difference in the mean number of drugs to which isolates showed 




Table 5.4 - Summary of anti-TB drug susceptibility results in Multi-drug 
Resistant and Drug-Sensitive Pulmonary Tuberculosis Patients 
All Re-Treatment Odds Ratio and 95% 
cases Cases Confidence interval (CI) 
(n=136)' Yes No Point CI 
(n=73) (n=63) Estimate 
Number (%) of isolates 
DRUG-SENSITIVE T8 74 (54) 24 (33) 50 (79) 
MULTI-DRUG RESISTANT T8 62 (46) 49 (67) 13 (21) 7.85 3.34 - 18.77 
2 drug resistant (i.e. INH & RFA 1 (0.7) 1 (1.4) 0(0) 
only) 
3 drug resistant 6 (4.4) 6 (8.2) 0(0) 
4 drug resistant 3 (2.2) 2 (2.7) 1 (1 .6) 
5 drug resistant 5 (3.7) 4 (5.5) 1 (1.6) 
6 drug resistant 14 (10.3) 9 (12.3) 5 (7.9) 
> 6 drug resistant 33 (24.3) 27 (37) 6 (9.5) 
Mean ± SO number of drugs to 6.8 ± 2.2 6.7 ± 2.3 6.6 ± 1.5 
which the MDR-T8 isolates were 
resistant . . 





By definition, patients with drug-sensitive TB were those who did not have combined 
resistance to INH and RFAbut who may have had resistance to other anti-TB drugs. 
This group included 51 patients with isolates sensitive to ALL drugs tested and 23 
patients with isolates resistant to 1 or more second-line anti-TB drugs other than INH 
and/or RFA. This latter subgroup consisted of 3 patients with resistance to 
streptomycin, 17 with resistance to ethionamide, 14 with resistance to cycloserine and 
5 with resistance to thiacetazone. These 23 patients complied with the clinical 
definition for drug-sensitive TB i.e. at least 3 consecutive monthly sputum smears that 
were negative for acid fast bacilli. 
The drug susceptibility profiles of the patients included in the study are recorded in 
Table 5.5. 
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Table 5.5 - Drug Susceptibility Profiles in Pulmonary Tuberculosis patients 
Drug Number of isolates Number (%) 
tested Resistant 
Isoniazid 0.2 ug/ml 115 55 (48) 
Isoniazid 1.0 ug/ml 129 64 (50) 
Rifampicin 129 61 (47) 
Ethionamide 119 61 (51) 
Streptomycin 2.0 ug/ml 123 47 (38) 
Streptomycin 10.0 ug/ml 116 37 (32) 
Ethambutol 129 45 (35) 
Thiacetazone 118 38 (32) 
Cycloserine 118 33 (28) 
Kanamycin 119 8 (7) 
Capreomycin 118 7 (6) 
Ciprofloxacin 119 4 (3) 
Ofloxacin 119 3 (2.5) 
The drugs most frequently (greater than 33%) associated with combined resistance to 
INH and RFA were ethionamide, streptomycin, ethambutol , thiacetazone and 
cycloserine. A lower prevalence of resistance (less than 8%) to kanamycin , 
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Figure 5.1 - Bar chart of isoniazid minimum inhibitory concentrations for isolates of 
Mycobacterium tuberculosis obtained from multi-drug resistant and drug-sensitive 
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Figure 5.2 - Bar chart of rifampicin minimum inhibitory concentrations for isolates of 
Mycobacterium tuberculosis obtained from multi-drug resistant and drug-sensitive 
tuberculosis patients (n=103). 
The majority of drug-sensitive TB patients had MICs below the lowest drug 
concentration tested for both INH (0.1 )..lg/ml) and RFA (0.5 )..lg/ml) - Figure 5.1 and 
Figure 5.2. Similarly, the majority of MDR-TB patients had MICs above the highest 
concentration tested for both drugs (INH - 16 )..lg/ml and RFA 12 )..lg/ml) . A mean MIC 
for INH of 7.2 ± 5.2 )..lg/ml was calculated among 39 isolates in which a MIC was 
recorded within the range of breakpoint concentrations tested. In the case of RFA, 
there were only 12 isolates with a MIC within the range of breakpoint concentrations 
tested. The mean MIC among these isolates was 5.3 ± 3.8 )..lg/ml. 
Drug Treatment Regimens and Drug Interactions 
The majority of the patients with drug-sensitive TB were treated with INH, RFA, 
pyrazinamide and ethambutol. The same regimen was administered to 12 of the 
MDR-TB patients who were awaiting drug susceptibility test results at the time of this 
study, and to the 2 patients whose drug susceptibility status was not classified. 
Another 2 patients received ethionamide instead of ethambutol. 
The MDR-TB patients received a regimen that contained at least pyrazinamide, an 
aminoglycoside (either streptomycin or kanamycin) and a quinolone (either 
ciprofloxacin or ofloxacin). MDR-TB patients received between 3 to 6 anti-TB drugs 
(mean 4.2 ± 0.8) - the other drug(s) in the regimen being ethambutol, ethionamide or 
thiacetazone. 
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In all cases, INH and RFA were not part of the anti-TB drug regimen for these patients 
and were added on for purposes of the present study . . 
The majority of the anti-TB drugs were given as a single daily dose either before 
meals (INH and RFA) or after meals (pyrazinamide, ETH, EMB, ciprofloxacin and 
ofloxacin) . The aminoglycosides were administered by intra-muscular injection at a 
dosing frequency of between 3 to 5 times per week. While most patients who had 
been prescribed the quinolones received single daily doses, there were some who 
were given twice daily doses. 
Thiacetazone (60 mg per tablet) was administered with INH (133 mg per tablet) in the 
combination preparation INATR and given 3 times a day. The patients who received 
ethionamide were prescribed a dose of 250 mg 3 times a day. 
In most cases, 2 dose levels of anti-TB drugs were prescribed - the patient's body 
mass of 50 kg dividing the low and the high dose level. Patients weighing less than 50 
kg received 300 mg of INH, 450 mg of RFA, 1000 or 1500 mg of pyrazinamide and 
500 mg of kanamycin or streptomycin . Those weighing above 50 kg received 400 mg 
of INH, 600 mg of RFA, 2000 mg of pyrazinamide and 750 or 1000 mg of the 
aminoglycoside respectively. The dose of ethambutol was between 800 and 1200 mg, 
ciprofloxacin between 750 and 1000 mg per day and ofloxacin 800 mg per day. 
A wide variety of concurrent medications were administered to the subjects in the 
study as part of their routine care. Table 5.6 records the number of individuals 
receiving drugs that were considered to have the potential to interfere with the 
pharmacokinetics of INH and RFA. 
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Table 5.6 - Concurrent Drug Therapy with the Potential to Interfere with INH and 
RFA Pharmacokinetics Administered within 48 Hours of the Pharmacokinetic 
Study Day 
Number %) of Patients 
Drug 
MDR-TS Drug-Sensitive EffecUMechanism Reference 
(n=62) TS 
(n=74) 
Enzyme inducers (Kenny and 
Rifampicin auto-induction Induction of the Strates, 1981; 
Before maximal RFA auto- 41 (66) 6 (8) cytochrome P45011iA DOl/ery, 1991) 
induction (~ 7 days . enzyme system. 
treatment) 
After maximal RFA auto- 21 (34) 68 (92) 
induction (> 7 days 
treatment) 
Carbamazepine 1 (2) 3 (4) Main effect is to reduce (Gelman and 
carbamazepine Rumack, 1998) 
concentrations but INH 
metabolism may also be 
increased. 
Corticosteroid 1 (2) 1 (1) Prednisolone may ,j.. INH (Gelman and 
concentrations by 25% in Rumack, 1998) 
slow acetylators and 40% 
in fast acetylators 
Ketoconazole 0 1 (1) Main effect is to ,j.. (Stockley, 1996; 
ketoconazole Gelman and 
concentrations but INH Rumack, 1998) 
serum concentrations may 
be ,j.. by 25 - 40% and RFA 
serum concentrations may 
be ,j.. by 40 - 50% 
Enzyme inhibitors 
Ethionamide 28 (45) 2 (3) INH serum concentrations (Gelman and 
temporarily increased - not Rumack, 1998) 
necessarily an enzyme 
inhibitor effect 
Quinolones 40 (65) 0 Known inhibitor of 
(ci profloxacin/ofloxacin) microsomal enzymes but 
no reports of drug 




Antacids 5 (8) 3 (4) Absorption of INH (Stockley, 1996; 
decreased especially by Gelman and 
aluminium containing Rumack, 1998) 
antacids 
Hyoscine butyl bromide 4 (5) 0 Decreased gastrointestinal 
motility but no reports of 
interactions with the anti-
Metoclopramide 2 (3) 
TS drugs 
4 (5) Increased gastrointestinal 
motility but no reports of 
interactions with the anti-
TS druQS 
80 
Chapter 5 Results 
Protocol Deviations 
There was a low incidence of protocol deviations in this study. An extra dose of 
medication was administered to 9 patients on the morning of the second study day. In 
another patient, the RFA dose was inadvertently omitted. 
Liver function tests and radiographs were not specifically performed for this study but 
formed part of the routine care of the patient. There were 15 patients with no liver 
function test results in their file and the radiographs of 3 patients were not available at 
the time of this study. 
Non-Compartmental Pharmacokinetic Analysis 
DATA 
The patients participating in the non-compartmental analysis consisted of 106 patients 
on RFA and 92 patients on INH. 
The excluded patients consisted of 22 patients who had insufficient data to 
characterise the full pharmacokinetic profile. Nine patients were excluded because 
they had received additional doses of drug. A further 15 patients who received INATR 
were excluded from the INH analysis while 1 patient was excluded from the RFA 
analysis because his dose had been omitted. 
A full listing of the dose and serum concentration data for RFA and INH is recorded in 
Appendix E and F respectively. 
RIFAMPICIN 
The pharmacokinetic parameters for RFA calculated using non-compartmental 
methods are recorded in Table 5.7. 
MDR-TB patients on RFA had higher AUC and Cmax values and lower CUF values 
than patients with drug-sensitive TB (p < 0.01) - Table 5.7. This was also noted in the 
weight and dose corrected AUC and Cmax values. There were no significant 
differences with the other pharmacokinetic parameters. The MDR-TB patients had 
recent commencement of RFA (and INH) therapy and were likely to be in a pre-
enzyme induced state. After patients had been separated according to the likelihood 
of maximal RFA enzyme auto-induction, i.e. before and after 7 days of daily treatment, 
the differences in the parameters were no longer evident. 
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Table 5.7 - Pharmacokinetic Parameters (mean ± sd) for Rifampicin (before and 
after auto-induction) in Multi-drug Resistant and Drug-Sensitive Pulmonary 
Tuberculosis Patients calculated using Non-Compartmental Analysis Methods 
PARAMETER 
ALL MDR-TB ANOVA 
HIV+ HIV-
DRUG-SENSITIVE TB 
HIV+ HIV-PATIENTS1 p : 
All Patients (n=106j ] 
L-----------~---n-=~1706~--"---n-=~1~6~--,----n~=3~5~--:----n-=~25~--,----n~=~2~7--~------- . 
I Dose (mg/kg) 
i AUC ( ~g hr/ml) 
I cAUC (kg .hr/L) 












I Tmax (hr) 
I ti (hr) 
I CUF (Uhr) 
I V/F (L) 
Dose (mg/kg) 








9.70 ± 1.30 9.52 ± 1.12 ! 9.98 ± 1.24 9.57 ± 1.50 9.55 ± 1.36 0.5 (ns) 
<0.001 4547 ± 2492 , 5037 ± 2116 i 5781± 3227 3381± 1351 3832 ±1 599 
4.74 ± 2.65 ! fr.29 ± 2.18 I 5.88 ± 3.46 ! 3.56 ± 1.34 4.12 ± 2.02 i 
filtt~ III ,~JJJJI i I~~{~I II JJ.WJJ, 
43.81 + 33.33 45.54 ± 30.91 i 37.13 ± 26.11 45.20 ± 21.25 
Patients on rifampicin treatment for < 7 days (n=38) 
n=38 
9.79 ± 1.29 
64.04 ± 28.85 
6.63 ± 3.12 
10.97 ± 4.57 
1.15 ± 0.S4 
2.16 ± 0.70 
2.34 ± 0.43 
9.15 ± 4.07 
30.99 ± 16.58 
n=9 
9.58 ± 1.24 
60.22 ± 18.19 
6.34 ± 1.90 
9.86 ± 2.14 
1.03 ± 0.2 
1.96 ± 0.31 
2.57 ± 0.19 
8.76 ± 2.72 
32.57 ± 11.28 
n=25 
9.95 ± 1.31 
65.60 ± 33.72 
6.69 ± 3.66 
11 .29 ± 5.45 
1.17 ± 0.64 
2.27 ± 0.81 
2.29 ± 0.47 
9.34 ± 4.64 











Patients on rifampicin treatment for c 7 days (n=68) 
n=68 
9.65 ± 1.31 
35.09 ± 14.45 
3.68 ± 1.58 
0.71 ± 0.26 
6.84 ± 2.53 
2.41 ± 1.58 
2.12 ± 0.65 
17.09 ± 9.95 
50.98 ± 37.99 
I 
n=6 I n=10 I n=24 
, 9.45 ± 1.03 I 10.04 ± 1.13 I 9.52 ± 1.51 
I 41 .89 ± 16.33 , 38.33 ± 17.71 I 31 .97 ±10.14 
I 3.93 ±1.79 I 3.85 ± 1.80 1 3.40 ± 1.12 
i
l 
0.74 ± 0.25 . 0.75 ± 0.30 I' 0.73 ± 0.21 
8.02 ± 2.35 I 7.44 ± 2.94 6.92 ± 2.09 
I 1.77 ± 0.41 i 2.78 ± 1.16 II 1.98 ± 0.80 
I 2.47 ± 0.34 I 2.2 ± 0.76 , 2.00 ± 0.62 
I 13.54 ± 5.74 " 16.63 ± 7.63 I 16.63 ± 7.17 
1 48.11 ± 17.36 j 51 .86 + 35.26 46.22 + 21 .07 
7.10 ± 2.81 
0.001 
0.02 
0.05 0.76 ± 0.33 ! 
2.46 ± 1.86 
2.10 ± 0.68 
Q.27 (ns) 
! 0.03 (ns) 
0.003 17.00 ± 12.41 









13.49; 9.14 ! 
25.80; 32.43 
n=25 
9.65 ± 1.33 
37.07 ± 15.60 
3.91 ± 1.84 
0.71 ± 0.28 
6.73 ± 2.58 
2.53 ± 1.92 
2.12 ± 0.68 
17.45 ± 12.78 



















ANOVA = analysIs of vanance, AUC = area under the serum concentration versus time curve, cAUC = weight and dose corrected AUC, 
Cmax = serum concentration at tmax; cCmax = weight and dose corrected Cmax; tmax = time at which maximum serum concentration 
is achieved; t1 = serum half-life; CUF = apparent clearance; V/F = apparent volume of distribution 
'The total number of MDH-TB and Drug-sensitive TB patients does not add up to total number of patients included in the study. This is 
because the drug susceptibility status of 2 patients (1 HIV+ and 1 HIV-) could not be classified as they were found to be resistant to 
INH alone. The HIV status of 1 drug-sensitive patient could not be determined as the patient withdrew consent for HIV testing after 
recruitment into the study. 
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ISONIAZID 
The results of the non-compartmental pharmacokinetic analysis for INH are recorded 
in Table 5.8. The HIV+, MDR-TB patients had higher AUC and Cmax values than the 
patients from the other 3 groups (p ~ 0.03) . These patients also received a higher 
mean dose but this was not significantly higher than that received by patients in the 
other 3 groups. Using an INH half-life of 2 hours as the boundary between the slow 
and fast acetylators (Gelman and Rumack, 1998), there were 7 (8%) slow acetylators 
and 85 (92%) fast acetylators in the present study. 
Table 5.8 - Pharmacokinetic Parameters (mean ± sd) for Isoniazid in Multi-drug 
Resistant and Drug-Sensitive Pulmonary Tuberculosis Patients calculated using 
. Non-Compartmental Analysis Methods 
ALL PATIENTS MDR-TB DRUG-SENSITIVE TB 
PARAMETER (n = 92)1 HIV+ HIV- HIV+ HIV-
ANOVA 
n=13 n=24 n=25 n=27 p 
Dose (mg/kg) 6.53 ± 1.23 7.23 ± 2.09 6.61 ± 0.96 6.41 ± 1.15 6.24 ± 0.94 0.2 (ns) 
AUC (Ilg.hr/ml) 34.45 ± 17.83 52.03 ± 29.91 32.40 ± 12.37 29.65 ± 11 .16 33.47 ± 15.78 0.03 
cAUC (kg .hr/L) 5.26 ± 2.20 7.02 ± 2.32 5.01 ± 2.00 4.67 ± 1.75 5.36 ± 2.37 0.03 
Cmax (Ilg/ml) 6.74 ± 2.26 8.59 ± 2.42 6.75 ± 2.28 6.32 ± 1.50 6.53 ± 2.37 0.02 
cCmax (kg/L) 1.05 ± 0.36 1.23 ± 0.31 1.06 ± 0.44 0.99 ± 0.23 1.05 ± 0.36 0.28 (ns) 
Tmax (hr) 1.35 ± 0.55 1.26 ± 0.46 1.43 ± 0.48 1.33 ± .068 1.33 ± 0.48 0.81 (ns) 
t! (hr) 3.17 ± 0.88 3.55 ± 1.07 3.15 ± 0.91 3.10 ± 0.66 3.11 ± 0.99 0.47 (ns) 
CUF (Uhr) 12.39 ± 5.28 8.56 ± 3.76 12.95 ± 4.33 13.23 ± 5.10 12.87 ± 6.16 0.05 (ns) 
V/F (L) 55.28 + 26.40 39.86 ± 13.69 57.38 + 20.55 59.83 ± 27.83 56.22 ± 31 .10 0.09 (ns) 
-ANOVA analysIs of vanance, AUC - area under the serum concentration versus time curve; cAUC = weight and dose corrected AUC; 
Cmax = serum concentration at tmax; tmax = time at which maximum serum concentration is achieved; ti = serum half-life; CUF = 
apparent clearance; V/F = apparent volume of distribution 
'The total number of MDR-TB and Drug-sensitive TB patients does not add up to total number of patients included in the study. This is 
because the drug susceptibility status of 2 patients (1 HIV+ and 1 HIV-) could not be classified as they were found to be resistant to 
INH alone. The HIV status of 1 drug-sensitive patient could not be determined as the patient withdrew consent for HIV testing after 
recruitment into the study. 
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Population Pharmacokinetic Analysis 
DATA 
All 138 patients participated in the population pharmacokinetic analysis for INH while 
1 patient was excluded from the RFA analysis because his dose had been omitted . 
A full listing of the dose and serum concentration data for RFA and INH is recorded in 
Appendix E and F respectively. 
Missing Data 
The drug susceptibility status of 2 of the 138 patients could not be classified as they 
were found to be resistant to INH alone. Another patient's HIV status could not be 
determined as the patient withdrew her consent for HIV testing after recruitment into 
the study. The former 2 patients were regarded as drug sensitive and the latter patient 
as HIV- for purposes of the population pharmacokinetic analysis. 
There were 15 patients with no liver function test results in their files . There was no 
record of any clinical features of liver function abnormality in these patients. The 
radiographs of 3 patients were not available at the time of the study and thus a 
radiographic severity score in these patients could not be obtained. In all these cases, 
the missing data was recorded as the group median value. 
Separate NONMEM runs were conducted in which the 15 patients with missing liver 
function test results were either included (with the missing data recorded as the group 
median values) or excluded from the dataset. In these runs the influence on the 
decision to include or exclude the relevant covariate from the model was evaluated. 
In the case of INH, there was no significant difference in the OBJ for these 2 alternate 
scenarios. For RFA, there were significant differences in OBJ when the missing liver 
function test results were recorded as the group median as opposed to excluding the 
relevant subjects. However, the decision to include or exclude the relevant covariate 
was not altered. 
RIFAMPICIN 
Basic Structural Pharmacokinetic Model 
The models tested in the development of the basic structural pharmacokinetic model 
for RFA are shown in Table 5.9. The complete list of NONMEM runs conducted during 
the analYSis is recorded in Appendix G. An example of a NONMEM control stream 
used during the RFA analysis is shown in Appendix H. 
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Table 5.9 - Development of the Basic Structural Pharmacokinetic Model for the 
Population Pharrnacokinetic Analysis of Rifampicin in Pulmonary Tuberculosis 
Patients (n=137) 
RUN MODEL INTER-INDIVIDUAL RESIDUAL OBF COMMENTS 
VARIABILITY VARIABILITY 
TJKA TJCUF TJVIF TJTLAG crccv crAnD 
% % % % % uQ/ml 
3 One 60 51 <1 - 45.6 0.53 1474.664 Model was parameterised as KA, CUF and V/F 
compartment - with exponential error terms on the inter-individual 
model with variabilty in the parameters. Residual variability 
first order was modelled with combined additive and 
absorption constant coefficient of variation error terms. Model 
is under-predicting but appears concentrated at 
PRED=11. Outliers were identified. 
9 One 54 53 19 - 49.2 0.05 863.349 Removed data points for patient 122 and 123 that 
compartment was swapped during sample preparation. No 
model with difference with respect to concentration of points 
first order now at PRED=7.5 
absorption 
14 One - 55 29 32 49 0.05 860.823 Implemented zero order bolus input and the 
compartment duration parameter. was estimated. Concentration 
Model with of points at PRED=7.5 a little better. 
zero order 
absorption 
15 One 57 51 24 59 41 0.05 804.652 Introduction of a lag time. Model predictions are 
compartment much better. The OBF value from this run was 
model with used as the reference against which all 
first order subsequent runs were compared in the univariate 
absorption covariate addition process. Concentration of 
Ipoints at PRED=7.5 gone. 
27 Two 51 53 18 - 50 0.05 858.735 Although the OBF is smaller than RUN 13, 
compartment goodness of fit plots are not any better than with 
Model with the one compartment model. The variability in 
first order parameter estimates are also not very much 
absorption better. 
42 One 47 42 <1 69 37 0.05 773.334 Estimated F1 - relative bioavailability for the 2 
compartment dose amounts i.e. 450mg and 600mg dose. Data 
model with can no longer estimate the variability in V/F once 
first order it is partitioned into F1 . 
absorption 
.. .. 
'1' Inter'lndlvldual vanablhty; KA - absorption rate constant, CUF - apparent clearance, V/F - apparent volume of dlstnbutlon, cr· Intra . 
individual variability, CCV - constant coefficient of variation, ADD - additive, OBF - minimum value of the objective function 
A one-compartment linear model parameterised in clearance (CUF) and volume of 
distribution (V/F) , was chosen to describe the pharmacokinetics of RFA in this 
population (Figure 5.3). The absorption profile was characterised by a first order 
process with an absorption lag time (TLAG). The sensitivity analysis procedure 
conducted on various fixed values of KA confirmed that the NONMEM estimate (0.7 
hou(1) was appropriate since the lowest value of OBF corresponded to the same fixed 
value of 0.7 hou(1. 
Initial indications were that there was a difference in the relative bioavailability (F) of 
the 2 different dose amounts (450mg and 600mg) of RFA. However, this model was 
not selected as the base model for examination of covariate effects in view of the 
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Figure 5.3 - Time course of rifampicin serum concentrations before (broken line) and 
after maximal enzyme auto-induction (solid line). The scatter of data points shows the 
rifampicin concentrations measured in 137 pulmonary tuberculosis patients. All serum 
concentration values have been normalised to a 600 mg dose. 
Covariate Model Development 
The univariate analysis of RFA identified 23 potentially important covariates with 
DOBFs of ~ 3.84 (Table 5.10 and Appendix I). The effect of RFA auto-induction on 
CUF caused the largest decrease in the OBF compared to the basic model. Several 
other covariates that also caused large DOBFs during the univariate analysis were 
found to be confounded e.g. patients on quinolones and ethionamide were also those 
who had MDR-TB. The MDR-TB patients were most likely to have received RFA for a 
period of time insufficient to allow for maximal RFA enzyme auto-induction. These 
covariates were excluded during the forward model building stage (Table 5.10), as 
they did not cause a significant DOBF of ~ 3.84 when added into the model that 




Table 5.10 - Development of the Covariate Pharmacokinetic Model for the 
Population Pharmacokinetic Analysis of Rifampicin in Pulmonary Tuberculosis 
Patients (n=137) - Univariate Analyses and Step-wise Build-up to the Full Model 
Significant Covariate Effects Identified 
During the Univariate Analysis in rank order 
of DOBF1 
. ~._._._ .......... _ .._ ..__ ..... _._ ... _ ... __ ......... _.- .... _ .._ ............. ·_·N··_··_···_·····N······· 
Rifamp"ici"nauto-induction on CLIF 
Quinolones on CLIF 
'Enzyme inhibitor on CUF 
MDR-T8 on CLIF 
Ethambutol on CUF 
Severity score for extent of lung cavitation on 
CLIF ' 
Log HIV viral load on V/F 
HIVon V/F 
Weight on CLIF 
Globulin on CUF 
Thiacetazone on CLIF 
Globulin on V/F 
Sex on V/F 
Iron preparations/anaemia on CLIF 
Drug resistance severity score on CLIF 
Rifampicin auto-induction on V/F 
Age on CLIF 
Enzyme inhibitor on V/F 
Iron preparations/anaemia on V/F 
HIV.on CUF 
Aspartate transaminase (AST) on CLIF 
Non-steroidal anti-inflammatory drug use on 
CUF 





























Retained in Full 
Model 
























'OOBF - difference In the minimum value of the objective function between 2 NONMEM runs. Chi square distributed - OOBF ~ 3.64, P 
~ 0.05 dt=1 , CUF - apparent clearance, V/F - apparent volume of distribution 
The forward model building stage retained only 6 out of the 23 covariates for inclusion 
in the full model. These were the effect of RFA auto-induction on CUF and on V/F, log 
HIV viral load on V/F, weight on CUF, globulin on CUF and sex on V/F. Several 
possible splits for the time to maximal RFA enzyme auto-induction were investigated. 
These were 7 and 14 days as suggested by the literature (Kenny and Strates, 1981), 
4.5 days as suggested by tree-based modelling, 10 days as suggested by the GAM 
analysis and an arbitrary value of 30 days. Tree based modelling and GAM analyses 
are options available within the XposeR program that assist in selecting important 
covariates in a NONMEM model. The split of 10 days produced the best fit of the data 
to the model. 
It was noted during the forward model building stage that several parameters had 
significant effects on both CUF and V/F. The covariance between these 2 parameters 
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was therefore modelled by implementation of a BLOCK OMEGA rather than a 
DIAGONAL OMEGA before the backward deletion stage. 
The 6 covariates included in the full model were deleted one-at-a-time and their 
relative importance was ranked according to the size of the DOBF caused by their 
deletion. Covariates were removed from the full model according to this rank order as 
recorded in Table 5.11. During the backward deletion of covariates, only 2 covariates 
caused an increase of ~ 11 in DOBF thereby confirming their retention in the final 
model. These were the effect of RFA auto-induction on both CLIF and on V/F. 
Table 5.11 - Development of the Covariate Pharmacokinetic Model for the 
Population Pharmacokinetic Analysis of Rifampicin in Pulmonary Tuberculosis 
Patients (n=137) - Step-wise Deletion to the Final Model 
Model 
CLIF = f(DAYS-10;WT;GLOB) 
V/F = f(DAYS-10;VIR;SEX) 
CLIF = f(DAYS-10;WT) 
V/F = f(DAYS-10;VIR;SEX) 
CLIF = f(DAYS-10;WT) 
V/F = f(DAYS-10;VIR) 
CLIF = f(DAYS-10;WT) 
V/F = f(DAYS-10) 
CLIF = f(DAYS-10;WT) 
CLIF = f(DA YS-1 0) 








Globulin does not significantly 
influence CLIF 
Sex does not significantly influence 
V/F 
Log HIV viral load does not 
significantly influence V/F 
Rifampicin auto-induction has a 
significant influence on V/F 
Weight does not signific~ntly 
influ~nce CLIF 
V/F = f(DAYS-10) 76 Rifampicin auto-induction has a 
significant influence on CLIF 
' DOBF - difference In the minimum value of the objective function between 2 NONMEM runs. Chi square dlstnbuted - DOBF ~ 11. P ~ 
0.001 df=1, CUF - apparent clearance. V/F - apparent volume of distribution. f- 'a function of ...•• DAYS-10 - number of days since 
starting rifampicin therapy with a minimum of 0 days and a maximum of 10 days. WT - patient weight centred on the median of 54 kg . 
GLOB - serum globulin concentration centred on the median of 52 giL. VIR - log HIV viral load. SEX - male or female sex 
Figure 5.4 compares plots of weighted residuals for the basic model with that for the 
final optimal model. The fit for the final model is shown to be superior with no biased 
clustering of data points. 
The final regression model for the typical values of CUF and V/F for RFA was as 
follows: 
CUF = 15.60 + 0.79 x (DAYS - 10) 
V/F = 42.10 + 1.57 x (DAYS - 10) 
Where DAYS - 10 is the number of days since starting RFA therapy with a minimum 
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Figure 5.4 - Assessment of goodness of fit: Plots of weighted residuals versus predicted rifampicin 
concentrations from the basic (top) and the final (bottom) NONMEM models. The individual lines 
connect the concentration points measured in 137 patients with pulmonary tuberculosis. 
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Table 5.12 - Population Pharmacokinetic Parameters for Rifampicin in 
Pulmonary Tuberculosis Patients (n=137) 
PARAMETER COVARIATE MEAN POPULATION RELATIVE 
INFLUENCE PARAMETER STANDARD ERROR 
ESTIMATE % 
(CI) 
CUF (Uhr) At commencement 7.70 (6.20,9.20) 18 
of rifampicin 
therapy 
After 10 days of 15.60 (14.10,17.10) 5 
daily rifampicin 
therapy 
Inter-individual Variability in 39 (29, 47) 23 
CUF (%CV) 
V/F (L) At commencement 26.40 (20.64, 32.16) 30 
of rifampicin 
therapy 
After 10 days of 42.10 (36.34, 47.86) 7 
daily rifampicin 
therapy 
Inter-individual Variability in 26 (0, 43) 100 
V/F (%CV) 
KA (h( ) 0.89 (0.59,1.19) 17 
Inter-individual Variability in KA 52 (0, 73) 51 
(%CV) 
TLAG (hr) 0.50 (0.35, 0.65) 15 




Proportional error (%CV) 39 (34, 45) 7 
Additive ().lg/ml) 0.05 (0.03, 0.07) 19 
KA-ab - -sorption rate constant, CUF apparent clearance, V/F apparent volume of distribution, TLAG - absorption lag time, 





Basic Structural Pharmacokinetic Model 
Various models were tested in order to determine the basic structural pharmacokinetic 
model for the INH population pharmacokinetic analysis (Table 5.13). The complete list 
of NONMEM runs conducted during the analysis is recorded in Appendix J. An 
example of a NONMEM control stream used during the INH analysis is shown in 
Appendix K. 
Table 5.13 - Summary of Models tested in the Development of the Basic 
Structural Model for the Population Pharmacokinetic Analysis of Isoniazid in 
Pulmonary Tuberculosis Patients (n=138). 
RUN MODEL INTER-INDIVIDUAL RESIDUAL OBF COMMENTS 
VARIABILITY VARIABILITY 
11KA 11CL(1)IF 11CL(Z)IF 11v crccv crADD 
(%) (%) (%) (%) (%) (l-Lg/ml) 
2 One compartment 2102 27 - 15 23 0.5 851 .055 Model was parameterised as KA, 
Model with first order CUF and VIF with exponential 
absorption error terms on the inter-individual 
variability in the parameters. 
Residual variability was modelled 
with combined additive and 
constant coefficient of variation 
error terms. 
KA estimate and variability are very 
large. 
9 One compartment 118 45 - 36 18 0.5 882.867 Results of the sensitivity analysis 
Model with first order procedure with KA fixed to 3.0. 
absorption Variability on KA is more realistic 
than RUN 2. 
17 One compartment - 45 - 34 23 0.53 901.258 Duration parameter for drug 
Model with zero order absorption is unrealistically small. 
absorption 
19 Two compartment 68 52 - 37 20 0.46 800.274 2 compartment model. Although 
Model with first order the OBF is smaller, goodness of fit 
absorption plots are not any better than with 
RUN 9. 
23 One compartment 127 43 43 43 29 0.02 289.890 Implemented Mixture modelling on 
Model with first order CUF. Significant .J.. in OBF. Lag 
absorption time on absorption. 
32 One compartment 146 43 38 43 29 0.02 289.640 Results of the sensitivity analysis 
Model with first order procedure with Ka fixed to 3.5 and 
absorption no lag time. The OBF value from 
this run was used as the reference 
against which all subsequent runs 
were compared in the univariate 
covariate addition process. 
'1 - Inter-Individual vanablhty, KA - absorption rate constant, CUF - apparent clearance, Cl(1 )/F- apparent clearance (fast), Cl(2)/F -
apparent clearance for slow acetylators, V/F - apparent volume of distribution, C1 - intra-individual variability, CCV - constant coefficient 
of variation, ADD - additive, OBF - minimum value of the objective function 
A one-compartment linear model parameterised via clearance (CUF) and volume of 
distribution (V/F) , was chosen to describe the pharmacokinetics of INH in this 
population. Implementation of the Mixture Modelling feature of NONMEM (Appendix 
L) resulted in a dramatic decrease in the OBF (-593). The distribution of individual 
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Bayesian posthoc CUF values before and after implementation of mixture modelling is 
shown in Figure 5.5 and 5.6 respectively . 
The non-compartmental analysis suggested that the absorption of INH (tmax=1 .35 
hour) was much more rapid than RFA (tmax=2.32 hour). Further, the model building 
process to determine the best pharmacokinetic structural model for INH was 
characterised by a very large inter-individual variability in KA and an occasional 
shifting of this variability into the inter-subject variability in V. These observations 
emphasized that there were insufficient samples taken during the absorption phase to 
accurately estimate the absorption characteristics of INH. 
In view of this, an estimate of KA was determined and fixed using the sensitivity 
analYSis procedure. In this procedure, KA was fixed to various values and the OBF's 
and parameter estimates obtained were compared. This was with a view to 
determining a value of KA that resulted in stable parameter estimates and/or the 
lowest OBF. In all subsequent runs the KA was constrained to a value of 3.5 h(1. 
In 7 patients, the pre-dose INH serum concentration was found to be higher than the 
last concentration measured approximately 12 hours previously (mean 0.98 vs 0.Of5 
)!g/ml, respectively) . There was no evidence to suggest that any doses had been 
administered during that interval. The aberrant higher concentrations were attributed 
to assay error and were deleted from the data file as their retention caused the 
Bayesian estimate for V/F to be very large (~ 120 L) in these patients. 
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Figure 5.6 Histogram of Bayesian posthoc individual clearance values for fast (top) 
and slow (bottom) acetylators of isoniazid in patients with pulmonary tuberculosis after 




Covariate Model Development 
A total of 28 covariates were tested in the univariate evaluation of potentially important 
covariate effects on INH CUF and V/F. These covariates have been described under 
the section labelled Data in this Chapter and their effects on the OBF are recorded in 
Appendix M. Of these covariates, 16 were identified for possible inclusion in the final 
model. They are listed in the first column of Table 5.14 in rank order of the decrease 
in OBF caused by their univariate addition into the model. 
Table 5.14 - Development of the Covariate Pharmacokinetic Model for the 
Population Pharmacokinetic Analysis of Isoniazid in Pulmonary Tuberculosis 
Patients (n=138) - Univariate Analyses and Step-wise Build-up to the Full Model 
Significant Covariate Effects Identified DOBF' during Covariate 
During the Univariate Analysis in rank order Step-wise Retained in Full 
of DOBF1 Addition of Mo.del 
covariates 
1 --Globulin on CUF 11 .6 Yes Enzyme inhibitors on CLIF 3.2 No 
Antihistamines on CLIF 4.4 Yes 
Log Viral Load on CUF +0.2 No 
Penicillins on V/F 5.7 Yes 
Hypoglycaemic agentslDiabetes mellitus on 1.1 No 
CLIF 
Severity score for extent of lung involvement on 6.7 Yes 
CUF 
Severity score for extent of lung involvement on 0.9 No 
V/F 
Drug resistance severity score on CLIF 0.2 No 
Penicillins on CLIF 0 No 
Weight on V/F +0.7 No 
Globulin on V/F 0.3 No 
Diuretics/hypertension on CUF 7.2 Yes 
Total Bilirubin on V/F 5.0 Yes 
Sex on CUF +10.1 No 
Severity score for extent of lung cavitation on +11 .0 No 
V/F 
' OOBF - difference in the minimum value of the objective function between 2 NONMEM runs. Chi square distributed - OOBF ~ 3.84 . P 
~ 0.05 df=1 , CUF - apparent clearance. V/F - apparent volume of distribution 
In the stepwise buildup to the full model, only 6 covariates were retained . These were 
the effect of serum globulin, concurrent antihistamine treatment; concurrent anti-
hypertensive treatment and extent of lung involvement on CUF, and the effect of total 
serum bilirubin concentration and concurrent penicillin treatment on V/F. 
These covariates were removed from the full model one-at-a-time. The consequent 
effect on the OBF formed the basis of developing the rank order for their removal from 
the full model (Table 5.15). During this backward deletion procedure, none of the 
covariates caused an increase in DOBF of;::: 11. Although globulin caused a 




Table 5.15 - Development of the Covariate Pharmacokinetic Model for the 
Population Pharmacokinetic Analysis of Isoniazid in Pulmonary Tuberculosis 
Patients (n=138) - Step-wise Deletion to the Final Model 
Model 
CLIF = f(GLOB;H1 B;EXT;HPT) 
V/F = f(PEN;BILI) 
CLIF = f(GLOB;EXT;HPT) 
V/F = f(PEN;BILI) 
CLIF = f(GLOB;HPT) 
V/F = f(PEN;BILI) 
CLIF = f(HPT) 
V/F = f(PEN;BILI) 
CLIF = f(GLOB;HPT) 
V/F = f(PEN) 
CLIF = f(GLOB) 
V/F = f(PEN) 










Concomitant antihistamine therapy 
does not influence isoniazid 
clearance 
Severity score for extent of lung 
involvement does not influence CLIF 
Serum globulin concentration has a 
marginally significant influence on 
CLIF 
Total serum bilirubin concentration 
does not significantly influence V/F 
Concomitant antihypertensive 
therapy does not influence isoniazid 
CLIF 
Concomitant penicillin therapy does 
not influence isoniazid V/F 
IOOBF - difference in the minimum value of the objective function between 2 NONMEM runs. Chi square distributed - OOBF <: II , p!> 0.001 df=I, CUF 
- apparent clearance, VIF - apparent volume of distribution,f - 'a function of ... ', GLOB - serum globulin concentration centred on the median of 52 gil, 
HIB - ingestion of concomitant antihistamine therapy, EXT - severity score for extent of lung involvement centred on the median of 5, HPT - mgestion of 
concomitant anti-hypertensive drug therapy. PEN - ingestion of concomitant penicillin therapy, BILl - total serum bilirubin concentration centred on the 
median of I 0 ~ollL 
Figure 5,7 compares plots of weighted residuals for the basic model with that for the 
final model. The fit of the final model is shown to be marginally better than the basic 
model. In particular, the absence of a clustering of data pOints at a predicted 
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Figure 5.7 - Assessment of goodness of fit: Plots of weighted residuals versus predicted isoniazid 
concentrations for the basic (top) and the final (bottom) NONMEM models. The individual lines 
connect the concentration points measured in 138 patients with pulmonary tuberculosis . 
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Table 5.16 records the final parameter estimates for the INH population 
pharmacokinetic analysis. 
Results 
The estimate of the mixing proportion indicates that this population comprised 
primarily of fast acetylators (85%). Among the fast acetylators there were 50 (43%) 
patients with MDR-TB and 66 (57%) with drug-sensitive TB. The number of MDR-TB 
and drug-sensitive TB patients among the slow acetylator group was 12 (60%) and 8 
(40%) respectively. There was no significant difference between fast and slow 
acetylators with respect to the proportions of MDR-TB and drug-sensitive TB patients 
(p=0.16). 
The slow acetylators had a 35% lower rate of metabolism than the fast acetylators. 
The time course of INH serum concentrations for the slow and fast acetylators is 
shown in Figure 5.8. 
The small 95% confidence inte'rval for error model parameters and the low RSE 
confirmed that the combined additive and CCV error model was appropriate for this 
data. 
Table 5.16 - Population Pharmacokinetic Parameters for Isoniazid in Pulmonary 
Tuberculosis Patients (n=138). 
Parameter Acetylator Population Parameter Relative 
Status Estimate Standard 
mean (el) Error (%) 
Mixing Proportion Fast 0.85 (0.78, 0.91} 4 
CUF (l itre/hour) 
Slow 4.73 (2.78, 6.98) 18 
Fast 13.00 (11 .88, 14.12) 4 
. Slope for globulin - 52 0.09 (0.04, 0.13) 26 
Inter-individual variability in 
CUF (%) Slow 32 (11 , 44) 18 
Fast 41 (35, 46} 44 
V/F (litre) 50.00 (45.52, 54.48) 5 
Inter-individual variability in V/F 41 (33, 48) 18 
(%) 
KA (hour' ) 
Inter-individual variability in KA 152 (61 , 207) 42 
(%) 
Residual Variability 
Proportional error (%) 28 (24, 31) 6 
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Figure 5.8 - Time course of isoniazid serum concentrations for slow (dashed line) and 
fast (solid line) acetylators. The scatter of pOints shows the isoniazid concentrations 
measured in 138 pulmonary tuberculosis patients. All serum concentrations have 
been normalised to a 400mg dose. 
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Table 5.17 - Population Pharmacodynamic Parameters for Isoniazid in Multi-
drug Resistant and Drug-Sensitive Pulmonary TB patients. 
, 




HIV+ HIV-! I j Parameter (n=86)1 (n=12) I (n=27) (n=21) (n=24) : 
Cmax: MIC 
..•.•.... M ........... H •.••••• ··_·_·_···········M •..• ·_ .•.•..•.•. _ ........... ... M .M •• _ •• __ • • _ ••• _ • •• M .M •• _ ••• __ •• _._.H ••••• M •••• •.•.•.•. ··H. __ • ··_·H. __ ··········M •. H··.·_····· . ........ _ ... M .. M._._ .... _ .._._. __ . __ ···_· . ._-,... .. ••• M ·····- i1-:;TS------r--·-i1;22 . 
Fast Acetylator ! n=73 n=8 
1 
n=23 I 
i I . Geometric Mean 
i 
7.42 0.73 i 0.66 j 42.93 
I 
52.28 , I 
Median 34.03 0.71 0.49 ! 51 .53 55.78 1 1 
t Range i 0.26 - 96.48 0.38 - 2.08 
, 0.26 - 34.03 , 5.43 - 86.47 5.16 - 96.48 
Slow Acetylator I n=13 n=4 ~ n=4 I n=3 I n=2 
Geometric Mean i 3.95 I 
1.04 0.59 i 51 .32 54.01 
Median 1.36 1.24 ! 0.58 
! 61 .23 55.35 ! ! RanQe I 0.31 - 67.46 0.37 - 2.03 ! 0.31 -1 .31 35.45 - 62.29 43.24 - 67.46 , 
Time> MIC (hours) 
____ J 
Fast Acetylator n = 73 n=8 ! n=23 I n=18 
I 
n=22 ! 
Mean 9.53 0.58 1.20 
, 
15.81 16.13 I 
Median 12.88 0 ! 0 I 15.32 15.71 
Range 0-23.99 0-4.6 0-13.65 ! 5.97 - 23.00 8.45 - 22.12 
Slow Acetylator n=13 n=4 I n=4 I n=3 n=2 Mean 10.33 2.48 
! 
1.10 i 24.00 24.00 Median 4.37 2.28 0 24.00 24.00 
RanQe 0-24.00 0-5.29 I 0-4.37 i 24.00 - 24.00 24.00 - 24.00 
AUC > MIC (flg.hr/ml) 
Fast Acetylator i n=73 n=8 n=23 
I 
n=18 n=22 
Geometric Mean 0 0 0 22.88 24.66 
Median 15.75 0 0 I 22.33 21 .63 
Range 0- 55.72 0-10.84 0-14.08 I 11.46 - 39.26 11 .97 - 55.72 
Slow Acetylator n=13 n=4 n=4 
I 
n=3 n=2 
Geometric Mean 0 0 0 41 .10 45.29 
Median 3.17 1.66 0 1 44.88 46.04 
RanQe 0- 54.30 0-12.66 0-3.17 30.52 - 50.66 37.79 - 54.30 
-Gmax - maximum serum concentration, MIG - minimum inhibitory concentration, AUG = area under the serum concentration time 
curve 
' The total number of MDR-TB and Drug-sensitive TB patients does not add up to total number of patients included in the study. This is 
because the drug susceptibility status of 2 patients (1 HIV+ and 1 HIV-) could not be classified as they were found to be resistant to 
INH alone. The HIV status of 1 drug-sensitive patient could not be determined as the patient withdrew consent for HIV testing after 
recruitment into the study. 
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Table 5.17 shows the derived population pharmacodynamic parameters for INH. The 
drug-sensitive TB patients experienced greater exposure to serum concentrations of 
INH in excess of the MIC. This is reflected in the higher pharmacodynamic 
parameters compared to the MDR-TB patients. 
For purposes of clinical utility, all subsequent statistical comparisons of these 
parameters were conducted within the drug-sensitive TB group only. 
Among the drug-sensitive TB patients, there was no significant difference between 
HIV+ and HIV- patients with regards to any of the 3 parameters for INH. The fast and 
slow acetylators did not display any difference with respect to the Cmax : MIC ratios . 
However, slow acetylators experienced serum drug concentrations above the MIC for 
the entire dosing interval compared to only approximately 16 hours for the fast 
acetylators (p < 0.001). Their AUCs were also significantly higher (p=0.004). 
The influence of altered pharmacokinetics on the pharmacodynamic parameters is 
illustrated in Figures 5.9 to 5.11 which show the frequency histograms of the 3 
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Figure 5.9 - Frequency histogram of Cmax: MIC ratio for isoniazid in drug-sensitive 
pulmonary tuberculosis patients (n = 86). 
The. majority of patients had ~max: MIC ratios for INH above 50, with only 6 patients 
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Figure 5.10 - Frequency histogram of time> MIC for isoniazid in drug-sensitive 
pulmonary tuberculosis patients (n = 86). 
Results 
In the majority of patients, serum concentrations were maintained above the MIC for 
more than 15 hours of the dosing interval. There were 3 patients who had 
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Figure 5.11 - Frequency histogram of AUC > MIC (J..lg .hr/ml) for isoniazid in drug-
sensitive pulmonary tuberculosis patients (n = 86). 
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Most of the drug-sensitive patients achieved an AUC > MIC for INH of greater than 19 
~g.hr/ml. There were no patients with a value of less than 11 ~g . hr/ml for this 
parameter (Figure 5.11). 
Table 5.18 - Population Pharmacodynamic Parameters for Rifampicin in Multi-
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16.18 - 55.82 I 18.46 - 44.39 
Cmax - maximum serum concentration, MIC = minimum Inhibitory concentration, AUC = area under the serum concentration time 
curve 
' The total number of MDR-TB and Drug-sensitive TB patients does not add up to total number of patients included in the study. This is 
because the drug susceptibility status of 2 patients (1 HIV+ and 1 HIV-) could not be classified as they were found to be resistant to 
INH alone. The HIV status of 1 drug-sensitive patient could not be determined as the patient withdrew consent for HIV testing after 
recruitment into the study. 
Tabie 5.18 shows the derived population pharmacodynamic parameters for RFA. As 
noted for INH, the drug-sensitive TB patients experienced greater exposure to serum 
concentrations of RFA in excess of the MIC. This is reflected in the higher values of 
the pharmacodynamic parameters compared to the MDR-TB patients. There were 6 
MDR-TB patients who achieved AUC>MIC and t>MIC values similar to the drug-
sensitive patients, but only 1 patient had a Cmax:MIC ratio within the range of values 
seen in the drug-sensitive patients. In these patients, the AUC>MIC ranged from 
15.32 to 42.31 ~g.hr/ml and serum concentrations were maintained above the MIC for 
approximately 6 and 12 hours. 
Among the drug-sensitive patients, there was no significant difference between HIV+ 
and HIV- patients with regards to any of the 3 parameters for RFA. Figures 5.12 to 
5.14 shows the frequency distributions for the 3 derived pharmacodynamic 
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Figure 5.12 - Frequency Histogram of Cmax: MIC ratio for rifampicin in Drug-
Sensitive Pulmonary Tuberculosis Patients (n = 96). 
Figure 5.12 shows that the majority of patients had RFA concentrations more than 13 
times that of the MIC for RFA. In 5 patients the Cmax:MIC ratio was less than 10, the 
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Figure 5.13 - Frequency Histogram of time > MIC (hour) for rifampicin in Drug-
Sensitive Pulmonary Tuberculosis Patients (n = 96). 
103 
Chapter 5 Results 
Serum concentrations were maintained above the MIC for more than 9 hours of the 24 
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Figure 5.14 - Frequency Histogram of AUC > MIC (ug .hr/ml) for rifampicin in Drug-
Sensitive Pulmonary Tuberculosis Patients (n = 96) . 
All except 1 drug-sensitive patient achieved an AUC>MIC for RFA of greater than 18 
).lg.hr/ml (Figure 5.14). 
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The rising prevalence of MDR-TB internationally (Edlin et al. 1992; Iseman, 1993; 
Bloch et al. 1994; Neville et al. 1994; Cohn et al. 1997) has been confirmed locally 
in this study for KwaZulu-Natal (Chapter 3) with an increase from 2.2% in 1983 to 
3.7% in 1995 (p=0.01). MDR-TB renders TB virtuqlly incurable (Cole and Telenti, 
1995b). The situation has been likened to that observed in the late 1960's prior to the 
introduction of RFA when an increase in resistance to the first line anti-TB drugs was 
noted (Grassi and Peona, 1995). The major difference is however, that since 1970 no 
new anti-TB drug has been introduced by the pharmaceutical industry specifically to 
treat TB (Cole and Telenti, 1995a) . This emphasises the importance of searching for 
factors that counter the emergence of drug resistance. Further, we need to re-
examine our rapidly declining armamentarium against TB with a view to finding better 
ways of utilising the available agents. 
This study in 138 pulmonary TB patients found no clinically relevant or statistically 
significant difference between MDR-TB patients and drug-sensitive TB patients with 
regards to any of their pharmacokinetic characteristics for RFA and INH. If any 
differences were noted, they were shown to be due to factors other than MDR per se. 
Similarly, no statistically significant differences were noted between HIV+ and HIV-
patients with regard to the pharmacokinetic or pharmacodynamic characteristics of 
INH and RFA. 
These findings contradict the hypothesis of pharmacokinetic differences being 
implicated in the acquisition of MDR-TB as suggested by (Bradford et al. 1996) and 
several other authors (Frieden et al. 1993; Patel et al. 1995). They proposed that 
malabsorption due to HIV infection, and consequent lower drug exposure contributes 
to the acquisition of MDR-TB. 
The lack of differences between HIV+ and HIV- patients is in contrast to the reports 
suggesting malabsorption of the anti-TB drugs in HIV+ patients (Berning et al. 1992; 
Peloquin et a/. 1993; Patel et al. 1995; Peloquin et al. 1996; Sahai et al. 1997) 
primarily emanating from researchers at the National Jewish Centre for Immunology 
and Respiratory Medicine in Denver, USA. 
This is the first study to address the important and clinically relevant research 
question of whether there is an association between pharmacokinetics and MDR-TB 
in a group of patients stratified according to HIV status. 
In general, conditions likely to influence the pharmacokinetics of drugs are those 
which affect normal functioning of the gastrointestinal tract (GIT), hepatic and renal 
systems. Patients with HIV infection and/or AIDS have been reported to have altered 
functioning of all 3 of these systems (Unadkat and Agosti, 1990). These have been 
reviewed in Chapter 2. 
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Diarrhoea is the most common GIT symptom reported in AIDS. While this is caused 
by a wide variety of diarrhoeal pathogens, the human immunodeficiency virus itself 
has been found to infect the GIT mucosa and is associated with enteropathy. 
Opportunistic infections that affect immunocompromised hosts may also predispose to 
malabsorption (Unadkat and Agosti, 1990). 
Some of the opportunistic infections or the drugs used in their treatment may also 
result in aberrations in liver function that may alter the pharmacokinetics of the anti-TB 
drugs (Unadkat and Agosti, 1990; Mandell and Petri, 1996). 
A distinct form of HIV-associated renal disease with a broad spectrum of severity and 
sometimes associated with proteinuria has been reported (Unadkat and Agosti, 1990). 
However, with the exception of severe renal disease, this is unlikely to cause 
alterations in the pharmacokinetics of INH and RFA, as the kidneys constitute a minor 
route of drug elimination for these drugs. 
The studies that have addressed the role of altered pharmacokinetics of the anti-TB 
drugs in the presence of HIV infection have been comprehensively reviewed in 
Chapter 2. The salient issues are summarised hereunder. 
The early studies consisted of case reports of patients with AIDS and TB in whom 
malabsorption of the anti-TB drugs was noted (Berning et al. 1992; Peloquin et aJ. 
1993; Peloquin et al. 1996). These studies were largely retrospective evaluations of a 
2-hour post-dose serum drug concentration in relation to the authors' proposed 
normal range. The normal range was based on data from non-HIV infected patients 
and did not consider the possibility of delayed absorption. Further, a sample drawn at 
2 hours post-dose corresponds to the most variable part of the pharmacokinetic profile 
and is very difficult to interpret. 
Another report (Patel et al. 1995) highlighted the role of malabsorption in the 
acquisition of drug resistance. In this communication, 2 patients with HIV infection 
being treated for TB relapsed with drug-resistant isolates. In one of the 2 patients, the 
low drug bioavailability was confirmed using serial drug measurements over the entire 
pharmacokinetic profile. However it was the report by Sahai et al1997 that appeared 
to provide the definitive evidence for malabsorption in the presence of immune 
compromise. This study used a full prospective pharmacokinetic trial design and 
investigated patients at various stages of HIV infection as well as patients with 
diarrhoea. 
More recently, 2 studies from Africa have failed to confirm malabsorption in the 
presence of HIV infection, AIDS or diarrhoea (Choudhri et al. 1997; Taylor and Smith, 
1998). It is interesting to note that the principal author of the Sahai et al (1997) paper 
that confirmed malabsorption was also a co-author on the first study (Choudhri et al. 
1997) to contradict the hypothesis. The study by Taylor and Smith (1998) was 
noteworthy in that these authors observed better absorption (higher AUCs) for RFA 
among AIDS patients. 
The present study adds to the current knowledge with respect to these contradictory 
results. It was conducted in a larger sample (n = 138) of patients than those used 




sensitive pulmonary TB patients stratified according to HIV status. The HIV+ patients 
were at various stages of HIV disease as determined using HIV viral loads. 
Detailed Discussion 
PHARMACOKINETIC PARAMETERS 
The pharmacokinetic parameters obtained from the non-compartmental method of 
data analysis did not differ in any marked or systematic way from the NONMEM 
results. The non-compartmental analysis constituted part of the exploratory data 
analysis and helped to provide initial estimates and guides for the population analysis. 
The population approach was the primary data analytical method used. In addition to 
several advantages of this approach that will be highlighted in the ensuing discussion, 
the NONMEM analysis quantifies the size of the inter-individual variability for each 
pharmacokinetic parameter, together with identification. of the covariates that cause 
the variability. Thus in this study, it was possible to search for the influence of 
covariates on the pharmacokinetic parameters other than those associated with the 
primary research questions of MDR-TB and HIV status. 
Rifampicin 
The absorption of RFA was relatively rapid with a KA of 0.B3 h(1 . This is in agreement 
with other reports indicating that in general , the absorption of RFA is rapid and 
complete. However, several studies have observed unexplained delays in drug 
absorption (Kenny and Strates, 1981). In the present study, the use of the absorption 
lag time parameter appears to reduce the inter-individual variability in KA to the 
relatively low value of 52%. However, like others(Kenny and Strates, 1981}\ a wide 
range in shape and AUC was noted for the RFA serum concentration versus time 
curves. 
The effect of type and quality of food on RFA absorption has been widely studied and 
reviewed (Kenny and Strates, 1981; Zent and Smith, 1995). While most authors have 
shown a reduction in the rate of absorption , some have suggested that the extent may 
also be reduced (Kenny and Strates, 1981). In this study, the ward routine of drug 
administration at 05hOO with breakfast being served 3 to 4 hours later at 
approximately OBh30 eliminated the confounding influence of food effects on 
absorption. 
This study found that upon initiation of treatment, the typical value of CUF for RFA 
was 7.7 Uhr (Table 5.12) . Other authors have reported similar values of between 4.6 
and 9.4 Uhr after initiation of RFA treatment with 1 study reporting a CL of 17.B Uhr 
(Table 2.1). Daily treatment thereafter results in an increase in the rate of drug 
metabolism. This occurs as a result of the induction of hepatic endoplasmic reticular 
enzyme system (P450111A) i.e. RFA auto-induction (Kenny and Strates 1981; Dol/ery 
1991b). In the present study, maximal enzyme induction was reached at 
approximately 10 days after treatment at which time the CUF was 15.6 Llhr. This post 
enzyme auto-induction CUF value is similar to that calculated from data reported by 
others viz 6.B to 15.0 Uhr (Table 2.1). 
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The mean population V/F for RFA was 26.4 L at initiation of treatment and was 42.1 L 
after 10 days of therapy. A review of the literature suggested a V for RFA of 0.9 to 1.0 
Llkg (Table 2.1). Using the median mass of 54kg for this population, the V/F obtained 
in this study was 0.53 Ukg (pre-induction) and 0.74 Llkg after induction. There was 
therefore reasonably good agreement between this study and the literature. 
The dependence of V/F on auto-induction appears strange but has a sound 
mechanistic basis. After metabolism in the liver, RFA and its main metabolite 
desacetylrifampicin are excreted in the bile. The RFA is then reabsorbed into the 
blood while the desacetylrifampicin is not i.e. RFA undergoes enterohepatic recycling 
(Reynolds, 1993). When a drug is reabsorbed after biliary secretion during 
enterohepatic recycling, the biliary secretion is not a route of elimination but rather it 
constitutes a component of distribution (Zeind et a/. 1996). 
During the 10 day period during which enzyme auto-induction increases to a 
maximum, the conversion of RFA to its metabolites increases and thus the amount of 
RFA contributed by biliary secretion decreases. Since the total amount of drug being 
introduced into the body from the dose remains the same during this time, the 
decreased concentration in plasma reflects as an increased V/F. 
Isoniazid 
The one compartment model was also chosen to describe the pharmacokinetics of 
INH. During the NONMEM analysis of INH, the estimate of KA was constrained to a 
value of 3.5 hou(1 since it was found that there was insufficient data to characterise 
the absorption of INH in this study. The value of 3.5 hou(1 was determined using the 
sensitivity analysis procedure. This strategy was in accordance with the 
recommendations of Wade et al (1993) that if the data contains minimal information 
about KA, then its value should be fixed and a parameter for inter-individual variability 
in KA should form part of the model. The results of a series of simulation studies 
conducted by these authors confirmed that this procedure prevented the variabiiity in 
KA being manifested in V/F. This shifting of the variability between KA and V/F was 
noted in the present study during the structural pharmacokinetic model building stage 
before fixing KA (Appendix J) . The authors noted further that mis-specification of KA 
had no effect on the estimation of CUF (Wade et a/. 1993). 
The pharmacokinetics of INH is widely reported to be characterised by a bimodal 
distribution based on genetic polymorphism of fast and slow acetylation (Dol/ery, 
1991a). It was therefore decided to use the mixture modelling feature of NONMEM to 
determine the proportions of slow and fast acetylators. An examination of the 
distribution of the post hoc Bayesian individual CUF values prior to implementation of 
mixture modelling (Figure 5.5) provided only a suggestion of the presence of a multi-
modal distribution in CUF values. It must be noted that in this data set, examination of 
this picture alone would not have been convincing evidence of the presence of 
multiple distinct populations. The very large decrease in OBF and associated better fit 
of the data upon implementation of NONMEM's mixture modelling option provided the 
necessary confirmation. This was corroborated by the distribution of half-life values for 
INH after the non-compartmental analysis. 
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The results of the non-compartmental analysis indicated that the HIV+, MDR-TB 
patients had higher AUC and Cmax values than patients in the other 3 groups 
(p~0.03~. These patients also received a higher mean dose of INH although this 
difference was not statistically significant. Upon correction for the patient's mass and 
dose the cAUC for the HIV+, MDR-TB patients was still higher but the difference in 
cCmax was no longer evident. Thus differences in weight and dose may offer a 
potential explanation. Neither of these differences were translated into effects on the 
pharmacokinetic parameters of CUF and V/F determined by either the non-
compartmental methods or the population analysis method. 
In this study, using the NONMEM mixture-modelling feature , the proportion of fast 
acetylators in the population was found to be in the majority (85%). After the non-
compartmental analysis on a subset of the NONMEM data set, and using a popular 
cut-off value of a half-life of 2 hours (Gelman and Rumack 1998) to distinguish 
between slow and fast acetylators, the proportion of fast acetylators was found to be 
very similar viz. 92%. The main population group in this study was Black Africans. 
Using the half-life to determine acetylator status, Bach et al (1976) found that 59% of 
Black South African patients were fast acetylators while Buchanan et al (1976) noted 
that 73% were fast acetylators. More recently, Parkin et al (1997) studied the 
phenotype and genotype of INH acetylation and noted that a larger proportion of 
South African patients was fast acetylators. These latter authors (Parkin et al. 1997) 
also noted a tri-modal distribution in INH acetylator elimination behaviour rather than 
the bimodal distribution previously described. 
Confirmation of these proportions using an independent marker for INH acetylation is 
the subject of a separate follow-up study. This latter study will use restriction-
fragment-length chain polymorphism (RFLP) to characterise the acetylase genotype. 
When complete, this should provide a valuable validation of NONMEM mixture 
models. 
Some reports suggest that the clinical relevance of INH acetylator status is that the 
slow acetylators comprise a group at risk of various INH-related toxicities including 
peripheral neuropathy and various drug interactions. Thus it would appear that Black 
South African patients would be at lower risk of these toxicities since they are usually 
fast acetylators. On the other hand it has been postulated that hepatoxicity may be 
more common in fast acetylators, owing to the production of larger amounts of the 
metabolite acetylhydrazine which is thought to be involved in the development of this 
side-effect. However Ellard (1984) evaluated the literature and concluded that 
clinically important hepatic toxicity is unrelated to acetylator status. 
The mean population CUF for slow acetylators was found to be 4.7 Uhr while fast 
acetylators had a CUF of 13.0 Uhr (Table 5.16). The CUF for slow acetylators 
calculated from data or parameters reported in previous studies was 2.7 to 11 .3 Uhr 
while that in fast acetylators was 7.2 to 27.2 Uhr (Table 2.4). Thus in this study, CUF 
values were within the range of values noted previously in the literature. 
The V/F obtained in this study of 50.0 L (equivalent to 0.93 Ukg in a 54-kg patient) 
compares well with that reported in the literature of 0.6 to 0.8 Ukg (Table 2.4). 
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There was no significant difference between the number of fast and slow acetylators 
in the MDR-TB and drugs-sensitive groups. This argues against acetylator status 
being implicated in the acquisition of drug resistance. 
PHARMACODYNAMIC PARAMETERS 
Tables 5.17 and 5.18 show the derived population pharmacodynamic parameters for ' 
INH and RFA respectively. These parameters attempt to integrate the individual 
patient's pharmacokinetics with the MIC of INH and RFA determined from organisms 
isolated from that patient's sputum. 
The pharmacodynamic parameters calculated in this study are an important 
contribution to new knowledge as they have been calculated using pharmacokinetic 
and pharmacodynamic information within the same patient. In a previous study, 
Peloquin and Berning (1994) calculated the parameters using published MIC values 
and pharmacokinetic data obtained from the literature. Direct comparison of the 
parameters obtained in this study with those obtained by Peloquin and Berning (1994) 
is difficult due to the absence of dosing information as well as the range in MIC values 
that were recorded in their report. Both of these will have large infll:lences on the value 
of the derived pharmacodynamic parameters. However, there is broad general 
agreement as noted below. 
Studies conducted with bactericidal drugs against aerobic bacteria suggest that for the 
cell wall active drugs (e.g. beta-Iactam antimicrobials) , maintaining the serum 
concentration above the MIC for the entire dosing interval (t>MIC) is the most 
important parameter for eradicating the organism (Peloquin, 1996). INH acts primarily 
against the cell wall and thus t>MIC would be an important parameter to optimise 
when dosing with this drug. 
On the other hand, in the case of drugs that exert their effect on intra-cellular targets 
(e.g. aminoglycosides) the Cmax:MIC ratio is considered important as this ensures 
adequate penetration into the site of action. RFA would fall into this category as it acts 
on RNA polymerase within the cell (Peloquin, 1996). 
The AUC>MIC parameter provides an overall impression of drug exposure that 
incorporates information on how high the serum concentrations increased above the 
MIC as well as the duration of exposure to these concentrations. 
While the t>MIC parameter is easy to conceptualise, it is more difficult to appreciate 
the impact of the parameters of Cmax:MIC and AUC>MIC given the absence of 
comparative data that is corroborated with clinical evidence of success or failure with 
regimens. 
It is to be expected that (by definition) the drug-sensitive patients will experience 
greater exposure to serum concentrations of INH and RFA in excess of the MIC. Thus 
the values of their pharmacodynamic parameters were higher compared to those of 
the MDR-TB patients. 
The possibility of TOM as an option (Peloquin, 1996) for the treatment of MDR-TB 
cannot be totally excluded based on the results of this study. However, the MIC 
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results that showed that the majority of isolates were either very resistant or very 
sensitive to INH and RFA are not very encouraging. This is typical of M tuberculosis 
and unlike other species of mycobacterium e.g. M avium where moderate resistance 
is frequently noted. The range of breakpoint concentrations tested in this study was 
based on an evaluation of the concentrations that were likely to be achievable in the 
clinical setting without producing unacceptable toxicity. This suggests that the dose 
required to produce drug exposure in excess of the MIC may be toxic to the patient 
and argues against using aggressively large doses of INH and RFA to treat MDR-TB.· 
Among the drug-sensitive patients, there was no significant difference between HIV+ 
and HIV- patients with regards to any of the pharmacodynamic parameters for both 
INH and RFA. This reflects the absence of pharmacokinetic differences between HIV+ 
and HIV- patients seen in this study. 
Rifampicin 
Among the drug-sensitive patients, there was no significant difference between HIV+ 
and HIV- patients with regards to any of the 3 pharmacodynamic parameters for RFA 
(Table 5.18). 
As mentioned earlier, the Cmax:MIC would be important for RFA as this drug affects 
intracellular bacterial targets. The majority of patients had ratios in excess of 13 
(Figure 5.12), while 5 patients had lower ratios of ~ 10. When compared to the value 
of 24 reported by Peloquin and Berning (1994) , there is the suggestion that these 
patients are at risk of being under-dosed with RFA. 
The AUC>MIC for RFA was greater than 23 /-!g.hr/ml in the majority of patients. Only 1 
patient experienced a low AUC>MIC of 16 /-!g.hr/ml. Peloquin and Berning (1994) 
reported a value of 39.9 /-!g.hr/ml for this parameter. As mentioned above, the 
absence of information regarding the range in MIC values and dosing information in 
the study from which the pharmacokinetic parameters were obtained makes it difficult 
to ascertain the clinical significance of the lower AUC>MIC see-n in the present study 
Serum concentrations were maintained above the MIC for approximately 9 hours of 
the 24 hour dosing interval after RFA treatment in drug-sensitive patients. 
Isoniazid 
A mean Cmax:MIC ratio for INH of approximately 55 was obtained in both fast and 
slow acetylators as compared to a value of 40 reported by Peloquin and Berning 
(1994). These authors did not note any difference due to acetylator status either. This 
is not surprising since the numerator (Cmax) in the ratio is dependent on the 
absorption process rather than drug elimination, the latter being responsible for the 
distinction between slow and fast acetylators. 
The frequency histograms of the pharmacodynamic parameters for INH (Figures 5.9 
to 5.11) shows the effect of inter-individual variability in pharmacokinetics on the 
pharmacodynamic parameters. While the majority of patients have Cmax:MIC ratios 
of greater than 50 for INH, there were 6 patients who had values of less than 36 for 
this parameter. Similarly, there were a small number of patients who had relatively 
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lower t>MIC and AUC>MIC compared to the majority of the drug-sensitive patients. 
The exact clinical relevance of this is uncertain. A follow-up study is currently being 
conducted to examine these pharmacodynamic parameters in relation to patient 
outcome variables such as acquisition of drug resistance and response to treatment. 
The 5 drug-sensitive slow acetylators experienced serum drug concentrations of INH 
above the MIC for the entire dosing interval compared to only approximately 16 hours 
for the fast acetylators (p<O.001) . Their AUCs were also significantly higher (p=O.004). 
Comparative values for slow and fast acetylators obtained by Peloquin and Berning 
(1994) were 19.2 and 11 .6 hours. 
There are clear implications for the derivation of integrated pharmacokinetic and 
pharmacodynamic indices of anti-TB drug activity and their use to establish 
individualised antibiotic dosage regimens in special high-risk groups. Such high-risk 
groups would include patients with MDR-TB or patients with high rates of drug 
clearance among the drug-sensitive patients. Whether the parameters determined in 
this study could be regarded as target breakpoint values requires correlation with 
information relating to clinical outcome in these patients. The parameters thus hold 
promise as a benchmark for further comparative evaluation. 
The discussion hereafter is presented with a view to assist in generalising these 
results. 
Race 
Almost all the patients (135/138) recruited into this study were Black Africans. 
Although the author does not subscribe to divisions of people according to ethnic or 
racial lines, this is necessary in studies involving diseases that are distributed 
according to socio-economic status. Thus the large number of patients of African race 
highlights TB as a socio-economic disease affecting mainly the poor and the 
disadvantaged. In South Africa, poor and disadvantaged is synonymous with being 
Black. 
Age 
The present study also noted a significantly lower mean age in the HIV+ patients 
compared to the HIV- patients (31 .0 ± 8.5 vs. 39.4 ± 12.1 years; p<0.0001) . This 
highlights the crisis posed by the HIV epidemic in South Africa and sub-Saharan 
Africa as it affects the economically active age groups. This observation and warning 
that young adults comprise the age group most often affected by the dual epidemics 
of TB and HIV, particularly in developing countries, has been recorded by several 
authors (De Cock et al. 1991; Nunn et al. 1992; Houston et al. 1994). More recently, 
this has been confirmed in KwaZulu-Natal (Wilkinson and Moore, 1996b). 
History of Prior treatment for TB 
The greatest predictor for drug resistant TB is a history of prior treatment for TB 
(Frieden et al. 1993). This has also been our experience in a previous study conducted 
at KGV (Anastasis et al. 1997). It is not surprising therefore that this was again 
corroborated in this study. There were Significantly more MDR-TB patients who had a 
history of previous treatment for TB (79%) compared to new cases (21%) (odds ratio 
112 
ChapterS Discussion 
7.85, CI 3.34 to 18.77; p<0.0001). Among the re-treatment cases that had developed 
MDR-TB, there was a larger proportion of patients whose previous treatment had 
been interrupted or failed (odds ratio 2.34, CI 0.74 to 7.48, p=0.08). 
Clearly, the greatest challenge in TB continues to be the issue of ensuring adherence 
(compliance) to treatment. Experts increasingly acknowledge adherence as a 
behavioural problem and recommend behavioural and social research efforts into the 
problem (Sumartojo, 1993). In South Africa, with its diverse cultural heritage there has 
been little to no research into socio-behavioural factors leading to poor compliance. 
The success of directly observed treatment (DOT) regimens in New York (Frieden et 
al. 1995) and in some centres in South Africa (Wilkinson et al. 1996a) demands 
wider investigation of its implementation according to modifications to suit local needs. 
Simultaneously with these research endeavours, tuberculosis control programs and 
research units need to evaluate the pharmacodynamic response to such regimens. 
The present study may help to .provide the basis for such population pharmacokinetic-
pharmacodynamic studies. 
HIV status and Viral Loads 
Although patients were recruited into the study with due regard of their MDR-TB and 
HIV status, no conscious effort was made to balance the groups with regard to sex. It 
is thus interesting to note that the sample consisted of a significantly larger proportion 
of HIV+ females than HIV+ males (53% vs. 31% p = 0.01) . In the early 1980s in South 
Africa, HIV infection predominantly affected gay white men. There was a slower 
spread of infection to the Black heterosexual population. In the last decade however, 
the pattern of the HIV epidemic in South Africa has become similar to that seen in 
other African countries (McIntyre, 1996). In heterosexually transmitted HIV infection 
as occurs currently in South Africa, women are at greater risk of infection than men 
are. This observation is reflected in the results of a seroprevalence study conducted in 
KwaZulu-Natal that noted a 3.2-fold higher prevalence of HIV-1 infection in females 
than males (Abdool Karim et a/. 1992). A study in Hlabisa, KwaZulu-Natal noted a 
higher prevalence of HIV-related TB among women as a consequence of the high 
baseline prevalence of HIV in the province (Wilkinson and Moore, 1996b). 
During recruitment of patients into this study, the group that was most difficult to find 
was that of patients who had MDR-TB and who were HIV+. This group comprised of 
21 patients while the other 3 groups had more than 35 patients each. This observation 
corroborates our previous report that there is currently no association between drug 
resistant TB and HIV status in KwaZulu-Natal (Anastasis et al. 1997). 
II") this study, HIV viral loads were used as the method of grading the patient's level of 
immune compromise. Most researchers report CD4+ lymphocyte counts for this 
purpose (Choudhri et al. 1997; Sahai et al. 1997). However, CD4+ lymphocyte 
counts were not measured in this study. This was because funds were not available to 
perform this when the study was conducted. Measurement of CD4+ lymphocytes 
requires the use of fresh whole blood, drawn according to a strict protocol. Thus 
samples which were stored frozen could not be used for analysis at a later stage 
when the financial situation had improved. 
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Consequently, the more reliable (and more expensive) HIV viral loads were measured 
towards the end of the data collection phase of the study using serum that had been 
frozen at -84°C. The International AIDS Society guidelines for the treatment of HIV 
infection recommend viral RNA measurements to CD4+ counts (Carpenter et al. 
1996). They indicate that HIV viral loads are a more accurate indication of prognosis 
and treatment benefit especially in asymptomatic patients with CD4+ counts of > 350 
cells/J..l1. In recent reports , the HIV viral load was the most significant virological 
predictor of clinical progression of HIV infection (Mellors et al. 1996; Brun-Vezinet et 
al. 1997). While baseline CD4+ counts were also an independent predictor, its 
predictive power was not sustained throughout the clinical course of infection 
especially in the milieu of drug therapy (Brun-Vezinet et al. 1997). 
There is a negative correlation between HIV viral load and CD4+ cell counts i.e. as 
the viral load increases, the CD4+ count decreases. At the local Virology laboratory, 
patients with viral load less than 10 000 copies per millilitre are classified as having 
mild immune compromise, those with levels up to 70 000 as moderate and those with 
levels greater than 70 000 as having severe immune compromise (personal 
communication S Singh, Medical Virology, University of Natal). This classification is in 
keeping with the observations of Mellors et al 1996 regarding viral load as a 
prognostic indicator. Thus the patients in this study with a median viral load of 69 000 
copies per millilitre are classified as having a moderate to severe level of immune 
compromise. These viral loads must be interpreted in the context of the reports of an 
accelerated course of immune deficiency seen in patients with concurrent T8 and HIV 
(Whalen et al. 1995). 
In general, the methodology used, PCR nucleic acid amplification , performed well 
under the operating conditions used. There were 3 samples that were considered 
problematic. Two of these had inadequate internal controls and 1 sample persistently 
recorded low RNA levels. There was little doubt that these patients were in fact HIV+. 
The definition of HIV seropositivity used in this study was stringent and followed 
internationally accepted criteria which requires at least 2 positive immunoassay tests. 
The majority of the HIV+ patients in this study had at least 3' tests conducted - the first 
done during their routine clinical care and the latter 2 confirmatory tests done for 
purposes of this study as per the protocol. The discrepant HIV viral load results may 
have been due to the absence of free virus in the patient's blood or because of a level 
undetectable by the assay system. 
The median HIV viral load observed in this study among the HIV+ patients was 6.9 x 
104 copies per millilitre (range 200 to 2.7 X 106 copies per millilitre) . No significant 
differences were noted between MDR-T8 and drug-sensitive T8 patients with regard 
to their viral loads. 
Thus the groups were comparable with regards to HIV disease severity. Peloquin et al 
1993 suggested that severity of HIV disease (using CD4+ counts) might be a marker 
for anti-TB drug malabsorption. The results of the present study showed that 
irrespective of the degree of immune compromise, there was no difference in 
pharmacokinetics of INH and RFA. 
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Concomitant Diseases 
While m,any of the patients in this study had oral candidiasis (14 of 59 HIV: patients) , 
there were few other opportunistic infections in the HIV+ patients. Two patients had 
genital herpes and 1 patient had Karposi 's sarcoma. The absence of widespread 
opportunistic infections corroborates the opinion that TB occurs early in the spectrum 
of opportunistic infections in a patient infected with HIV. Further since opportunistic 
infections have been implicated in the aetiology of drug malabsorption and liver 
function aberrations (Unadkat and Agosti, 1990), this may also partially explain the 
absence of differences in the pharmacokinetics of INH and RFA in HIV+ and HIV-
patients seen in this study. 
Liver Function 
Hepatotoxicity induced by anti-TB drugs is well described in the literature. In addition , 
minor temporary elevations in liver function tests (LFT) are a common occurrence 
early in the course of treatment. The elevations are considered by most TB physicians 
to be clinically unimportant as the elevated values often return to normal levels with 
continued treatment (Brausch and Bass, 1993; Zeind et a/. 1996). A baseline LFT is 
generally recommended at the commencement of TB treatment and this is standard 
policy at KGV. This is repeated if clinical symptoms suggest hepatotoxicity. 
In this study, the median values of the LFTs were within the laboratory's normal 
range. However, individual values in excess of the upper limit of normal (ULN) were 
noted. Several patients had GGT levels in excess of the ULN. This enzyme is 
frequently elevated in patients with alcohol abuse and is often used for screening 
purposes (Sherlock, 1981). In the context of drug induced liver injury however, the 2 
enzymes of particular interest (Vial et a/. 1997) are AL T values in excess of 2 x ULN 
and AST values in excess of 5 x ULN. Only 1 patient had an AL T value> 2 x ULN viz. 
112 uti while no patient had an AST value> 5 x ULN. 
One may argue that those patients with elevated liver enzymes should have been 
excluded from this study. However, the relevance of population pharmacokinetic 
studies is again highlighted as their inclusion allows one to search for potential 
covariate markers that influence drug metabolism. 
In this study, there was no relationship between any liver function measurement and 
the pharmacokinetics of INH and RFA. 
Albumin and globulin together comprise the measure of total protein according to the 
assay system used by the KGV laboratory. These show an inverse relationship to 
each other (Sherlock, 1981). The HIV-, MDR-TB patients had significantly higher 
albumin levels than patients from the other groups (p < 0.001). This observation could 
not be extended into a statistically significant difference between either the MDR-TB 
and drug-sensitive patients or the HIV+ and HIV- patients. It was also noted that HIV-
patients had lower globulin levels than the HIV+ patients (p<0.001). 
These may have implications for drug binding. However, during the NONMEM 
analysis, the data did not unequivocally support the inclusion of globulin as a 
covariate affecting pharmacokinetics. In the case of INH, a marginally significant 
influence of serum globulin on CUF was noted. Although globulin was included in the 
finallNH model, further investigation of this covariate is considered necessary to 
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exclude a potentially spurious effect. This is especially important since it is known that 
binding of INH to plasma proteins is low i.e. between 4 and 30% (Gelman and 
Rumack 1998) . 
Radiology 
The majority of the patients included in the study had extensive lung field involvement 
with multiple cavities as noted from the radiological assessments. This was to be . 
expected in this select population from a specialist referral hospital where one is likely 
to encounter patients with more severe disease. There was no statistically significant 
difference between MDR-TB and drug-sensitive patients with respect to the severity 
scores. However, the HIV+ patients had lower radiographic severity scores than the 
HIV- patients (extent 4.8 ± 1.1 vs. 5.2 ± 1.0 p = 0.02; cavitation 3.8 ± 1.6 vs. 4.3 ± 1.4 
p = 0.06) . 
This apparent incongruity is well described in the literature. As the HIV disease 
progresses, the clinical and pathological picture of pulmonary TB changes. There is 
less necrosis and cavitation, bacilli become abundant and the chest radiograph shows 
infiltration (Zeind et al. 1996; Wilkinson and Moore, 1996b). It should be noted that 
necrosis and cavitation occurs as the immune response to TB infection. 
The method upon which the radiographic classification system was based dates back 
to 1966 (Simon, 1966). However, its relevance and utility is emphasised by this 
method being frequently quoted and used by relatively modern studies after minor 
modifications. One of the difficulties with evaluation of radiographs for research 
purposes is that of observer-error (Simon, 1966). In this study, a specialist radiologist 
with several decades of experience in TB was responsible for all radiographic 
evaluations. In addition, free discussion of the score for each radiograph was 
conducted with the principal investigator. 
The purpose of the radiographic classification in the present analysis was to ensure 
that there was no bias in terms of distribution of patients according to severity of 
disease. In some disease states patients with more severe disease tend to have 
altered pharmacokinetics e.g. quinine in acute malaria (Mandell and Petri, 1996). In 
this study there was no effect of severity of pulmonary involvement on the 
pharmacokinetics of INH and RFA. 
Of necessity, certain aspects of the scoring system will be debatable; e.g. a score of 3 
for a patient with a single large cavity occupying almost an entire lung field vs. a score 
of 4 for someone with multiple small cavities may not correlate with clinical severity. 
Despite this limitation, the scoring system provides a quantitative tool for the 
assessment of pulmonary involvement using chest radiographs. 
Study Site 
This study was conducted at the TB unit of a large specialist referral unit for patients 
primarily from KwaZulu-Natal. The patients recruited into the study were thus likely to 
be those with more severe disease. The case-control design of the study reduced the 
effect of this bias on the results relating to the primary research questions of the 
study. ~owever, any differences between TB patients in general and this study 
population need to be borne in mind when generalising and interpreting the results. 
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Missing Data 
This study included several patients in whom some data were missing e.g. LFT results 
or microbiology results . These missing results did not represent a source of bias 
because the missing values were evenly distributed among the groups - hence 
retaining comparability of the groups. The missing values were highlighted during the 
presentation of the results and included several patients with incomplete 
pharmacokinetic profiles. These latter patients had to be excluded from the non-
compartmental analysis procedure since a representative AUC could not be 
calculated. Their inclusion in the NONMEM analysis highlights another advantage of 
the population approach to pharmacokinetic parameter estimation i.e. the use of data 
from protocols that have sparse sampling schedules. 
During population pharmacokinetic data analysis, there are often concerns about 
assuming that missing indicator variables are negative or about setting missing data 
to the group median value. In this study, 1 patient who withdrew her consent for HIV 
testing after recruitment into the study was assumed to be HIV- and 2 patients who 
were resistant to INH alone were assumed to be drug sensitive. This low incidence of 
missing indicator variables was considered to be unlikely to influence the data 
analysis. As regards the 15 patients with missing liver function test results, the 
absence of clinical features of liver function abnormality was confirmed before setting 
these patient's missing data to the group median value. In addition, NONMEM runs in 
which these patient's data was excluded were compared to runs where the data was 
included as the group median value. In all cases, there was no change to the decision 
regarding the covariate model development, thus confirming the validity of this 
procedure. 
Sampling Strategy 
There were several reasons for employing the unusual sampling strategy of drawing 
the pharmacokinetic profiles over two days. The main reason was to minimise 
disruption of a ward with 30 to 50 sleeping patients at 05hOO - the usual time of dose 
administration so as to attempt venipuncture on a large number of patients. It was 
more convenient to insert the in-dwelling venous cannula and commence sampling 
the day before. An alternative would have been to alter the time of dose 
administration, but this was considered unacceptable since the study protocol 
required that there be minimal changes to the usual clinical scenario. It was the 
intention to study drug usage under operational conditions - an important advantage 
and requirement of the population approach. 
One advantage of using this strategy was that it provided more information on intra-
individual variability since blood samples were collected over 2 dosing intervals. It did 
however, require the assumption that sampling was done over a single dosing interval 
when conducting the non-compartmental pharmacokinetic analysis. 
Protocol Deviations 
The conscious and constant attempts to minimise disruption of the normal ward 
routine were ~mportant for .the population approach protocol and was appreCiated by 
both the medical and nursing personnel. This was also reflected in the high quality of 
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the data and the small number of protocol deviations. When these occurred, the 
principal investigator was promptly made aware of the breach. An unavoidable 
change to the ward routine was the instruction to withhold drug administration on the 
second study day until the pre-dose sample had been collected. On only 1 of the 13 
days over which the study was conducted was this instruction disregarded and 9 
patients inadvertently received a second dose of drug. 
Failure to dose with RFA for a period of time sufficient to attain maximal enzyme auto-
induction presented a confounder for MDR-TB since these patients were in the 
majority in this group. However, this offered an opportunity to investigate RFA auto-
induction from a NONMEM perspective. The exploratory data analytical tools such as 
the GAM analysis were especially useful in deciding on the best estimate of the time 
to maximal enzyme auto-induction. 
Concurrent Medications 
Ethical considerations and minimal disruption of normal ward routine also dictated that 
there were no restrictions on the use of occasional medication prescribed for 
temporary relief of symptom e.g. analgesics and antacids. The population approach 
allows for such possible drug interactions to be imJestigated although cell sizes are 
often not large enough to make definitive conclusions. These observations of potential 
interactions are usually hypothesis generating. There was a low incidence of 
concurrent drug therapy in this study. 
Drug Assay 
RFA and INH are both reported to be unstable compounds in biological fluids (Weber 
et al. 1983; Hutchings et al. 1983). Anti-TB drug assays were conducted at a WHO 
recognised analytical laboratory that adheres to stringent Good Laboratory Practice 
(GLP) standards. A strict protocol was employed during sampling preparation, storage 
andtransport of samples at -8SoC. Some analysts recommend the inclusion of anti-
oxidants (e.g. ascorbic acid) in samples containing RFA to prevent its degradation 
prior to assay (Weber et al. 1983). The method employed in the present study was to 
employ short runs of not more than 10 samples per run. The laboratory has not 
observed any significant degradation in sample or difficulties with regard to stability of 
samples in their on-going quality control procedures. 
Population Pharmacokinetic Model Building 
The procedure used for model building during the NONMEM analysis was the 
traditional and tedious method. Several authors have recommended the use of newer 
exploratory data analysis techniques such as the GAM analysis and tree based 
modelling techniques (Mandema et al. 1992; Verotta, 1997). These greatly expedite 
the process of identification of important covariates. These were used in the present 
analysi~ on an ad hoc basis. It is acknowledged that the path to the final model (see 
AppendIx G and J) could have been accelerated if there had been wider 
implementation of these techniques. 
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Definitions 
In this study, strict definitions for the primary research outcome parameters of HIV and 
drug resistance confirmation were used. A patient was defined as drug resistant only if 
confirmed with drug susceptibility tests conducted according to strict laboratory 
procedures. This was invariably corroborated with a poor clinical response to standard 
chemotherapy. In a similar manner, the majority of drug sensitive patients were 
confirmed with susceptibility tests. However, since drug sensitive patients frequently 
have rapid clearance of AFB from the sputum, microbiological confirmation of 
susceptibility was not always possible. In 10 cases, the classification was based on the 
presence of at least 3 consecutive monthly sputum smears that were negative for acid 
fast bacilli. This definition is in keeping with accepted clinical practice (Anonymous1996) . 
HIV status was confirmed using 2 and in most cases 3 immunoassay tests. The HIV viral 
load provided further confirmation of the HIV status. A potential but unavoidable difficulty 
was the possibility that some of the HIV - patients were in the so-called 'window period' 
during which they have immunologically undetectable infection (Fauci and Lane, 1991). 
The definition of MDR-TB as being resistant to at least both INH and RFA used in this 
study is that suggested by the WHO (Kochi et a/. 1993). Further, for purposes of this 
study, patients with drug-sensitive TB were those who did not have resistance to INH 
or RFA. However, this group included 23 patients (32%) with resistance to 1 or more 
second-line anti-TB drugs other than INH and/or RFA. This consisted of 3 patients 
with resistance to streptomycin, 17 with resistance to ethionamide, 14 with resistance 
. to cycloserine and 5 with resistance to thiacetazone. These patients also complied 
with the clinical definition of drug-sensitive viz. at least 3 consecutive monthly sputum 
smears that were negative for acid fast bacilli. 
The inclusion of these patients in the drug-sensitive group does not minimise the 
importance of the resistance they displayed - rather the intention was to emphasise 
the importance of resistance to INH and RFA. These 2 drugs are essential 
components for the rapid bactericidal effect required in the WHO's short course . 
chemotherapy regimen. 
However, the possibility of methodological difficulties with the susceptibility testing 
such as the definition and interpretation of breakpoints for susceptibility for the second 
line anti-TB drugs may have contributed to detection of drug resistance in the drug-
sensitive group (Johnson, 1991). 
Among the MDR-TB patients, only 1 patient had resistance to 2 drugs i.e. INH and 
RFA only. The majority of patients, 52 of 62 (84%) patients, displayed resistance to ~ 
5 drugs. This highlights the dismal and depressing scenario faced by the clinician that 
attempts to treat MDR-TB. Resistance to the first line anti-TB drugs leaves one with 
having to choose from less effective and usually more toxic second and third line 
agents. This corroborates Mitchison's hypothesis that INH and RFA are resistance 
protective agents i.e. they prevent the emergence of resistance to their companion 
drugs (Mitchison, 1992). The removal of INH and RFA from the regimen due to drug 
resistance results in the rapid acquisition of resistance to the other drugs in the 
regimen. 
The therapeutic dilemma posed by this scenario highlights the urgent need for 
research into new TB drugs or treatments and the better utilisation of available 
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agents. Recent reports (Grassi and Peona, 1995) cast little hope about the former -
hence our attention defaults to the latter option . 
. 
Treatment Protocols 
The mainstay of treatment for the MDR-TB patients in this study was a quinolone and 
an aminoglycoside. It was noteworthy that this study showed a low level of resistance 
to these drugs among all patients tested i.e. 3-4% for the quinolones and 8% for 
kanamycin. Pyrazinamide continues to be used despite a lack of knowledge of its 
susceptibility patterns. Due to methodological difficulties pyrazinamide resistance is 
not routinely assessed at KGV. However, the need for ongoing surveillance of 
microbiological trends as highlighted in Chapter 3 cannot be ignored. 
Summation 
In summary therefore, this study found no association between the pharmacokinetics 
of INH and RFA and MDR-TB. Neither was there any association between HIV status 
or degree of immune compromise and the pharmacokinetics of INH and RFA. Using 
the population approach, the pharmacokinetics of INH and RFA were described in a 
population of pulmonary TB patients stratified according to HIV status. The 
importance of enzyme auto-induction on CUF and V/F for RFA and the higher 
proportion of fast acetylators for INH in Black South Africans were noted. Population 
pharmacodynamic parameters for INH and RFA were described and represent 
potential benchmarks for future prospective clinical evaluation . 
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No significant difference between MDR-TB patients and drug-sensitive TB patients was 
found with regards to the pharmacokinetic characteristics of INH and RFA. 
Similarly, no difference was noted between HIV+ and HIV- patients with regard to the 
pharmacokinetic characteristics of INH and RFA. 
This study found that upon initiation of treatment, the average 54-kg patient has a CUF 
for RFA of 7.7 Llhr. After continuous daily treatment, maximal enzyme auto-induction was 
reached at approximately 10 days at which time the CUF was 15.6 Llhr. The mean 
population V/F for RFA was 26.4 L at initiation of treatment and 42.1 L after 10 days of 
therapy. The inter-individual variability expressed as a % coefficient .of variation (CV) for 
RFA was 39% for CUF and 26% for V/F. Residual or intra-individual variability was 
described with a proportional component of 39% and an additive component of 0.05 
Ilg/ml. 
The population pharmacokinetic parameters for RFA obtained in this study agree well 
with that reported in the literature. 
In this study, the proportion of INH fast acetylators in the population was found to be in 
the majority (85%). This proportion is in agreement with reports in the literature that fast 
acetylators are in the majority in South African Black patients - the main population 
group studied. . 
The mean population CUF for slow acetylators of I NH was found to be 4.7 Uhr while fast 
acetylators had a CUF of 13.0 Uhr. The V/F for INH obtained in this study was 50.0 L. 
These values are similar to those reported in the literature. The inter-individual variability 
in I NH CUF was 32% for slow acetylators and 41 % for fast acetylators while there was a 
41 % variability in V/F. Intra-individual variability was described with a proportional 
component of 28% and an additive component of 0.02 Ilg/ml. 
Drug-sensitive TB patients displayed higher and more prolonged drug concentrations in 
excess of the MIC than MDR-TB patients. This is reflected in the higher values for their 
pharmacodynamic parameters. 
Chapter 7 Conclusions 
The majority of drug-sensitive patients had Cmax concentrations in excess of 50 x the 
MIC for INH and 13 x the MIC for RFA. 
Slow acetylators of INH experienced drug concentrations above the MIC for the entire 
dosing interval compared to only approximately 16 hours for fast acetylators. In the case 
of RFA, serum concentrations were maintained above the MIC for greater than 9 hours of 
the dosing interval in the majority of drug-sensitive patients. 
A small group of drug-sensitive patients displayed low drug exposure pharmacokinetic 
parameters (AUC>MIC) for INH. The clinical relevance of this is unknown. 
There was no association between INH acetylator status and drug resistance. 
There were no differences between HIV+ and HIV- patients with respect to their 
pharmacodynamic parameters. 
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TUBERCULOSIS DRUG RESISTANCE STUDY 
PATIENTNOLUNTEER INFORMATION SHEET 
Thank you for your interest in this study. 
Objective 
This purpose of this study is to determine why particular patients with tuberculosis 
(TB) develop resistance to their anti-TB drug treatment. 
Importance of your participation 
Although highly effective treatment against TB is available, the TB bacillus is 
constantly developing resistance to the drugs used. Resistance to anti-TB drug 
treatment is therefore a problem of great importance to medical science and research 
in this area is a major priority. 
As a patient with TB, this study may have immediate implications for your treatment. 
In addition, on the long term, it will benefit other TB patients. 
Instructions 
All volunteers must ensure that they take their anti-TB treatment regularly for at least 
1-week before the day of the study. If any doses are omitted, this must be reported to 
the clinic staff. 
An overnight fast (no food or drink) from 22hOO (1 Opm) on the evening before the 
study day will be imposed. One glass of water will be permitted upon awakening on 
the morning of the study day. 
DO NOT TAKE YOUR ANTI-TB MEDICATION ON THE MORNING OF THE STUDY 
DAY, HOWEVER, IT MUST BE CARRIED WITH YOU TO THE STUDY CENTRE, AS 
THIS WILL BE ADMINISTERED TO YOU AFTER THE FIRST BLOOD SAMPLES 
HAVE BEEN WITHDRAWN. 
We require your permission to collect information from your clinic and/or hospital 
records. The following tests will be conducted if your doctor has not already done 
them: 
HIV status 
Anti-TB drug levels 
Sputum examinations 
Procedure 
On the morning of the study day, patients will report to the study centre at 07hOO after 
an overnight fast of at least 10 hours and after rectal and bladder emptying. 
A -1 29 
Appendix A 
Upon entry into the study centre, a blood sample (8 ml) will be withdrawn prior to you 
taking your medications. Patients will then be asked to take their anti-TB medication 
under supervision and the time will be recorded. 
Thereafter, further blood samples (8ml each) will be withdrawn at 1, 2, 4, 8 and 12 
hours after medication administration. 
Patients will be required to return to the study centre 1 week later at which time the 
results of the above tests will be discussed with you. 
Hospital in-patients may have the above schedule adjusted to follow the normal ward 
routine. 
Contacts 
If there are any further questions that you may wish to ask, please contact the people 
mentioned below. 
Mr G Pillai (Principal Investigator) 
Department of Pharmacology 
University of Durban-Westville 
Private Bag X54001, DURBAN 4000 
Telephone : 2044767(W) 2692729 (H) 
Professor R Miller (Study Supervisor) 
Food and Drug Administration 
5600 Fishers Lane 
Rockville , MD 20857, United States of America 
Telephone: (301) 8275440 (W) (301) 2795878(H) 
Professor SS Abdool Karim (Study Supervisor & Medical Officer) 
Centre for Epidemiological Research in South Africa 
Medical Research Council 
Umbilo Road, Congella 
Telephone: 251481 (W) 4042383 (H) 
Dr N Padayatchi 
Medical Superintendent 
King George V Hospital 
P.O. Dormerton, DURBAN 
Telephone : 287121(W) 
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Date of History of Date of Weight Height 
SEX Admission TB MDR HIV Group Study (kg) (em) 
yy/mm/dd treatment Ivv/mm/dd 
1 96/10/15 5 1 1 1 97/03/19 51 .8 170 
1 96/12/18 3 0 1 3 97/03/19 48.7 171 .5 
1 96/08/29 0 0 1 3 97/03/19 70 178 
1 97/02/24 4 1 1 1 97/03/19 43.3 169 
1 96/11/26 0 0 1 3 97/03/19 58 175 
1 96/09/27 0 1 0 2 97/03/19 55.7 170 
1 97/02/10 5 1 0 2 97/03/19 99.5 176 
1 96/10107 5 1 0 2 97/04/09 57.25 173 
1 97/01/28 5 0 0 4 97/04/09 65.5 163 
1 97/02/20 0 0 1 3 97/04/09 62 176.5 
1 97/01/20 5 1 0 2 97/04/09 55.5 172.5 
1 96/11/11 5 1 0 2 97/04/09 48.75 169 
1 96/08/26 5 1 0 2 97/04/09 57.25 167 
1 97/03/24 5 1 0 2 97/04/16 49 167.5 
1 96/07/11 0 1 0 2 97/04/16 65 168 
1 97/03/13 5 1 0 2 97/04/16 57 175.5 
1 97/04/01 5 1 0 2 97/04/16 41 167 
1 97/02/21 1 1 0 2 97/04/16 55 171 
1 96/11/13 4 1 1 1 97/04/16 45 163 
1 96/11/21 5 1 1 1 97/04/16 40 169 
1 96/11/27 5 1 0 2 97/04/16 62 183 
1 96/12/24 4 1 0 2 97/04/16 62 169 
1 97/04/07 5 1 0 2 97/04/16 60 176 
1 97/02/20 5 1 0 2 97/04/16 60 173 
1 97/01/28 0 0 0 4 97/04/23 86.4 184 
1 97/d4/08 3 0 0 4 97/04/23 82.2 174 
1 97/01/21 4 0 0 4 97/04/23 63.3 171 
1 97/03/12 5 1 0 2 97/04/23 53.8 165 
1 96/11/11 5 1 0 2 97/04/23 57 182 
1 97/01/16 0 0 1 3 97/04/23 65.2 165 
1 97101/16 3 0 0 4 97/04/23 48.5 154 
1 97101/29 5 2 1 97104/23 45 161 
1 96/12/10 0 1 0 2 97/04/23 43.5 156.5 
1 97/02106 4 0 0 4 97/04/23 59 173 
1 97/03/25 3 0 1 3 97/04/23 61 177 
1 97/01/06 0 0 0 4 97/04/23 40 163 
1 97/04/04 0 0 1 3 97/04/23 56 171 
1 97/03/26 0 0 0 4 97/04/23 60 166.5 
1 97/03/03 0 0 0 4 97/04/23 59 173.5 
1 96/12/31 0 0 0 4 97/04/23 56 159.5 
1 97/03/26 2 0 0 4 97/05/07 46 134.5 
1 97/04/30 0 0 0 4 97/05/07 46.7 174 
1 97/02/24 4 0 0 4 97/05/07 75.3 172 
1 97/02/06 0 0 0 4 97105/07 60.1 173 
1 97103/27 0 0 1 3 97/05/07 49 135 
1 97/03/11 0 0 1 3 97/05/07 62.8 183 



















































SEX - O=female, 1 =male; History of TB treatment - O=new case, 1 =re-treatment case, 2&3=re-treatment after previous cure or treatment 
completion; 4&5=re-treatment after previous treatment interuption or failure; MDR - O=no, 1 =yes, GROUP - 1=MDR+ & HIV+, 2=MDR+ & 




Date of Date of History of Date of Weight Height AGE 
10 Birth SEX Admission TB MDR HIV Group Study (kg) (em) (years) 
RACE 
Iyy/mm/dd yy/mm/dd treatment Iyy/mm/dd 
48 49112109 1 97/04/15 3 0 0 4 97/05/07 65.5 178 48 
49 55/04/14 1 97/02/12 3 0 0 4 97/05/07 76.5 178 42 
50 69/09/19 1 97/01/07 0 0 1 3 97/05/07 73 174.5 28 
51 79/12/24 0 97/04/11 0 2 0 97/05/14 46.3 160 18 
52 79/02/07 0 97/01/06 0 0 0 4 97/05/14 60.5 164.5 18 
53 69/12/21 0 97/02/14 0 0 1 3 97/05/14 65 163 28 
54 75/11/18 0 97/04/02 0 0 1 3 97/05/14 52 152 22 
55 80109/05 0 97/03/24 3 0 0 4 97/05/14 43.6 152 18 
56 66/02/18 0 97/01/21 4 0 1 3 97/05/14 59.9 162.5 31 2 
57 46/12/30 0 97/04/15 0 0 0 4 97/05/14 64.5 164.5 51 
58 75/07/30 0 97/02/02 0 0 1 3 97/05/14 46.5 152 22 
59 69/12/09 0 97/04/14 0 0 1 3 97/05/14 52 154 28 
60 47/12/26 0 97/02/12 0 0 0 4 97/05/14 45.1 155 50 
61 76/07/10 0 97/02/06 4 0 0 4 97/05/14 71 .3 171 .5 21 
62 37/10108 0 97/03/10 0 0 0 4 97/05/14 78.3 152 60 
63 73/10/28 0 96/07/26 4 1 1 1 97/05/21 52.3 158 24 
64 60/12/15 0 97/02/14 0 0 1 3 97/05/21 54.2 153.4 37 
65 77/06102 0 97/02/04 0 0 1 3 97/05/21 54.3 161 20 
66 43/12/24 0 97/03/14 0 1 0 2 97/05/21 56.4 159.5 54 
67 74/07/01 0 97/03/12 0 0 1 3 97/05/21 43.9 155.1 23 
68 71/08/17 0 96/08/13 0 1 1 1 97/05/21 51 166.4 26 
69 72/04/12 0 96/09/16 0 1 0 2 97/05/21 45.7 156.5 25 
70 57/04/20 0 96/10107 4 1 0 2 97/05/21 73.5 160.5 40 
71 65/07/01 0 97/02/07 0 0 1 3 97/05/21 52.4 148.8 32 
72 32/02/02 0 97/04/25 0 0 0 4 97/05/21 48 163 65 2 
73 52/07/01 0 97/04/29 0 0 1 3 97/05/21 39.5 149.3 45 
74 47/03/06 0 97/02/25 4 1 0 2 97/05/21 41 .7 150.3 50 3 
75 50101/11 0 96/11/15 0 1 1 1 97/05/21 81 .8 161 47 . 
76 65/03/21 0 97/01/29 0 1 1 1 97/05/21 44 158 32 
77 73/05/23 0 97/04/08 5 1 0 2 97/05/21 45.2 155.5 24 
78 49/06/25 0 96/09/02 4 1 0 2 97/05/21 70.8 159 48 
79 60104/21 1 97/02/25 3 1 1 1 97/05/28 46 164 37 
80 32/07/01 1 96/12/19 2 1 0 2 97/05/28 52 140 65 
81 75/02103 1 97/04/21 4 1 1 1 97/05/28 57 150 22 
82 71/08/08 1 97/02111 4 1 0 2 97/05/28 52 171 .5 26 
83 58/09/20 1 97/04/29 2 1 0 2 97/05/28 52 166 39 
84 47/11/25 1 96/10/22 4 1 0 2 97/05/28 50 175 50 
85 47/07/01 1 96/10/24 4 1 0 2 97/05/28 51 166 50 
86 32/04/12 1 97/04/18 0 0 0 4 97/05/28 62.5 162 65 
87 38/06/11 1 97/01/08 2 1 0 2 97/05/28 52.5 172 59 
88 49/07/27 0 97/04/17 0 0 0 4 97/06/11 43.3 149 48 
89 72101118 0 97/06/10 5 1 1 1 97/06/11 66 171 25 
90 73/01/22 0 96/12/24 3 0 0 4 97/06/11 49.2 150 24 
91 74/11/25 0 97/04/14 0 0 1 3 97/06/11 34.8 146 23 
92 66/08/07 0 97/03/03 0 0 1 3 97106/11 44.1 161 31 
93 63/01/07 0 96/12109 4 1 0 2 97106/11 44 152 34 
94 69/06/06 0 97101/21 5 1 1 1 97106/11 47.5 165 28 
SEX - O=female, 1 =male; History of TB treatment - O=new case, 1 =re-treatment case, 2&3=re-treatment after previous cure or treatment 
completion; 4&5=re-treatment after previous treatment interuption or failure; MDR - O=no, 1=yes, GROUP - 1=MDR+ & HIV+, 2=MDR+ & 



















































Date of History of Date of Weight Height 
SEX Admission TB MDR HIV Group Study (kg) (em) 
vv/mm/dd treatment Ivv/mm/dd 
0 97103/19 3 1 0 2 97106/11 67.1 164 
0 97102/10 3 1 0 2 97106/11 55 155.5 
0 97101/24 0 1 1 1 97107109 47.3 152 
0 97102/24 4 0 1 3 97107109 77 174 
0 97106/17 0 0 1 3 97107109 48.1 153 
0 97102/13 4 0 0 4 97107109 54.8 166.5 
0 97106/04 0 0 1 3 97107109 45.9 149 
0 97105/27 0 0 0 4 97107109 44.4 160 
0 97105/13 0 0 0 4 97107109 41 159 
0 97106/03 0 0 1 3 97107109 42.3 160 
0 96/10/31 3 1 0 2 97107109 73.2 152 
0 97105/03 4 0 1 3 97107109 48.6 156 
0 97106/04 4 0 1 3 97107/23 47.2 152 
0 97105/02 4 0 1 3 97107/23 62 163 
0 96/10/28 4 1 1 1 97107/23 51 .5 154 
0 97104/25 0 0 1 3 97107/23 53 154.5 
0 96/12/06 4 1 0 2 97107/23 38.5 157 
0 96/10/29 2 1 0 2 97107/23 54 165 
0 96/11/12 0 1 0 2 97107/23 79 168 
0 97104/22 4 1 0 2 97108106 54 120.5 
0 97102/05 2 1 0 2 97108/06 46.5 120.5 
0 97107/30 4 0 97108/06 46 120.5 
0 97107/22 0 0 1 3 97108/06 59 120.1 
0 97106/09 0 0 1 3 97108/06 45 120.1 
0 97104/17 0 0 0 4 97108/06 46 110.5 
0 97105/29 4 1 0 2 97108/06 47 120.2 
0 97103/13 4 1 0 2 97108106 58 120.4 
0 97108/01 0 0 1 3 97108/06 63 158 
0 97104/29 0 1 1 1 97108/06 61 156 
0 97104/01 0 1 1 1 97108/06 45.8 157 
0 97107/24 3 1 1 1 97108/13 56.5 157.5 
1 97107104 3 1 1 1 97108/13 61.5 165 
1 97104/10 4 1 1 1 97108/13 48.5 159.5 
0 97107108 5 0 1 3 97108/13 41 .75 150 
0 97106/30 0 0 0 4 97108/13 64 155.5 
0 97105/14 0 0 1 3 97108/13 65 164.5 
0 97108/01 0 0 1 3 97108/13 55.8 154 
0 97107/22 0 0 1 3 97108/13 50.2 165.5 
0 97107/23 3 0 0 4 97108/13 41 .7 161 
0 97108/04 2 1 1 1 97108/13 41 .2 154 
0 97107/23 0 0 0 4 97108/13 51 161.5 
0 97106/23 0 0 0 4 97108/13 53 160.5 
0 96/12104 0 1 1 1 97108/13 78.8 156.5 
















































SEX - O=female, 1 =male; History of TB treatment - O=new case, 1 =re-treatment case, 2&3=re-treatment after previous cure or treatment 
completion; 4&5=re-treatment after previous treatment interuption or failure; MDR - O=no, 1=yes, GROUP - 1=MDR+ & HIV+, 2=MDR+ & 
HIV-, 3=MDR- & HIV+, 4=MDR- & HIV-; RACE - Blank = Attican, 2 = "Coloured", 3 = VVhite. 
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LIVER FUNCTION TEST RESULTS & HIV VIRAL LOAD 
ID ALK Bill ALB GLOB GGT ALT AST VIRAL LOAD 
u/L ~mollL gIL gIL u/L u/L u/L copies/ml 
1 65 9 24 73 21 10 27 30598 
2 108 12 16 77 134 15 27 17857 
3 272483 
4 84 15 16 49 39 14 50 587185 
5 21 25 64 60 18 95640 
6 70 9 27 57 60 31 50 
7 57 14 40 43 74 27 35 
8 88 15 28 44 78 34 29 
9 128 14 38 37 100 13 21 
10 9442 
11 49 8 30 48 26 12 28 
12 110 14 19 51 29 15 23 
13 64 11 35 52 35 23 41 
14 65 9 28 43 21 5 18 
15 87 17 35 39 31 15 
16 54 10 31 51 34 15 22 
17 130 33 20 87 34 27 94 
18 100 16 20 57 42 11 23 
19 261 13 14 67 105 7 28 289655 
20 135 9 18 77 150 28 47 120072 
21 
22 74 13 29 52 35 7 26 
23 55 8 37 38 27 16 19 
24 58 18 32 46 20 27 25 
25 211 14 24 39 110 17 31 
26 85 10 36 42 31 14 23 
27 91 7 25 49 19 10 29 
28 
29 79 21 36 63 31 19 30 
30 86 8 27 51 30 15 40 
31 232 22 26 54 233 21 75 
32 88 13 21 50 43 10 24 1891 
33 79 8 24 53 23 12 22 
34 59 11 19 46 28 20 40 
35 73 15 33 52 23 12 24 13747 
36 75 10 20 44 32 18 24 
37 110 11 23 55 80 19 42 304267 
38 67 18 23 44 25 16 25 
39 45 12 23 53 44 12 17 
40 
41 51 12 19 42 29 16 32 
42 139 9 26 42 34 26 32 
43 102 13 27 51 47 20 38 
44 61 10 30 54 34 16 26 
45 544444 
46 188 11 28 50 99 55 55 726686 
47 118 17 22 50 101 17 23 
48 87 6 23 53 23 15 33 
49 84 9 37 36 169 32 28 
50 107 15 36 37 116 31 33 19916 
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LIVER FUNCTION TEST RESULTS & HIV VIRAL LOAD 
ID ALK Bill ALB GLOB GGT ALT AST VIRAL LOAD 
u/L Ilmoi/L giL giL u/L u/L u/L copies/ml 
51 96 10 22 47 32 11 27 
52 70 9 23 53 19 13 38 
53 68 14 26 47 33 18 36 11392 
54 100 14 30 55 46 17 37 23210 
55 74 11 31 57 25 8 15 
56 89 2 30 57 77 25 22 2721348 
57 
58 128 10 16 57 53 14 35 1026087 
59 83 12 18 59 19 12 40 170317 
60 194 13 28 43 171 24 42 
61 55 8 26 49 34 13 25 
62 78 12 23 54 97 19 22 
63 114 9 36 60 43 26 56 49101 
64 133 10 15 65 22 19 32 102211 
65 68 7 35 44 97 112 87 200 
66 74 10 30 36 21 17 21 
67 103 8 24 56 55 14 33 222790 
68 83 18 31 48 48 37 41 11900 
69 65 5 34 52 28 23 43 
70 47 8 35 43 24 11 18 
71 71 7 29 56 92 15 34 172330 
72 52 4 29 56 50 16 23 
73 84 23 23 54 65 43 27 665761 
74 69 6 39 48 22 16 27 
75 105 4 24 68 47 22 37 4550 
76 47 11 19 79 38 11 28 623558 
77 48 11 36 42 18 9 23 
78 119 4 26 47 67 24 43 
79 152 8 22 71 64 17 34 16567 
80 · 
81 71 10 34 60 77 9 25 1493 
82 112 9 20 55 26 9 22 
83 
84 
85 110 14 38 46 65 44 61 
86 55 20 46 43 27 52 46 
87 73 11 36 41 18 11 15 
88 72 13 24 47 86 9 31 
89 74 21 35 65 54 17 33 25478 
90 78 10 24 50 32 10 39 
91 165 23 16 51 71 59 71 6408 
92 51 2 26 44 45 15 23 31907 
93 65 5 32 53 23 5 21 
94 74 9 32 61 56 17 24 150698 
95 65 6 37 41 30 13 23 
96 129 11 30 54 156 23 28 
97 79 12 25 60 75 30 66 2382183 
98 100 9 17 60 25 11 34 72273 
99 46895 
100 184 18 17 48 46 38 52 
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LIVER FUNCTION TEST RESULTS & HIV VIRAL LOAD 
10 ALK Bill ALB GLOB GGT ALT AST VIRAL LOAD 
u/L Ilmoi/L gIL gIL u/L u/L u/L copies/ml 
101 61 7 22 77 21 13 33 936691 
102 192 10 16 58 25 21 38 
103 221 17 20 48 39 18 62 
104 97 8 21 73 23 18 32 18197 
105 100 6 40 38 52 17 20 
106 202 19 17 60 86 14 47 
107 58 15 17 107 37 13 35 704947 
108 97 11 24 72 12 20 52 58831 
109 152 9 29 62 44 18 31 26949 
110 100 17 21 46 31 16 48 1012308 
111 78 7 19 50 37 20 30 
112 100 17 25 61 102 66 24 
113 54 10 30 31 18 11 20 
114 76 16 27 44 34 16 29 
115 124 7 30 52 95 27 38 
116 45 7 18 66 18 7 33 18546 
117 59 6 25 52 19 13 17 4575 
118 85 9 18 58 37 13 30 18473 
119 231 16 17 52 46 10 27 
120 131 6 26 48 85 8 18 
121 102 11 23 50 73 45 93 
122 47 9 19 51 32 29 58 93225 
123 65183 
124 43 7 26 54 37 10 16 
125 95 3 17 75 36 18 36 337319 
126 66 8 23 77 30 10 30 1135294 
127 64 8 19 82 56 8 27 144325 
128 13310 
129 61 9 27 49 19 16 31 
130 117 15 15 58 54 23 53 156800 
131 85 11 29 97 94 29 29 468 
132 77 9 21 66 31 9 21 21388 
133 69 8 24 46 43 14 19 
134 658537 
135 54 11 29 80 36 30 37 
136 99 9 20 42 37 45 104 
137 46 14 23 64 30 12 34 2649 
138 99 16 27 47 59 11 33 
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(J) (J) (,) w (,) I- :E :E 
1 1 1 1 1 0 0 1 0 0 0 0 
2 0 0 0 
3 
. 
4 1 1 1 0 0 1 0 1 0 0 0 0 1 >16 >12 
5 0 0 0 
6 1 1 1 0 0 1 0 1 0 0 0 0 1 >16 4 
7 1 1 1 1 1 1 0 1 0 0 0 0 0 8 >12 
8 1 1 1 1 1 1 0 1 0 1 0 0 1 16 >12 
9 0 0 0 1 1 0 0 1 0 0 0 0 0 1 <0.5 
10 0 0 0 0 0 0 0 1 1 0 0 0 1 1 <0.5 
11 1 1 1 0 0 1 0 0 1 1 0 0 0 >16 >12 
12 1 1 1 1 1 1 0 0 0 0 0 0 1 4 >12 
13 1 1 1 1 1 1 0 1 0 0 0 0 1 8 >12 
14 1 1 1 1 1 1 0 0 1 0 0 0 1 >16 8 
15 1 1 1 1 1 1 1 1 1 1 0 0 0 16 >12 
16 1 1 1 1 1 1 0 0 0 0 0 0 1 16 >12 
17 1 1 1 1 1 1 0 1 0 0 0 0 0 >16 >12 
18 1 1 1 1 1 1 0 1 1 0 0 0 1 4 12 
19 1 1 1 1 1 1 0 1 1 0 0 0 1 8 >12 
20 1 1 1 1 1 1 0 1 0 0 0 0 1 4 >12 
2.1 1 1 1 0 0 1 0 1 0 0 0 0 1 >16 8 
22 1 1 1 0 0 0 0 0 0 0 0 0 0 8 >12 
23 1 1 1 1 1 0 0 0 0 1 
24 1 1 1 1 1 1 0 1 0 1 0 0 1 >16 >12 
25 0 0 0 0 0 0 0 1 0 0 0 0 0 <0.1 <0.5 
26 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
27 0 0 0 
28 1 1 1 1 1 1 1 1 1 1 1 
29 1 1 1 0 0 1 1 1 0 1 0 0 1 >16 2 
30 
31 0 0 0 
32 1 0 0 0 0 0 0 1 0 0 0 0 
33 1 1 1 0 0 1 1 1 1 0 0 0 1 >16 4 
34 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
35 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
36 
37 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
38 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
39 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
40 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
41 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
o = sensitive. 1 = resistant Blank = not known. 
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DRUG SUSCEPTIBILITY RESULTS 
c c c (I) (I) c (I) E E c ';3 - ';3 e '0 ';3 :'2 c ';3 c :'2e :'2e c ';3 c 0 - -';3 >.E - >. '': IV ';3 C) C) >.- ::l E N N- N- 'Q. E- E C) .Q E (I) >. >< IV IV ::1. ::1. 
C 
IV C) IV C) o C) o ::1. E 0 
IV II) E 0 >< - J: IV '2 ::1. '2 ::1. E _ ::1. -0 (I) c 0 IV ;;: 0 (I) c t ON 00 .!! Q.o Q., IV ... ,2 U c 0 ;;: CJ " I .!!!O II) , (I) , (1)0 J: Q. IV ... ,!! ~ ~ J: >. Q. 0 _ .... Q: ... N .::. .... - IV - ~ J: - W U en en u w u ~ ::E ::E 
42 
43 0 0 0 1 1 0 0 1 0 0 0 0 1 <0.1 <0.5 
44 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
45 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
46 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
47 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
48 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
49 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
50 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
51 1 1 0 0 0 0 0 1 0 0 0 0 0 4 <0.5 
52 1 1 0 0 0 0 0 0 0 0 0 0 0 <0.5 
53 0 0 0 0 0 0 0 0 0 0 0 0 0 , 
54 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
55 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
56 0 0 0 0 0 0 0 0 1 0 0 0 0 <0.1 <0.5 
57 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
58 0 0 0 0 0 0 0 0 0 0 0 0 0 
59 0 0 0 0 0 0 0 0 0 0 0 0 0 <1 <0.5 
60 0 0 0 0 0 0 0 0 1 0 0 0 0 <0.1 <0.5 
61 0 0 0 
62 0 0 0 0 0 0 0 0 1 0 0 0 0 <0.1 <0.5 
63 1 1 1 1 1 1 1 1 0 1 0 0 0 >16 12 
64 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
65 0 0 0 0 0 0 0 1 0 0 0 0 0 1 <0.5 
66 1 1 1 1 1 0 0 1 0 0 0 0 1 4 >12 
67 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
68 1 1 1 1 1 1 0 0 0 0 0 0 0 8 >12 
69 1 1 1 1 1 1 0 1 0 0 0 0 0 8 >12 
70 1 1 1 1 0 1 0 1 0 0 0 0 1 >16 >12 
71 
72 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
73 0 0 0 0 0 0 0 1 0 0 0 0 0 <0.1 <0.5 
74 1 1 1 1 1 1 0 1 1 0 0 0 1 16 4 
75 1 1 1 0 0 1 1 0 0 0 1 
76 1 1 1 1 1 0 0 1 0 0 0 0 0 4 >12 
77 1 1 1 1 1 1 0 1 1 0 0 0 1 >16 >12 
78 1 1 1 1 1 1 0 1 1 0 1 0 1 16 >12 
79 1 1 1 1 1 1 0 1 1 0 0 0 1 >16 2 
80 1 1 1 1 1 0 0 0 0 0 0 0 0 16 >12 
81 1 1 1 1 1 1 0 1 0 0 0 0 0 4 >12 
82 1 1 1 1 1 1 0 0 1 0 0 0 0 4 >12 
o = sensitive, 1 = resistant, Blank = not known. 
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c c c (1) (1) c (1) E E c '(3 E "0 '(3 :2 c c :2E 'tI- u- c '(3 u c 0 - -,- E '(3 >-E - >- E '':: ns '(3 en en >-- :::l >- >< N ~ N- N- 'Q. E- E en ,Q E (1) ns ns ~ 
9 
ns en ns en o en o ~ E 0 
ns (I) E 0 >< - .:: ~ '~ ~ '~ ~ E - ~ o.C! (1) c 0 ns ;;: 0 (1) C ON 00 J! Q.o ns ... ,9 U c e ;;: u " I 
~o 
(I) , (1) , 2!0 .:: Q. .:: >- ns Q. 0 ,~ ~ ~ -"I'"" i:E ... N - ns - ~ .:: - _"I'"" W (.) en en (.) w (.) I- :i :i 
83 1 1 1 0 0 1 0 1 0 0 0 0 0 4 >12 
84 1 1 1 1 1 1 1 1 1 1 1 1 1 >16 >12 
85 1 1 1 0 0 1 0 1 1 0 0 0 0 4 >12 
86 
87 1 1 1 0 0 0 0 0 0 0 0 0 0 8 >12 
88 
89 1 1 1 1 1 1 0 1 0 0 0 0 1 8 >12 
90 0 0 0 1 1 '0 0 0 1 0 0 0 0 <0.1 <0.5 
91 0 0 0 0 0 0 0 1 1 0 0 0 0 <0.1 <0.5 
92 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
93 1 1 1 1 1 1 0 1 0 Q 0 0 0 4 >12 
94 1 1 1 1 0 1 0 0 0 1 
95 1 1 1 0 0 0 1 0 0 0 1 1 0 >16 >12 
96 1 1 1 1 1 1 0 1 0 0 0 0 1 8 >12 
97 1 1 1 1 1 0 0 0 1 0 0 0 0 4 >12 
98 0 0 0 0 0 0 0 1 1 0 0 0 1 <0.1 <0.5 
99 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
100 0 0 0 0 0 0 0 1 1 0 0 0 0 <0.1 <0.5 
101 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
102 0 0 0 o . 0 0 0 1 0 0 0 0 0 <0.1 <0.5 
103 0 0 0 0 0 0 0 1 1 0 0 0 0 <0.1 <0.5 
104 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
105 1 1 1 0 0 0 0 1 0 0 0 0 1 16 4 
106 
107 
108 0 0 0 0 0 0 0 0 1 0 0 0 0 <0.1 <0.5 
109 1 1 1 1 1 1 0 1 0 0 0 0 1 >16 >12 
110 0 0 0 0 0 0 0 1 1 0 0 0 0 
111 1 1 1 1 1 0 0 1 1 0 0 0 1 4 2 
112 1 1 1 0 0 0 0 0 0 0 0 
113 1 1 1 1 1 1 0 1 0 0 0 0 1 
114 1 1 1 0 0 0 0 1 0 0 0 0 0 16 >12 
115 1 1 1 1 0 1 0 0 0 0 1 
116 0 0 0 0 0 0 <0.1 <0.5 
117 0 0 0 0 0 0 0 0 0 0 0 0 0 
118 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
119 0 0 0 0 0 0 0 1 0 0 0 0 1 <0.1 <0.5 
120 1 1 1 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
121 0 0 1 0 0 1 0 1 0 0 0 0 1 8 2 
122 0 0 0 0 0 0 
123 1 1 1 1 0 0 0 0 0 0 0 0 0 >16 >12 
o = sensitive, 1 = resistant, Blank = not known. 
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c c 
"0 
c Q) Q) ,5 Q) E E ,5 '(j E '(j :2 c c :2E :2E (,)- - C '(j (,) ,5 0 - -(,) >-E >-- :::l >- E ''::: ns (,) N CI CI N- N- 'Q. E- E CI E Q) >- >< :::1. :::1. ns CI ns CI ,Q ns E 0 ns ns C 'c :::1. 'c :::1. E o CI o :::1. E 0 en >< - .c ns _ :::1. -0 Q) c 0 ns ;;::: 0 Q) c 't: ON 00 .! c..o c.. ns ... ,2 c:; c 0 ;;::: (,) " I en ' en ' Q) • Q)o .c c.. .c ns ... ,~ ~ ~ _0 _ .... ii: ...N - >- ,9- 0 - b .... w ns - U ~ .c (J) (J) u w U I- ::E ::E 
124 1 1 1 1 1 1 0 1 0 0 0 0 0 8 >12 
125 1 1 1 
126 1 1 1 1 1 0 0 1 0 0 0 0 0 
127 1 1 0 0 0 0 0 0 0 0 0 0 0 
128 0 0 0 0 0 0 
129 0 0 0 0 0 0 
130 0 0 0 0 0 0 0 1 1 0 0 0 0 1 <0.5 
131 0 0 0 0 0 0 0 1 1 0 0 0 1 <0.5 
132 0 0 0 0 0 0 0 0 0 0 0 0 0 <0.1 <0.5 
133 0 0 0 0 0 0 0 0 0 0 0 0 0 
134 1 1 1 0 0 0 0 0 0 0 0 0 0 >16 >12 
135 0 0 0 0 0 0 0 0 0 0 0 0 0 1 <0.5 
136 0 0 0 0 0 0 0 1 0 0 0 0 1 <0.1 <0.5 
137 1 1 1 1 0 1 0 0 0 0 0 0 0 
138 0 0 0 0 0 0 0 1 1 0 0 0 0 <0.1 <0.5 
o = sensitive. 1 = resistant. Blank = not known. 
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RIFAMPICIN DOSE AND CONCENTRATION DATA 
DATE TIME DOSE CONC 10 (mm/ddlyy) mg jlg/ml 
10 DATE TIME DOSE CONC 
(mm/dd/yy) mg ~ml 
1 3119197 05:27 450 6 3/20/97 06:18 0.03 
1 3/19/97 15:34 2.78 6 3/20/97 07:25 2.04 
1 3/20/97 05:00 450 6 3/20/97 09:35 2.44 
1 3/20/97 05:19 0.03 6 3/20/97 13:47 0.77 
1 3/20/97 06:14 8.23 7 3/19/97 05:25 600 
1 3/20/97 07:20 6.71 7 3/19/97 15:59 1.09 
1 3/20/97 09:25 4.63 8 4/9/97 05:00 600 
1 3/20/97 13:30 1.19 8 4/9/97 12:50 3.25 
2 3/19/97 05:30 450 8 4/9/97 16:05 1.2 
2 3/19/97 15:50 0.94 9 4/9/97 05:00 600 
2 3/20/97 05:00 450 9 4/9/97 12:44 0.4 
2 3/20/97 05:50 0.15 9 4/9/97 16:08 0.18 
2 3/20/97 06:40 3.59 9 4/10/97 05:20 600 
2 3/20/97 07:34 6 9 4/10/97 05:20 0.03 
2 3/20/97 09:50 4.8 9 4/10/97 06:20 0.03 
2 3/20/97 13:21 2.51 9 4/10/97 07:27 12.5 
3 3/19/97 05:30 600 9 4/10/97 09:22 7.14 
3 3/19/97 15:46 0.24 10 4/9/97 05:00 600 
3 3/20/97 05:00 600 10 4/9/97 12:39 0.89 
3 3/20/97 05:49 5.13 10 4/9/97 15:37 0.2 
3 3/20/97 06:35 7.16 10 4/10/97 05:34 0.03 
3 3/20/97 07:41 5.13 10 4/10/97 05:35 600 
3 3/20/97 09:58 1.62 10 4/10/97 06:28 7.51 
3 3/20/97 13:45 1.21 10 4/10/97 07:37 8.09 
4 3/19/97 05:25 450 10 4/10/97 09:43 3.63 
4 3/19/97 15:55 0.12 11 4/9/97 05:10 600 
4 3/20/97 05:00 450 11 4/9/97 12:30 4.02 
4 3/20/97 05:35 1.26 11 4/9/97 16: 11 1.74 
4 3/20/97 06:30 5.09 11 4/10/97 05:29 0.08 
4 3/20/97 07:46 2.22 11 4/10/97 05:30 600 
4 3/20/97 14:02 0.33 11 4/10/97 06:24 1.9 
5 3/19/97 05:30 600 11 4/10/97 07:30 12.7 
5 3/19/97 15:39 0.06 11 4/10/97 09:38 8.03 
5 3/20/97 05:00 600 12 4/9/97 05:00 600 
5 3/20/97 05:30 8.44 12 4/9/97 12:22 5.4 
5 3/20/97 06:23 7.58 12 4/9/97 15:45 2.56 
5 3/20/97 07:28 3.69 12 4/10/97 05:50 0.03 
5 3/20/97 09:45 0.92 12 4/10/97 05:51 600 
5 3/20/97 13:53 0.58 12 4/10/97 06:37 0.03 
6 3/19/97 05:37 600 12 4/10/97 07:55 5.44 
6 3/19/97 15:43 0.61 12 4/10/97 09:51 6.98 
6 3/20/97 05:00 600 13 4/9/97 05:00 600 
6 3/20/97 05:25 0.03 13 4/9/97 12:15 4.03 
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RIFAMPICIN DOSE AND CONCENTRATION DATA 
DATE TIME DOSE CONC 10 (mm/ddlyy) mg ~g/ml 10 
DATE TIME DOSE CONC (mm/ddlyy) mg ~g/ml 
13 4/9/97 15:55 1.73 19 4/17197 07:38 7.3 
13 4/10/97 05:11 0.03 19 4/17197 09:50 5.08 
13 4/10/97 05:12 600 20 4/16/97 04:30 450 
13 4/10/97 06:13 3.96 20 4/16/97 13:42 0.97 
13 4/10/97 07:21 12.5 20 4/16/97 17:15 0.25 
13 4/10/97 09:27 10.3 20 4/17197 07:28 450 
14 4/16/97 04:35 450 20 4/17/97 08:20 0.03 
14 4/16/97 18:00 0.42 21 4/16/97 05:10 600 
14 4/17/97 05:30 0.03 21 4/16/97 12:43 0.39 
14 4/17/97 05:34 450 21 4/16/97 17:50 0.03 
14 4/17197 06:30 2.7 21 4/17197 06:19 600 
14 4/17197 07:32 12.4 21 4/17/97 06:19 0.03 
14 4/17/97 09:43 6.64 21 4/17197 07:03 2.4 
15 4/16/97 05:09 600 21 4/17/97 08:15 7.25 
15 4/16/97 12:50 1.77 21 4/17/97 10:26 3.7 
15 4/16/97 17:31 0.25 22 4/16/97 05:13 600 
15 4/17/97 06:04 0.03 22 4/16/97 12:56 1.61 
15 4/17/97 06:06 600 22 4/16/97 18:18 0.18 
15 4/17/97 06:58 12.1 22 4/17197 06:15 600 
15 4/17197 08:07 12.5 22 4/17/97 06:15 0.03 
15 4/17197 10:15 5.62 22 4/17/97 08:15 9.3 
16 4/16/97 04:45 600 22 4/17/97 10:21 4.52 
16 4/16/97 13:11 5.68 23 4/16/97 05:07 600 
16 4/16/97 17:27 1.26 23 4/16/97 12:38 1.07 
16 4/17/97 05:43 0.08 23 4/17/97 05:55 600 
16 4/17197 05:45 600 23 4/17/97 07:52 5.56 
16 4/17/97 06:39 3.39 23 4/17/97 08:30 9.42 
16 4/17/97 07:43 13.4 24 4/16/97 05:05 600 
16 4/17197 09:56 7 24 4/16/97 13:27 1.03 
18 4/16/97 04:38 600 24 4/16/97 18:12 0.26 
18 4/16/97 12:22 4.97 24 4/17/97 05:57 0.03 
18 4/16/97 17:15 0.78 24 4/17/97 05:59 600 
18 4/17/97 06:22 600 24 4/17/97 06:47 0.51 
18 4/17197 06:22 0.03 24 4/17/97 07:55 6.94 
18 4/17197 07:19 0.06 24 4/17/97 10:10 3.68 
18 4/17/97 08:20 4.37 25 4/23/97 05:00 600 
18 4/17/97 10:03 5.44 25 4/23/97 12:40 0.72 
19 4/16/97 05:00 450 25 4/23/97 17:02 0.03 
19 4/16/97 12:29 4.52 25 4/24/97 06:16 0.03 
19 4/16/97 17:00 1.44 25 4/24/97 06:19 600 
19 4/17/97 05:36 450 25 4/24/97 07:27 6.45 
19 4/17/97 05:36 0.02 25 4/24/97 08:40 3.97 
19 4/17/97 06:35 3.13 25 4/24/97 09:43 3.32 
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ID DATE TIME DOSE 
CONC 
(mm/ddlyy) mg l!g/ml 
ID DATE TIME DOSE CONC (mm/ddlyy) mg tlg/ml 
26 4123/97 05:00 600 31 4124/97 06:55 2.66 
26 4/23/97 13:06 3.15 31 4/24/97 08:08 8.15 
26 4/23/97 16:38 1.23 31 4/24/97 10:05 5.08 
26 4/24/97 05:19 0.03 32 4/23/97 05:00 450 
26 4/24/97 05:21 600 32 . 4/23/97 13:23 1.29 
26 4/24/97 06:30 10.9 32 4/23/97 16:52 0.03 
26 4/24/97 07:38 10.4 32 4/24/97 05:43 450 
26 4/24/97 09:41 5.23 32 4/24/97 06:50 0.13 
27 4/23/97 05:00 600 32 4/24/97 07:55 1.63 
27 4/23/97 12:48 1.3 32 4/24/97 09:59 2.74 
27 4/23/97 16:55 0.15 33 4/23/97 05:14 450 
27 4/24/97 06:10 0.03 33 4/23/97 13:13 1.59 
27 4/24/97 06:11 600 34 4/23/97 05:12 600 
27 4/24/97 07:23 4.68 34 4/23/97 13:34 0.91 
27 4/24/97 08:35 7.09 34 4/23/97 16:15 0.26 
27 4/24/97 10:02 3.85 34 4/24/97 05:27 0.03 
28 4/23/97 05:00 600 34 4/24/97 05:31 600 
28 4/23/97 13:00 1.71 34 4/24/97 06:27 0.03 
28 4/23/97 16:42 0.38 34 4/24/97 07:13 1.25 
28 4/24/97 05:25 0.03 34 4/24/97 08:23 3.48 
28 4/24/97 05:28 600 35 4/23/97 04:55 600 
28 4/24/97 06:40 7.39 35 4/23/97 13:23 0.26 
28 4/24/97 07:46 5.42 35 4/23/97 16:44 0.09 
28 4/24/97 09:46 3.33 35 4/24/97 05:18 0.03 
29 4/23/97 05:34 600 36 4/23/97 04:50 450 
29 4/24/97 05:32 0.03 36 4/23/97 1-2:46 4.96 
29 4/24/97 05:34 600 36 4/23/97 16:20 2.01 
29 4/24/97 07:03 6.72 36 4/24/97 06:05 0.03 
29 4/24/97 08:30 8.55 36 4/24/97 06:10 450 
29 4/24/97 09:56 4.4 36 4/24/97 07:00 0.03 
30 4/23/97 05:00 450 36 4/24/97 08:00 0.75 
30 4/23/97 12:50 0.69 36 4/24/97 09:05 6.13 
30 4/23/97 17:06 0.03 37 4/23/97 04:52 450 
30 4/24/97 06:00 450 37 4/23/97 14:10 1.02 
30 4/24/97 06:00 0.03 37 4/23/97 16:53 0.45 
30 4/24/97 07:15 3.26 38 4/23/97 04:53 600 
30 4/24/97 08:19 4.93 38 4/23/97 13:45 1.27 
30 4/24/97 09:51 3.05 38 4/23/97 16:50 0.18 
31 4/23/97 05:00 450 38 4/24/97 05:37 0.03 
31 4/23/97 12:57 3.08 38 4/24/97 05:42 600 
31 4/23/97 16:35 1.07 38 4/24/97 06:50 0.32 
31 4/24/97 05:50 0.03 38 4/24/97 07:48 3.51 
31 4/24/97 05:52 450 38 4/24/97 08:51 3.1 
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10 
DATE TIME DOSE CONC 
(mm/ddlyy) mg ~g/ml 
10 
DATE TIME DOSE CONC 
(mm/ddlyy) m~ ~g/ml 
39 4/23197 05:15 600 45 5nJ97 04:55 600 
39 4/23/97 13:03 2.38 45 5nJ97 13:06 0.91 
39 4/23/97 16:37 0.54 45 5nJ97 18:18 1.03 
39 4/24/97 06:15 0.03 46 5nJ97 04:55 600 
39 4/24/97 06:19 600 46 5nJ97 11 :45 1.42 
39 4/24/97 07:08 10.8 46 5nJ97 17:30 0.13 
39 4/24/97 08:10 12.4 47 5nJ97 06:04 450 
39 4/24/97 09:12 7.35 47 5/8/97 06:02 0.03 
40 4/23/97 05:10 600 47 5/8/97 06:04 450 
40 4/23/97 13:28 0.64 47 5/8/97 07:11 5.79 
40 4/23/97 17:00 0.15 47 5/8/97 08:05 7.13 
40 4/24/97 05:50 0.03 47 5/8/97 09:40 5.28 
40 4/24/97 05:55 600 48 5nJ97 06:12 600 
40 4/24/97 06:47 5.89 48 5/8/97 06:11 0.Q3 
40 4/24/97 07:41 6.96 48 5/8/97 06:12 600 
40 4/24/97 08:41 7.43 48 5/8/97 07:16 0.33 
41 5nJ97 04:55 600 48 5/8/97 08:11 4.7 
41 5nJ97 13:11 0.96 48 5/8/97 09:35 4.15 
41 5nJ97 17:19 0.17 49 5nJ97 04:55 600 
41 5/8/97 05:57 0.03 49 5nJ97 11 :27 3.47 
41 5/8/97 05:59 600 49 5nJ97 17:40 0.28 
41 5/8/97 06:59 0.03 49 5/8/97 05:18 0.03 
41 5/8/97 07:53 8.47 49 5/8/97 05:20 600 
41 5/8/97 09:15 6.13 49 5/8/97 06:25 7.73 
42 5nJ97 05:54 450 49 5/8/97 07:24 6.97 
42 5/8/97 05:53 0.03 49 5/8/97 09:09 4.18 
42 5/8/97 05:54 450 50 5nJ97 04:55 600 
42 5/8/97 06:56 5.78 50 5nJ97 11 :32 1.28 
42 5/8/97 07:41 6.4 50 5nJ97 17:56 0.07 
43 5nJ97 04:55 600 50 5/8/97 05:30 0.03 
43 5nJ97 12:08 1.08 50 5/8/97 05:32 600 
43 5nJ97 18:00 0.03 50 5/8/97 06:31 5.03 
43 5/8/97 05:34 0.03 50 5/8/97 07:30 4.57 
43 5/8/97 05:38 600 50 5/8/97 09:22 3.1 
43 5/8/97 06:41 9 51 5/14/97 04:58 450 
43 5/8/97 07:35 7.82 51 5/14/97 13:39 2.64 
43 5/8/97 09:28 3.98 51 5/14/97 17:46 0.63 
44 5nJ97 04:55 600 51 5/15/97 05:43 0.03 
44 5nJ97 11 :55 0.47 51 5/15/97 05:45 450 
44 5nJ97 18:11 0.03 51 5/15/97 07:02 0.2 
44 5/8/97 05:46 600 51 5/15/97 08:25 2.54 
44 5/8/97 06:48 9.14 52 5/14/97 04:52 450 
44 5/8/97 08:36 7.25 52 5/14/97 12:55 1.13 
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Appendix E 
RIFAMPICIN DOSE AND CONCENTRATION DATA 
DATE TIME DOSE CONC ID (mm/ddlyy) mg ~g/ml ID 
DATE TIME DOSE CONC 
(mm/ddlyy) mg Ilg/ml 
52 5/14/97 17:23 0.28 59 5/15/97 06:25 450 
52 5/15/97 05:58 450 59 5/15/97 09:25 301 
52 5/15/97 08:49 7.41 60 5/14/97 04:51 450 
53 5/14/97 04:53 600 60 5/14/97 12:42 0.66 
53 5/14/97 13:48 0.66 60 5/14/97 18:10 0.1 
53 5/15/97 05:50 0.03 60 5/15/97 05:17 0.03 
53 5/15/97 05:53 600 60 5/15/97 05:18 450 
53 5/15/97 07:08 8.4 60 5/15/97 06:34 605 
53 5/15/97 08:49 5.24 60 5/15/97 07:32 3.87 
54 5/14/97 04:55 450 60 5/15/97 09:20 2.5 
54 5/14/97 13:22 0.68 61 5/14/97 04:54 600 
54 5/14/97 17:28 0.14 61 5/14/97 14:05 0.26 
54 5/15/97 06:11 0.03 61 5/14/97 17:33 0.16 
54 5/15/97 06:13 450 61 ' 5/15/97 06:08 600 
54 5/15/97 07:26 4.76 61 5/15/97 09:18 7.56 
54 5/15/97 08:12 4.79 62 5/14/97 05:02 600 
54 5/15/97 09:41 2.7 62 5/14/97 13:17 0.54 
55 5/14/97 04:59 450 62 5/14/97 17:42 0.09 
55 5/14/97 13:12 0.72 62 5/15/97 05:33 0.03 
55 5/14/97 18:03 0.03 62 5/15/97 05:34 600 
55 5/15/97 06:16 0.03 62 5/15/97 06:46 0.07 
55 5/15/97 06:17 450 62 5/15/97 07:37 0.19 
55 5/15/97 07:19 0.03 62 5/15/97 09:28 2.09 
55 5/15/97 08:10 0.09 63 5/21/97 04:33 600 
56 5/14/97 05:00 600 63 5/21/97 13:22 0.74 
56 5/14/97 13:52 0.58 63 5/21/97 17:32 0.3 
56 5/14/97 18:20 0.03 63 5/22/97 05:15 600 
56 5/15/97 05:36 0.03 63 5/22/97 05:15 0.03 
56 5/15/97 05:37 600 63 5/22/97 06:20 4.62 
56 5/15/97 06:52 2.42 63 5/22/97 07:24 13.6 
56 5/15/97 07:42 2.19 63 5/22197 09:19 8.9 
56 5/15/97 09:35 1.21 64 5/21/97 04:30 450 
57 5/14/97 04:56 600 64 5/21/97 13:15 0.2 
57 5/14/97 13:00 0.44 64 5/21/97 17:51 0.06 
57 5/14/97 18:15 0.03 64 5/22197 05:50 0.06 
58 5/14/97 04:57 450 64 5/22/97 05:51 450 
58 5/14/97 13:05 0.97 64 5/22/97 06:55 5.31 
58 5/15/97 05:28 450 64 5/22/97 07:40 5.73 
58 5/15/97 05:28 0.13 64 5/22/97 09:56 1.89 
58 5/15/97 08:00 2.89 65 5/21/97 04:34 450 
59 5/14/97 04:50 450 65 5/21/97 12:39 1.5 
59 5/14/97 12:35 0.82 65 5/21/97 17:40 0.15 
59 5/14/97 17:06 0.13 65 5/22/97 05:39 450 
E-150 
Appendix E 
RIFAMPICIN DOSE AND CONCENTRATION DATA 
DATE TIME DOSE CONC 10 (mm/ddlyy) mg !!g/ml 10 
DATE TIME DOSE CONC 
(mm/ddlyy) mJ! ~ml 
65 5122/97 06:32 3.1 71 5/21/97 13:12 2.94 
65 5/22/97 07:31 8.64 71 5/21/97 17:23 0.44 
65 5/22/97 09:40 5.2 71 5/22/97 05:33 0.03 
66 5/21/97 04:35 600 71 5/22/97 05:34 450 
66 5/21/97 12:45 0.49 71 5/22/97 06:39 3.63 
66 5/21/97 17:10 0.03 71 5/22/97 07:37 9.35 
66 5/22/97 05:27 0.03 71 5/22/97 09:53 4.19 
66 5/22/97 05:29 600 72 5/21/97 04:38 450 
66 5/22/97 06:30 0.03 72 5/21/97 12:57 1.49 
66 5/22/97 07:30 5.36 72 5/21/97 17:17 0.19 
66 5/22/97 09:35 5.95 72 5/22/97 05:53 0.03 
67 5/21/97 04:31 450 72 5/22/97 05:54 450 
67 5/21/97 13:37 1.17 72 5/22/97 07:04 7.96 
67 5/21/97 17:20 0.15 72 5/22/97 07:58 10.1 
67 5/22/97 05:40 0.03 72 5/22/97 09:45 5.67 
67 5/22/97 05:41 450 73 5/21/97 04:39 450 
67 5/22/97 06:35 0.03 73 5/21/97 13:06 0.06 
67 5/22/97 07:36 6.03 73 5/21/97 17:46 0.03 
67 5/22/97 09:49 4.02 73 5/22/97 06:04 0.03 
68 5/21/97 04:32 450 73 5/22/97 06:05 450 
68 5/21/97 13:29 2.09 73 5/22/97 06:50 0.03 
68 5/21/97 17:29 0.67 73 5/22/97 07:47 4.39 
68 5/22/97 06:02 450 73 5/22/97 10:10 7.1 9 
68 5/22197 06:52 3.91 74 5/21/97 04:15 450 
68 5/22197 07:53 11 .1 74 5/21/97 13:56 1.08 . 
68 5/22/97 10:10 5.69 74 5/21/97 . 18:06 0.19 
69 5/21/97 04:40 450 74 5/22/97 06:17 450 
69 5/21/97 13:33 2.94 74 5/22/97 07:03 9.48 
69 5/21/97 17:35 0.71 74 5/22/97 08:01 9.77 
69 5/22197 05:48 0.03 74 5/22/97 10:26 5.94 
69 5/22197 05:49 450 75 5/21/97 04:25 600 
69 5/22197 06:43 0.03 75 5/21/97 14:03 0.22 
69 5/22197 07:49 5.98 75 5/21/97 18:02 0.06 
69 5/22197 10:00 9.76 75 5/22197 06:25 600 
70 5/21/97 04:41 600 75 5/22/97 07:18 2.19 
70 5/21/97 12:52 1.69 75 5/22/97 08:12 2.91 
70 5/21/97 17:42 0.28 75 5/22/97 10:19 1.15 
70 5/22/97 05:44 0.03 76 5/21/97 04:20 450 
70 5/22/97 05:45 600 76 5/21/97 14:12 2.08 
70 5/22/97 06:45 0.97 76 5/21/97 17:59 0.78 
70 5/22/97 07:43 3.31 76 5/22/97 06:10 0.27 
70 5/22197 09:31 2.59 76 5/22/97 06:13 450 
71 5/21/97 04:37 450 76 5/22/97 07:08 3.48 
E-151 
Appendix E 
RIFAMPICIN DOSE AND CONCENTRATION DATA 
DATE TIME DOSE CONC 10 (mm/ddlyy) mg J.!g/ml 
10 
DATE TIME DOSE CONC 
(mm/ddlyy) mg J:!9Iml 
76 5122/97 08:10 10.5 82 5/29/97 07:04 1.4 
76 5/22/97 10:31 6.55 82 5/29/97 08:01 5.28 
77 5/21/97 04:15 450 82 5/29/97 10:00 4.24 
77 5/21/97 13:53 1.83 83 5/28/97 05:00 600 
77 5/21/97 17:55 0.53 83 5/28/97 12:25 2.62 
77 5/22/97 06:10 450 83 5/28/97 15:56 0.75 
77 5/22/97 07:01 0.06 83 5/29/97 05:32 600 
77 5/22/97 08:06 6.13 83 5/29/97 05:32 0.03 
77 5/22/97 10:23 4.76 83 5/29/97 06:37 3.44 
78 5/21 /97 04:42 600 83 5/29/97 07:37 4.8Q 
78 5/21/97 13:41 1.37 84 5/28/97 04:50 600 
78 5/21/97 17:14 0.52 84 5/28/97 12:58 2.76 
78 5/22/97 05:22 0.03 84 5/28/97 15:43 1 
78 5/22197 05:25 600 84 5/29/97 05:55 600 
78 5/22/97 06:26 0.31 84 5/29/97 08:45 8.34 
78 5/22/97 07:26 2.65 85 5/28/97 04:50 450 
78 5/22/97 09:25 6.99 85 5/28/97 12:44 2.23 
79 5/28/97 04:56 450 85 5/28/97 17:52 0.26 
79 5/28/97 12:35 3.13 85 5/29/97 05:22 450 
79 5/28/97 16:05 1.46 85 5/29/97 05:22 0.03 
79 5/29/97 05:37 450 85 5/29/97 06:28 5.74 
79 5/29/97 05:37 0.03 85 5/29/97 07:29 7.46 
79 5/29/97 06:41 5.73 85 5/29/97 09:32 3.42 
79 5/29/97 07:42 7.16 86 5/28/97 05:15 600 
79 5/29/97 09:55 4 86 5/28/97 12:36 3.02 
80 5/28/97 04:58 600 86 5/28/97 17:48 0.64 
80 5/28/97 12:20 5.29 86 5/29/97 05:11 600 
80 5/28/97 15:52 2.48 86 5/29/97 05:11 0.03 
80 5/29/97 05:42 600 86 5/29/97 06:16 5.93 
80 5/29/97 05:42 0.02 86 5/29/97 07:16 5.67 
80 5/29/97 06:45 11 .3 86 5/29/97 09:16 5.52 
80 5/29/97 07:49 11.3 87 5/28/97 05:15 450 
81 5/28/97 04:51 600 87 5/28/97 12:26 0.48 
81 5/28/97 12:40 4.36 87 5/28/97 17:43 0.03 
81 5/28/97 16:22 2.9 87 5/29/97 05:15 450 
81 5/29/97 05:49 0.1 87 5/29/97 05:15 0.03 
81 5/29/97 05:50 600 87 5/29/97 06:22 1.88 
81 5/29/97 06:51 10.2 87 5/29/97 07:23 3.06 
81 5/29/97 07:55 10.6 87 5/29/97 09:23 4.24 
81 5/29/97 10:04 4.37 88 6/11/97 05:22 450 
82 5/28/97 04:55 600 88 6/11/97 12:48 1.76 
82 5/28/97 12:30 0.03 88 6/11/97 17:15 0.66 
82 5/29/97 05:44 600 88 6/12/97 05:50 450 
E-152 
Appendix E 
RIFAMPICIN DOSE AND CONCENTRATION DATA 
DATE TIME DOSE CONC 10 (mm/ddlyy) mg ~g/ml 10 
DATE TIME DOSE CONC 
(mm/ddlyy) mg ~g/ml 
88 6/12197 05:50 0.03 94 6/11197 05:16 450 
88 6/12/97 06:58 7.83 94 6/11/97 13:02 0.15 
88 6/12/97 07:46 7.66 94 6/11/97 17:32 0.38 
88 6/12/97 09:50 4.56 94 6/12/97 05:44 450 
89 6/11/97 05:10 600 94· 6/12/97 05:44 0.14 
89 6/11/97 13:03 1.86 94 6/12/97 06:46 2.5 
89 6/11/97 17:10 0.82 94 6/12/97 07:41 9.3 
89 6/12/97 05:30 600 94 6/12/97 09:45 4.3 
89 6/12/97 05:30 0.03 95 6/11/97 05:20 600 
89 6/12/97 06:31 1.36 95 6/11/97 13:12 1.9 
89 6/12/97 07:32 7.62 95 6/11/97 17:20 0.4 
89 6/12/97 09:43 6.11 95 6/12/97 05:22 600 
90 6/11/97 05:17 450 95 6/12/97 05:22 0.03 
90 6/11/97 12:37 0.46 95 6/12/97 06:21 . 0.03 
90 6/11/97 17:25 0.03 95 6/12/97 07:25 13.9 
90 6/12/97 05:51 450 95 6/12/97 09:19 9.9 
90 6/12/97 06:35 0.17 96 6/11/97 05:00 450 
90 6/12/97 07:48 7.27 96 6/11/97 13:24 3.3 
90 6/12/97 09:53 4.29 96 6/11/97 17:52 1.1 
91 6/11/97 05:15 450 96 6/12/97 06:03 450 
91 6/11/97 13:09 1.5 96 6/12/97 06:03 0.03 
91 6/11/97 17:38 0.26 96 6/12/97 07:08 8.7 
91 6/12/97 05:27 450 96 6/12/97 08:05 5.4 
91 6/12/97 05:27 0.03 96 6/12/97 10:05 5.1 
91 6/12/97 06:27 3.8 97 7/9/97 05:15 450 
91 6/12/97 07:29 6.53 97 7/9/97 13:56 0.45 
91 6/12/97 09:25 4.56 97 7/9/97 17:21 0.41 
92 6/11/97 05:20 600 97 7/10/97 05:42 0.26 
92 6/11/97 12:29 0.91 97 7/10/97 05:43 450 
92 6/11/97 17:07 0.18 97 7/10/97 06:48 2.9 
92 6/12197 05:18 600 97 7/10/97 07:42 6.6 
92 6/12197 05:18 0.Q3 97 7/10/97 09:39 3.3 
92 6/12197 06:18 1.52 98 7/9/97 05:19 600 
92 6/12/97 07:20 12.1 98 7/9/97 13:37 0.5 
92 6/12/97 09:14 5.49 98 7/9/97 17:12 0.1 
93 6/11/97 05:21 450 98 7/10/97 05:40 600 
93 6/11/97 12:55 2.04 98 7/10/97 05:40 0.03 
93 6/11/97 17:30 0.36 98 7/10/97 06:45 2.1 
93 6/12/97 05:36 450 98 7/10/97 07:45 7.4 
93 6/12197 05:36 0.03 98 7/10/97 09:43 4.9 
93 6/12197 06:44 7.52 99 7/9/97 05:10 450 
93 6/12197 07:37 12.2 99 7/9/97 14:33 2.9 
93 6/12/97 09:38 5.33 99 7/9/97 17:31 0.6 
E·153 
Appendix E 
RIFAMPICIN DOSE AND CONCENTRATION DATA 
DATE TIME DOSE CONC 10 (mm/ddlyy) mg Ilg/ml 10 
DATE TIME DOSE CONC 
(mm/dd/yy) mg Ilg/ml 
99 7/10/97 05:37 450 106 7/9/97 14:15 3 
99 7/10/97 05:37 0.03 106 7/10/97 05:30 450 
99 7/10/97 06:44 8 106 7/1 0/97 08:38 5.2 
99 7/10/97 07:39 8.9 107 7/23/97 04:15 450 
99 7/10/97 09:35 4.8 107 7/23/97 13:50 0.4 
100 7/9/97 05:11 600 107 7/23/97 17:52 0.03 
100 7/9/97 14:04 0.03 107 7/24/97 05:15 450 
100 7/9/97 17:28 0.03 107 7/24/97 05:15 0.03 
100 7/10/97 05:52 600 107 7/24/97 06:30 1.4 
100 7/10/97 05:52 0.03 107 7/24/97 07:20 6.8 
100 7/10/97 06:55 7.2 107 7/24/97 09:25 4.1 
100 7/1 0/97 07:49 8 108 7/23/97 04:16 600 
100 7/10/97 09:50 3.5 108 7/23/97 13:03 0.2 
101 7/9/97 05:14 450 108 7/23/97 17:28 0.03 
101 7/9/97 14:30 0.4 108 7/24/97 05:10 0.03 
101 7/9/97 17:25 0.14 108 7/24/97 05:11 600 
101 7/10/97 05:47 450 108 7/24/97 07:19 5 
101 7/10/97 08:31 7.3 108 7/24/97 09:55 1.3 
102 7/9/97 05:10 450 109 7/23/97 04:57 600 
102 7/9/97 13:25 1.8 109 7/23/97 12:43 6 
102 7/10/97 05:25 450 109 7/23/97 17:25 2.7 
102 7/10/97 08:34 4.1 109 7/24/97 05:27 600 
103 7/9/97 05:18 450 109 7/24/97 05:27 0.03 
103 7/9/97 13:45 3.9 109 7/24/97 06:42 7.4 
103 7/9/97 17:37 1.6 110 7/23/97 04:55 450 
103 7/10/97 05:28 450 110 7/23/97 12:53 1.2 
103 7/10/97 05:28 0.Q7 110 7/23/97 17:34 0.2 
103 7/10/97 06:33 0.14 110 7/24/97 05:19 450 
103 7/10/97 08:25 1.7 110 7/24/97 05:19 0.03 
104 7/9/97 05:22 450 110 7/24/97 06:23 5.5 
104 7/9/97 13:50 1.1 110 7/24/97 07:15 6.4 
104 7/9/97 17:19 0.2 110 7/24/97 09:16 4.5 
104 7/10/97 05:34 450 111 7/23/97 04:56 450 
104 7/10/97 05:34 0.03 111 7/23/97 14:04 0.9 
104 7/10/97 06:38 5.6 111 7/23/97 17:47 0.2 
105 7/9/97 05:20 600 111 7/24/97 05:34 450 
105 7/9/97 13:30 1.3 111 7/24/97 05:34 0.03 
105 7/9/97 17:08 0.3 111 7/24/97 06:49 5.9 
105 7/10/97 05:23 0.03 111 7/24/97 07:35 11 .2 
105 7/10/97 05:24 600 111 7/24/97 09:47 6.4 
105 7/10/97 06:26 0.7 112 7/23/97 04:59 600 
105 7/10/97 08:23 8.1 112 7/23/97 13:38 8.4 
106 7/9/97 05:15 450 112 7/23/97 17:37 4.1 
E-154 
Appendix E 
RIFAMPICIN DOSE AND CONCENTRATION DATA 
DATE TIME DOSE CONC 10 (mm/ddlyy) mg Ilg/ml 
10 DATE TIME DOSE CONC 
(mm/ddlyy) mg ~~ml 
112 7/24197 05:22 600 117 8/7/97 07:41 6.6 
112 7/24/97 05:22 0.04 117 8/7/97 09:41 3.8 
112 7/24/97 06:35 0.8 118 8/6/97 05:12 450 
112 7/24/97 07:26 22.5 118 8/6/97 12:49 1.1 
112 7/24/97 09:30 16.5 118 8/6/97 17:50 0.3 
113 7/23/97 04:58 600 118 817197 05:36 9·03 
113 7/23/97 13:23 5.1 118 8/7/97 05:37 450 
113 7/23/97 17:41 2.4 118 8/7/97 06:31 9.8 
113 7/24/97 05:25 600 118 817197 07:32 9.2 
113 7/24/97 05:25 0.03 118 8/7/97 09:39 5 
113 7/24/97 06:38 9.4 119 8/6/97 05:10 450 
113 7/24/97 07:28 25 119 8/6/97 13:01 1.2 
113 7/24/97 09:37 14.3 119 8/6/97 17:39 0.3 
114 8/5/97 05:15 600 119 817197 05:23 0.03 
114 8/5/97 09:05 6.6 119 817197 05:24 450 
114 8/6/97 05:15 600 119 817197 06:24 0.3 
114 8/6/97 13:04 1.9 119 817197 07:23 8.4 
114 8/6/97 17:57 0.2 119 817197 09:22 7 
114 817197 05:26 0.03 120 8/6/97 05:10 450 
114 8/7/97 05:27 600 120 8/6/97 12:53 2.8 
114 817197 06:27 7.9 120 817197 05:50 450 
114 en/97 07:27 13.6 120 8/7/97 05:50 0.03 
114 8/7/97 09:25 7.4 120 8/7/97 06:51 4 
115 8/6/97 05:11 450 120 817197 08:00 15.2 
115 · 8/6/97 12:45 5.8 120 817197 10:02 5.7 
115 817197 05:41 0.1 121 8/6/97 05:08 450 
115 817197 05:42 450 121 8/6/97 13:08 1.9 
115 8/7/97 06:41 11 .1 121 8/6/97 17:30 0.2 
115 817197 07:48 20.8 121 817197 05:38 450 
115 817197 09:48 11.3 121 817197 05:38 0.03 
116 8/6/97 05:05 450 121 817197 06:39 8.1 
116 8/6/97 13:17 3.3 121 817197 07:47 12.7 
116 817197 05:44 0.03 121 817197 09:45 5.6 
116 817197 05:45 450 122 8/6/97 05:20 600 
116 817197 06:47 3.1 122 8/6/97 13:36 0.03 
116 817197 07:55 9.2 122 8/6/97 18:02 0.03 
116 817197 09:55 5 122 817197 06:02 600 
117 8/6/97 05:06 600 122 817197 07:04 0.03 
117 8/6/97 13:10 0.36 122 817197 08:09 2.9 
117 8/6/97 17:52 0.04 122 817197 10:09 3.1 
117 817197 05:35 0.03 123 8/6/97 04:55 600 
117 817197 05:36 600 123 8/6/97 13:31 1.1 
117 817197 06:35 6.3 123 8/6/97 18:18 0.25 
E-155 
Appendix E 
RIFAMPICIN DOSE AND CONCENTRATION DATA 
DATE TIME DOSE CONC 10 (mm/ddlyy) mg J-Lg/ml 10 
DATE TIME DOSE CONC 
(mm/ddlyy) mg J!9Iml 
123 8/7/97 06:05 0.07 129 8/14/97 04:45 600 
123 8/7/97 06:06 600 129 8/14/97 05:20 600 
123 8/7/97 07:08 11 .2 129 8/14/97 05:20 0.03 
123 817197 10:13 5.2 129 8/14/97 06:41 37.9 
124 8/6/97 05:05 450 129 8/14/97 07:33 34.7 
124 8/6/97 10:13 7.4 129 8/14/97 09:18 13.3 
124 8/6/97 13:41 4.3 130 8/13/97 04:30 600 
124 8/6/97 18:08 0.9 130 8/13/97 12:49 0.79 
125 8/13/97 05:00 600 130 8/13/97 18:32 0.03 
125 8/13/97 11 :55 3.3 130 8/14/97 05:37 0.03 
125 8/13/97 17:30 0.4 130 8/14/97 05:38 600 
125 8/14/97 06:09 0.03 130 8/14/97 06:58 0.03 
125 8/14/97 06:10 600 130 8/14/97 07:57 4.2 
125 8/14/97 07:30 5.6 130 8/14/97 09:38 4.3 
125 8/14/97 08:21 9.6 131 8/13/97 04:30 600 
125 8/14/97 10:03 7 131 8/13/97 12:40 0.5 
126 8/13/97 05:00 450 131 8/13/97 18:28 0.03 
126 8/13/97 12:15 2.9 131 8/14/97 04:45 600 
126 8/13/97 17:42 0.9 131 8/14/97 05:28 600 
126 8/14/97 06:25 0.03 131 8/14/97 05:28 2.7 
126 8/14/97 06:26 450 131 8/14/97 06:47 7.7 
126 8/14/97 07:42 4.3 131 8/14/97 07:50 14.5 
126 8/14/97 08:27 7.2 131 8/14/97 09:33 10.5 
126 8/14/97 10:13 4.6 132 8/13/97 04:30 450 
127 8/13/97 05:25 450 132 8/13/97 12:45 0.55 
127 8/13/97 13:10 6.4 132 8/13/97 18:18 0.08 
127 8/13/97 17:10 2.7 132 8/14/97 04:45 450 
127 8/14/97 06:18 0.18 132 8/14/97 05:41 450 
127 8/14/97 06:19 450 132 8/14/97 05:41 8.6 
127 8/14/97 07:36 7.9 132 8/14/97 09:15 15.6 
127 8/14/97 08:31 11 .8 133 8/13/97 04:30 450 
127 8/14/97 10:20 8.5 133 8/13/97 12:43 0.5 
128 8/13/97 05:00 450 133 8/13/97 18:35 0.05 
128 8/13/97 13:05 3.3 133 8/14/97 04:45 450 
128 8/13/97 17:57 1.5 133 8/14/97 05:45 1.7 
128 8/14/97 05:53 0.03 133 8/14/97 05:46 450 
128 8/14/97 05:57 450 133 8/14/97 07:02 24.2 
128 8/14/97 07:10 10.6 133 8/14/97 08:05 17.1 
128 8/14/97 08:11 13.3 133 8/14/97 09:43 14.2 
128 8/14/97 09:52 7.2 134 8/13/97 04:35 450 
129 8/13/97 04:30 600 134 8/13/97 12:56 2.1 
129 8/13/97 12:34 1.12 134 8/13/97 18:24 0.3 
129 8/13/97 18:08 0.03 134 8/14/97 04:45 450 
E-156 
Appendix E 
RIFAMPICIN DOSE AND CONCENTRATION DATA 
10 
DATE TIME DOSE CONC 
(mm/ddlyy) mg ua/ml 
134 8/14197 05:15 450 
134 8/14/97 05:15 2.4 
134 8/14/97 06:42 9.3 
134 8/14/97 08:00 21 .1 
134 8/14/97 09:1 5 18.1 
135 8/13/97 04:35 450 
135 8/13/97 12:46 0.09 
135 8/13/97 18:14 0.1 
135 8/14/97 04:45 450 
135 8/14/97 05:31 2.7 
135 8/14/97 05:32 450 
135 8/14/97 06:44 12 
135 8/14/97 07:38 12.1 
135 8/14/97 09:26 8.2 
136 8/13/97 04:35 450 
136 8/13/97 12:50 0.3 
136 8/13/97 18:21 0.03 
136 8/14/97 04:45 450 
136 8/14/97 05:25 450 
136 8/14/97 05:25 3 
136 8/14/97 06:53 8 
136 8/14/97 07:58 16.7 
136 8/14/97 09:40 14.6 
137 8/13/97 04:35 600 
137 8/13/97 12:38 1 
137 8/13/97 18:39 0.15 
137 8/14/97 04:45 600 
137 8/14/97 05:23 600 
137 8/14/97 05:23 0.03 
137 8/14/97 06:46 14.1 
137 8/14/97 07:48 29.3 
137 8/14/97 09:22 19.8 
138 8/13/97 04:10 450 
138 8/13/97 13:20 0.4 
138 8/13/97 18:44 0.07 
138 8/14/97 05:42 450 
138 8/14/97 05:42 0.03 
138 8/14/97 07:16 1.47 
138 8/14/97 09:30 7.2 
E-157 




ISONIAZID DOSE AND CONCENTRATION DATA 
ID DATE TIME DOSE CONC ID DATE TIME DOSE CONC 
(mm/dd/yy) mg Ilg/ml (mm/dd/yy) mg Ilg/ml 
1 3119/97 05:27 400 6 3120/97 06:18 2.12 
1 3/19/97 08:15 133 6 3/20/97 07:25 3.9 
1 3/19/97 14:00 133 6 3/20/97 09:35 3.31 
1 3/19/97 15:34 1.56 6 3/20/97 13:47 1.08 
1 3/19/97 17:00 133 7 3/19/97 05:25 400 
1 3/20/97 05:19 400 7 3/19/97 15:59 0.48 
1 3/20/97 05:19 0.96 7 3/20/97 05:10 0.025 
1 3/20/97 06:14 6.49 7 3/20/97 05:15 400 
1 3/20/97 07:20 3.97 7 3/20/97 06:10 7.64 
1 3/20/97 08:15 133 7 3/20/97 07:17 4.87 
1 3/20/97 09:25 2.08 7 3/20/97 09:30 1.7 
1 3/20/97 13:30 1.17 7 3/20/97 17:55 0.2 
2 3/19/97 05:30 400 8 4/9/97 05:00 400 
2 3/19/97 15:50 0.57 8 4/9/97 12:50 1.74 
2 3/20/97 05:50 0.025 8 4/9/97 16:05 0.96 
2 3/20/97 05:51 400 8 4/10/97 05:45 0.025 
2 3/20/97 06:40 8.54 8 4/10/97 05:46 400 
2 3/20/97 07:34 5.99 8 4/10/97 09:40 3.44 
2 3/20/97 09:50 3.86 9 4/9/97 05:00 400 
2 3/20/97 13:21 1.48 9 4/9/97 12:44 1.16 
3 3/19/97 05:30 400 9 4/9/97 16:08 0.57 
3 3/19/97 15:46 0.48 9 4/10/97 05:20 400 
3 3/20/97 05:49 400 9 4/10/97 05:20 0.025 
3 3/20/97 05:49 0.025 9 4/10/97 06:20 4.4 
3 3/20/97 06:35 6.22 9 4/10/97 07:27 5.09 
3 3/20/97 07:41 3.6 9 4/10/97 09:22 2.6 
3 3/20/97 09:58 1.61 10 4/9/97 05:00 400 
3 3/20/97 13:45 0.61 10 4/9/97 12:39 1.44 
4 3/19/97 05:25 400 10 4/9/97 15:37 0.98 
4 3/19/97 15:55 1.88 10 4/10/97 05:34 0.025 
4 3/20/97 05:35 0.5 10 4/10/97 05:35 400 
4 3/20/97 05:38 400 10 4/10/97 06:28 6.03 
4 3/20/97 06:30 6.01 10 4/10/97 07:37 4.8 
4 3/20/97 07:46 7 10 4/10/97 09:43 2.33 
4 3/20/97 14:02 3.36 11 4/9/97 05:10 400 
5 3/19/97 05:30 400 11 4/9/97 12:30 0.85 
5 3/19/97 15:39 1.35 11 4/9/97 16:11 0.41 
5 3/20/97 05:30 400 11 4/10/97 05:29 0.025 
5 3/20/97 05:30 0.025 11 4/10/97 05:30 400 
5 3/20/97 06:23 7.78 11 4/10/97 06:24 4.29 
5 3/20/97 07:28 6.18 11 4/10/97 07:30 6.84 
5 3/20/97 09:45 2.95 11 4/10/97 09:38 3.3 
5 3/20/97 13:53 1.59 12 4/9/97 05:00 400 
6 3/19/97 05:37 400 12 4/9/97 09:00 133 
6 3/19/97 15:43 0.45 12 4/9/97 12:22 7.32 
6 3/20/97 05:25 400 12 4/9/97 14:00 133 
6 3/20/97 05:25 0.025 12 4/9/97 15:45 6.25 
F-159 
Appendix F 
ISONIAZID DOSE AND CONCENTRATION DATA 
10 DATE TIME DOSE CONC 10 DATE TIME DOSE CONC 
(mm/ddlyy) mg I ~g/ml (mm/ddlyy) mg ~g/ml 
12 4/9/97 17:00 133 17 4/16/97 13:05 1.2 
12 4/10/97 05:50 2.88 17 4/16/97 14:40 133 
12 4/10/97 05:51 400 17 4/16/97 16:45 133 
12 4/10/97 06:37 7.19 17 4/16/97 17:05 0.64 
12 4/10/97 07:55 10.68 17 4/17/97 06:01 0.025 
12 4/10/97 09:00 133 17 4/17197 06:53 0.025 
12 4/10/97 09:51 9.86 17 4/17/97 08:00 0.025 
13 4/9/97 05:00 400 17 4/17/97 09:14 133 
13 4/9/97 12:15 2.79 17 4/17/97 10:35 1.86 
13 4/9/97 15:55 1.96 18 4/16/97 04:38 300 
13 4/10/97 05:11 0.34 18 4/16/97 12:22 1.11 
13 4/10/97 05:12 400 18 4/16/97 17:15 0.14 
13 4/10/97 06:13 5.67 18 4/17/97 06:22 300 
13 4/10/97 07:21 6.28 18 4/17/97 06:22 0.025 
13 4/10/97 09:27 4.12 18 4/17/97 07:19 1.25 
14 4/16/97 08:40 133 18 4/17197 08:20 3.62 
14 4/16/97 14:30 133 18 4/17/97 10:03 2.25 
14 4/16/97 16:45 133 19 4/16/97 05:00 300 
14 4/16/97 18:00 2.04 19 4/16/97 12:29 2.51 
14 4/17/97 05:30 1.01 19 4/16/97 17:00 1.02 
14 4/17/97 06:30 0.81 19 4/17/97 05:36 300 
14 4/17/97 07:32 0.71 19 4/17/97 05:36 0.23 
14 4/17/97 09:01 133 19 4/17/97 06:35 11 .77 
14 4/17/97 09:43 . . 0.52 19 4/17/97 07:38 9.74 
15 4/16/97 08:35 133 19 4/17/97 09:50 5.1 
15 4/16/97 12:50 0.66 20 4/16/97 04:30 300 
15 4/16/97 14:47 133 20 4/16/97 13:42 0.6 
15 4/16/97 16:35 133 20 4/16/97 17:15 0.18 
15 4/16/97 17:31 2.55 20 4/17/97 07:28 300 
15 4/17/97 06:04 0.18 20 4/17/97 08:20 0.82 
15 4/17/97 06:58 0.08 21 4/16/97 05:10 400 
15 4/17/97 08:07 0.1 21 4/16/97 12:43 2.22 
15 4/17/97 09:15 133 21 4/16/97 17:50 0.76 
15 4/17/97 10:15 0.48 21 4/17/97 06:19 400 
16 4/16/97 04:45 400 21 4/17/97 06:19 0.025 
16 4/16/97 08:45 133 21 4/17/97 07:03 5.17 
16 4/16/97 13:11 0.76 21 4/17/97 08:15 6.61 
16 4/16/97 14:30 133 21 4/17/97 10:26 3.62 
16 4/16/97 16:45 133 22 4/16/97 05:13 400 
16 4/16/97 17:27 1.17 22 4/16/97 12:56 0.9 
16 4/17/97 05:43 0.08 22 4/16/97 18:18 0.34 
16 4/17/97 05:45 400 22 4/17197 06:15 400 
16 4/17/97 06:39 7 22 4/17/97 06:15 0.025 
16 4/17/97 07:43 3.6 22 4/17/97 08:15 3.46 
16 4/17/97 09:05 133 22 4/17/97 10:21 1.99 
16 4/17/97 09:56 2.64 23 4/16/97 05:07 300 
17 4/16/97 08:30 133 23 4/16/97 12:38 0.79 
F-\60 
Appendix F 
ISONIAZID DOSE AND CONCENTRATION DATA 
10 DATE TIME DOSE CONC 10 DATE TIME DOSE CONC 
(mm/ddlyy) mg ~g/ml (mm/ddlyy) mg ~g/ml 
23 4/17/97 05:55 300 30 4/23/97 12:50 2.53 
23 4/17/97 07:52 2.22 30 4/23/97 17:06 0.51 
23 4/17/97 08:30 2.3 30 4/24/97 06:00 300 
24 4/16/97 05:05 300 30 4/24/97 06:00 0.16 
24 4/16/97 13:27 1.39 30 4/24/97 07:15 6.34 
24 4/16/97 18:12 0.58 30 4/24/97 08:19 6.23 
25 4/23/97 05:00 400 30· 4/24/97 09:51 4.05 
25 4/23/97 12:40 0.56 31 4/23/97 05:00 300 
25 4/23/97 17:02 0.19 31 4/23/97 12:57 1 01 
25 4/24/97 06:16 0.025 31 4/23/97 16:35 0.53 
25 4/24/97 06:19 400 31 4/24/97 05:50 0.025 
25 4/24/97 07:27 4.24 31 4/24/97 05:52 300 
25 4/24/97 08:40 2.54 31 4/24/97 06:55 8.41 
25 4/24/97 09:43 1.97 31 4/24/97 08:08 6.17 
26 4/23/97 05:00 400 31 4/24/97 10:05 3.34 
26 4/23/97 13:06 0.9 32 4/23/97 05:06 300 
26 4/23/97 16:38 0.36 32 4/23/97 13:23 0.99 
26 4/24/97 05:19 0.025 32 4/23/97 16:52 048 
26 4/24/97 05:21 400 32 4/24/97 05:43 300 
26 4/24/97 06:30 7.3 32 4/24/97 06:50 4.96 
26 4/24/97 07:38 5.12 32 4/24/97 07:55 4.54 
26 4/24/97 09:41 2.8 32 4/24/97 09:59 2.95 
27 4/23/97 05:00 400 33 4/23/97 05:14 300 
27 4/23/97 12:48 0.73 33 4/23/97 13:13 1.81 
27 4/23/97 16:55 0.34 34 4/23/97 05:12 300 
27 4/24/97 06:10 0.025 34 4/23/97 13:34 0.91 
27 4/24/97 06:11 400 34 4/23/97 .16:15 0.42 
27 4/24/97 07:23 6.06 34 4/24/97 05:27 0.025 
27 4/24/97 08:35 4.29 34 4/24/97 05:31 300 
27 4/24/97 10:02 2.6 34 4/24/97 06:27 1.19 
28 4/23/97 05:00 400 34 4/24/97 07:13 1.03 
28 4/23/97 13:00 0.54 34 4/24/97 08:23 1.44 
28 4/23/97 16:42 0.25 35 4/23/97 04:55 400 
28 4/24/97 05:25 0.025 35 4/23/97 13:23 1.39 
28 4/24/97 05:28 400 35 4/23/97 16:44 0.56 
28 4/24/97 06:40 7.93 35 4/24/97 05:18 0.025 
28 4/24/97 07:46 5.79 36 4/23/97 04:50 300 
28 4/24/97 09:46 1.44 36 4/23/97 12:46 0.85 
29 4/23/97 05:00 400 36 4/23/97 16:20 0.37 
29 4/23/97 13:17 0.35 36 4/24/97 06:05 0.09 
29 4/23/97 17:10 0.025 36 4/24/97 06:10 300 
29 4/24/97 05:32 0.025 36 4/24/97 07:00 0.73 
29 4/24/97 05:34 400 36 4/24/97 08:00 2.56 
29 4/24/97 07:03 8.16 36 4/24/97 09:05 241 
29 4/24/97 08:30 7.03 37 4/23/97 04:52 300 
29 4/24/97 09:56 4.77 37 4/23/97 14:10 0.82 
30 4/23/97 05:00 300 37 4/23/97 16:53 0.76 
F-161 
Appendix F 
ISONIAZID DOSE AND CONCENTRATION DATA 
10 DATE TIME DOSE CONC 10 DATE TIME DOSE CONC 
(mm/ddlyy) mg Illg/ml (mm/ddlyy) mg ~ml 
38 4/23/97 04:53 400 44 5n197 04:55 400 
38 4/23/97 13:45 0.53 44 5n197 11 :55 1.55 
38 4/23/97 16:50 0.29 44 5/7/97 18: 11 0.44 
38 4/24/97 05:37 0.025 44 5/8/97 05:46 400 
38 4/24/97 05:42 400 44 5/8/97 06:48 7.52 
38 4/24/97 06:50 5.05 44 5/8/97 08:36 4.07 
38 4/24/97 07:48 4.26 45 5n197 04:55 400 
38 4/24/97 08:51 1.94 45 5n197 13:06 0.76 
39 4/23/97 05:15 300 45 5n197 18:18 0.69 
39 4/23/97 13:03 1.51 46 5/7/97 04:55 400 
39 4/23/97 16:37 0.71 46 5/7/97 11 :45 0.96 
39 4/24/97 06:15 0.16 46 5/7/97 17:30 0.37 
39 4/24/97 06:19 300 47 5n197 04:55 400 
39 4/24/97 07:08 4.64 47 5n197 12:03 3.59 
39 4/24/97 08:10 5.6 47 5n197 17:50 0.85 
39 4/24/97 09:12 3.42 47 5/8/97 06:02 0.025 
40 4/23/97 05:10 300 47 5/8/97 06:04 400 
40 4/23/97 13:28 0.21 47 5/8/97 07:11 9.75 
40 4/23/97 17:00 0.1 47 5/8/97 08:05 9.47 
40 4/24/97 05:50 0.025 47 5/8/97 09:40 5.67 
40 4/24/97 05:55 300 48 5n197 04:55 400 
40 4/24/97 06:47 2.74 48 5n197 11 :37 2.55 
40 4/24/97 07:41 2.53 48 5n197 17:45 0.76 
40 4/24/97 08:41 1.51 48 5/8/97 06:11 0.025 
41 5n197 04:55 400 48 5/8/97 06:12 400 
41 5n197 13: 11 0.43 48 5/8/97 07:16 8.25 
41 5n197 17:19 0.025 48 5/8/97 08:11 7.61 
41 5/8/97 05:57 0.025 48 5/8/97 09:35 4.11 
41 5/8/97 05:59 400 49 5n197 04:55 400 
41 5/8/97 06:59 3.76 49 5n197 11 :27 1.15 
41 5/8/97 07:53 7.57 49 5n197 17:40 0.28 
41 5/8/97 09:15 3.38 49 5/8/97 05:18 0.025 
42 5n197 04:55 400 49 5/8/97 05:20 400 
42 5n197 13:03 2.36 49 5/8/97 06:25 4.86 
42 5n197 18:06 0.75 49 5/8/97 07:24 3.4 
42 5/8/97 05:53 2.29 49 5/8/97 09:09 1.78 
42 5/8/97 05:54 400 50 5n197 04:55 300 
42 5/8/97 06:56 7.95 50 5n197 11 :32 0.41 
42 5/8/97 07:41 7.9 50 5n197 17:56 0.81 
43 5n197 04:55 400 50 5/8/97 05:30 0.025 
43 5n197 12:08 0.36 50 5/8/97 05:32 300 
43 5n197 18:00 0.025 50 5/8/97 06:31 3.22 
43 5/8/97 05:34 0.025 50 5/8/97 07:30 2.63 
43 5/8/97 05:38 400 50 5/8/97 09:22 1.23 
43 5/8/97 06:41 4.84 51 5/14/97 04:58 300 
43 5/8/97 07:35 3.39 51 5/14/97 13:39 0.37 
43 5/8/97 09:28 1.17 51 5/14/97 17:46 0.23 
F-162 
Appendix F 
ISONIAZID DOSE AND CONCENTRATION DATA 
ID DATE TIME DOSE CONC ID DATE TIME DOSE CONC 
(mm/ddlyy) mg llg/ml (mm/ddlyy) mg : llg/ml 
51 5115197 05:43 0.025 59 5114197 12:35 0.44 
51 5/15/97 05:45 300 59 5/14/97 17:06 0.16 
51 5/15/97 07:02 1.56 59 5/15/97 06:25 300 
51 5/15/97 08:25 2.19 59 5/15/97 09:25 2.79 
52 5/14/97 04:52 300 60 5/14/97 04:51 300 
52 5/14/97 12:55 0.49 60 5/14/97 12:42 0.94 
52 5/14/97 17:23 0.36 60 5/14/97 18:10 0.025 
52 5/15/97 05:58 300 60 5/15/97 05:17 0.025 
52 5/15/97 08:49 0.025 60 5/15/97 05:18 300 
53 5/14/97 04:53 400 60 5/15/97 06:34 8.61 
53 5/14/97 13:48 0.56 60 5/15/97 07:32 4.83 
53 5/15/97 05:50 0.025 60 5/15/97 09:20 3.15 
53 5/15/97 05:53 400 61 5/14/97 04:54 400 
53 5/15/97 07:08 7.31 61 5/14/97 14:05 1.03 
53 5/15/97 08:49 2.41 61 5/14/97 17:33 0.28 
54 5/14/97 04:55 300 61 5/15/97 06:08 400 
54 5/14/97 13:22 0.34 61 5/15/97 09:18 3.8 
54 5/14/97 17:28 0.17 62 5/14/97 05:02 400 
54 5/15/97 06:11 0.025 62 5/14/97 13:17 0.87 
54 5/15/97 06:13 300 62 5/14/97 17:42 0.24 
54 5/15/97 07:26 4.3 62 5/15/97 05:33 0.025 
54 5/15/97 08:12 2.64 62 5/15/97 05:34 400 
54 5/15/97 09:41 1.7 62 5/15/97 06:46 7.79 
55 5/14/97 04:59 . 300 62 5/15/97 07:37 5.84 
55 5/14/97 13:12 0.6 62 5/15/97 09:28 1.65 
55 5/14/97 18:03 0.08 63 5/21/97 04:33 400 
55 . 5/15/97 06:16 0.025 63 5/21/97 08:35 133 
55 5/15/97 06:17 300 63 5/21/97 13:22 2.83 
55 5/15/97 07:19 5 63 5/21/97 14:25 133 
55 5/15/97 08:10 4.87 63 5/21/97 17:05 133 
56 5/14/97 05:00 400 63 5/21/97 17:32 3.85 
56 5/14/97 13:52 0.31 63 5/22/97 05:15 400 
56 5/14/97 18:20 0.12 63 5/22/97 05:15 0.56 
56 5/15/97 05:36 0.025 63 5/22/97 06:20 7.84 
56 5/15/97 05:37 400 63 5/22197 07:24 8.9 
56 5/15/97 06:52 5.39 63 5/22/97 08:35 133 
56 5/15/97 07:42 3.27 63 5/22/97 09:19 5.87 
,56 5/15/97 09:35 1.37 64 5/21/97 04:30 300 
57 5/14/97 04:56 400 64 5/21/97 13:15 1.61 
57 5/14/97 13:00 0.4 64 5/21/97 17:51 0.65 
57 5/14/97 18:15 0.21 64 5/22197 05:50 0.025 
58 5/14/97 04:57 300 64 5/22/97 05:51 300 
58 5/14/97 13:05 0.48 64 5/22197 06:55 7.28 
58 5/15/97 05:28 300 64 5/22/97 07:40 5.99 
58 5/15/97 05:28 0.025 64 5/22/97 09:56 3.93 
58 5/15/97 08:00 3.53 65 5/21/97 04:34 300 
59 5/14/97 04:50 300 65 5/21/97 12:39 0.34 
F-163 
Appendix F 
ISONIAZID DOSE AND CONCENTRATION DATA 
10 DATE TIME DOSE CONC 10 DATE TIME DOSE CONC 
(mm/ddlyy) mg Illg/ml (mm/ddlyy) mg Ilg/ml 
65 5/21/97 17:40 0.025 70 5122/97 09:31 3.28 
65 5/22/97 05:39 300 71 5/21/97 04:37 300 
65 5/22/97 06:32 5.25 71 5/21/97 13:12 2.11 
65 5/22/97 07:31 4.72 71 5/21/97 17:23 0.64 
65 5/22/97 09:40 2.15 71 5/22/97 05:33 0.025 
66 5/21/97 04:35 400 71 5/22/97 05:34 300 
66 5/21/97 12:45 2.53 71 5/22/97 06:39 8.49 
66 5/21/97 17:10 1.11 71 5/22/97 07:37 6.31 
66 5/22/97 05:27 0.4 71 5/22/97 09:53 3.53 
66 5/22/97 05:29 400 72 5/21/97 04:38 300 
66 5/22/97 06:30 3.59 72 5/21/97 12:57 2.72 
66 5/22/97 07:30 11 .71 72 5/21/97 17:17 1.33 
66 5/22/97 09:35 5.98 72 5/22/97 05:53 0.32 
67 5/21/97 04:31 300 72 5/22/97 05:54 300 
67 5/21/97 13:37 1.41 72 5/22/97 07:04 8.64 
67 5/21/97 17:20 0.91 72 5/22/97 07:58 7.78 
67 5/22/97 05:40 0.86 72 5/22/97 09:45 4.79 
67 5/22/97 05:41 300 73 5/21/97 04:39 300 
67 5/22/97 06:35 3.62 73 5/21/97 13:06 0.09 
67 5/22/97 07:36 9.19 73 5/21/97 17:46 0.025 
67 5/22/97 09:49 3.73 73 5/22/97 06:04 0.025 
68 5/21/97 04:32 300 73 5/22/97 06:05 300 
68 5/21/97 13:29 0.3 73 5/22/97 06:50 7.6 
68 5/21/97 17:29 0.15 73 5/22/97 07:47 8.89 
68 5/22/97 06:02 300 73 5/22/97 10:10 4.24 
68 5/22/97 06:52 5.87 74 5/21/97 04:15 300 
68 5/22/97 07:53 5.78 74 5/21/97 13:56 0.34 . 
68 5/22/97 10:10 2.54 74 5/21/97 . 18:06 0.13 
69 5/21/97 04:40 300 74 5/22/97 06:17 300 
69 5/21/97 08:30 133 74 5/22/97 07:03 5.41 
69 5/21/97 13:33 1.87 74 5/22/97 08:01 4.42 
69 5/21/97 14:15 133 74 5/22/97 10:26 1.26 
69 5/21/97 17:00 133 75 5/21/97 04:25 400 
69 5/21/97 17:35 1.59 75 5/21/97 14:03 1.03 
69 5/22197 05:48 0.32 75 5/21/97 18:02 0.63 
69 5/22197 05:49 300 75 5/22/97 06:25 400 
69 5/22197 06:43 4.43 75 5/22/97 07:18 8.31 
69 5/22/97 07:49 5.95 75 5/22197 08:12 6.6 
69 5/22/97 09:30 133 75 5/22/97 10:19 3.25 
69 5/22/97 10:00 4.63 76 5/21/97 04:20 300 
70 5/21/97 04:41 400 76 5/21/97 14:12 1.46 
70 5/21/97 12:52 2.25 76 5/21/97 17:59 0.78 
70 5/21/97 17:42 0.76 76 5/22/97 06:10 0.28 
70 5/22/97 05:44 0.18 76 5/22197 06:13 300 
70 5/22/97 05:45 400 76 5/22/97 07:08 9.4 
70 5/22/97 06:45 8.61 76 5/22/97 08:10 8.09 
70 5/22197 07:43 6.76 76 5/22/97 10:31 4.06 
F-164 
Appendix F 
ISONIAZID DOSE AND CONCENTRATION DATA 
ID DATE TIME DOSE CONC ID DATE TIME DOSE CONC 
(mm/ddlyy) mg lj..Lg/ml (mm/dd/yy) mg j..Lg/ml 
77 5/21/97 04:15 300 82 5/29/97 07:04 4.67 
77 5/21/97 13:53 0.78 82 5/29/97 08:01 4.2 
77 5/21/97 17:55 0.24 82 5/29/97 08:42 133 
77 5/22/97 06:10 300 82 5/29/97 10:00 4.47 
77 5/22/97 07:01 3.28 83 5/28/97 05:00 400 
77 5/22/97 08:06 6.5 83 5/28/97 12:25 0.58 
77 5/22/97 10:23 2.87 83 5/28/97 15:56 0.28 
78 5/21/97 04:42 400 83 5/29/97 05:32 400 
78 5/21/97 13:41 0.32 83 5/29/97 05:32 0.025 
78 5/21/97 17:14 0.25 83 5/29/97 06:37 7.62 
78 5/22/97 05:22 0.54 83 5/29/97 07:37 5.93 
78 5/22/97 05:25 400 84 5/28/97 04:50 400 
78 5/22/97 06:26 5.65 84 5/28/97 12:58 2.29 
78 5/22/97 07:26 4.58 84 5/28/97 15:43 0.94 
78 5/22/97 09:25 1.98 84 5/29/97 05:55 400 
79 5/28/97 04:56 400 84 5/29/97 08:45 3.37 
79 5/28/97 12:35 0.26 85 5/28/97 04:50 400 
79 5/28/97 16:05 0.025 85 5/28/97 08:15 133 
79 5/29/97 05:37 400 85 5/28/97 12:44 2.19 
79 5/29/97 05:37 0.025 85 5/28/97 14:00 133 
79 5/29/97 06:41 9.2 85 5/28/97 17:00 133 
79 5/29/97 07:42 4.79 85 5/28/97 17:52 0.46 
79 5/29/97 09:55 1.99 85 5/29/97 05:22 400 
80 5/28/97 04:58 400 85 5/29/97 05:22 0.025 
80 5/28/97 08:00 133 85 5/29/97 06:28 5.29 
80 5/28/97 12:20 8.32 85 5/29/97 07:29 4.88 
80 5/28/97 14:00 133 85 5/29/97 08:25 133 
80 5/28/97 15:52 5.21 85 5/29/97 09:32 3.28 
80 5/28/97 18:00 133 86 5/28/97 05:15 400 
80 5/29/97 05:42 400 86 5/28/97 12:36 4.15 
80 5/29/97 05:42 2.46 86 5/28/97 17:48 1.5 
80 5/29/97 06:45 10.55 86 5/29/97 05:11 400 
80 5/29/97 07:49 11.62 86 5/29/97 05:11 0.97 
81 5/28/97 04:51 400 86 5/29/97 06:16 8.23 
81 5/28/97 12:40 2.88 86 5/29/97 07:16 6.69 
81 5/28/97 16:22 1.11 86 5/29/97 09:16 4.33 
81 5/29/97 05:49 0.025 87 5/28/97 05:15 400 
81 5/29/97 05:50 400 87 5/28/97 12:26 0.74 
81 5/29/97 06:51 9.59 87 5/28/97 17:43 0.29 
81 5/29/97 07:55 6.88 87 5/29/97 05:15 400 
81 5/29/97 10:04 4.72 87 5/29/97 05:15 0.025 
82 5/28/97 04:55 400 87 5/29/97 06:22 3.16 
82 5/28/97 08:00 133 87 5/29/97 07:23 3.04 
82 5/28/97 12:30 0.69 87 5/29/97 09:23 1.55 
82 5/28/97 14:00 133 88 6/11/97 05:22 300 
82 5/28/97 18:00 133 88 6/11/97 12:48 1.76 
82 5/29/97 05:44 400 88 6/11/97 17:15 0.2 
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Appendix F 
ISONIAZID DOSE AND CONCENTRATION DATA 
10 DATE TIME DOSE CONC 10 DATE TIME DOSE CONC 
(mm/ddlyy) mg I !!JlIml (mm/ddlyy) mg Jl:9fml 
88 6/12/97 05:50 300 94 6/12/97 05:44 600 
88 6/12/97 05:50 0.025 94 6/12/97 05:44 6.4 
88 6/12/97 06:58 10.01 94 6/12/97 06:46 13.73 
88 6/12/97 07:46 7.76 94 6/12/97 07:41 11 .6 
88 6/12/97 09:50 5.22 94 6/12/97 09:45 9.3 
89 6/11/97 05:10 400 95 6/11/97 05:20 400 
89 6/11/97 13:03 2.49 95 6/11/97 08:55 133 
89 6/11/97 17:10 1.05 95 6/11/97 13:12 2.56 
89 6/12/97 05:30 400 95 6/11/97 14:10 133 
89 6/12/97 05:30 0.1 95 6/11/97 17:20 3.01 
89 6/12/97 06:31 6.98 95 6/11/97 18:02 133 
89 6/12/97 07:32 9.17 95 6/12/97 05:22 400 
89 6/12/97 09:43 5.32 95 6/12/97 05:22 0.22 
90 6/11/97 05:17 300 95 6/12/97 06:21 4.97 
90 6/11/97 12:37 2.07 95 6/12/97 07:25 5.96 
90 6/11/97 17:25 0.57 95 6/12/97 08:25 133 
90 6/12/97 05:51 300 95 6/12/97 09:19 4.72 
90 6/12/97 06:35 9.06 96 6/11/97 05:00 400 
90 6/12/97 07:48 8.41 96 6/11/97 13:24 0.44 
90 6/12/97 09:53 6.02 96 6/11/97 17:52 0.22 
91 6/11/97 05:15 300 96 6/12/97 06:03 400 
91 6/11/97 13:09 3.04 96 6/12/97 06:03 0.025 
91 6/11/97 17:38 1.01 96 6/12/97 07:08 4.4 
91 6/12/97 05:27 300 96 6/12/97 08:05 4.36 
91 6/12/97 05:27 0.18 96 6/12/97 10:05 2.06 
91 6/12/97 06:27 3.69 97 7/9/97 05:15 300 
91 6/12/97 07:29 5.45 97 7/9/97 13:56 1.59 
91 6/12/97 09:25 6.74 97 7/9/97 .17:21 0.82 
92 6/11/97 05:20 400 97 7/10/97 05:42 0.025 
92 6/11/97 12:29 1.63 97 7/10/97 05:43 300 
92 6/11/97 17:07 0.85 97 7/10/97 06:48 8.23 
92 6/12197 05:18 400 97 7/10/97 07:42 8.28 
92 6/12197 05:18 0.025 97 7/10/97 09:39 4.76 
92 6/12197 06:18 5.15 98 7/9/97 05:19 400 
92 6/12197 07:20 4.51 98 7/9/97 13:37 0.66 
92 6/12197 09:14 2.46 98 7/9/97 17:12 0.31 
93 6/11/97 05:21 300 98 7/10/97 05:40 400 
93 6/11/97 12:55 0.98 98 7/10/97 05:40 0.025 
93 6/11/97 17:30 0.36 98 7/10/97 06:45 4.7 
93 6/12/97 05:36 300 98 7/10/97 07:45 3.72 
93 6/12197 05:36 0.025 98 7/10/97 09:43 1.71 
93 6/12/97 06:44 7.78 99 7/9/97 05:10 300 
93 6/12197 07:37 6.16 99 7/9/97 14:33 0.96 
93 6/12197 09:38 3.5 99 7/9/97 17:31 0.38 
94 6/11/97 05:16 600 99 7/10/97 05:37 300 
94 6/11/97 13:02 4.97 99 7/10/97 05:37 0.025 
94 6/11/97 17:32 2.43 99 7/10/97 06:44 6.32 
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Appendix F 
ISONIAZID DOSE AND CONCENTRATION DATA 
ID DATE TIME DOSE CONC ID DATE TIME DOSE CONC 
(mm/ddlyy) mg Ilg/ml (mm/ddlyy) mg LillJIml 
99 7/10/97 07:39 4.51 107 7/24/97 06:30 6 
99 7/10/97 09:35 1.78 107 7/24/97 07:20 4.9 
100 7/9/97 05:11 400 107 7/24/97 09:25 2.4 
100 7/9/97 14:04 1.58 108 7/23/97 05:40 400 
100 7/9/97 17:28 0.91 108 7/23/97 13:03 0.82 
100 7/10/97 05:52 400 108 7/23/97 17:28 0.24 
100 7/10/97 05:52 0.025 108 7/24/97 05:10 0.025 
100 7/10/97 06:55 9.81 108 7/24/97 05:11 400 
100 7/10/97 07:49 8.69 108 7/24/97 07:19 4.58 
101 7/9/97 05:14 300 108 7/24/97 09:55 1.9 
101 7/9/97 14:30 0.46 109 7/23/97 05:40 400 
101 7/9/97 17:25 0.21 109 7/23/97 12:43 1.56 
101 7/10/97 05:47 300 109 7/23/97 17:25 0.47 
101 7/10/97 08:31 3.16 109 7/24/97 05:27 400 
102 7/9/97 05:10 300 109 7/24/97 05:27 0.025 
102 7/9/97 13:25 0.36 109 7/24/97 06:42 7.9 
102 7/10/97 05:25 300 109 7/24/97 07:31 5.64 
102 7/10/97 08:34 1.3 109 7/24/97 09:42 4.01 
103 7/9/97 05:18 300 110 7/23/97 05:38 300 
103 7/9/97 13:45 0.5 110 7/23/97 12:53 0.99 
103 7/9/97 17:37 0.24 110 7/23/97 17:34 0.24 
103 7/10/97 05:28 300 . 110 7/24/97 05:19 300 
103 7/10/97 05:28 0.025 110 7/24/97 05:19 0.025 
103 7/10/97 06:33 4.88 110 7/24/97 06:23 5.74 
103 7/10/97 08:25 3.9 110 7/24/97 07:15 4.55 
104 7/9/97 05:22 300 110 7/24/97 09:16 2.11 
104 7/9/97 13:50 0.31 111 7/23/97 05:38 300 
104 7/9/97 17:19 0.1 111 7/23/97 14:04 0.9 
104 7/10/97 05:34 300 111 7/23/97 17:47 0.32 
104 7/10/97 05:34 0.025 111 7/24/97 05:34 300 
104 7/10/97 06:38 6.01 111 7/24/97 05:34 0.025 
105 7/9/97 11 :22 400 111 7/24/97 06:49 7.91 
105 7/9/97 13:30 1.21 111 7/24/97 07:35 5.64 
105 7/9/97 17:08 1.91 111 7/24/97 09:47 2.42 
105 7/10/97 05:23 0.32 112 7/23/97 05:36 400 
105 7/10/97 05:24 400 112 7/23/97 08:45 133 
105 7/10/97 06:26 7.96 112 7/23/97 13:38 3.12 
105 7/10/97 08:23 3.72 112 7/23/97 14:00 133 
106 7/9/97 05:15 300 112 7/23/97 17:37 3.19 
106 7/9/97 14:15 0.92 112 7/23/97 18:00 133 
106 7/10/97 05:30 300 112 7/24/97 05:22 400 
106 7/10/97 08:38 3.31 112 7/24/97 05:22 0.62 
107 7/23/97 05:40 300 112 7/24/97 06:35 14.06 
107 7/23/97 13:50 0.91 112 7/24/97 07:26 12.93 
107 7/23/97 17:52 0.34 112 7/24/97 08:45 133 
107 7/24/97 05:15 300 112 7/24/97 09:30 9.4 
107 7/24/97 05:15 0.08 113 7/23/97 05:37 400 
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Appendix F 
ISONIAZID DOSE AND CONCENTRATION DATA 
10 DATE TIME DOSE CONC 10 DATE TIME DOSE CONC 
(mm/ddlyy) mg Illg/ml (mm/ddlyy) mg Ilglml 
113 7/23/97 13:23 1.3 118 8/7/97 05:37 300 
113 7/23/97 17:41 0.4 118 8/7/97 06:31 6.19 
113 7/24/97 05:25 400 118 8/7/97 07:32 2.87 
113 7/24/97 05:25 0.025 118 8/7/97 09:39 1.26 
113 7/24/97 06:38 10 119 8/6/97 05:10 300 
113 7/24/97 07:28 6.78 119 8/6/97 13:01 1.99 
113 7/24/97 09:37 3.44 119 8/6/97 17:39 0.88 
114 8/5/97 05:15 400 119 8/7/97 05:23 0.025 
114 8/5/97 09:05 2.97 119 8/7/97 05:24 300 
114 8/6/97 05:15 400 119 8/7/97 06:24 7.72 
114 8/6/97 13:04 0.81 119 8/7/97 07:23 8.13 
114 8/6/97 17:57 0.17 119 8/7/97 09:22 4.87 
114 8/7/97 05:26 0.025 120 81.6/97 05:10 300 
114 8/7/97 05:27 400 120 8/6/97 12:53 0.59 
114 8/7/97 06:27 7.97 120 8/7/97 05:50 300 
114 8/7/97 07:27 5.38 12P 8/7/97 05:50 0.025 
114 8/7/97 09:25 3.58 120 8/7/97 06:51 2.71 
115 8/6/97 05:11 300 120 8/7/97 08:00 3.16 
115 8/6/97 08:32 133 120 8/7/97 10:02 1.17 
115 8/6/97 12:45 2.31 121 8/6/97 05:08 400 
115 8/6/97 14:14 133 121 8/6/97 13:08 2.84 
115 8/6/97 17:05 133 121 8/6/97 17:30 0.68 
115 8/7/97 05:41 0.38 121 8/7/97 05:38 400 
115 8/7/97 05:42 300 121 8/7/97 05:38 0.025 
115 8/7/97 06:41 6.09 121 8/7/97 06:39 9.63 
115 8/7/97 07:48 4.96 121 8/7/97 07:47 9.11 
115 8/7/97 09:00 133 121 8/7/97 09:45 4.47 
115 8/7/97 09:48 2.84 122 8/6/97 05:20 400 
116 8/6/97 05:05 300 122 8/6/97 13:36 0.85 
116 8/6/97 13:17 0.69 122 8/6/97 18:02 0.43 
116 8/7/97 05:44 0.19 122 8/7/97 06:02 400 
116 8/7/97 05:45 300 122 8/7/97 07:04 0.71 
116 8/7/97 06:47 5.14 122 8/7/97 08:09 6.38 
116 8/7/97 07:55 4.74 122 8/7/97 10:09 4.85 
116 8/7/97 09:55 1.75 123 8/6/97 04:55 400 
117 8/6/97 05:06 400 123 8/6/97 13:31 1.02 
117 8/6/97 13:10 0.63 123 816197 18:18 0.26 
117 8/6/97 17:52 0.22 123 8/7/97 06:05 0.025 
~17 8/7/97 05:35 0.025 123 8/7/97 06:06 400 
117 8/7/97 05:36 400 123 8/7/97 07:08 6.12 
117 8/7/97 06:35 6.79 123 8/7/97 10:13 2.26 
117 8/7/97 07:41 4.03 124 8/6/97 05:05 400 
117 8/7/97 09:41 1.91 124 8/6/97 10:13 1.02 
118 8/6/97 05:12 300 124 8/6/97 13:41 0.31 
118 8/6/97 12:49 0.47 124 8/6/97 18:08 0.025 
118 8/6/97 17:50 0.16 125 8/13/97 05:00 400 
118 8/7/97 05:36 0.025 125 8/13/97 08:55 133 
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Appendix F 
ISONIAZID DOSE AND CONCENTRATION DATA 
ID DATE TIME DOSE CONC ID DATE TIME DOSE CONC 
(mm/ddlyy) mg I ~g/ml (mm/dd/yy) mg ~ml 
125 8/13/97 11 :55 6.04 130 8/14/97 05:38 400 
125 8/13/97 14:05 133 130 8/14/97 06:58 0.84 
125 8/13/97 16:40 133 130 8/14/97 07:57 4.9 
125 8/13/97 17:30 7.58 130 8/14/97 09:38 1.38 
125 8/14/97 06:09 3.96 131 8/13/97 04:30 400 
125 8/14/97 06:10 400 131 8/13/97 12:40 2.21 
125 8/14/97 07:30 10.42 131 8/13/97 18:28 0.78 
125 8/14/97 08:21 9.15 131 8/14/97 04:45 400 
125 8/14/97 08:50 133 131 8/14/97 05:28 400 
125 8/14/97 10:03 8.92 131 8/14/97 05:28 11.76 
126 8/13/97 05:00 300 131 8/14/97 06:47 23.58 
126 8/13/97 12:15 1.01 131 8/14/97 07:50 11 .21 
126 8/13/97 17:42 0.7 131 8/14/97 09:33 11 .81 
126 8/14/97 06:25 0.025 132 8/13/97 04:30 300 
126 8/14/97 06:26 300 132 8/13/97 12:45 1.74 
126 8/14/97 07:42 4.73 132 8/13/97 18:18 0.34 
126 8/14/97 08:27 3.28 132 8/14/97 04:45 300 
126 8/14/97 10:13 1.68 132 8/14/97 05:41 300 
127 8/13/97 05:00 400 132 8/14/97 05:41 10.28 
127 8/13/97 13:10 2.51 132 8/14/97 09:15 11 .17 
127 8/13/97 17:10 1.21 133 8/13/97 04:30 300 
127 8/14/97 06:18 0.2 133 8/13/97 12:43 2.56 
127 8/14/97 06:19 400 133 8/13/97 18:35 1.07 
127 8/14/97 07:36 8.42 133 8/14/97 04:45 300 
127 8/14/97 08:31 6.64 133 8/14/97 05:45 10.26 
127 8/14/97 10:20 4.71 133 8/14/97 05:46 300 
128 8/13/97 05:00 300 133 8/14/97 07:02 21 .96 . 
128 8/13/97 13:05 0.62 133 8/14/97 . 08:05 14.03 
128 8/13/97 17:57 0.36 133 8/14/97 09:43 13.28 
128 8/14/97 05:53 0.025 134 8/13/97 04:35 300 
128 8/14/97 05:57 300 134 8/13/97 12:56 0.025 
128 8/14/97 07:10 6.72 134 8/13/97 18:24 0.025 
128 8/14/97 08:11 4.41 134 8/14/97 04:45 300 
128 8/14/97 09:52 1.88 134 8/14/97 05:15 300 
129 8/13/97 04:30 400 134 8/14/97 05:15 11 .03 
129 8/13/97 12:34 0.35 134 8/14/97 06:42 18.39 
129 8/13/97 18:08 0.025 134 8/14/97 08:00 9.18 
129 8/14/97 04:45 400 134 8/14/97 09:15 7.3 
129 8/14/97 05:20 400 135 8/13/97 04:35 300 
129 8/14/97 05:20 2.38 135 8/13/97 12:46 1.34 
129 8/14/97 06:41 11 .1 135 8/13/97 18:14 0.64 
129 8/14/97 07:33 8.63 135 8/14/97 04:45 300 
129 8/14/97 09:18 2.53 135 8/14/97 05:31 7.9 
130 8/13/97 04:30 400 135 8/14/97 05:32 300 
130 8/13/97 12:49 0.84 135 8/14/97 06:44 10.97 
130 8/13/97 18:32 0.3 135 8/14/97 07:38 8.19 
130 8/14/97 05:37 0.025 135 8/14/97 09:26 6.01 
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Appendix F 
ISONIAZID DOSE AND CONCENTRATION DATA 
, 
ID DATE TIME DOSE CONC 
(mm/ddlyy) mg ~g/ml 
136 8/13/97 04:35 300 
136 8/13/97 12:50 0.025 
136 8/13/97 18:21 0.025 
136 8/14/97 04:45 300 
136 8/14/97 05:25 300 
136 8/14/97 05:25 8.37 
136 8/14/97 06:53 13.12 
136 8/14/97 07:58 8.95 
136 8/14/97 09:40 6.45 
137 8/13/97 04:35 400 
137 8/13/97 12:38 0.1 
137 8/13/97 18:39 0.025 
137 8/14/97 04:45 400 
137 8/14/97 05:23 400 
137 8/14/97 05:23 0.025 
137 8/14/97 06:46 7.01 
137 8/14/97 07:48 6.44 
137 8/14/97 09:22 5.01 
138 8/13/97 04:10 300 
138 8/13/97 13:20 0.025 
138 8/13/97 18:44 0.025 
138 8/14/97 05:42 300 
138 8/14/97 05:42 0.53 
138 8/14/97 07:16 4.75 
138 8/14/97 09:30 2.69 
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Appendix G 
NONMEM RUN SUMMARY - RIFAMPICIN 
RUN ADVAN ERROR KA CUF VlF TlAG llKA llClJF llViF llTLAG crccv crACC DATA OBF COMMENTS 
% % % % % Ilg/ml 
1 2 ADD+CCV 91exp(1l1 ) 92exp(1l2) 93exp(1l3) - 60 44 223 - 4540 10-4 RFA1 .CSV 1803.550 Prepared sdtab for data checkout in 
Xpose . Model is under-predicting but 
appears concentrated at PRED= 11 . 
$ERROR code appears incorrect. 
2 2 ADD + CCV 91exp(1l1) 92exp(1l2) 93exp(1l3) - 60 45 223 - 4540 10-4 RFA1.CSV 1803.548 Removed upper bound on V/F. No 
difference w.r.t. Concentration of points 
at PRED=11 . $ERROR code appears 
incorrect. 
3 2 ADD+CCV 91 exp(1l1) 92exp(1l2) 93exp(1l3) - 60 51 <1 - 45.6 0.53 RFA1 .CSV 1474.664 Removed constraint on additive portion 
of error model. Concentration of points 
now at PRED=7.5. Additive error = cr*94 
4 2 ADD+CCV 91exp(1l1) 92exp(1l2) 93exp(1l3) - 15 49 62 - 39.9 0.57 RFA1 .CSV 1486.416 Removed upper bound on CUF as well. 
No difference w.r.t. concentration of 
Ipoints now at PRED=7.5 
5 2 ADD+CCV 91exp(1l1) 92exp(1l2) 93exp(1l3) - 60 52 3 - 45.6 0.53 RFA1 .CSV 1474.665 Removed upper bound on ALL 9's. No 
difference w.r.t. concentration of points 
now at PRED-7.5 
6 2 ADD+CCV 91exp(1l1) 92exp(1l2) 93exp(1l3) - 10'- 65 34 - 61 .3 0.54 RFA1 .CSV 1612.403 Fixed $SIGMA to 1. Included 2 9's in the 
$ERROR block. Added scatters. 
Clustering of points at 7.5 now OK but 
KA and its CV are unrealistic. 
7 2 ADD+CCV 91exp(1l1) 92exp(1l2) 93exp(1l3) - 53 52 19 - 48.9 0.05 RFA2.CSV 855.716 Removed Patient 122 (outlier) 
completely. No difference w.r.t. 
concentration of points at PRED=7.5 
8 2 ADD+CCV 91exp(1l1) 92exp(1l2) 93exp(1l3) - 60 51 <1 - 45.6 0.54 RFA1 .CSV 1474.664 Used the conventional method of coding 
$ERROR to check that the Xpose2 way 
of coding is correct. Results - Run3 
9 2 ADD+CCV 91exp(1l1) 92exp(1l2) 93exp(1l3) - 54 53 19 - 49.2 0.05 RFA3.CSV 863.349 Now using $ERROR as per Run3. 
Removed Cp for patient 122 and 123 that 
was swapped during sample prep. No 
difference w.r.t. concentration of points at 
PRED=7.5 
10 2 ADD+CCV 91exp(1l1) 92exp(1l2) 93exp(1l3) - 55 52 20 - 49 0.05 RFA5.CSV 862.357 Data file updated to include dose amount 
(600mg) or and days since starting RFA therapy. No 
96exp(1l1) significant effect of dose amount on KA. 
450mg 
11 2 ADD+CCV 91 exp(1l1) 92exp(1l2) 93exp(1l3) 96 67 53 22 - 47 0.05 RFA5.CSV 844.418 A basic run but now with a lag time. No 
difference w.r.t. Concentration of points 
at PRED=7.5. OBF is better than 
Iprevious basic run (RUN 9). 
'1 - inter-individual variability; KA - absorption rate constant, CUF - apparent clearance; V/F - apparent volume of distribution; TLAG - absorption lag time; a - intra-individual variability; CCV - constant coefficient of 
variation; ADD - additive; OBF - minimum value of the Objective function. 
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Appendix G 
NONMEM RUN SUMMARY - RIFAMPICIN 
RUN ADVAN ERROR KA CUF VlF TLAG T]KA T]cUF T]VIF T]TLAG <rccv <rADD DATA OBF COMMENTS 
% % % % % ua/ml 
12 1 ADD+CCV - 92exp(112) 93exp(T]3) - - 59 37 - 52 0.05 RFA7.CSV 865.335 Implemented zero order bolus input. Data 
file has RATE=-2. 01 parameter 
estimated. Concentration of points at 
PRED-7.5 a little better. 
13 1 ADD+CCV - 92exp(T]2) 93exp(T]3) 96 - 59 37 - 52 0.05 RFA7.CSV 865.314 As per RUN 12 but with a lag time. 
Graphs are no different TLAG very small. 
14 1 ADD+CCV - 92exp(T]2) 93exp(T]3) - - 55 29 - 49 0.05 RFA7.CSV 860.823 As per RUN 12 but added in an ETA on 
01 (32%). 
15 2 ADD+CCV 91exp(T]1) 92exp(T]2) 93exp(T]3) 96exp(T]4) 57 51 24 59 41 0.05 RFA5.CSV 804.652 As per RUN 11 but added in an ETA on 
TLAG1 . Concentration of points at 
PRED-7.5 gone. 
16 2 ADD+CCV 91 exp(T] 1) 92exp(T]2) 93exp(T]3) - 53 52 16 - 49 0.05 RFA5.CSV 864.274 Sensitivity Analysis: KA fixed to 0.7 
17 2 ADD+CCV 91exp(T]1) 92exp(T]2) 93exp(T]3) - 54 53 21 - 49 0.05 RFA5.CSV 863.833 Sensitivity Analysis: KA fixed to 0.8 
18 2 ADD+CCV 91exp(T]1) 92exp(T]2) 93exp(T]3) - 58 54 23 - 49 0.05 RFA5.CSV 867.862 Sensitivity Analysis: KA fixed to 0.9 
19 2 ADD+CCV 91exp(11 1) 92exp(T]2) 93exp(T]3) - 63 54 25 - 49 0.05 RFA5.CSV 874.465 Sensitivity Analysis: KA fixed to 1.0 
20 2 ADD+CCV 91exp(11 1) 92exp(T]2) 03exp(113) - 70 54 <1 - 49 0.05 RFA5.CSV 882.273 Sensitivity Analysis: KA fixed to 1.1 
21 2 ADD+CCV 91exp(11 1) 92exp(T]2) 93exp(113) - 52 51 <1 - 49 0.05 RFA5.CSV 871.405 Sensitivity Analysis: KA fixed to 0.6 
22 2 ADD+CCV 91exp(T]1 ) 92exp(T]2) 93exp(T]3) - 44 51 <1 - 50 0.05 RFA5.CSV 888.473 Sensitivity Analysis: KA fixed to 0.5 
23 2 ADD+CCV 91exp(T]1) 92exp(T]2) 93exp(T]3) - <1 51 42 - 50 0.05 RFA5.CSV 902.203 Sensitivity Analysis: KA fixed to 0.4 
24 2 ADD+CCV 91exp(T]1) 92exp(112) 93exp(T]3) - 53 52 19 - 49 0.05 RFA5.CSV 863.360 Sensitivity Analysis: KA fixed to 0.75-
lowest value of OBF 
25 2 ADD+CCV 91exp(T]1) 92exp(T]2) 93exp(T]3) - 54 53 20 - 49 0.05 RFA5.CSV 863.440 Sensitivity Analysis: KA fixed to 0.775 
26 2 ADD (fixed) 91exp(11 1) 92exp(T]2) 93exp(113) - 39 19 10 - 70 fixed RFA5.CSV 1122.353 Fixed additive part of error to 0.0006 i.e. 
+CCV 0.25*La**2. 
27 4 ADD+CCV 91exp(T]1) 92exp(T]2) V2=93exp(T]3) - 51 53 18 - 50 0.05 RFA5.CSV 858.735 Used ADVAN4. No diff w.r.t. points at 
a V3 PRED=7.5 
28 2 ADD+CCV 91exp(T]1) 92exp(T]2) 93exp(T]3) - 57 51 24 - 41 0.05 RFA8.CSV 875.889 Data file has some of the below La levels 
removed i.e. those with an above La 
concentration nearby. 
29 2 ADD+CCV 91exp(T]1) 92exp(T]2) 93exp(T]3) 96exp(T]4) 57 51 24 - 41 0.05 RFA9.CSV 804.652 Identical to RUN 15 but data file contains 
ALL the covariates. Preparing the tables 
for GAM analysis in Xpose2. 
'30 2 ADD+CCV 91 exp(T] 1) Non-inducer: 93exp(T]3) 96exp(T]4) 56 51 25 59 41 0.05 RFA9.CSV 802.498 Subsequently realised that only 3 
92exp(T]2) individuals were on inducers. 
Inducer: 97exp(112) 
11 - inter-indivldual variability; KA - absorption rate constant, CUF - apparent clearance; V/F - apparent volume of distribution; TLAG - absorption lag time; cr - intra-individual variability; CCV - constant coefficient of 
variation; ADD - additive; OBF - minimum value of the Objective function. 
G-J73 
Appendix G 
NONMEM RUN SUMMARY - RIFAMPICIN 
RUN ADVAN ERROR KA CUF V/F TlAG T]KA T]CUF T]VIF T]TLAG <rccv <rADD DATA OBF COMMENTS 
% % % % % IlQ/ml 
31 2 ADD+CCV 91 exp(T] 1) Non-inhibitor: 93exp(T]3) 96exp(T]4) 54 47 26 62 40 0.05 RFA9.CSV 766.899 Enzyme inhibitor reduces CUF by 84%. 
92exp(T]2) Significant effect. 
Inhibitor: 97exp(T]2) 
32 2 ADD+CCV 91exp(T]1 ) 92exp(T]2) Non-inhibitor: 96exp(T]4) 57 52 25 59 41 0.05 RFA9.CSV 797.184 Effect of enzyme inhibitor on V/F . 
93exp(T]3) Significant effect. May disappear in the 
Inhibitor: full model. 
97exp(T]3) 
33 2 ADD+CCV 91exp(T]1) 92exp(T]2) + IOV 93exp(T]3) + IOV - 57; 89; 51 ; - 40 0.05 RFA10.CSV 833.171 Inter-occasion variability i.e. day1 vs 
+IOV 116 43 30 day2 implemented on KA, CUF and V/F . 
Removed TlAG from model because of 
restriction on the no. of T]s. Data file has 
new variable OCC. Day2 fit has less 
variability for CUF & V/F but more for KA. 
34 2 ADD+CCV 91 exp(T] 1 ) 92exp(T]2) 93exp(T]3) 96exp(T]4) 60 53 19 67 41 0.05 RFA11.CSV 646.148 Removed all Day2 data from the patients 
in Ward L who had been given the extra 
dose. 
35 2 ADD+CCV 91 exp(T] 1 ) Females: 93exp(T]3) 96exp(T]4) 57 51 24 59 41 0.05 RFA9.CSV 804.606 SEX on CUF. Not significant 
92exp(T]2) 
Males: 97exp(TJ2) 




37 2 ADD+CCV 91exp(T]1) SENS: 92exp(TJ2) 93exp(T]3) 96exp(T]4) 57 46 24 62 40 0.05 RFA9.CSV ' 778.309 MDR on CUF. Significant 
MDR: 97exp(T]2 
38 2 ADD+CCV 91exp(T]1) 92exp(T]2) SENS: 96exp(T]4) 57 51 24 59 41 0.05 RFA9.CSV 802.326 MDR on V/F. Not significant. 
93exp(T]3) 
MDR: 97exp(T]3) 
39 2 ADD+CCV 91exp(T]1) Non-HIV: 93exp(T]3) 96exp('I14) 56 52 26 58 40 0.05 RFA9.CSV 797.720 HIV on CUF. Significant 
92exp(T]2) 
HIV: 97exp(T]2 
40 2 ADD+CCV 91 exp(T] 1 ) 92exp(T]2) Non-HIV: 96exp(T]4) 56 51 26 59 40 0.05 RFA9.CSV 788.925 HIV on VlF. Significant 
93exp(T]3) 
HIV: 97exp(T]3) 
41 2 ADD+CCV 91exp(T]1) 92exp(T]2) 93exp(T]3) 96exp(T]4) 59 51 25 58 40 0.05 RFA9.CSV 803.824 KA for the 2 different dose amounts. Not 
(450mg) or significant. 
97exp(T]1 ) 
600mg 
11 - Inter-individual variability; KA - absorption rate constant, CUF - apparent clearance; V/F - apparent volume of distribution; TLAG - absorption lag time; (J - intra-individual variability; CCV - constant coefficient of 




NONMEM RUN SUMMARY - RIFAMPICIN 
RUN AOVAN ERROR KA CUF V/F HAG T)KA T)CUF T)VIF T)TLAG crccv crADD DATA OBF COMMENTS 
% % % % % !-Ig/ml 
42 2 AOO+CCV 91exp(T)1) 92exp(T)2) 93exp(T)3) 96exp(T)4) 47 42 <1 69 37 0.05 RFA9.CSV 773.334 Estimated F1 - relative bioavailability for 
the 2 dose amounts i.e. 450mg and 
600mg dose. Data can no longer 
estimate the variability in V/F once it is 
partitioned into F1 . 
43 2 AOO+CCV 91exp(T)1) 92exp(T)2) 93exp(T)3) 96exp(T)4) 56 50 24 61 40 0.05 RFA9.CSV 789.010 As for RUN 42 but no ETA on F1 . 
44 2 AOO+CCV 91exp(T)1) 92exp(T)2) 93exp(T)3) (450) 96exp(T)4) 57 51 24 59 41 0.05 RFA9.CSV 804.657 Effect of dose amount on V/F. Not 
97exp(T)3) (600) significant. 
45 2 AOO+CCV 91exp(T)1) (no 92exp(T)2) 93exp(T)3) 96exp(T)4) 57 51 25 59 41 0.05 RFA9.CSV 804.647 Effect of absorption drug interaction on 
01) 97exp(n1) 01 KA. Not significant. 
46 2 AOO+CCV 91 exp(T) 1) 92exp(T)2) (no 01) 93exp(T)3) 96exp(T)4) 58 51 24 59 41 0.05 RFA9.CSV 804.650 Effect of absorption drug interaction on 
or 97exp(n2) 01 CUF. Not significant 
47 2 AOO+CCV 91exp(T)1) 92exp(T)2) 93exp(T)3) (no 96exp(T)4) 57 51 24 69 41 0.05 RFA9.CSV 805.115 Effect of absorption drug interaction on 
01) or 97exp(T)3) V/F. Not significant 
01 
48 2 AOO+CCV 91 exp(T) 1 ) 92exp(T)2) (no 01) 93exp(T)3) 96exp(T)4) 55 50 26 61 41 0.05 RFA9.CSV 799.782 Effect of NSAIO use on CUF. Significant. 
or 97exp(T)2) 01 
49 2 AOO+CCV 91 exp(T) 1 ) 92exp(T)2) 93exp(T)3) (no 96exp(T)4) 56 51 25 60 41 0.05 RFA9.CSV 802.575 Effect of NSAIO use on V/F. Not 
01) or 97exp(T)3) significant 
01 
50 2 AOO+CCV 91exp(T)1) (no 92exp(T)2) 93exp(T)3) 96exp(T)4) 62 51 24 55 41 0.05 RFA9.CSV 802.404 Effect of Iron preps on KA. Not significant 
01) or 97exp(T)1) 
01 
51 2 AOO+CCV 91exp(T)1 ) 92exp(T)2) (no 01) 93exp(T)3) 96exp(T)4) 56 50 26 65 40 0.05 RFA9.CSV 793.535 Effect of Iron preps/anaemia on CUF. 
or 97exp(T)2) 01 Significant 
52 2 AOO+CCV 91exp(T)1) 92exp(T)2) 93exp(T)3) (no 96exp(T)4) 56 52 25 61 41 0.05 RFA9.CSV 797.490 Effect of Iron preps/anaemia on V/F. 
01) or 97exp(T)3) Significant 
01 
53 2 AOO+CCV 91exp(T)1) 92exp(T)2) (no 01) 93exp(T)3) 96exp(T)4) 57 51 24 64 41 0.05 RFA9.CSV 804.411 Effect of antihistamines on CUF. Not 
or 97exp(TJ.2}DI significant 
54 2 AOO+CCV 91exp(T)1) 92exp(T)2) 93exp(T)3) (no 96exp(T)4) 58 51 24 59 41 0.05 RFA9.CSV 804.579 Effect of antihistamines on V/F. Not 
01) or 97exp(T)3) significant 
01 
55 2 AOO+CCV 91exp(T)1) 92exp(T)2) (no 01) 93exp(T)3) 96exp(T)4) 58 51 24 59 41 0.05 RFA9.CSV 804.068 Effect of hypoglycaemic agents/diabetes 
or 97exp(T)2) 01 on CUF. Not significant 
56 2 AOO+CCV 91 exp(T) 1) 92exp(T)2) 93exp(T)3) (no 96exp(T)4) 58 51 24 59 41 0.05 RFA9.CSV 804.081 Effect of hypoglycaemic agents/diabetes 
01) or 97exp(T)3) on V/F. Not significant 
01 
T] - inter-lndivldual variability; KA - absorption rate constant, CUF - apparent clearance; V/F - apparent volume of distribution; TLAG - absorption lag time; cr - intra-individual variability; CCV - constant coefficient of 




NONMEM RUN SUMMARY - RIFAMPICIN 
RUN AOVAN ERROR KA CUF V/F TLAG llKA llcUF llvlF llTLAG O"ccv O"ADD DATA OBF COMMENTS 
% % % % % llg/ml 
57 2 AOO+CCV 91exp(1l1) 92exp(1l2) (no 01) 93exp(1l3) 96exp(1l4) 57 51 24 59 41 0.05 RFA9.CSV 804.643 Effect of diuretics/hypertension on CUF. 
or 97exp(n2) 01 Not significant 
58 2 AOO+CCV 91exp(1l1 ) 92exp(1l2) 93exp(1l3) (no 96exp(1l4) 57 51 23 64 41 0.05 RFA9.CSV 804.004 Effect of diuretics/hypertension on V/F. 
01) or 97exp(1l3) Not significant 
01 
59 2 AOO+CCV 91exp(1l1) 92exp(1l2) (no 01) 93exp(1l3) 96exp(1l4) 57 49 25 61 40 0.05 RFA9.CSV 790.085 Effect of INAT on CUF. Significant 
or 97exp(1l2) 01 
60 2 AOO+CCV 91 exp(1l1) 92exp(1l2) 93exp(1l3) (no 96exp(1l4) 57 51 77 59 41 0.05 RFA9.CSV 804.594 Effect of INAT on V/F. Not significant 
01) or 97exp(1l3) 
01 
61 2 AOO+CCV 91exp(1l1) 92exp(1l2) (no 01) 93exp(1l3) 96exp(1l4) 52 45 26 64 40 0.05 RFA9.CSV 766.502 Effect of quinolones on CUF. Significant 
or 97exp(n2) 01 
62 2 AOO+CCV 91exp(1l1) 92exp(1l2) 93exp(1l3) (no 96exp(1l4) 57 51 25 58 41 0.05 RFA9.CSV 802.379 Effect of quinolones on V/F. Not 
01) or 97exp(1l3) significant 
01 
63 2 AOO+CCV 91exp(1l1) 92exp(1l2) (no 01) 93exp(1l3) 96exp(1l4) 55 49 27 62 40 0.05 RFA9.CSV 784.252 Effect of ethambutol on CUF. Significant 
or 97exp(1l2) 01 
64 2 AOO+CCV 91exp(1l1) 92exp(1l2) 93exp(1l3) (no 96exp(1l4) 57 51 25 60 41 0.05 RFA9.CSV 802.233 Effect of ethambutol on VlF. Not 
01) or 97exp(1l3) significant 
01 
65 2 AOO+CCV 91exp(1l1) 92exp(1l2) (no 01) 93exP(1l3) 96exp(1l4) 59 51 23 58 41 0.05 RFA9.CSV 1\01 .707 Effect of candidiasis on CUF. Not 
or 97exp(1l2) 01 significant. 
66 2 AOO+CCV 91exp(1l1) 92exp(1l2) 93exp(1l3) (no 96exp(1l4) 59 51 23 58 41 0.05 RFA9.CSV 801 .630 Effect of candidiasis on V/F. Not 
01) or 97exp(1l3) significant. 
01 
67 2 AOO+CCV 91 exp(ll 1 ) 92exp(1l2) (no Tx) 93exp(1l3) 96exp(1l4) 58 50 23 60 41 0.05 RFA9.CSV 793.945 Effect of prior TB treatment on CUF. 
or 97exp(n2) Tx Significant 
68 2 AOO+CCV 91exp(1l1) 92exp(1l2) 93exp(1l3) (no 96exp(1l4) 57 51 23 60 41 0.05 RFA9.CSV 800.280 Effect of prior TB treatment on V/F. 
Tx) or 97exp(1l3) Significant. 
Tx 
69 2 AOO+CCV 91 exp(1l1) (92+97*(WT-54)) 93exp(1l3) 96exp(1l4) 59 49 22 58 41 0.05 RFA9.CSV 789.177 Effect ofWT on CUF. Significant. 
exp(1l3) 
70 2 AOO+CCV 91 exp(1l1) 92exp(1l2) (93+97*(WT-54)) 96exp(1l4) 58 51 24 58 41 0.05 RFA9.CSV 802.493 Effect ofWT on V/F. Not significant. 
exp(n3) 
71 2 AOO+CCV 91exp(1l1) (92+97*(AGE-33)) 93exp(1l3) 96exp(1l4) 58 51 23 60 41 0.05 RFA9.CSV 796.967 Effect of AGE on CUF. Significant. 
exp(n3) 
72 2 AOO+CCV 91exp(1l1) 92exp(1l2) (93+97*(AGE- 96exp(1l4) 57 51 24 59 41 0.05 RFA9.CSV 802.282 Effect of AGE on V/F. Not significant. 
33)) exp(1l3) 
'I - Inter-individual variability; KA - absorption rate constant, CUF - apparent clearance; VlF - apparent volume ot distribution; TLAG - absorption lag time; cr - intra-individual variability; CCV - constant coefficient ot 





NONMEM RUN SUMMARY - RIFAMPICIN 
RUN ADVAN ERROR KA CUF V/F TLAG TjKA TjCUF TjVIF TjTLAG crccv crADD DATA OBF COMMENTS 
% % % % % ua/ml 
73 2 ADD+CCV 91 exp(Tj 1) (92+97*(DA YS-41» 93exp(Tj3) 96exp(Tj4) 55 47 24 65 40 0.05 RFA9.CSV 747.816 Effect of no. of days since starting RFA 
exo(n3) therapy on CUF. Significant 
74 2 ADD+CCV 91 exp(Tj 1 ) 92exp(Tj2) (93+97* (DA YS- 96exp(Tj4) 57 52 26 60 42 0.05 RFA9.CSV 795.039 Effect of no. of days since starting RFA 
41» exo(n3) therapy on V/F. Significant 
75 2 ADD+CCV 91exp(Tj1) (92+97*(ALKP-84» 93exp(Tj3) 96exp(Tj4) 57 51 25 59 41 0.05 RFA9.CSV 804.643 Liver Function tests - ALK PHOS on 
exo(n3) CUF. Not significant 
76 2 ADD+CCV 91exp(Tj1) 92exp(Tj2) (93+97*(ALKP- 96exp(Tj4) 58 51 23 59 41 0.05 RFA9.CSV 803.910 Liver Function tests - ALK PHOS on V/F. 
84)) exp(n3) Not significant 
77 2 ADD+CCV 91 exp(Tj 1) (92+97*(BILI-10» 93exp(Tj3) 96exp(Tj4) 57 51 25 59 40 0.05 RFA9.CSV 803.856 Liver Function tests - Total Bilirubin on 
exp(n3) CUF. Not significant. 
78 2 ADD+CCV 91exp(Tj1) 92exp(Tj2) (93+97*(BILI- 96exp(Tj4) 57 51 23 61 41 0.05 RFA9.CSV 803.307 Liver Function tests - Total Bilirubin on 
10)) exp(n3) V/F. Not significant. 
79 2 ADD+CCV 91exp(Tj1) (92+97*(ALB-25» 93exp(Tj3) 96exp(Tj4) 57 51 24 59 41 0.05 RFA9.CSV 804.269 Liver Function tests - Albumin on CUF. 
exp(n3) Not significant. 
80 2 ADD+CCV 91 exp(Tj1) 92exp(Tj2) (93+97*(ALB- 96exp(Tj4) 58 51 24 59 41 0.05 RFA9.CSV 801.302 Liver Function tests - Albumin on V/F. 
25» exp(n3) Not significant. I 
81 2 ADD+CCV 91 exp(Tj1) (92+97*(GLOB-52» 93exp(Tj3) 96exp(Tj4) 59 50 22 59 41 0.05 RFA9.CSV 789.276 Liver Function tests - Globulin on CUF. I 
exp(n3) Significant. 
82 2 ADD+CCV 91exp(Tj1) 92exp(Tj2) (93+97*(GLOB- 96exp(Tj4) 60 51 22 58 41 0.05 RFA9.CSV 790.857 Liver Function tests - Globulin on V/F. 
52» exp(Tj3) Significant. 
83 2 ADD+CCV 91exp(Tj1) (92+97*(AL T-16» 93exp(Tj3) 96exp(Tj4) 57 51 24 59 41 0.05 RFA9.CSV 804.666 Liver Function tests - ALTon CUF. Not 
exo(n3) significant. 
84 2 ADD+CCV 91exp(Tj1) 92exp(Tj2) (93+97*(AL T- 96exp(Tj4) 57 51 24 59 41 0.05 RFA9.CSV 804.501 Liver Function tests - ALTon V/F. Not 
16)) exp(n3) significant. 
85 2 ADD+CCV 91exp(Tj1) (92+97*(AST-31» 93exp(Tj3) 96exp(Tj4) 54 51 26 61 41 0.05 RFA9.CSV 798.580 Liver Function tests - AST on CUF. 
exp(n3) Significant. 
86 2 ADD+CCV 91exp(Tj 1) 92exp(Tj2) (93+97*(AST- 96exp(Tj4) 57 51 25 59 41 0.05 RFA9.CSV 803.666 Liver Function tests - AST on V/F. Not 
31)) exp(n3) significant. 
87 2 ADD+CCV 91 exp(Tj 1) (92+97*(GGT -37» 93exp(Tj3) 96exp(Tj4) 58 50 24 59 41 0.05 RFA9.CSV 803.624 Liver Function tests - GGT on CUF. 
exp(n3) Significant. 
88 2 ADD+CCV 91 exp(Tj 1) 92exp(Tj2) (93 + 97*(GGT- 96exp(Tj4) 57 51 24 61 41 0.05 RFA9.CSV 804.253 Liver Function tests - GGT on V/F. Not 
37» exp(Tj3) significant. 
89 2 ADD+CCV 91 exp(Tj 1) (92+97*(VIRU- 93exp(Tj3) 96exp(Tj4) 56 52 27 60 42 0.05 RFA9.CSV 803.561 Effect of HIV viral load on CUF. Not 
65183.49» exp(n3) significant. 
90 2 ADD+CCV 91exp(Tj1) (92+97*(VIR-5» 93exp(Tj3) 96exp(Tj4) 57 52 29 59 440 0.05 RFA9.CSV 800.541 Effect of log HIV viral load on CUF. Not 
exp(n3) significant. 
'1 - inter-individual variability; KA - absorption rate constant, CUF - apparent clearance; VlF - apparent volume of distribution; TLAG - absorption lag time; <J - intra-individual variability; CCV - constant coefficient of 
variation; ADD - additive; OBF - minimum value of the Objective function. 
G- I77 
Appendix G 
NONMEM RUN SUMMARY - RIFAMPICIN 
RUN ADVAN ERROR KA CUF V/F TlAG 11KA T]CUF T]VIF T]TLAG O"cc v O"ADD DATA OBF COMMENTS 
% % % % % ~g/ml 
91 2 ADD+CCV 91 exp(T] 1) 92exp(T]2) (93 + 97*(VIRU- 96exp(T]4) 56 50 24 57 42 0.04 RFA9.CSV 783.170 Effect of HIV viral load on V/F. 
65183.49» Significant. 
exp(T]3) 
92 2 ADD+CCV 91 exp(T] 1 ) 92exp(T]2) (93+97*(VIR-5» 96exp(T]4) 55 51 27 61 40 0.05 RFA9.CSV 788.569 Effect of log HIV viral load on V/F. 
exp(T]3) Significant. 
93 2 ADD+CCV 91exp(T]1) (92+97*(NMDR-7» 93exp(T]3) 96exp(T]4) 58 50 24 61 41 0.05 RFA9.CSV 794.096 Effect of severity of MDR on CUF i.e. no. 
exp(T]3) of drugs patient was resistant to 
concurrently. Significant. 
94 2 ADD+CCV 91 exp(T] 1) (92+97*MDR+ 93exp(1l3) 96exp(T]4) 57 46 24 63 40 0.05 RFA9.CSV 774.075 Effect of PRESENCE and SEVERITY of 
98*(NMDR-7» MDR on CUF i.e. RUN 37+RUN 93. 
exp(T]3) Significant. 
95 2 ADD+CCV 91exp(T]1 ) 92exp(T]2) (93 +97* 96exp(T]4) 57 51 25 59 41 0.05. RFA9.CSV 803.322 Effect of severity of MDR on V/F i.e. no. 
(NMDR-7» of drugs patient was resistant to 
exp(1l3) concurrently. Significant. 
96 2 ADD+CCV 91exp(T]1) (92+97*(EXT -5» 93exp(T]3) 96exp(T]4) 57 51 24 59 41 0.05 RFA9.CSV 804.594 Effect of Extent of X-rayon CUF. Not 
exp(T]3) significant. 
97 2 ADD+CCV 91exp(T]1) 92exp(T]2) (93+97*(EXT-5» 96exp(T]4) 56 51 24 59 41 0.05 RFA9.CSV 803.806 Effect of Extent of X-rayon V/F. Not 
exp(T]3) significant. 
98 2 ADD+CCV 91exp(T]1) (92+97*(CAV-4» 93exp(1l3) 96exp(T]4) 60 50 21 60 41 0.05 RFA9.CSV 786.806 Effect of Extent of cavitation on X-rayon 
exp(T]3) CUF. significant. 
99 2 ADD+CCV 91exp(T]1) 92exp(T]2) (93+97*(CAV-4» 96exp(T]4) 58 51 24 60 .41 0.05 RFA9.CSV 801 .763 Effect of Extent of cavitation on X-rayon 
exp(T]3) V/F. Not significant. 
100 2 ADD+CCV 91 exp(T] 1) (92+97*(DA YS-1 0» 93exp(1l3) 96exp(T]4) 50 43 25 75 40 0.05 RFA9.CSV 730.138 Model Build-up starts. Days - max-1 O. 
exp(T]2) Compare with RUN 15 (OBF=804.652). 
OBF.!. by 74.5 
101 2 ADD+CCV 91exp(1l 1) (92+97*(DA YS-1 0)- 93exp(T]3) 96exp(T]4) 50 42 25 76 40 0.05 RFA9.CSV 729.478 Add in quinolones. Change in OBF (0.7) 
98*QUl)exP(T]2) not significant. 
102 2 ADD+CCV 91exp(1l 1) (92+97*(DA YS-1 0)- 93exp(T]3) 96exp(1l4) 51 43 26 67 40 0.05 RFA9.CSV 730.389 Removed quinolones, add in inhibitors. 
98*INHI)exp(T]2) Change in OBF (i) not significant. 
103 2 ADD+CCV 91exp(1l 1) (92+97*(DA YS-1 0)- 93exp(T]3) 96exp(T]4) 27 41 42 83 145 0.05 RFA9.CSV 726.885 Removed inhibitors, added MDR. 
98*MDR)exp(T]2) Change in OBF (.!. 3.3) not significant. 
104 2 ADD+CCV 91exp(1l 1) (92+97*(DA YS-1 0)- 93exp(T]3) 96exp(T]4) 50 43 25 75 40 0.05 RFA9.CSV 729.995 Removed MDR, added in EMB. Change 
98*EMB)exp(1l2) in OBF (.!. 0.2) not significant. 
105 2 ADD+CCV 91exp(1l 1) (92+97*(DA YS-1 0)- 93exp(1l3) 96exp(T]4) 53 43 24 67 40 0.05 RFA9.CSV 728.051 Removed EMB, added in severity score 
98*(CAV-4» for cavitation. Change in OBF (.!. 2.1) not 
exp(T]2) significant. 
'1 - inter-individual variability; KA - absorption rate constant, CUF - apparent clearance; VlF - apparent volume of distribution; TLAG - absorption lag time; a - intra-individual variability; CCV - constant coefficient of 
variation; ADD - additive; OBF - minimum value of the Objective function. 
G-178 
Appendix G 
NONMEM RUN SUMMARY - RIFAMPICIN 
RUN ADVAN ERROR KA CUF VlF HAG l]KA l]cUF l]VIF l1TLAG crccv crADD DATA OBF COMMENTS 
% % % % % Ilg/ml 
106 2 ADD+CCV 91exp(l]1) (92+97*(DA YS-1 0)- (93+99*(VIR-5» 96exp(l]4) 46 44 30 73 36 0.05 RFA9.CSV 707.986 Did not remove sev~rity score for 
98*(CAV-4» exp(l]3) cavitation (mistake) . Added in Log viral 
exp(l]2) load on V/F. OBF .!- 22.2 
107 2 ADD+CCV 91exp(l]1) (92+97*(DA YS-1 0)- (93+99*(VIR-5» 96exp(l]4) 48 44 28 89 40 0.05 RFA9.CSV 710.681 As for previous run but coded in all 
98*(CAV-4» exp(T]3) patients - not just the HIV +ve patients. 
exp(T]2) HIV-ve patients recorded as log viral 
10ad=0. OBF .!- 19.5. NB Inclusion of CAV 
on CUF in the model is an error. 
108 2 ADD+CCV 91exp(l]1) (92+97*(DA YS-1 0)- (93+99*(VIR-5) 96exp(l]4) 47 44 29 74 39 0.05 RFA9.CSV 710.024 Added in HIV status on VlF as well. No 
98*(CAV-4» +910*HIV) additional effect over log viral load (OBJ 
exp(l]2) exp(l]3) .!- 0.7). NB Inclusion of CAV on CUF in 
the model is an error. 
109 2 ADD+CCV 91exp(T]1) (92+97*(DA YS-1 0)- (93+99*(VIR-5) 96exp(l]4) 45 44 31 71 39 0.05 RFA9.CSV 711.045 Fixed CAY to zero . OBJ i 0.4. Therefore 
98*(CAV-4» +910*HIV) confirmed its exclusion and ability to 
exp(l]2) exp(T]3) continue with further additions to the 
model with it included. To be removed at 
the end. 
110 2 ADD+CCV 91exp(l]1) (92+97*(DA YS-1 0)- (93+99*(VIR-5» 96exp(l]4) 47 37 26 82 39 0.05 RFA9.CSV 652.622 Removed HIV on VlF. Added in WT on 
98*(CAV-4) exp(l]3) CUF. OBF .!- 58.1. NB Inclusion of CA V 
+910*(WT-54» on CUF in the model is an error. 
exp(n2) 
111 2 ADD+CCV 91 expel] 1) (92+97*(DA YS-1 0)- (93+99*(VIR-5» 96exp(l]4) 48 38 24 85 39 0.05 RFA9.CSV 648.267 Added in GLOB. OBF .!- 4.4. NB Inclusion 




112 2 ADD+CCV 91exp(1]1) (92+97*(DA YS-1 0)- (93+99*(VIR-5» 96exp(l]4) 48 38 24 86 39 0.05 RFA9.CSV 648.115 Added in effect of INAT on CUF. No 
98*(CAV-4) exp(l]3) significant change in OBF (.!- 0.2). NB 
+910*(WT-54) Inclusion of CA V on CUF in the model is 
+911*(GLOB-52) an error. 
+912*INAT)exp(l]2) 
113 2 ADD+CCV 91exp(l]1) (92+97*(DA YS-1 0)- (93+99*(VIR-5)+ 96exp(l]4) 48 38 26 80 38 0.05 RFA9.CSV 646.158 Removed INAT, added in GLOB on V/F . 
98*(CAV-4) 912*(GLOB-52» No significant change in OBF (.!- 2.0). NB 
+910*(WT-54) exp(T]3) Inclusion of CA V on CUF in the model is 
+911*(GLOB-52» an error. 
exp(l]2) 
-
T] - inter-individual variability; KA - absorption rate constant, CUF - apparent clearance; V/F - apparent volume of distribution; TLAG - absorption lag time; a - intra-individual variability; CCV - consta!lt coefficient of 
variation; ADD - additive; OBF - minimum value of the Objective function. 
G-179 
Appendix G 
NONMEM RUN SUMMARY - RIFAMPICIN 
RUN ADVAN ERROR KA CUF V/F TLAG llKA llcuF llvlF llTLAG crccv crADD DATA OBF COMMENTS 
% % % % % ~g/ml 
114 2 ADD+CCV 91exp(1l1) (92+97*(DA YS-1 0)- (93+99*(VIR-5) 96exp(1l4) 48 37 72 70 38 0 .05 RFA9.CSV 641 .745 Removed GLOB on V/F, added in SEX 
98*(CAV4)+ +912*SEX) on V/F. OBF t 4.4. NB Inclusion of CAV 
910*(WT-54) exp(1l3) on CUF in the model is an error. 
+911 *(GLOB-52» 
eXP(n2) 
115 2 ADD+CCV 91exp(1l1 ) (92+97*(DA YS-1 0)- (93+99*(VIR-5) 96exp(T]4) 49 37 19 94 38 0.05 RFA9.CSV 639.772 Added in effect of iron preps on CUF. No 
98*(CAV-4)+ +912*SEX) significant effect on OBF (t 2.0). NB 
910*(WT-54) exp(1l3) Inclusion of CA V on CUF in the model is 
+911 *(GLOB-52) an error. 
+913*FEF)exP(n2) 
116 2 ADD+CCV 91exp(1l1) (92+97*(DAYS-10)- (93+99*(VIR-5) 96exp(1l4) 51 36 14 95 38 0.05 RFA9.CSV 639.400 Removed iron preps. Added in MDR 
98*(CAV-4) +912*SEX) severity score. No significant change in 
+910*(WT-54) exp(1l3) OBF (t 2.4). NB Inclusion of CAVan 
+911*(GLOB-52) CUF in the model is an error. 
+913*(NMDR-7» 
exo(n2) 
117 2 ADD+CCV 91exp(1l1) (92+97*(DA YS-1 0)- (93+99*(VIR-5) 96exp(1l4) 51 36 18 81 38 0.05 RFA9.CSV 628.151 Removed MDR severity score, Added in 
98*(CAV-4) +912*SEX+ DAYS since starting RFA on V/F. OBF t 
+910*(WT-54) 913*(DAYS-10» 13.6. NB Inclusion of CA V on CUF in the 
+911 *(GLOB-52» exp(1l3) model is an error. 
exp(n2) 
118 2 ADD+CCV 91exp(1l1) (92+97*(DA YS-1 0)- (93+99*(VIR-5) 96exp(1l4) 52 36 18 82 38 0.05 RFA9.CSV 625.875 Added in Age on CUF. No significant 
98*(CAV-4) +912*SEX + change in OBF (t 2.3). NB Inclusion of 
+910*(WT-54) 913*(DAYS-10» CA Von CUF in the model is an error. 
+911 *(GLOB-52) exp(1l3) 
+914*(AGE-33» 
eXP(n2) 
119 2 ADD+CCV 91exp(1l1) (92+97*(DA YS-1 0)- (93+99*(VIR-5) 96exp(1l4) 58 35 2 76 38 0.05 RFA9.CSV 628.584 Added in inhibitors on V/F. OBF t 0.4 . 
98*(CAV-4) +912*SEX NB Inclusion of CA Von CUF in the 
+910*(WT-54) +913*(DAYS-10) model is an error. 
+911 *(GLOB-52» +914*INHI) 
exp(1l2) exp(1l3) 
120 2 ADD+CCV 91exp(1l1) (92+97*(DA YS-1 0)- (93+99*(VIR-5) 96exp(1l4) 52 36 18 83 38 0.05 RFA9.CSV 626.919 Added in Iron preps/anaemia on V/F. 
98*(CAV-4) +912*SEX OBF t 1.2. NB Inclusion of CAVan CUF 
+910*(WT-54) +913*(DAYS-10) and INHI on VlF in the model is an error. 
+911 *(GLOB-52» +914*INHI-
exp(1l2) 915*FEF) . 
exp(1l3) 
TJ - inter-individual variability; KA - absorption rate constant, CUF - apparent clearance; V/F - apparent volume of distribution; TLAG - absorption lag time; (J - intra-individual variability; CCV - constant coefficient of 
variation; ADD - additive; OBF - minimum value of the Objective function. 
G-J80 
Appendix G 
NONMEM RUN SUMMARY - RIFAMPICIN 
RUN ADVAN ERROR KA CUF V/F TLAG nKA nCUF nVIF nTLAG O"ccv O"ADD DATA OBF COMMENTS 
% % % % % Ilg/ml 
121 2 ADD+CCV 91exP(n 1) (92+97*(DA YS-1 0)- (93+99*(VIR-S) 96exP(n4) SO 36 21 70 37 O.OS RFA9.CSV 626.014 Added in HIV on CUF. OBF .l. 2.1. NB 
98*(CAV-4) +912*SEX Inc/usion of CA V on CUF and INHI on 
+910*(WT-54) +913*(DAYS-10) V/F in the model is an error. 
+911*(GLOB-S2)- +914*INHI) 
91S*HlV)exp(n2) eXP(n3) 
122 2 ADD+CCV 91exP(n1) (92+97*(DA YS-1 0)- (93+99*(VIR-S) 96exP(n4) S2 36 17 84 38 O.OS RFA9.CSV 627.048 Added in AST on CUF. OBF.l. O.S. NB 
98*(CAV-4)+ +912*SEX Inclusion of CA V on CUF and INHI on 




123 2 ADD+CCV 91exP(n1) (92+97*(DA YS-1 0)- (93+99*(VIR-S) 96exP(n4) S2 36 17 83 38 O.OS RFA9.CSV 626.8S9 Added in NSAIDS on CUF. OBF .l. 1.3. 
98*(CAV-4) +912*SEX NB Inclusion of CA Von CUF and INHI 
+91 O*(WT -S4) +913*(DA YS-1 0) on V/F in the model is an error. 
+911*(GLOB-S2) +914*INHI) 
+91S*NSID)exP(n2) exp(n3) 
124 2 ADD+CCV 91exP(n1) (92+97*(DA YS-1 0)- (93+99*(VIR-S) 96exP(n4) S2 3S 17 84 38 O.OS RFA9.CSV 627.026 Added in Log Viral load on CUF. OBF 
98*(CAV-4) +912*SEX .l.1 .1. NB Inclusion of CA Von CUF and 




12S 2 ADD+CCV 91exP(n1) (92+97*(DA YS-1 0)- (93+99*(VIR-S) 96exP(n4) S1 39 27 77 3S O.OS RFA9.CSV 606.918 Implemented BLOCK OMEGA on CUF & 
98*(CAV-4) +912*SEX V/F. Found a high correlation (0.967). 
COV step does not work with the +910*(WT-54) +913*(DA YS-1 0) 
+911*(GLOB-S2» +914*INHI) BLOCK OMEGA. NB Inc/usion of CA V ani 
eXP(n2) eXP(n3) 
CUF and INHI on V/F in the model is an 
error. 
126 2 ADD+CCV 91exP(n1) (92+97*(DA YS-1 0)- (93+99*(VIR-S) 96exP(n4) 46 39 33 73 3S O.OS RFA9.CSV 630.799 Fixed CAV, GLOB on CUF. Also SEX, 
98*(CAV-4) +912*SEX DAYS & INHI on V/F. All except DAYS 
+910*(WT-S4) +913*(DA YS-1 0) on V/F were not significant at p=O.OOS on 
+911*(GLOB-S2» +914*INHI) model buildup. IGNORE THIS RUN. 
exp(n2) eXP(n3) 
127 2 ADD+CCV 91 eXP(n1) (92+97*(DA YS-1 0)- (93+99*(VIR-S) 96exP(n4) S8 3S 0.2 76 38 O.OS RFA9.CSV 628.S84 Reverted to DIAG OMEGA. 
98*(CAV-4) +912*SEX Implemented COV on RUN119.KA vs 
+910*(WT-S4) +913*(DAYS-10) V/F (0.868); KA vs TLAG (0.843). NB 
+911*(GLOB-52» +914*INHI) Inclusion of CA V on CUF and INHI on 
exo(n2) exp(n3) V/F in the model is an error. 
TJ - inter-individual variability; KA - absorption rate constant, CUF - apparent clearance; V/F - apparent volume of distribution; TLAG - absorption lag time; CJ - intra-individual variability; CCV - constant coefficient of 




NONMEM RUN SUMMARY - RIFAMPICIN 
RUN ADVAN ERROR KA CUF V/F . TlAG TJKA TJCUF TJVIF TJTLAG crccv crADD DATA OBF COMMENTS 
% % % % % Ilg /ml 
128 2 AOO+CCV 91exp(TJ1) (92+97*(OA YS-1 0)- (93+99*(VIR-5) 96exp(TJ4) 52 39 26 79 35 0.05 RFA9.CSV 607.751 CAVfixed to 0 i.e. reconfirmed RUN 106. 
98*(CAV-4) +912*SEX Establishing rank order for backward 
+910*(WT-54) +913*(OAYS-10) deletion. BLOCK OMEGA hence 
+911*(GLOB-52» +914*INHI) 
compare with RUN 125. (CORR=0.82). 
exp(TJ2) exp(TJ3) 
OBF no signficant change. NB Inclusion 
of INHI on VIF in the model is an error. 
129 2 AOD+CCV 91 exp(TJ 1) (92+97*(OA YS-1 0)- (93+99*(VIR-5) 96exp(TJ4) 50 39 28 76 35 0.05 RFA9.CSV 611 .296 GLOB fixed to O. Establishing rank order 
98*(CAV-4) +912*SEX for backward deletion. BLOCK OMEGA 
+91 O*(WT -54) +913*(OAYS-10) hence compare with RUN 125. 
+911*(GLOB-52» +914*INHI) (CORR=0.78). OBF t 4.38. NB Inclusion 
exp(TJ2) exp(TJ3) 
of CAVan CUF and INHI on VIF in the 
model is an error. 
130 2 ADO+CCV 91 exp(TJ1) (92+97*(OA YS-1 0)- (93+99*(VIR-5) 96exp(TJ4) 51 38 26 77 35 0.05 RFA9.CSV 616.410 LOGHIV fixed to O. Establishing rank 
98*(CAV-4) +912*SEX order for backward deletion. BLOCK 
+910*(WT-54) +913*(OAYS-10) OMEGA hence compare with RUN 125. 
+911*(GLOB-52» +914*INHI) (CORR=0.80) . OBF t by 9.5. NB 
exp(TJ2) exp(TJ3) 
Inclusion of CA Von CUF and INHI on 
VIF in the model is an error. 
131 2 AOO+CCV 91exp(TJ1) (92+97*(OA YS-1 0)- (93+99*(VIR-5) 96exp(TJ4) 50 39 40 74 35 0.05 RFA9.CSV 613.148 SEX fixed to O. Establishing rank order 
98*(CAV-4) +912*SEX for backward deletion. BLOCK OMEGA 
+910*(WT-54) +913*(OAYS-10) hence compare with RUN 125. 
+911*(GLOB-52» +914*INHI) . (CORR=0.71). OBF t by 6.2. NB 
exp(TJ2) exp(TJ3) 
Inclusion of CA V on CUF and INHI on 
VIF in the model is an error. 
132 2 AOO+CCV 91exp(TJ1) (92+97*(OA YS-1 0)- (93+99*(VIR-5) 96exp(TJ4) 50 39 27 76 35 0.05 RFA9.CSV 609.105 INHI on VlF fixed to O. Establishing rank 
98*(CAV-4)+ +912*SEX order for backward deletion. BLOCK 
910*(WT-54) +913*(OAYS-10) OMEGA hence compare with run 125. 
+911*(GLOB-52» +914*INHI) (CORR=0.69). OBF t by 2.2. NB 
exp(TJ2) exp(TJ3) 
Inclusion of CA V on CUF and INHI on 
VIF in the model is an error. 
133 2 AOO+CCV 91exp(TJ1) (92+97*(OA YS-1 0)- (93+99*(VIR-5) 96exp(TJ4) 50 40 29 77 35 0.05 RFA9.CSV 617.531 DAYS on V/F fixed to O. Establishing 
98*(CAV-4) +912*SEX rank order for backward deletion. BLOCK' 
+910*(WT-54) +913*(OAYS-10) OMEGA hence compare with RUN 125. 
+911*(GLOB-52» +914*INHI) (CORR=0.97). OBF t by 10.6. NB 
exp(TJ2) exp(TJ3) 
Inclusion of CA Von CUF and INHI on 
VIF in the model is an error. 
T] - inter-individual variability; KA - absorption rate constant, CUF - apparent clearance; VIF - apparent volume of distribution; TLAG - absorption lag time; cr • intra-individual variability; CCV - constant coefficient of 
variation; ADD - additive; OBF - minimum value of the Objective function. 
G-182 
Appendix G 
NONMEM RUN SUMMARY - RIFAMPICIN 
RUN ADVAN ERROR KA CUF V/F TLAG TJKA TJCUF TJVIF TJTLAG crccv crADD DATA OBF COMMENTS 
% % % % % Jlg/ml 
134 2 ADD+CCV 91exp(TJ1) (92+97*(DA YS-1 0)- (93+99*(VIR-5) 96exp(TJ4) 49 51 31 93 38 0.05 RFA9.CSV 698.802 DAYS on CL fixed to O. Establishing rank 
98*(CAV-4) +912*SEX order for backward deletion. BLOCK 
+910*(WT-54) +913*(DAYS-10) OMEGA hence compare with RUN 125. 
+911 *(GLOB-52» +914*INHI) (CORR=0.81). OBF t by 91 .9 . NB 
exp(TJ2) exp(TJ3) Inclusion of CA V on CUF and INHI on 
VIF in the model is an error. 
135 2 ADD+CCV 91exp(TJ1) (92+97*(DA YS-1 0)- (93+99*(VIR-5) 96exp(TJ4) 64 40 20 92 34 0.05 RFA9.CSV 658.203 wr fixed to O. Establishing rank order for 
98*(CAV-4) +912*SEX backward deletion. BLOCK OMEGA 
+910*(WT-54) +913*(DAYS-10) hence compare with RUN 125. 
+911 *(GLOB-S2» +914*INHI) (CORR=1). OBF t by 51.3. NB Inclusion 
exp(TJ2) exp(TJ3) of CAVan CUF and INHI on VIF in the 
model is an error. 
136 2 ADD+CCV 91exp(TJ1) (92+97*(DA YS-1 0)- (93+99*(VIR-5) - 54 38 12 - 45 0.05 RFA9.CSV 684.098 Removed lag time. COV does not work. 
98*(CAV-4) +912*SEX NB Inclusion of CA Von CUF and INHI 
+910*(WT-54) +913*(DAYS-10) on VlF in the model is an error. 
+911 *(GLOB-S2» +914*INHI) 
eXP(n2) exp(n3) 
137 2 ADD+CCV 91exp(TJ1) (92+97*(DA YS-1 0) (93+98*(VIR-5) 96exp(TJ4) 51 38 26 77 35 0.05 RFA9.CSV 610.291 Full Model 
+99*(WT-54) +911*SEX 
+910*(GLOB-S2)) +912*(DAYS-
eXP(n2) 10)) exp(n3) 
138 2 ADD+CCV 91exp(TJ1) (92+97*(DA YS-1 0) (93+98*(VIR-5) 96exp(TJ4) 51 38 27 77 35 0.05 RFA9.CSV 617.187 Stepwise Rank Order Deletion to Final 
+99*(WT-54) +911*SEX Model. GLOB fixed to O. OBF t 6.9 
+910*(GLOB-52» +912*(DAYS- Hence exclude. 
exp(n2) 10» exp(n3) 
139 2 ADD+CCV 91exp(TJ1) (92+97*(DA YS-1 0) (93+98*(VIR-5) 96exp(TJ4) 49 38 30 75 35 0.05 RFA9.CSV 623.253 Stepwise Rank Order Deletion to Final 
+99*(WT-54) +911*SEX ' Model. GLOB and SEX fixed to O. OBF t 
+910*(GLOB-S2» +912*(DAYS- 6.1. Hence exclude. 
exp(n2) 10)) exp(n3) 
140 2 ADD+CCV 91exp(TJ1) (92+97*(DA YS-1 0) (93+98*(VIR-5) 96exp(TJ4) 48 38 30 73 36 0.05 RFA9.CSV 630.091 Stepwise Rank Order Deletion to Final 
+99*(WT-54) +911*SEX Model. GLOB, SEX, LOGHIV fixed to O. 
+910*(GLOB-52» +912*(DAYS- OBF t 6.8. Hence exclude. 
exp(n2) 10)) exp(n3) 
141 2 ADD+CCV 91 exp(TJ 1) (92+97*(DA YS-1 0) (93+98*(VIR-5) 96exp(TJ4) 33 38 20 158 38 0.05 RFA9.CSV 675.854 Stepwise Rank Order Deletion to Final 
+99*(WT-54) +911*SEX Model. GLOB, SEX, LOGHIV and DAYS 
+910*(GLOB-52» +912*(DAYS- on V/F fixed to O. OBF t 45.8. Hence 
exp(n2) 10» exp(n3) . can 't exclude DAYS on V/F . 
'1 - Inter-individual variability; KA - absorption rate constant, CUF - apparent clearance; V/F - apparent volume of distribution; TLAG - absorption lag time; cr - intra-individual variability; CCV - constant coefficient of 
variation; ADD - additive; OBF - minimum value of the Objective function. 
G-\83 
Appendix G 
NONMEM RUN SUMMARY - RIFAMPICIN 
RUN ADVAN ERROR KA CUF V/F TLAG llKA 'lCUF llvlF TJTLAG accv aADD DATA OBF COMMENTS 
% % % % % ~g/ml 
142 2 ADD+CCV 81 exp(1l1) (82+87*(DA YS-1 0) (83+88*(VIR-5) 86exp(1l4) 51 41 31 75 36 0.05 RFA9.CSV 684.214 Stepwise Rank Order Deletion to Final 
+89*(WT-54) +811*SEX Model. GLOB, SEX, LOGHIV and WT 
+810*(GLOB-52» +812*(DAYS- fixed to O. OBF t 8.4. Hence exclude. 
exp(1l2) 10)) exp(n3) 
143 2 ADD+CCV 81exp(1l1) (82+87*(DA YS-1 0) (83+88*(VIR-5) 86exp(1l4) 47 53 34 70 38 0.05 RFA9.CSV 760.214 Stepwise Rank Order Deletion to Final 
+89*(WT-54) +811*SEX Model. GLOB, SEX, LOGHIV, WT and 
+810*(GLOB-52» +812*(DA YS- DAYS on CUF fixed to O. OBF t 76. 
exp(1l2) 10» exp(1l3) Hence can't exclude DAYS on CUF. 
144 2 ADD+CCV 81exp(TJ1) (82+87*(DA YS-1 0) (83+88*(VIR-5) 86exp(TJ4) 52 39 26 69 39 0.05 RFA9.CSV 701 .922 FINAL RUN. Removed all covariates that 
+89*(WT-54) +811*SEX caused a s 11 DOBF when fixed to NULL 
+810*(GLOB-52» +812*(DAYS- during backward deletion i.e. GLOB, 
exp(1l2) 10» exp(TJ3) SEX, LOGHIV, WT. Implemented COV. 
No BLOCK OMEGA. 
145 2 ADD+CCV 81 exp(ll 1) (82+87*(DA YS-30)- (83+89*(VIR-5) 86exP(1l4) 56 37 19 69 39 0.05 RFA9.CSV 673.780 Runs 144 to 149 are a record of the 
88*(CAV-4) +812*SEX attempt to find the best fit for maximal 
+810*(WT-54) +813*(DA YS-30) enzyme induction. 
+811 *(GLOB-52» +814*INHI) MAX=30 Arbitrary choice. 
eXP(n2) exp(1l3) 
146 2 ADD+CCV 81exp(1l1) (82+87*(DA YS- (83+89*(VIR-5) 86exp(TJ4) 48 38 20 127 41 0.05 RFA9.CSV 668.526 MAX-4.5 as suggested by TREE 
4.5)-e8*(CAV-4) +812*SEX+813* modelling. 
+810*(WT-54) (DAYS-4.5) 
+811 *(GLOB-52» +814*INHI) 
e~2) exp(1l3) 
147 2 ADD+CCV 81exp(1l1) (82+87*(DAYS-7)- (83+89*(VIR-5) 86exp(TJ4) 49 34 18 130 41 0.05 RFA9.CSV 660.323 MAX-7 (literature says between 7 and 14 
88*(CAV-4) +812*SEX days) 
+810*(WT-54) +813*(DAYS-7) 
+811 *(GLOB-52» +814*INHI) 
exp(TJ2) exp(n3) 
148 2 ADD+CCV 81exp(1l1) (82+87*(DAYS-14)- (83+89*(VIR-5) 86exp(1l4) 51 35 15 134 40 0.05 RFA9.CSV 675.287 MAX=14 (literature says between 7 and 




149 2 ADD+CCV 81exp(1l1 ) (82+87*(DA YS-1 0)- (83+89* (VIR-5) 86exp(1l4) 54 34 19 74 39 0.05 RFA9.CSV 654.089 MAX-10 as suggested by GAM natural 
88*(CAV-4) +812*SEX+813* cubic spline at 9.7. No correlations of 
+810*(WT-54) (DAYS-10) significance in the matrix. CORR of etas 
+811 *(GLOB-52» +814*INHI) CUF vs V/F = 0.75. 
exp(1l2) exp(1l3) 
------ ---------
'1 - inter-lndividual variability; KA - absorption rate constant, CUF - apparent clearance; V/F - apparent volume of distribution; TLAG - absorption lag time; 0' - intra-individual variability; CCV - constant coefficient of 
variation; ADD - additive; OBF - minimum value of the Objective function. . . 
G-184 




NONMEM CONTROL STREAM - RIFAMPICIN 
$PROB RIFAMPICIN KINETICS IN TUBERCULOSIS PATIENTS 
$INPU ID DATE=DROP TIME DOSE=AMT RATE=DROP DV=CONC SS II 
SEX TBHX=DROP MDR HIV WT AGE=DROP DAMT=DROP DAYS 
ALKP=DROP BILI=DROP PROT=DROP ALB=DROP GLOB GGT=DROP ALT=DROP 
AST=DROP ALP=DROP PLAT=DROP LYMC=DROP LYMP=DROP VIRU INDU=DROP INHI 
ABS1=DROP ABS2=DROP MIS1=DROP MIS2=DROP NSID=DROP FEFL H1B=DROP 
PEN=DROP BS=DROP DIUR=DROP INAT=DROP QUIN=DROP AG=DROP EMB PZA=DROP 
ANAE=DROP HPT=DROP DM=DROP EPIL=DROP CAND=DROP NMDR EXT=DROP CAV 
WALL=DROP 
$ DATA RFA9.CSV IGNORE=# 
$SUBROUTINES ADVAN2 TRANS2 
$PK 
DAY=DAYS 
IF (DAYS.GE.10) DAY = 10 
TVKA = THETA(l) i KA 
TVCL = THETA (2)+THETA(7)* (DAY-10)+THETA(8)*(WT-54) 
IF (TVCL.LE.O ) EXIT 1 100 
TVV = THETA(3)+THETA(9)* (DAY-10) 
IF (TVV.LE.O) EXIT 1 200 
KA TVKA*EXP(ETA(l)) 











Y=IPRED + W*EPS(l) 
$SIGMA 1 FIXED 
$THETA (0,1,50) i 1: KA 
(10 ) 
therapy on CL 
therapy on V 
(0 , 36) 
(0,0.2) 
(0.09) 
(0, ° .1) 
(0.06) 
(0.06) 
(0 . 05) 
$OMEGA 0.25 0.25 0.25 0.25 
2: CL intercept 
3: V intercept 
4: CCV part of residual error 
5: additive part of residual error 
6: lag time 
7: Slope for DAYS since starting RFA 
8: Effect of WT on CL 
9: Slope for DAYS since starting RFA 
$EST NOABORT MAXEVAL=9999 POSTHOC MSF=rfa 
$TABLES ID TIME IPRED IWRES KA CL V ALAG1 DAY ETA1 ETA2 ETA3 ETA4 
ONE HEADER NOPRINT FILE=sdtab148 
$COV 
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COVARIATE MODEL BUILDING - RIFAMPICIN 
Covariate Effect DOBF' Retained
Z in Retained
J in Final 
Forward Model Model 
Build-u~ - -'---
RFA auto-induction on CLIF 74.5 Yes Yes 
Quinolones on CLIF 38.15 No No 
Enzyme inhibitor on CLIF 37.753 No No 
MDR-TB on CLIF 26.343 No No 
Ethambutol on CLIF 20.4 No No 
Severity score for extent of lung cavitation on 17.846 No No 
CLIF 
Log HIV viral load on V/F 16.083 Yes No 
HIVon V/F 15.727 No No 
'NT on CLIF 15.475 Yes No 
Globulin on CLIF 15.376 Yes No 
Thiacetazone on CUF 14.567 No No 
Globulin on V/F 13.795 No No 
Sex on V/F 12.167 Yes No 
Iron preparations/anaemia on CLIF 11 .117 No No 
Drug resistance severity score on CLIF 10.556 No No 
RFA auto-induction on V/F 9.613 Yes Yes 
AGE on CLIF 7.685 No No 
Enzyme inhibitor on V/F 7.468 No No 
Iron preparations/anaemia on V/F 7.162 No No 
HIVon CLIF 6.932 No No 
AST on CLIF 6.072 No No 
Non-steroidal anti-inflammatory drug use on 4.87 No No 
CUF 
Log HIV viral load on CLIF 4.081 No No 
Albumin on V/F 3.35 n/a n/a 
Candidiasis on V/F 3.022 n/a n/a 
Candidiasis on CLIF 2.945 n/a n/a 
Severity score for extent of lung cavitation on 2.889 n/a . n/a 
V/F 
Ethambutol on V/F 2.419 n/a n/a 
AGE on V/F 2.37 n/a n/a 
MDR-TB on V/F 2.326 n/a n/a 
Quinolones on V/F 2.273 n/a n/a 
Iron preparations on KA 2.248 n/a n/a 
WTon V/F 2.159 n/a n/a 
Non-steroidal anti-inflammatory drugs on V/F 2.077 n/a n/a 
Total Bilirubin on V/F 1.345 n/a n/a 
Drug resistance severity score on V/F 1.33 n/a n/a 
GGTon CUF 1.028 n/a n/a 
AST on V/F 0.986 n/a n/a 
Severity score for extent of lung involvement on 0.846 n/a n/a 
V/F 
Dose amount on KA 0.828 n/a n/a 
Total Bilirubin on CLIF 0.796 n/a n/a 
ALK PHOS on V/F 0.742 n/a n/a 
Diuretics/hypertension on V/F 0.648 n/a n/a 
Hypoglycaemic agents/diabetes mellitus on 0.584 n/a n/a 
CUF 
Hypoglycaemic agents/diabetes mellitus on V/F 0.571 n/a n/a 
'DOBF - difference In the minimum value of the objective function between 2 NONMEM runs. Chi square distributed - 2DOBF ~ 3.84 p .s 0.05 
df=1 ; JDOBF ~ 11, P .s 0.001 df=1 ' 
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COVARIATE MODEL BUILDING - RIFAMPICIN 
Covariate Effect DOBF' Retained~ in Retained J in Final 
Forward Model Model 
Build-up 
GGT on V/F 0.399 n/a n/a 
Albumin on CLIF 0.383 n/a n/a 
Antihistamines on CLIF 0.241 n/a n/a 
ALT on V/F 0.151 n/a n/a 
Antihistamines on V/F 0.073 n/a n/a 
Severity score for extent of lung involvement on 0.058 n/a n/a 
CLIF 
Thiacetazone on V/F 0.058 n/a n/a 
Sex on CUF 0.046 n/a n/a 
ALK PHOS on CLIF 0.009 n/a n/a 
Diuretics/hypertension on CUF 0.009 n/a n/a 
Absorption drug interaction on KA 0.005 n/a n/a 
Absorption drug interaction on CLIF 0.002 n/a n/a 
Dose amount on V/F -0.005 n/a n/a' 
ALT on CLIF -0.014 n/a n/a 
Absorption drug interaction on V/F -0.463 n/a n/a 
'OOB; - difference in the minimum value of the objective function between 2 NONMEM runs. Chi square distributed _ 'OOBF ~ 3 84 005 
dp1; OOBF ~ 11, P S 0.001 dp1 . , P S . 
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Appendix J 
NONMEM RUN SUMMARY - ISONIAZID 
RUN ADVAN ERROR KA CUF VD TLAG l]KA l]CUF l]v O"ccv O"ADD DATA OBF COMMENTS 
% % % % Illg/ml 
1 2 ADD+CCV 91exp(l]1) 92exp(l]2) 93exp(l]3) - 68 45 439 40 0.05 INH2.CSV 1128.050 Prepared tables for data checkout 
in Xpose2. Model is under-
predicting. Some parameter 
estimates are unrealistic. Run 
times are long. 
2 2 ADD+CCV 91 exp(l] 1 ) 92exp(l]2) 93exp(l]3) - 2102 27 15 23 0.5 INH5.CSV 851 .055 Implemented new $ERROR code 
as per Mats suggestion. IWRES 
has unit variance. KA estimate and 
l] is very large. Data file has ALL 
the covariates. 
3 2 ADD+CCV 91exp(l]1) 92exp(l]2) 93exp(l]3) - 80 39 16 17 0.7 INH5.CSV 1196.276 Sensitivity Analysis: KA fixed to 
0.5. V estimate unrealistic. 
4 2 ADD+CCV 91exp(l]1) 92exp(l]2) 93exp(l]3) - 40 42 <1 29 0.7 INH5.CSV 1160.628 Sensitivity Analysis: KA fixed to 
0.6. V estimate still small. 
5 2 ADD+CCV 91exp(l]1) 92exp(l]2) 93exp(l]3) - 61 44 <1 29 0.6 INH5.CSV 1131.429 Sensitivity Analysis: KA fixed to 
0.7. V estimate still small 
6 2 ADD+CCV 91 exp(l] 1) 92exp(l]2) 93exp(l]3) - 97 50 22 23 0.6 INH5.CSV 1017.531 Sensitivity Analysis: KA fixed to 
1.0. V estimate now realistic. 
7 2 ADD+CCV 91exp(l]1) 92exp(l]2) 93exp(l]3) - 78 47 34 18 0.5 INH5.CSV 930.859 Sensitivity Analysis: KA fixed to 
1.5. 
8 2 ADD+CCV 91exp(l] 1) 92exp(l]2) 93exp(l]3) - 76 46 35 18 0.5 INH5.CSV 897.293 Sensitivity Analysis: KA fixed to 
2.0 OBF.J.. 
9 2 ADD+CCV 91exp(l]1) 92exp(l]2) 93exp(l]3) - 118 45 36 18 0.5 INH5.CSV 882.867 Sensitivity Analysis: KA fixed to 
3.0 OBF.J.. 
10 2 ADD+CCV 91exp(l]1) 92exp(l]2) 93exp(l]3) - 225 44 36 18 0.5 INH5.CSV 881 .798 Sensitivity Analysis: KA fixed to 
4.0 l]KA is large. OBF .J.. . 
11 2 ADD+CCV 91 exp(l] 1) 92exp(l]2) 93exp(l]3) - 315 42 35 19 0.5 INH5.CSV 881.112 Sensitivity Analysis: KA fixed to 
4.5. l1KA is larger. OBF .J... 
12 2 ADD+CCV 91exp(l]1 ) 92exp(l]2) 93exp(l]3) - 442 40 34 19 0.5 INH5.CSV 879.296 Sensitivity Analysis: KA fixed to 
5.0 l]KA is larger. OBF .J... 
13 2 ADD+CCV 91exp(l]1) 92exp(l]2) 93exp(l]3) - 773 33 31 21 0.5 INH5.CSV 870.946 Sensitivity Analysis: KA fixed to 
6.0. 'lKA is larger. OBF .J... 
14 2 ADD+CCV 91exp(TJ1) 92exp(l]2) 93exp(l]3) - 1204 27 26 22 0.5 INH5.CSV 860.979 Sensitivity Analysis: KA fixed to 
8.0. l]KA is larger. OBF .J.. . 
15 2 ADD+CCV 91 exp(l] 1) 92exp(TJ2) 93exp(l]3) 94 116 46 36 18 0.5 INH5.CSV 882.085 Added in a lag time and KA is not 
fixed . Goodness of fits plots are 
better and estimates are more 
realistic. 
'1 - Inter-individual variability - where 2 values are recorded they are the estimates for the first and second populations; KA - absorption rate constant; CUF - apparent clearance; Cl(1)1F- apparent clearance (fast); 
Cl(2)/F - apparent clearance for slow acetylators; VfF - apparent volume of distribution; TLAG - absorption lag time; (J - intra-individual variability; CCV - constant coefficient of variation; ADD - additive; OBF - minimum 
value of the Objective function. 
J-191 
Appendix J 
NONMEM RUN SUMMARY - ISONIAZID 
RUN ADVAN ERROR KA CUF VD TLAG llKA llcUF llv O"ccv O"ADD DATA OBF COMMENTS 
% % % % If.!g/ml 
16 2 ADD+CCV 91 exp(111) 92exp(112) 93exp(113) 94exp(114) 444 22 22 19 0.52 INH5.CSV 838.242 As per RUN 15 but with an T] on 
TLAG. OCCURS DURING SEARCH FOR ETA AT 
A NONZERO VALUE OF ETA. PK PARAMETER FOR 
ABSORPTION LAG IS GREATER THAN OR EQUAL 
TO STEADY STATE DOSE INTERVAL. PROGRAM 
TERMINATED BY FNLETA. MESSAGE ISSUED 
FROM TABLE STEP 
TLAG very small (10.4 ) and 
variabilitv very large (106 ) . 
17 1 ADD+CCV - 91exp(11 1 ) 92exp(112) - - 45 34 23 0.53 INH5.CSV 901 .258 ADVAN 1 and estimated D1 
parameter. Duration parameter 
very small. 
18 1 ADD+CCV - 91exp(T]1) 92exp(T]2) 93 - 47 34 23 0.5 INH5.CSV 901 .117 ADVAN 1, D1 and TLAG 
I parameter. 
19 4 ADD+CCV 91exp(11 1) 92exp(T]2) 93exp(T]3) - 68 52 37 20- 0.46 INH5.CSV 800.274 2 compartment model. Although 
the OBF is smaller, goodness of 
fits plots are not any better than 
using RUN 15. Hence the simpler 
model was chosen as the basic 
model. 
20 2 ADD+CCV 91 (INAT) 92exp(T]2) 93exp(T]3) 94 37 46 34 22 0.49 INH5.CSV 846.845 Effect of PREP on KA but illogical 
91 +96(INH» to try and determine KA for INAT 
expT] 1 as there were no samples drawn 
at descriptive times. Therefore . ignore this run . 
21 2 ADD+CCV 91 exp(111) 92exp(112) 93exp(113) 94 - - - - - INH5.CSV 801.676 F1 for PREP. Rounding errors and 
see comments for RUN 20. 
22 2 ADD+CCV 92exp(11 1) CL(1 )/F=96exp(112) V1 =98exp(T]3) 93 127 42/42 411 29 0.02 INH5.CSV 296.172 Mixture Modelling on both CUF 
CL(2)/F=96*97exP(n4) V2=98*9ge~p(n5) 41 and V . Dramatic.j.. in OBF. 
23 2 ADD+CCV 92exp(11 1) CL(1 )/F-96exp(T]2) 98exp(113) 93 127 43/43 43 29 0.02 INH5.CSV 289.890 Full BLOCK matrix on $OMEGA. 
CL(2)/F=96*97exp(T]4 ) Mixture modelling on CUF only. 
Significant.j.. in OBF. 
24 2 ADD+CCV 92exp(T]1) CL(1 )/F=96exp(T]2) 98exp(113) 93 4393 14 22 32 0.03 INH5.CSV 301.755 Diagonal matrix on $OMEGA. 
CL(2)/F=96*97exp(T]4 ) Mixture modelling on CUF only. 
Very large estimate and T] for KA. 
OBF t. 
25 2 ADD+CCV 92exp(11 1 ) CL(1 )/F-96exp(112) 98exp(113) 93 100 44/38 44 28 0.02 INH5.CSV 303.829 Mixture Modelling. Fixed KA t02 .0. 
CL(2)/F=96*97exp(T]4) Estimate of TLAG very small. KA 
variability is more reasonable. 
26 2 ADD+CCV 92exp(11 1 ) CL(1 )/F=96exp(T]2) 93exp(113) - 100 44/38 44 28 0.02 INH5.CSV 303.829 Mixture Modelling. Removed 
CL(2)/F=96*97exP(n4) TLAG. OBF no change. 
'1 - inter-lndividual variability - where 2 values are recorded they are the estimates for the first and second populations; KA - absorption rate constant; CUF - apparent clearance; CL(1)1F- apparent clearance (fast); 
CL(2)IF - apparent clearance for slow acetylators; VIF - apparent volume of distribution; TLAG - absorption lag time; a - intra-lndlvidual variability; CCV - constant coefficient of variation; ADD - additive; OBF - minimum 
value of the Objective function. 
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NONMEM RUN SUMMARY - ISONIAZID 
RUN ADVAN ERROR KA CUF VD TLAG TJKA TJCUF TJv O"ccv O"ADD DATA OBF COMMENTS 
% % % % ~g/ml 
27 2 ADD+CCV 92exp(TJ1) CL(l )/F=96exp(TJ2) 93exp(TJ3) - 117 43/38 43 29 0.02 INH5.CSV 290.405 Mixture Modelling. Sensitivity 
CL(2)/F=96*97exP(n4) Analysis : KA fixed to 3.0 
28 2 ADD+CCV 92exp(TJ1) CL(l )/F-96exp(TJ2) 93exp(TJ3) - 1479 43/35 49 30 <1 INH5.CSV 365.167 Mixture Modelling. Sensitivity 
CL(2)/F=96*97exp(TJ4) Analysis: KA fixed to 1.0. OBF i 
TJ KA i 
29 2 ADD+CCV 92exp(TJ1) CL(l )/F-96exp(TJ2) 93exp(TJ3) - 185 43/38 43 29 0.02 INH5.CSV 289.910 Mixture Modelling. Sensitivity 
CL(2)/F=96*97expin4) Analysis: KA fixed to 4.0. OBF .!. 
30 2 ADD+CCV 92exp(TJ1) CL(l )/F=96exp(TJ2) 93exp(TJ3) - 293 42/37 42 30 0.02 INH5.CSV 291.432 Mixture Modelling. Sensitivity 
CL(2)/F=96*97exp(n4) Analysis: KA fixed to 5.0. OBF .!. 
31 2 ADD+CCV 92exp(TJ1) CL(l )/F-96exp(TJ2) 93exp(TJ3) - 423 41/37 41 30 0.02 INH5.CSV 293.259 Mixture Modelling. Sensitivity 
CL(2)/F=96*97expin4) Analysis: KA fixed to 6 .0. OBF .!.. 
32 2 ADD+CCV 92exp(TJ1) CL(l )/F-96exp(TJ2) 93exp(TJ3) - 146 43/38 43 29 0.02 INH5.CSV 289.640 Mixture Modelling. Sensitivity 
CL(2)/F=96*97exp(TJ4) Analysis : KA fixed to 3.5. Lowest 
value . This value used as the fixed 
value for KA in all subsequent 
runs. 
33 2 ADD+CCV 92exp(TJ1) CL( 1 )/F=(96+98*(AGE-33) )exp(TJ2) 93exp(TJ3) - 145 43/38 43 29 0.02 INH5.CSV 289.232 Mixture Modelling. Age on CUF. 
CL(2)/F=(96+98*(AGE-33» Not significant. 
*97exp(n4) 
34 2 ADD+CCV 92exp(TJ1) CL(l )/F-96exp(TJ2) (93+98*(AGE-33» - 145 43/38 43 29 0.02 INH5.CSV 288.714 Age on V. Not significant. 
CL(2)/F=96*97expin4 ) exp(T)3) 
35 2 ADD+CCV 92exp(TJ1) CL(l )/F=(96+98*(ALK-84 ))exp(TJ2) 93exp(TJ3) - 146 43/38 43 29 0.02 INH5.CSV 289.529 Liver Function Tests. Alk Phos on 
CL(2)/F=(96+98*(ALK-84 )*97 CUF. Not significant. 
exp(T)4) 
36 2 ADD+CCV 92exp(TJ1) CL(l )/F-96exp(TJ2) (93+98*(ALK-84)) - 145 43/38 43 29 0.02 INH5.CSV 289.262 Liver Function Tests . Alk Phos on 
CL(2)/F=96*97exp(T)4) exp(TJ3) V . Not significant. 
37 2 ADD+CCV 92exp(TJ1) CL(l )/F-(96+98*(BIL-l 0))exp(TJ2) 93exp(TJ3) - 148 43/38 43 29 0.02 INH5.CSV 289.122 Liver Function Tests. Total 
CL(2)/F=(96+98*(BIL-10)*97exp(T)4) Bilirubin on CUF. Not significant. 
38 2 ADD+CCV 92exp(TJ1) CL(l )/F=96exp(TJ2) (93+98*(BIL-l0)) - 149 43/37 42 29 0.02 INH5.CSV 284.743 Liver Function Tests. Total 
CL(2)/F=96*97expin4) expin3) Bilirubin on V. Significant 
39 2 ADD+CCV 92exp(TJ1) CL(l )/F=(96+98*(ALBU-25»exp(TJ2) 93exp(TJ3) - 143 43/38 43 29 0.02 INH5.CSV 288.621 Liver Function Tests. Albumin on 
CL(2)/F=(96+98*(ALBU-25)) *97 CUF. Not significant 
expin4) 
40 2 ADD+CCV 92exp(TJ1) CL(l )/F=96exp(TJ2) (93+98*(ALBU- - 140 43/38 43 29 0.02 INH5.CSV 285.967 Liver Function Tests. Albumin on 
CL(2)/F=96*97 exp( n4) 25» eXP(n3) V . Not significant 
'1 - Inter-individual variability - where 2 values are recorded they are the estimates for the first and second populations; KA - absorption rate constant; CUF - apparent clearance; CL(1)1F- apparent clearance (fast); 
CL(2)IF - apparent clearance for slow acetylators; VIF - apparent volume of distribution; TLAG - absorption lag time; CJ - intra-individual variability; CCV - constant coefficient of variation; ADD - additive; OBF - minimum 




NONMEM RUN SUMMARY - ISONIAZID 
-RUN ADVAN ERROR KA CUF VD TLAG T]KA T]CLJF T]v O"ccv O"AOD DATA OBF COMMENTS 
% % % % Illglml 
41 2 ADD+CCV 92exp(T]1) CL(1 )IF=(96+98*(GLOB-52» 93exp(T]3) - 153 41139 43 29 0.02 INH5.CSV 265.483 Liver Function Tests. Globulin on 
exp(T]2) CUF. Significant 
CL(2)IF=(96+98*(GLOB-52» *97 
exp(n4) 
42 2 ADD+CCV 92exp(T]1) CL(1 )IF=96exp(T]2) (93+98*(GLOB- - 148 44140 44 29 0.02 INH5.CSV 284.418 Liver Function Tests . Globulin on 
CL(2)IF=96*97exp(T]4 ) 52» exp(n3) V . Significant. 
43 2 ADD+CCV 92exp(T]1) CL(1 )IF=(96+98*(GGT-37»exp(T]2) 93exp(T]3) - 147 43138 43 29 0.02 INH5.CSV 288.910 Liver Function Tests. GGT on 
CL(2)IF=(96+98*(GGT-37»*97 CUF. Not significant. 
exp(n4) 
44 2 ADD+CCV 92exp(T]1) CL( 1 )IF-96exp( T]2) (93+98*(GGT-37» - 145 43138 43 29 0.02 INH5.CSV 289.338 Liver Function Tests. GGT on V. 
CL(2)IF=96*97exp(n4) exp(n3) Not significant. 
45 2 ADD+CCV 92exp(T]1) CL(1 )IF=(96+98*(AL T-16»exp(T]2) 93exp(T]3) - 145 43138 43 29 0.02 INH5.CSV 287.662 Liver Function Tests . ALT on CUF. 
CL(2)/F=(96+98*(AL T-16»*97 Not significant. 
exp(T]4) 
46 2 ADD+CCV 92exp(T]1) CL(1 )/F=96exp(T]2) (93+98*(AL T -16» - 145 43138 43 29 0.02 INH5.CSV 289.592 Liver Function Tests. ALTon V. 
CL(2)IF=96*97exp(n4 ) exp(n3) Not significant. 
47 2 ADD+CCV 92exp(T]1) CL(1 )IF=(96+98*(AST -31 »exp(T]2) 93exp(T]3) - 145 43/38 43 29 0.02 INH5.CSV 289.596 Liver Function Tests. AST on 
CL(2)/F=(96+98*(AST-31 ))*97 CUF. Not significant. 
exp(T]4) 
48 2 ADD+CCV 92exp(T]1 ) CL(1 )/F=96exp(T]2) (93+98*(AST-31» - 146 43/38 43 29 0.02 INH5.CSV 288.350 Liver Function Tests . AST on V. 
CL(2)IF=96*97exp(n4) exp(n3) Not significant. 




50 2 ADD+CCV 92exp(T]1) CL(1 )IF=96*(exp(Tj2) (93+98*(VIRU- - 146 43/38 43 29 0.02 INH5.CSV 289.616 Viral load on V. Not significant. 
CL(2)/F=96*97exp(T]4) 65183.49»exp(Tj3) 
51 2 ADD+CCV 92exp(T]1) CL(1 )/F=(96+98*(VIR-5» exp(T]2) 93exp(T]3) - 147 43/38 43 29 0.02 INH5.CSV 287.667 Log Viral Load on CUF. Not 
CL(2)/F=(96+98*(VIR-5» significant. 
*97exp(Tj4) 
52 2 ADD+CCV 92exp(T]1) CL(1 )/F=96*(exp(T]2) (93+98*(VIR- - 148 43/38 43 29 0.02 INH5.CSV 281 .546 Log Viral load on V. Significant. 
CL(2)IF=96*97exp(T]4 ) 5»exp(Tj3) 
53 2 ADD+CCV 92exp(T]1) CL(1 )/F=(96*(1-ABS) 93exp(T]3) - 145 45133 42 30 0.02 INH5.CSV 273.929 Drug interactions. Drugs affecting 
+98*ABS)*exp(T]2) absorption on CUF. Significant but 
CL(2)IF=(96*(1- illogical grouping of drugs 
ABS)+98*ABS)*97exp(n4) together. See next run . 
- - '---
n - inter-indlvldual variability - where 2 values are recorded they are the estimates for the first and second populations; KA - absorption rate constant; CUF - apparent clearance; CL(1)/F- apparent clearance (fast); 
CL(2)IF - apparent clearance for slow acetylators; VIF - apparent volume of distribution; nAG - absorption lag time; a - Intra-individual variability ; CCV - constant coefficient of variation; ADD - additive; OBF - minimum 
value of the Objective function. 
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NONMEM RUN SUMMARY - ISONIAZID 
RUN ADVAN ERROR KA CUF VD TLAG T]KA T]cUF T]v CTccv CTADD DATA OBF COMMENTS 
% % % % j.lg/ml 
54 2 ADD+CCV 92exp(T]1) Cl( 1 )/F=96*exp( T]2) 93exp(T]3) - 145 43/38 43 29 0.02 INH5.CSV 289.639 Drug interactions. Drugs affecting 
Cl(2)/F=96*97exp(T]4) absorption. Teased out the effect 
of antacids only on F1 . Not 
siQnificant. 
55 2 ADD+CCV 92exp(T]1) Cl(1 )/F-96exp(T]2) (93*(1-ABS) - 146 43/38 43 29 0.02 INH5.CSV 289.322 Drug interactions. Drugs affecting 
Cl(2)1F=96*97 exp(T]4) +98*ABS) exp(n3) absorption on V. Not significant. 
56 2 ADD+CCV 92exp(T]1) Cl(1 )/F=(96*(1-NSID) 93exp(T]3) - 145 43/37 43 29 0.02 INH5.CSV 287.404 Drug interactions. NSAID's on 
+98*NSID)exp(T]2) CUF. Not significant. 
Cl(2)/F=(96*(1-NSID) 
+98*NSIDl*97exp(T]4) 
57 2 ADD+CCV 92exp(T]1 ) Cl(1 )/F=96exp(T]2) (93*(1-NSID) - 145 43/38 43 29 0.02 INH5.CSV 286.970 Drug interactions. NSAID's on V. 
Cl(2)/F=96*97 exp( T]4) +98*NSID) Not significant. 
exp(n3) 
58 2 ADD+CCV 92exp(T]1 ) Cl(1 )/F=(96*(1-FEFL) 93exp(T]3) - 145 43/38 43 29 0.02 INH5.CSV 288.818 Drug interactions. Iron 
+98*FEFl)exp(T]2) Preps/Anaemia on CUF. Not 
Cl(2)/F=(96*(1-FEFL) + significant 
98*FEFl)*97)exP(n4) 
59 2 ADD+CCV 92exp(T]1) Cl(1 )/F=96exp(T]2) (93*(1-FEFL)+ - 146 43/38 43 29 0.02 INH5.CSV 287.807 Drug interactions. Iron 
Cl(2)/F=96*97 exp(T]4) 98*FEFl)exp(T]3) Preps/Anaemia on V. Not 
significant. 
60 2 ADD+CCV 92exp(T]1) CL(1 )/F-(96*(1-H1 B) 93exp(T]3) - 148 43/39 43 29 0.02 INH5.CSV 281 .260 Drug interactions. Antih istamines 
+98*H18)exp(T]2) . on CUF. Not significant. 
Cl(2)/F=96*(1 -H1 B) 
+98*H1 B)*97exp(n4) 
61 2 ADD+CCV 92exp(T]1) Cl(1 )/F=(96exp(T]2) (93*(1-H1B) - 144 43/38 43 29 0.02 INH5.CSV 289.132 Drug interactions. Antihistamines 
Cl(2)/F=96*97exP(n4) +98*H1 B)exp(T]3) on V. Not significant. 
62 2 ADD+CCV 92exp(T]1) Cl(1 )/F-(96*(1-PEN) 93exp(T]3) - 145 43/38 43 29 0.02 INH5.CSV 283.709 Drug interactions. Pen icillin on 
+98*PEN)exp(T]2) CUF Significant. 
Cl(2)/F=(96*(1-PEN) 
+98*PEN)*97exp(n4) 
63 2 ADD+CCV 92exp(T]1 ) Cl(1 )/F-96exp(T]2) 93*(1- - 138 43/38 43 29 0.02 INH5.CSV 282.263 Drug interactions. Penicillin on V. 
Cl(2)/F=96*97exp(T]4) PEN)+98*PEN)ex Significant. 
Ip(n3) 
64 2 ADD+CCV 92exp(T]1) Cl(1 )/F=(96*(1-BS)+88*BS)exp(T]2) 93exp(T]3) - 139 43/38 43 29 0.02 INH5.CSV 282.644 Drug interactions. Hypoglycaemic 
Cl(2)/F=(96*(1-BS) agents/diabetes on CUF. 
+98*BS)*97exp(n4) Significant but? reason. 
'1 - Inter-individual variability - where 2 values are recorded they are the estimates for the first and second populations; KA - absorption rate constant; CUF - apparent clearance; CL(1)/F- apparent clearance (fast) ; 
CL(2)IF - apparent clearance for slow acetylators; VIF - apparent volume of distribution; TLAG - absorption lag time; a - intra-individual variability; CCV - constant coefficient of variation; ADD - additive; OBF - minimum 
value of the Objective function. 
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Appendix J 
NONMEM RUN SUMMARY - ISONIAZID 
RUN ADVAN ERROR KA CUF VD TLAG Th<A T]CLJF T]v (Jccv (JADD DATA OBF COMMENTS 
% % % % j.l9/ml 
S5 2 ADD+CCV 92exp(T]1) Cl(1 )/F=9Sexp(T]2) (93*(1-BS) - 145 43/38 43 29 0.02 INH5.CSV 289.284 Drug interactions. Hypoglycaemic 
Cl(2)/F=9S*97exp(T]4 ) +98*8S) exp(T]3) agents/diabetes on V. Not 
significant. 
66 2 ADD+CCV 92exp(T]1) Cl(1 )/F=(9S*(1-DIUR) 93exp(T]3) - 149 42/38 43 29 0.02 INH5.CSV 284.S03 Drug interactions. 
+98*DIUR)exp(T]2) Diuretics/hypertension on CUF. 
Cl(2)/F=(9S*(1-DIUR) Significant but? reason . 
+98*DIUR)*97 exp(114) 
S7 2 ADD+CCV 92exp(T]1) Cl( 1 )/F=96exp( T]2) (93*(1-DIUR)+ - 145 43/38 43 29 0.02 INH5.CSV 28S.S3S Drug interactions. 
Cl(2)/F=9S*97exp(1]4) 98*DIUR)exp(T]3) Diuretics/hypertension on V. Not 
significant. 
S8 2 ADD+CCV 92exp(T]1) Cl( 1 )/F=(9S*( 1-INAT) 93exp(T]3) 
_. 148 43/38 43 29 0.02 INH5.CSV 289.037 Drug interactions. INAT on CUF. 
+98*INAT)exp(T]2) Not significant. 
Cl(2)/F=(9S*(1 -INAT)+ 
98*INAT)*97exp(1]4) 
S9 2 ADD+CCV 92exp(T]1) Cl(1 )/F=9Sexp(T]2) (93*(1-INAT)+ - 145 43/38 43 ?9 0.02 INH5.CSV 289.S07 Drug interactions. INA T on V. Not 
Cl(2)/F=9S*97exp(114) 98*INAT)exp(1]3) significant. 
70 2 ADD+CCV 92exp(T]1) Cl(1 )/F=(9S*(1-QUIN) 93exp(T]3) - 145 43/39 43 29 0.02 INH5.CSV 287.92S Drug interactions. Quinolones on 
+98*QUIN)exp(T]2) CUF. Not significant. 
Cl(2)/F=(9S*(1 -QUIN)+ 
98*QUIN)*97 exp(114) 
71 2 ADD+CCV 92exp(T]1) Cl(1 )/F=9Sexp(T]2) (93*(1-QUIN) - 145 43/38 43 29 0.02 INH5.CSV 289.334 Drug interactions. Quinolones on 
Cl(2)/F=9S*97exp(1]4) +98*QUIN) V. Not significant. 
exp(113) 
72 2 ADD+CCV 92exp(T]1) Cl(1 )/F-(9S*(1-INHI) 93exp(T]3) - 143 43/37 43 29 0.02 INH5.CSV 279.555 Drug interactions. Enzyme 
+98*INHI)exp(T]2) inhibitors on CUF. Significant. 
Cl(2)/F=(9S*(1-INHI) 
+98*INHI)*97exp(T]4) 
73 2 ADD+CCV 92exp(T]1) Cl( 1 )/F-9Sexp( T]2) (93*(1-INHI) - 14S 43/38 43 29 0.02 INH5.CSV 289.S40 Drug interactions. Enzyme 
Cl(2)/F=9S*97exp(114) +98*INHI)exp(113) inhibitors on V . Not significant. 
74 2 ADD+CCV 92exp(T]1) Cl(1 )/F=(9S*(1-INHIQ) 93exp(T]3) - 14S 43/38 43 29 0.02 INH5.CSV 288.739 Drug interactions. Enzyme 
+98*INHIQ)exp(T]2) inhibitors + quinolones on CUF. 
Cl(2)/F=(9S(9S*(1-INHIQ) Not significant. 
+98*INHIQ)*97exp(114) 
75 2 ADD+CCV 92exp(T]1) Cl( 1 )/F=9Sexp( T]2) (93(9S*(1-INHIQ) - 145 43/38 43 29 0.02 INH5.CSV 289.S39 Drug interactions. Enzyme 
Cl(2)/F=9S*97exp(1]4 ) +98*INHIQ) inhibitors + quinolones on V. Not 
exp(T]3) significant. 
11 - Inter-indivldual variability - where 2 values are recorded they are the estimates for the first and second populations; KA - absorption rate constant; CUF - apparent clearance; CL(1)JF- apparent clearance (fast); 
CL(2)JF - apparent clearance for slow acetylators; V/F - apparent volume of distribution; nAG - absorption lag time; a - intra-individual variability; CCV - constant coefficient of variation; ADD - additive; OBF - minimum 





NONMEM RUN SUMMARY - ISONIAZID 
RUN ADVAN ERROR KA CUF VD TLAG T]KA T]CUF T]v Uccv UAOO DATA OBF COMMENTS 
% % % % Illglml 
76 2 ADD+CCV 92exp(T]1) CL(1 )IF-(96*(1-EMB) 93exp(T)3) - 146 43138 43 29 0.02 INH5.CSV 289.515 Drug interactions. Ethambutol on 
+98*EMB)exp(T]2) CUF. Not significant. 
CL(2)IF=(96(1-EMB)+ 
98*EMB)*97exp(n4) 
77 2 ADD+CCV 92exp(T]1) CL(1 )IF-96exp(T)2) (93(1-EMB) - 146 43138 43 29 0.02 INH5.CSV 289.478 Drug interactions. Ethambutol on 
CL(2)IF=96*97exp(114 ) +98*EMB)exp(n3) V . Not significant. 
78 2 ADD+CCV 92exp(T)1) CL(1 )IF=(96*(1-CAND) 93exp(T)3) - 146 43138 43 29 0.02 INH5.CSV 289.351 Disease interactions. Candidiasis 
+98*CAND)exp(T]2) on CUF. Not significant. 
CL(2)IF=(96*(1-CAND)+ 
98*CAND)*97exp(114) 
79 2 ADD+CCV 92exp(T)1) CL(1 )IF-96exp(112) 93*(1-CAND)+ - 145 43138 43 29 0.02 INH5.CSV 289.551 Disease interactions. Candidiasis 
CL(2)IF=96*97exP(n4 ) 98*CAND)exp(113) on V . Not significant. 
80 2 ADD+CCV 92exp(T)1) CL(1 )IF-(96+98*(NMDR-7» exp(T]2) 93exp(T)3) - 155 43/38 43 29 0.02 INH5.CSV 283.657 Effect of No. of drugs resistant to 
CL(2)/F=(96+98*(NMDR-7) ) on CUF. Significant. 
*97exp(114) 
81 2 ADD+CCV 92exp(T)1) CL( 1 )/F -96exp( T)2) (93+ 98*(NMDR- - 147 43/38 43 29 0.02 INH5.CSV 288.953 Effect of no. of drugs resistant to 
CL(2)/F=96*97 exp( n4) 7» exp(113) on V. Not significant. 
82 2 ADD+CCV 92exp(T]1) CL(1 )/F-(96+98*(EXT-5» exp(T)2) 93exp(T)3) - 145 43/37 43 29 0.02 INH5.CSV 282.737 Extent of X-ray severity on CUF. 
CL(2)/F=(96+98*(EXT-5»*97 Significant but? reason . 
exp(114) 
83 2 ADD+CCV 92exp(T)1) CL(1 )/F-96exp(T)2) (93+98*(EXT -5» - 145 43/37 42 29 0.02 INH5.CSV 282.778 Extent of X-ray severity on V. 
CL(2)/F=96*97exP(n4) eXP(n3) Significant but? reason. 
84 2 ADD+CCV 92exp(T]1) CL(1 )/F-(96+98*(CAV-4»exp(T)2) 93exp(T)3) - 146 43/38 43 29 0.02 INH5.CSV 288.020 Severity of cavitation on CUF. Not 
CL(2)/F=(96+98*(CAV-4» significant. 
*97exp(T)4) 
85 2 ADD+CCV 92exp(T)1) CL( 1 )/F -96exp( T]2) (93+98*(CAV- - 145 43/38 43 29 0.02 INH5.CSV 285.697 Severity of cavitation on V. 
CL(2)/F=96*97exP(n4) 4))exP(n3) Marginally significant. 
86 2 ADD+CCV 92exp(11 1) CL(1 )/F-(96+98*(WT-54»exp(112) 93exp(T)3) - 139 43/37 42 29 0.02 INH5.CSV 286.765 WT on CUF. Not Significant. 
CL(2)/F=(96+98*(WT-54»*97 
exp(114) 





88 2 ADD+CCV 92exp(T)1) CL(1 )/F-96exp(T)2) (93*(1-SEX) - 153 41/35 43 27 0.05 INH5.CSV 288.580 Sex on V . Not significant 
CL(2)/F=96*97exP(n4 ) +98*SEX)exP(n3) 
1] - inter-individual variability - where 2 values are recorded they are the estimates for the first and second populations; KA - absorption rate constant; CUF - apparent clearance; CL(1)1F- apparent clearance (fast); 
CL(2)IF - apparent clearance for slow acetylators; VIF - apparent volume of distribution; TLAG - absorption lag time; (J - intra-individual variability; CCV - constant coefficient of variation; ADD - additive; OBF - minimum 
value of the Objective function. 
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Appendix J 
NONMEM RUN SUMMARY - ISONIAZID 
RUN ADVAN ERROR KA CUF VD TLAG TjKA TjCUF Tjv Uccv UAOD DATA OBF COMMENTS 
0/0 0/0 0/0 0/0 Illglml 
89 2 ADD+CCV 92exp(Tj1) CL( 1 )IF=96exp( Tj2) 93*(1 -MDR) - 147 43138 43 29 0.02 INH5.CSV 289.348 MDR on V. Not significant 
Cl(2)IF-96*97exp(n4) +98*MDR)exp(Tj3) 








92 2 ADD+CCV 92exp(Tj1) CL(1 )IF-96exp(Tj2) (93*(1-HIV)+ - 147 43138 43 29 0.02 INH5.CSV 287.798 HIV on V. Not significant 
CL(2)IF=96*97exp(Tj4) 98*HIV)exp(n3) 
93 2 ADD+CCV 92exp(Tj1) CL(1 )/F-96exp(Tj2) 93exp(Tj3) - 154 42133 41 28 0.02 INH9.CSV 204.112 Data File has the 7 outlier values 
CL(2)/F=96*97exp(Tj4) removed i.e. those values that 
were hiClh prior to dosing. 
94 2 ADD+CCV 92exp(Tj1) 91exp(Tj1) 92exp(Tj2) 93exp(Tj3) 77 46 36 18 0.5 INH9.CSV 877.033 REPEATED run with no mixture 
modellinCl with new data file . 




96 2 ADD+CCV 92exp(Tj1) CL(1 )/F-(96-98*(GLOB-52) 93exp(Tj3) - 148 41/35 41 28 0.02 INH9.CSV 189.342 Globulin & Ethionamide on CUF. 
+99*ETH) exp(T]2) OBF.J- 3.2 
CL(2)IF=(96-98*(GLOB-52) 
+99*ETH)*97exp(n4) 
97 2 ADD+CCV 92exp(Tj1) CL(1 )/F=(96-98*(GLOB-52) 9;3exp(T]3) - 157 41/34 41 28 0.02 INH9.CSV 188.108 Globulin and antihistamines on 
+99*H1 RB) exp(Tj2) CUF. OBF.J- 4.43 
CL(2)/F=(96-98*(GLOB-52) 
+99*H1 RB)*97exp(n4) 
98 2 ADD+CCV 92exp(Tj1) CL(1 )/F-(96-98*(GLOB-52) 93exp(Tj3) - 160 40/35 41 27 0.02 INH9.CSV 188.328 Globulin , antihistamines and log 
+99*H1 RB-91 0*(VIR-5» exp(Tj2) viral load on CUF. OBF - no 
CL(2)/F=(96-98*(GLOB-52) change . 
+99*H1 RB-91 0*(VIR-5»*97exp(n4) 
99 2 ADD+CCV 92exp(Tj1) CL( 1 )/F-(96-98*(GLOB-52) 93*(1-PEN) - 153 40/34 41 28 0.02 INH9.CSV 182.459 Globulin and antihistamines on 
+99*H1 RB) exp(T]2) +910*PEN) CUF. Penicillin on V OBF .J- 5.7 
CL(2)/F=(96-98*(GLOB-52) exp(n3) 
+99*H1 RB)*97exp(n4) 
T] - inter-lndividual variability - where 2 values are recorded they are the estimates for the first and second populations; KA - absorption rate constant; CUF - apparent clearance; CL(1VF- apparent clearance (fast); 
CL(2VF - apparent clearance for slow acetylators; VIF - apparent volume of distribution; TLAG - absorption lag time; cr - intra-individual variability; CCV - constant coefficient of variation; ADD - additive; OBF - minimum 





NONMEM RUN SUMMARY - ISONIAZID 
RUN ADVAN ERROR KA CUF VD TLAG 'lKA " 'lcUF 'lv O"ccv O"ADD DATA OBF COMMENTS 
% 0/0 % % I~g/ml 
100 2 ADD+CCV 92exp('l1) CL(1 )/F-(96-8S*(GLOB-52) 93*(1-PEN) - 15S 40/32 41 2S 0.02 INH9.CSV 1S1.339 Globulin, antihlstamines and 
+99*H1RB +911*BS) exp('l2) +910*PEN) hypoglycaemics 1 diabetes on 
CL(2)/F=(96-8S*(GLOB-52) exp('l3) CUF. Penicillin on V. OBF ,j, 1 
+99*H1 RB+911*BS)*S7exp('l4) 
101 2 ADD+CCV 92exp('l1) CL(1 )/F=(96-8S*(GLOB-52) 93*(1-PEN) - 156 40/32 41 2S 0.02 INH9.CSV 175.729 Globulin, antihistamines and 
+99*H1RB+911*EXT-5» exp('l2) +910*PEN) extent of X-ray involvement on 
CL(2)/F=(96-8S*(GLOB-52) exp('l3) CUF. Penicillin on V. OBF,J.. 5.7 
+99*H1 RB+911*EXT-5»*97exp('l4) 
102 2 ADD+CCV 92exp('l1) CL(1 )/F-(OO-8S*(GLOB-52) (93+910*PEN+912 - 157 40/32 40 2S 0.02 INH9.CSV 174.S37 Globulin, antihistamines and 
+99*H1 RB+911*EXT-5» exp('l2) *(EXT-5»exp('l3) extent of X-ray involvement on 
CL(2)/F=(96-8S*(GLOB-52) CUF. Penicillin and extent of x-ray 
+99*H1 RB+911*EXT-5»*97exp('l4) involvement on V. OBF ,J.. 1 
103 2 ADD+CCV 9Zexp('l1) CL(1 )/F-(96-8S*(GLOB-5Z) 93*(1-PEN) - 156 40/32 41 2S 0.02 INH9.CSV 175.514 Globulin, antihistamines, extent of 
+99*H1 RB+911*EXT-5) +910*PEN) X-ray involvement and "No. of 
+912*(NMDR-7» exp('l2) exp('l3) drugs resistant to" on CUF. 
CL(2)/F=(96-8S*(GLOB-5Z) Penicillin on V. OBF no change. 
+99*H1 RB+911*EXT-5) 
104 Z ADD+CCV 92exp('l1) 
+912*(NMDR-7»*97exp(T}4) 
CL(1 )/F-(96-8S*(GLOB-5Z) 93*(1-PEN) - 157 40/32 40 2S 0.02 INH9.CSV 175.716 Globulin, antihistamines, extent of 
+99*H 1 RB+9 11*EXT -5»+9 1Z*PEN +910*PEN) X-ray involvement and penicillin on 




105 2 ADD+CCV 92exp('l1) CL(1 )/F-(96-8S*(GLOB-5Z) (93*+910*PEN+91 - 165 39/33 39 26 0.03 INH9.CSV 176.436 Globulin, antihistamines and 
+99*H1 RB+911*EXT-5» exp('l2) 2*(WT-54» extent of X-ray involvement on 
CL(2)/F=(96-8S*(GLOB-52) exp('l3) CUF. Penicillin and weight on V. 
+99*H1RB+911*EXT-5»*97exp(n4) OBFt 
106 2 ADD+CCV 92exp('l1) CL(1 )/F=(96-8S*(GLOB-52) (93*+910*PEN+91 - 156 40/32 40 28 0.02 INH9.CSV 175.414 Globulin, antihistamines and 
+99*H1 RB+911*EXT-5» exp('l2) 2*(GLOB- extent of X-ray involvement on 
CL(2)/F=(96-9S*(GLOB-52) 52»exp('l3) CUF. Penicillin and globulin on V. 
+99*H1 RB+911*EXT-5»*97exp(n4) OBF no change 
TJ - inter-individual variability - where 2 values are recorded they are the estimates for the first and second populations; KA - absorption rate constant; CUF - apparent clearance; CL(1)/F- apparent clearance (fast); 
CL(2)IF - apparent clearance for slow acetylators; VIF - apparent volume of distribution; TLAG - absorption lag time; a - intra-individual variability; CCV - constant coefficient of variation; ADD - additive; OBF - minimum 
value of the Objective funCtion. 
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Appendix J 
NONMEM RUN SUMMARY - ISONIAZID 
RUN ADVAN ERROR KA CUF VD TLAG llKA llCUF llv O"ccv O"ADD DATA OBF COMMENTS 
% % % % Illg/ml 
107 2 ADD+CCV 92exp(T]1) CL(1 )/F=(96-eS*(GLOB-S2) (93*(1-PEN) - 1S9 40/32 40 2S 0.02 INH9.CSV 16S.S16 Globulin , antihistamines, extent 
+99*H1 RB+911*EXT-S)+912*HPT) +910*PEN) of X-ray involvement and anti-
exp(1l2) exp(1l3) hypertensives on CUF. Penicillin 
CL(2)/F=(96-eS*(GLOB-S2) on V. OBF -l. 7.2 
+99*H1 RB+911*EXT-S) 
+912*HPT)*97exP(n4) 
10S 2 ADD+CCV 92exp(T]1 ) CL(1 )/F-(96-eS*(GLOB-S2) (93+910*PEN- - 164 39/32 40 2S 0.02 INH9.CSV 163.44S Globulin , antihistamines, 
+99*H 1 RB+911*EXT -S)+912*Hpn 913*(BILI-10» antihypertensivess and extent of 
exp(1l2) exp(1l3) X-ray involvement on CUF. 
CL(2)/F=(96-eS*(GLOB-S2) Penicillin and bilirubin on V. OBF -l. 
+99*H1 RB+911*EXT-S) S. Decision after RUNs 109 and 
+912*HPT)*97exp(T]4) 110 is that this is the FULL 
MODEL. 
109 2 ADD+CCV 92exp(T]1) CL(1 )/F-(96-9S*(GLOB-S2) (93+910*PEN- - 164 40/22 42 27 0.02 INH9.CSV 173.S62 Globulin, antihistamines, extent of 
+99*H1 RB+911*EXT-S) 913*(BILI-10» X-ray involvement, anti-
+912*HPT +914*SEX) exp(1l2) exp(T]3) hypertensives and sex on CUF. 
CL(2)/F=(96-eS*(GLOB-S2) + Penicillin, bilirubin on V. OBF t 
99*H 1 RB+911*EXT -S) 
+912*HPT+914*SEX)*97exP(n4) 
110 2 ADD+CCV 92exp(T]1) CL(1 )/F-(96-eS*(GLOB-S2) (93+910*PEN- - 162 40/19 43 27 0.02 INH9.CSV 174.421 Globulin, antihistamines, anti-
+99*H1 RB+911*EXT-S) 913*(BILI-10» hypertensives and extent of X-ray 
+912*HPT+914*CAV-4» exp(T]2) exp(T]3) involvement on CUF. Penicillin , 
CL(2)/F=(96-9S*(GLOB-S2) bilirubin , and lung cavitation on V. 
+99*H1 RB+911*EXT-S) OBFt 
+912*HPT +914*(CAV-4» 
*97exp(T]4) 
111 2 ADD+CCV 92exp(T]1) CL(1 )/F=(96-9S*(GLOB-S2) (93+910*PEN- - 162 40/32 40 2S 0.02 INH9.CSV 167.613 Establishing Rank Order for 
+99*H 1 RB+911*EXT -S)+912*HPT) 913*(BILI-10» Backward Deletion: Globulin 
exp(T]2) exp(T]3) (FIXED to 0), antihistamines, 
CL(2)/F=(96-9S*(GLOB-S2) antihypertensives and extent of I 
+99*H1 RB+911*EXT-S) X-ray involvement on CUF. 
+912*HPT)*97exp(T]4) Penicillin and bilirubin on V. OBF t 
4.2 
- ------
11 - Inter-individual variability - where 2 values are recorded they are the estimates for the first and second populations; KA - absorption rate constant; CUF - apparent clearance; CL(1)1F- apparent clearance (fast); 
CL(2)IF - apparent clearance for slow acetylators; VIF - apparent volume of distribution; TLAG - absorption lag time; a - intra-individual variability; CCV - constant coefficient of variation; ADD - additive; OBF - minimum 
value of the Objective funCtion. 
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Appendix J 
NONMEM RUN SUMMARY - ISONIAZID 
RUN ADVAN ERROR KA CUF VD TLAG llKA llcUF llv Uccv UADD DATA OBF COMMENTS 
% % % % l-lg/ml 
112 2 ADD+CCV 92exp(11 1) CL(1 )/F-(96-e8*(GLOB-52) (93+910*PEN- - 160 39/32 40 28 0.02 INH9.CSV 164.945 Establishing Rank Order for 
+99*H1 RB+911*EXT-5)+912*HPT) 913*(BILI-10» Backward Deletion: Globulin, 
exp(112) exp(113) antihistamines (FIXED to 0), 
CL(2)/F=(96-e8*(GLOB-52) antihypertensives and extent of 
+99*H1 RB+911*EXT-5) X-ray involvement on CUF. 
+912*HPT)*97exp(I]4) Penicillin and bilirubin on V. OBF i 
1.5 
113 2 ADD+CCV 92exp(11 1 ) CL(1 )/F-(96-e8*(GLOB-52) (93+910*PEN- - 165 39/32 40 28 0.02 INH9.CSV 167.334 Establishing Rank Order for 
+99*H1 RB+911 *EXT-5)+912*HPT) 913*(BILI~1 0» Backward Deletion: Globulin, 
exp(112) exp(113) antihistamines, antihypertensives 
CL(2)/F=(96-e8*(GLOB-52) and extent of X-ray involvement 
+99*H1 RB+911*EXT-5) (FIXED to 0) on CUF. Penicillin 
+912*HPT)*97exp(n4 ) and bilirubin on V. OBF t 3.88 
114 2 ADD+CCV 92exp(11 1) CL(1 )/F-(96-e8*(GLOB-52) (93+910*PEN- - 163 40/32 40 27 0.02 INH9.CSV 172.042 Establishing Rank Order for 
+99*H 1 RB+9 11*EXT -5)+9 12*HPT) 913*(BILI-10» Backward Deletion: Globulin , 
exp(112) exp(113) antihistamines, antihypertensives 
CL(2)/F=(96-98*(GLOB-52) (FIXED to 0) and extent of X-ray 
+99*H 1 RB+9 11 *EXT -5) involvement on CUF. Penicillin 
+912*HPT)*97exp(I]4) and bilirubin on V. OBF t 8.6 
115 2 ADD+CCV 92exp(11 1) CL(1 )/F-(96-e8*(GLOB-52) (93+910*PEN- - 168 39/32 40 27 0.02 INH9.CSV 172.203 Establishing Rank Order for 
+99*H 1 RB+9 11*EXT -5)+9 12*HPT) 913*(BILI-10» Backward Deletion: Globulin, 
exp(112) exp(113) 
. antihistamines, antihypertensives 
CL(2)/F=(96-e8*(GLOB-52) and extent of X-ray involvement 
+99*H1 RB+911*EXT-5) on CUF. Penicillin (FIXED to 0) 
+912*HPT)*97exp(n4) and bilirubin on V. OBF t 8.8 
116 2 ADD+CCV 92exp(11 1) CL(1 )/F-(96-e8*(GLOB-52) (93+910*PEN- - 159 40/32 40 28 0.02 INH9.CSV 168.516 Establishing Rank Order for 
+99*H1 RB+911*EXT-5)+912*HPT) 913*(BILI-10» Backward Deletion: Globulin , 
exp(112) exp(113) antihistamines, antihypertensives 
CL(2)/F=(96-e8*(GLOB-52) and extent of X-ray involvement 
+99*H 1 RB+9 11*EXT -5) on CUF. Penicillin and bilirubin 
+9 12*HPT)*97 exp( 1]4) (FIXED to 0) on V. OBF i 5 
117 2 ADD+CCV 92exp(11 1) CL(1 )/F-(96-e8*(GLOB-52) (93+910*PEN- - 160 39/32 40 28 0.02 INH9.CSV 164.945 Backward Deletion: Antihistamines 
+99*H1 RB+911*EXT-5)+912*HPT) 913*(BILI-10» on CUF fixed to o. OBF t 1.5. 
exp(I]2) exp(113) Hence exclude. 
CL(2)/F=(96-e8*(GLOB-52) 
+99*H 1 RB+9 11*EXT -5) 
+912*HPT)*97exp(n4) 
n - inter-individual variability - where 2 values are recorded they are the estimates for the first and second populations; KA - absorption rate constant; CUF - apparent clearance; CL(1)1F- apparent clearance (fast); 
Cl(2)IF - apparent clearance for slow acetylators; V/F - apparent volume of distribution; TLAG - absorption lag time; CJ - intra-individual variability; CCV - constant coefficient of variation; ADD - additive; OBF - minimum 





NONMEM RUN SUMMARY - ISONIAZID 
RUN ADVAN ERROR KA CUF VD TLAG llKA llcUF llv <rccv <rADD DATA OBF COMMENTS 
% % % % Illg/ml 
118 2 ADD+CCV 92exp(11 1) CL(1 )/F-(96-68*(GLOB-52) (93+910*PEN- - 162 39/32 40 28 0.02 INH9.CSV 168.238 Backward Deletion: Antihistamines 
+99*H1 RB+911 *EXT -5)+912*HPT) 913*(BILI-10)) and extent of X-ray involvement on 




119 2 ADD+CCV 92exp(11 1) CL(1 )/F-(96-68*(GLOB-52) (93+910*PEN- - 163 39/29 41 26 0.03 INH9.CSV 179.136 Backward Deletion: 
+99*H1 RB+911 *EXT-5)+912*HPT) 913*(BILI-10)) Antihistamines, extent of X-ray 
exp(112) exp(113) involvement and Globulin on CUF 
CL(2)/F=(96-68*(GLOB-52) fixed to O. OBF t 10.9. Marginally 
+99*H 1 RB+9 11 *EXT -5) significant, hence include globulin. 
+912*HPT)*97expln4) 
120 2 ADD+CCV 92exp(11 1) CL(1 )/F-(96-68*(GLOB-52) (93+910*PEN- - 150 40/35 41 28 0.02 INH9.CSV 179.071 Backward Deletion: 
+99*H1 RB+911*EXT-5)+912*HPT) 913*(BILI-10)) Antihistamines, extent of X-ray 
exp(112) exp(113) involvement on CUF and bilirubin 
CL(2)/F=(96-98*(GLOB-52) on V/F fixed to O. OBF t 0.1. 
+99*H1 RB+911*EXT-5) Hence exclude. 
+912*HPT)*97exp(n4) 
121 2 ADD+CCV 92exp(11 1) Cl(1 )/F-(96-68*(GLOB-52) (93+910*PEN- - 146 41/35 41 28 0.02 INH9.CSV 186.251 Backward Deletion: 
+99*H1 RB+911*EXT-5)+912*HPT) 913*(BILI-10)) Antihistamines, extent of X-ray 
exp(112) exp(113) involvement and antihypertensives 
Cl(2)/F=(96-98*(GLOB-52) on CUF and bilirubin on V/F fixed 
+99*H1 RB+911*EXT-5) to O. OBF t 7.2. Hence exclude. 
+912*HPT)*97expln4) 
122 2 ADD+CCV 92exp(11 1) Cl(1 )/F-(96-68*(GlOB-52) (93+910*PEN- - 151 41/35 42 28 0.02 INH9.CSV 192.538 Backward Deletion: 
+99*H 1 RB+9 11 *EXT -5)+912*HPT) . 913*(BILI-10)) Antihistamines, extent of X-ray 
exp(112) exp(113) involvement and antihypertensives 
Cl(2)/F=(96-fl8*(GLOB-52) on CUF and bilirubin and 
+99*H1 RB+911*EXT-5) penicillins on V/F fixed to O. OBF t 
+912*HPT)*97exp(114) 6.3. Hence exclude. 
FINAL MODEL 
11 - inter-individual variability - where 2 values are recorded they are the estimates for the first and second populations; KA - absorption rate constant; CUF - apparent clearance; CL(1)1F- apparent clearance (fast); 
CL(2)1F - apparent clearance for slow acetylators; VIF - apparent volume of distribution; TLAG - absorption lag time; cr - intra-individual variability; CCV - constant coefficient of variation; ADD - additive; OBF - minimum 
value of the Objective function. 
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NONMEM CONTROL STREAM - ISONIAZID 
$PROB ISONIAZID KINETICS IN TUBERCULOSIS PATIENTS MIXTURE MODEL 
$INPU 10 DATE=DROP TIME DOSE=AMT DAMT RATE=DROP DV=CONC SS II 
SEX=DROP TBHX=DROP MDR=DROP HIV=DROP WT AGE=DROP PREP ALKP=DROP 
BILI=DROP PROT=DROP ALB=DROP GLOB=DROP GGT=DROP ALT=DROP AST=DROP 
ALP=DROP PLAT=DROP LYMC=DROP LYMP=DROP VIRU=DROP INDU=DROP 
INHI=DROP ABSl=DROP ABS2=DROP MISl=DROP MIS2=DROP NSID=DROP 
FEFL=DROP HIB=DROP PEN=DROP BS=DROP DIUR=DROP INAT=DROP QUIN=DROP 
AG=DROP EMB=DROP PZA=DROP ANAE=DROP HPT=DROP DM=DROP 
EPIL=DROP CAND=DROP NMDR=DROP EXT=DROP CAV=DROP WALL=DROP 
$DATA INH9.CSV IGNORE=# 
$SUBROUTINES ADVAN2 TRANS2 MIX=mix 
$PK 
EST MIXEST 
TVKA THETA(2); KA 
KA TVKA*EXP (ETA (l)) 





IF (COMACT.NE.O) MM=MIXEST 
Q = 1 
IF (MM.EQ.2) Q=O 
CL Q*CLl+(1-Q)*CL2 



















(3 . 5 FIXED) 
(0,36) 
(0,0.5) 





1 : Mixing Fraction 
2 : KA 
3 : V 
4 : CCV 
5 : ADDITIVE 
6 : CL(l) 
7 : CL(2) 
Ka 
CL1 
0.01 0.25 V 
0.001 0.01 0.25 CL2 
$EST NOABORT MAXEVAL=9999 POSTHOC MSF=INH 
$TABLES 10 TIME CL1 CL2 V CL IPRED IWRES ETA1 DAMT EST DOSE WT 
ETA2 ETA3 ETA4 AUC TMAX CMAX ONEHEADER NOPRINT FILE=sdtab93 
$COV 
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Appendix L 
NONMEM MIX SUBROUTINE 
SUBROUTINE MIX (ICALL,NSPOP,P) 
COMMON /ROCMO/ THETA(20) 
DIMENSION P(*) 
DOUBLE PRECISION P,THETA 










COVARIATE MODEL BUILDING -ISONIAZID 
Retained;t in 
Covariate Effect DOBF1 
Forward Retained3 in 
Model Final Model 
........ ~------........ -. .• · ............. __ ....... ··H •. _···.· . ·····•····· ____ ·······H······· •• H·H •• ···_.·.·_.· __ ~~.tl~~p _ ............ __ ••••. ··H.·H._ •. _ .. _. 
Globulin on CUF 11 .6 Yes No 
Enzyme inhibitors on CUF 10.085 Yes No 
Antihistamines on CUF 8.38 No No 
Log Viral Load on CUF 8.094 No No 
Penicillins on V/F 7.377 No No 
Hypoglycaemic agents/Diabetes mellitus on CUF 6.996 No No 
Severity score for extent of lung involvement on CUF 6.903 No No 
Severity score for extent of lung involvement on V/F 6.862 No No 
Drug resistance severity score on CUF 5.983 No No 
Penicillins on CUF 5.931 No No 
Weight on V/F 5.486 Yes No 
Globulin on V/F 5.222 Yes Yes 
HIVon CUF 5.151 No No 
Diuretics/hypertension on CUF 5.037 No No 
Total Bilirubin on V/F 4.897 No No 
Sex on CUF 4.339 No No 
Severity score for extent of lung cavitation on V/F 3.943 No No 
Albumin on V/F 3.673 n/a n/a 
Diuretics/hypertension on V/F 3.004 n/a n/a 
Weight on CUF 2.875 n/a n/a 
Non-steroidal anti-inflammatory drugs on V/F 2.67 n/a n/a 
Non-steroidal anti-inflammatory drugs on CUF 2.236 n/a n/a 
ALT on CLIF 1.978 n/a n/a 
Log Viral Load on V/F 1.973 n/a n/a 
HIVon V/F 1.842 n/a n/a 
Iron Preparations on V/F 1.833 n/a n/a 
Quinolones on CUF 1.714 n/a n/a 
Severity score for extent of lung cavitation on CUF 1.62 n/a n/a 
AST on V/F 1.29 n/a n/a 
Sex on V/F 1.06 n/a n/a 
Albumin on CUF 1.019 n/a n/a 
Age on V/F 0.926 n/a n/a 
Iron Preparations on CUF 0.822 n/a n/a 
GGTon CUF 0.73 n/a n/a 
Drug resistance severity score on V/F 0.687 n/a n/a 
Thiacetazone on CUF 0.603 n/a n/a 
Total Bilirubin on CLIF 0.518 n/a n/a 
Antihistamines on V/F 0.508 n/a n/a 
MDR-TB on CUF 0.468 n/a n/a 
Age on CUF 0.408 n/a n/a 
Alkaline Phosphatase on V/F 0.378 n/a n/a 
Hypoglycaemic agents/Diabetes mellitus on V/F 0.356 n/a n/a 
'DOBF - difference In the minimum value of the objective function between 2 NONMEM runs. Chi square distributed _ 2DOBF ~ 3.84 
, P :!: 0.05 dt-1; 'DOBF ~ 11, P :!: 0.001 dt-1 
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COVARIATE MODEL BUILDING -ISONIAZID 
Retained" in 
Covariate Effect DOBF1 Forward 
Retained 3 in 
Model Final Model 
Buildu_~ __________________ ! 
Drugs affecting Absorption on V/F 0.318 n/a n/a 
Quinolones on V/F 0.306 n/a n/a 
GGT on V/F 0.302 n/a n/a 
MDR-TB on V/F 0.292 n/a n/a 
Candidiasis on CLIF 0.289 n/a n/a 
Ethambutol on V/F 0.162 n/a n/a 
Ethambutol on CLIF 0.125 n/a n/a 
Alkaline Phosphatase on CLIF 0.111 n/a n/a 
Candidiasis on V/F 0.089 n/a n/a 
AST on CLIF 0.05 n/a n/a 
ALTon V/F 0.048 n/a n/a 
Thiacetazone on V/F 0.033 n/a n/a 
Enzyme inhibitors on V/F 0 n/a n/a 
'DOBF - difference in the minimum value of the objective function between 2 NONMEM runs. Chi square distributed _ 2DOBF ~ 3 84 , P ~ 0.05 dt-1; 'DOBF ~ 11, P ~ 0.001 df=1 . 
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